Embedded Files
dfdsfdsBest,DaveDawindcr S. SidhuUniversity of Maryland(b)(6)dss@umbc.eduFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Tue, 5 May 2020 13:00:29 +0000Lipkin, Ian W.Subject: RE: SARS-CoV-2Thanks, Ian. I hope that you are well.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Lipkin, Ian W ------------(b)(6) Sent : Tuesday, May 5, 2020 8:39 AM -------=-:--:= To: Fauci, Anthony (NIH/NIAID) [E] --------- (b)(6) Subject: Fwd: SARS-CoV-2Tony,(b)( 4) Thisprompted the letter I sent to him last evening to which he responded this morn ing. I dont expect aresponse but wanted to keep you updated. We deeply appreciate your efforts in steering andmessaging.All my best,IanPs . Skell ju st invested $SM in pilot ing the GIDEoN internat ional capacity building andsurve illance netwo rk that includes Cliff and others in your intramu ral team .Begin forwarded message :From: ZhuChen Cb()6 )>Subj ect: Re:SARS -CoV-2(b)(6) >Date: May 5, 2020 at 8:16:23 AM EDTTo: Lipkin, Ian W. -----------Dear Ian,Thank ou for our email detailing the (b) (4)(b) (4)-------------------- CbH4>. I shall keep you informed of any progress in the coming weeks .Best,Zhu---- ------------- Original- -----------------------~--~--From: "Lipkin, Ian W "-~-- - -- -.~.-.--.-.---------- C_Hb. ...Date: Tue, May 5, 2020 06:06 AMTo: "ZhuChen t CbH~ >;Subj ect: SARS-CoV -2Dear Zhu ,The COVI D-19 pandemic poses an unprecedented threat not only to globa l public health butalso to economic and political stability . Uncerta inty about the origin of COVID-19 pandemic iscausing friction worldw ide, particular ly between China and the United States . There isagreement that the causative agent , SARS-CoV-2 originated in a bat. There is also a high levelof confidence that the virus was not deliberately modified in any laboratory. What we do notknow is the answers to two questio ns: (1) whether a precursor virus circulated in the humanpopulation before it evolved to become a pandem ic virus and 2 whether a recursor virusada ted to humans by first passing through another animal. CbH4>With great affection,IanW. Ian Lipkin, MDJohn Snow Professor of Epidemiology and DirectorCenter for Infection and ImmunityMailman School of Public HealthProfessor of Pathology and NeurologyCollege of Physicians & SurgeonsColumbia University722 West 168th Street, 17th FloorNew York, NY 10032Voice: Cb()6 )Fax: (212) 342-9044Email: CbH~droi oJstrntLve Coo cdinato~(b)(6)www.cii .columb ia.eduFollow CII on Twitter: CII_Columbia I Facebook : GIi.Coiumbia(b) (4)Frmn :Sent :To:Ei ubject:Attachments:Anthony S. Fauci, MDDirectorFauci, Anthony {NIH/N IAID) [E)Tue, 5 May 2020 12:40:52 +0000Barasch, Kimberly {NIH/NIAI D) [C)FW: VP slidesVP bri ef VRC Smay2020v2 .pptxNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: Cb()6 )FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Mascola, John (NIH/VRC) [E]- --------- (b)(6) Sent: Monday, May 4, 2020 7:07 PM ------ --=:= To: Fauci, Anthony (NIH/NIAID) [E] < ,.:::::=======6=- :- Cc: Conrad, Patricia (NIH/NIAID) [E] ---------- Subject: VP slidesTony, here are slides, including changes we discussed. Patty and all have them.JohnFrom:Sent :To:Subject:Mary:Fauci, Anthony (NIH/NIAID) [ElTue, 5 May 2020 12:06:24 +0000Harris, Mary (NIH/NIAID) [ElRE: Thank you, Dr. Fauci, Thank you so very much!Many t hanks fo r you r kind not e. It is much appreciat ed. St ay we ll.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail : Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Harris, Mary (NIH/NIAID) [El --------- (b)( >Sen t: Tuesday, May 5, 2020 8:04 AM ------- ~= To: Fauci, Anthony {NIH/NIAID) [El- -------- (b)(6) Subject: Thank you, Dr. Fauci, Thank you so very much !Dr. Fauci,I wanted to personally thank you for being the voice of reason, security, comfort and insight. (b)(6)As muchas I miss being in the office, I am grateful to say my Director is Dr. Anthony Fauci and share with myfamily, friends, and church that if you said it, it's gospel. They can bank on it ! You have given comfort tomy family and myself. You will never know how much ! I want you and those who in researchers whoare hard at work withou t much rest but tons of sacrifice including that of your fami lies to find a vaccine,give the Nation a sense of safety and security in this unprecedented time are great ly appreciated. Myfamily, friend and myself are send our prayers for your continued strength. Thank you doesn't seem likeenough. I couldn't be prouder to work at NIAID and specifically on the ih floor of Building 31.Simply Grateful,Mary HarrisNIAID Travel Policy SpecialistNIAID Travel Card Coordinator(b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [ElTue, 5 May 2020 00:37:21 +0000Lerner, Andrea (NIH/N IAID) [ElFW: CORONA and BACTERIAL SUPERINFECTIONAttachments : 1918 influenza insight- fauci.pdf, ESP el arroz epidemol.pdf, Infection andlmmunity-2015-Rynda-Apple-3764.full.pdf, JClinsightco -infection.pdf, lancet.png, Mail Esp.pdf, mailgermany 1.pdf, piramide.png, PLEASE FORWARD THIS MESSAGE TO error.pdf, portugal.pdf,Predomi nant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza - Dr Fauci.pdf,press usa.pdf, Recuperados.pdf, spanish f lu 1918 - eng original.pdf , tyska pres mail.pdf, US errormessage.pdf, Us mail 0408 .pdf, WHO-2019-nCoV-clinical-2020.4 -eng.pdf, virus piramdie eng.pngPlease take a look and decide. Thanks.From: Ola Melhus (b)(Sent: Monday, May 4, 2020 12:25 PM(b)(6) Fauci, Anthony(b)(6)To:(NIH/NIAID) [E] .-------------------------Subject: CORONA and BACTERIAL SUPERINFECTIONDear Doctors,I don't know if you have got this infomation.A truly deadly viruscannot spread very far . Why? Because people quickly get sick and die. Inother words, they cannot spread the virus further , which is a prerequisite fora large spread like corona. Covid-19 has spread throughout the world.The premise is that it is not very dangerous, it causes mild symptoms formost people, many do not even notice that they were sick. But the virus hasdifferent phases in the body, after a while it goes into a resting phase, youfee l better, but the virus is still present and can pass on. Covid-19 is anoptimally developed virus that spreads rapidly around the world. But if itwere really deadly, almost everyone would die.So far in our 4 billion long history, there have been no airborne viruses orbacteria. Yes, in the hollywood movie "outbreak" there was, but it was amovie. Why hasn't it?If it had existed, this planet would have been a dead planet without life. Itwould have killed all living. It is possible that there is somewhere else in theuniverse, but not here on planet Earth. Not now. Remember, this is not thefirst time a new virus is spreading in the world. What is happening now hashappened earlier in our long history .But people are die you say. Yes, but the virus don't kill them . The virus opena "door" in the cell wall thats allows for bacterias, how always are present,to invade the body and create an aggressiv bacterial superinfection. That'swhat kills them . See,1. Influenza and Bacterial Superinfection: Illuminating the Immunologic Mechanisms ofDisease.Reduced susceptlbllity(d1y 2-3 post-lAVIIncreased susceptibility{clay 6-7 post•IAV)FIG I Common pathw.!)'S of $umptibilit}'t o postinfluenu bacterials upennfectioru.E arlya fter influenu Virusi nfection,m ice show reduced rusccpt.ibilityt osupainfection that is at least in pan due to lncreasedp rodurtlon of IL-13.T his IL-I3 -ricb em'lronmentd oes not permnI FN•'Yp roduction.a llo\'oingu nalteredphagocytosls md clearance of bacteria. The rol, for either neutropbili. or macrophages (phagocytes) in lnnerbl dearance early dwing lnfluenu virus InfectionIm not bttn hillyi nvestigatedP. rogres.sioonf inRu,nz:av iTUSin fl'Ctionr esullsi n increasros u.1apnbilit)• to secondaryi nftction.T ypt I IFN (or lL-27)s ignalinginitialed in respo03et o inlluenz.aV irus inftction rer.ultsin downrtgulatedp roduction of IL-11a1n d 11-23a nd impairedt ype 17 immune resp o~. Inhibitiono fIL- 17 and IL-ll nduces production of antimiaobW peptides. Type I IFN signal ing also reduces levels of neutrophil diemoattr.ict:mts Cxdl and Cxc12 md caninduce fonnation of NETs.l L-27r nduced during influenza virus infectionf urthers uppresses1 1..-1p7r oducuon but stimulatesp roductiono f regulatory cytoklneIL-10,w hich contribwes to increaseds usctptibility to superinfection,p resumablyb y alterationo f lh• anti-influenz;in flammatoryr t5ponse.I AV , innuenu Avirus in~ction.and thi s reports:2. Deaths from Bacterial Pneumonia dur ing 1918-19 Influenza Pandemic3. The 1918 Influenza Pandemic: Insights for the 21st Century4. Interactions between influenza and bacterial respiratory pathogens : implica tions forpandemic preparedness5. Survival during influenza -associated bacterial superinfection improves following viral- andbacterial-spec ific monoclonal antibody treatment6. Predominant Role of Bacteria l Pneumonia as a Cause of Death in Pandemic Influenza :Implications for Pandemic Influenza PreparednessHow can this happen? How can the doctors be so blind . I have a t heoryabout this and here it comes:My ---CbH6)w as a psychologist. May she rest in peace in heaven.It seems that the corona virus has affected the brain more in a certain groupin society, name ly politicians, doctors, journalists and other with power andpositions in the society. The virus is not dangerous for this group, but it'sopens a door in the brain's cell wall that allows it to enter the fear center ofthe brain.This door has been closed for many years. We haven't had any major warsand nothing has threatened them. They have felt invulnerable. Convinced oft heir own superior abil ity and grea tness. Not only can they cont rol thepeople, they can now control the climate by turning the carbon dioxide tap.If they close it, the temperature drops, if they open it the temperature goesup. They don't know tha t the sun is 109 times as big as our planet. 109times . It seams so small when we look up in the sky. They thought theycould cont rol everything.Then came the VIRUS, they receive an abrupt awakening. They getscared. Polit icans get sick and die. Doctors die. The brain is attacked by fearvirus. They can no longer think clearly and logically. The pan ic is near, theyare reminded of their own morta lity. Just like a virus in a computer. It'sslows it down and it becomes unusable. Tha ts whats happen when a fearvirus attacks the brain.Here where I live, there are panic over 1600 confirmed cases. The telev isonis talking "infected persons" when t here is "confirmed laboratory cases". It'stwo different things. Misleading the people . Why panic over 1 600 infected?Closing all not nessecary bui ssness, all school s, all excep t for supe rmarket,gas station, banks. You can't go out after 5.00 pm. If you do, you getarrested.Why? They are scared. Because the ruling class is afraid. Everyone withthis masks. Doctors crying on television. The President with mask. They arescared . Doctors. Journalists. Polices.2020. The year when the world got completely crazy.You have an medical obligation to inform the world aboutthe truth.Kind regards,Ola MelhusFrom:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [E)Tue, 5 May 2020 00:36:13 +0000Barasch, Kimberly (NIH/NIAID) [C)FW: Therapeu tics and vaxNIAID SARS-CoV-2 Tx and Vax overview.docxPlease print out and put in folder labelled "COVID-19 Ther apeutics and Vaccines"From: Marston , Hilary (NIH/NIAID) [E] ________ Cb_H_6)Sent: Monday, May 4, 2020 12:32 PMTo: Fauci, Anthony {NIH/NIAID) [El -------:a- (b=H=6)>Cc: Conrad, Patricia (NIH/NIAID) [El- -------- (b)(6)•>; Barasch, Kimberly {NIH/NIAID) [CJ (b)(6)>Subject: Therapeutics and vaxFor your Therapeutics discussion lat er todayFrom: (b)(6)Sent: Mon, 4 May 2020 19:52: 45 -0400To: Troye, Olivia EOP/NSCCc: Hurst, Natalie R. EOP/OVP;Mascola, John (NIH/VRC) [E);Graham, Barney(NIH/VRC) [E);Francis CollinsSubject: Re: Email connecting usHere they are. ThanksOn May 4, 2020, at 7:46 PM, Troye, Olivia EOP/NSC(b)(6)Hi Dr. Fauci,Per our conversation, sending you a note. I'm copying Natalie who will he lp get themcleared in .Tha nk you!OliviaOlivia TroveSpecial Advisor to the Vice President forHomeland Security, Countert errorism, and North AmericaOffice of the Vice President, National Security AffairsWhit e House Coronavirus Task Force0: (b)(6) I M: (b)(6) (Does not receive texts)(b)(6)(bX5) -PCI
From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Mon, 4 May 2020 21:05:39 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6Please see me about thi s.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Collins, Francis (NIH/OD) [E] (b)(6)>Sent : Monday, May 4, 2020 11:18 AMTo: ICDDIR-L@LIST.NIH.GOVCc: Parker, Ashley (NIH/OD) [E) (b)(6); Whalley, David (FNIH) [T](b)( >; Melencio, Cheryl (FNIH) [T) (b)(6J> ______ _,Subject: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6Dear Colleagues,As you may be aware, the Accelerating COVID-19 Therape utic Interventions and Vaccines (ACTIV) publicprivatepartnership has been moving forw ard rapidly to address the global pandemic. We held ourinitial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads ofresearch and development . Four work ing grou ps were formed out of this meeti ng to focus onprecli nical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.Although some ICs have representatives participating in t he working groups, we recognize there is aneed to keep everyone looped in to the various activities and prog ress of the partnership, particula rly inview of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be deliveringt heir second report to the ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00 pm. I amwriting to invite the ICDs to listen-in on this meeting. There will be a lot to cover during the meet ing andthe members of the Leadership Group will be asking the questions . But to give a chance for us NI Hers todiscuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediatelyfollow ing the ACTIV leadership meeting.If you are available to take part, please send your responses to David Wholley and Cheryl Melencio ofFNIH (cc'd here) by noon tomorrow , May 5th . Once you confirm your attendance, Cheryl will send youa calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.Best regards,FrancisFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 15:28:08 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: RE: Need your help Covid-19 CAS-1O685I do not know this person. We should refer him to Brett Giroir.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Conrad , Patricia (NIH/NIAID) [E] (b)(6) •>Sent: Monday, May 4, 2020 10:04 AM ------ -=-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: FW: Need your help Covid-19 CAS-10685Do you know this person?Patricia L. ConradPublic Health Ana lyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7AO3Bethesda, Maryland 20892(b)(6)301-496 -4409 faxDisclaimer :The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.From: Harris, Kara (NIH/NIAID) [El (bH >Sent: Friday, May 1, 2020 8:38 AMTo: Conrad, Patricia (NIH/NIAID) [ElCc: Auchincloss, Hugh (NIH/NIAID) [El >; Billet, Courtney (NIH/NIAID) [El-------- (b)(6)>; Haskins, Melinda (NIH/NIAID) [El- --------- (b)(6) Subject: FW: Need your help Covid-19 CAS-10685Hi, Patty-This individua l states that he previously worked with Dr. Fauci and that he knows him. Please let meknow if you would like Public Inquiries to handle .Thanks,KaraFrom: Ray Rosa (b)(6)>Sent: Thursday , April 30, 2020 5:58 PMTo: NIAID Ocpostoffice (NIH/NIAID) <0CPOSTOFFICE@niaid. nih.gov>Subject: Need your help Covid-19I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I needsomeone to call me so I can ask specific questions . I worked with Dr Fauci back in 1998 when I was inthe Air Force. So he does know me. Ray Rosa is the name . Can you please call me.(b)(6) cellScot from AOL Mobile MailGet the new /\OL app· mail.mobile.aol.comFrom:Sent :Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]Mon, 4 May 2020 14:00:23 +0000To: NIAIDODAMSubject: FW: inquiryAnot her one that he will probably want to do.From:A ugustine M. K. Choi ---------- (b)( Sent: Monday, May 4, 2020 9:21 AMTo: Fauci, Anthony {NIH/NIAID) [E] ------ (=b)""('6=J>Cc: Conrad, Patric ia (NIH/NIAID) [E] ---------- (b)( > Subje ct; inquiryHi Tony,I can only imagine your schedule. Thank you for all you are doing for the country in our fight against thisvirus.Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcominggraduation if your schedule allows. The virtual graduation is on May 28th . We can tape your remarks atany time which fits your schedule, from now or up to right before May 28.If you able to accept this invitation, please let me know. If not, totally understandable and we wouldlove to have you back again after covid subsides.Thanks again!Augustine M.K. Choi, M.D.Stephen and Suzanne Weiss Dean, Weill Cornell MedicineProvost for Medical Affairs, Cornell UniversityWeill Cornell Medicine1300 York Avenue, Suite F-113 Box 83 I New York, NY 10065Telephone: 212-746-6005Fax: 212 -746 -8424Email: amc2056@med.cornell.eduFrom: Anthony Fauci (b) (6)Date: Monday, March 30, 2020 at 12:19 PMTo: Augustine Choi (b)(6)Subject: [EXTERNALR] E: all wearing masksMy work with the Coronavirus Task Force and the large volume of incomingemails precludes me or my staff from answering each individual message. I wouldencourage you to visit www .coronavirus.gov for the latest information andguidance related to COVID-19.Thank you, and best regards.Anthony S. Fauci, M.D.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 12:28:04 +0000To: Corey, LarrySubject: FW: [EXTERNAL] RE: OK to contac t Joe Menet ski to discuss opport unities foralignment/ col laborat ion on ACTIV activities?As an FYI for the 9:00 AM meet ing.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dolsten, Mikael (b)(6)>Sent : Monday, May 4, 2020 8:15 AM ------~ = To: Collins, Francis (NIH/OD) [E] ~ -;:::=====:::::.;.;,-s-r;,= Cc: Fauci, Anthony (NIH/NIAID) [E] >; Mascola, John (NIH/VRC) [E](b)(6)>; Lane, Cliff (NIH/N IAID) [E) CbH >; Lowy, Douglas (NIH/NCI) ":":"::-::=:======~ [E) (b)(6) ; Jansen, Kathrin (b)( >Subject: Re: [EXTERNAL) RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaborat ion on ACTIV activities?FrancisThanks for the responseWe appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccdhere) from PFE is working w the team on t his.(b)(4 )CbH4> It 's great to be collaborating w NIH-FDA for the best of our nation and global ______._.... _health.In the master protocol, I hope the work ing committee is discussing (b) (5)(b)( 5)(b) (5)These are just two examples we can discuss on Wednesday in the leadership meeting of times permits.I look forward to the meetingBestMikaelSent from my iPhoneOn May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] ______ (bH_6)> wrote:Hi Mikael,Wow, sounds like you are making fantastic progress with the vaccine program, andwe would certain ly not want to do anything to slow you down! I understand thatyou are evaluating several mRNA formats with BioNTech. If one of those turnedout to be ready for phase 11/111in late June, we would be most interested in thepossibility of includ ing that in the master protocol. Please keep Tony and me intouch with Pfizer's progress, including which mRNA format you choose to moveinto advanced development.Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday .There will be a lot to ta lk about!Best, Francis(b)(5)From: Dolsten, Mikael (b)(6)>Sent : Sunday, May 3, 2020 6:26 PM ------~ = To: Collins, Francis (NIH/OD) [El (b)( >Subject : Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?Hi FrancisWe certainly enjoy taking part in ACTIVI will check if we did get our drugs on the lists belowI will discuss w Kathrin Jansen if we may have an option to add one of our several vaccineformats that is less advanced or a refined format of our most advanced in the masterprotocol etc(b)(4)If we can agree about shared key endpoints, we can include that cross all studies Whethe rmaster protocol or more advanced sponsor trials which helps comparisonHappy to discuss w you and welcome your adviceMikaelMikael Dolsten, M.D., Ph.D.Chief Scientific Officer and President,Wor ldwide Research, Development and MedicalPfizer Inc.235 East 42nd StreetNew York, NY 10017On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [El-------- (b)(6)> wrote: MatsHi Mikael,Thanks for your note and this update on exciting progress on severalfronts. ACTIV is moving forward with gratifying speed andcommitment. With regard to vaccines, tomorrow the ACTIV vaccinesWG will be discussing a master protocol for a phase 11/11tr1ia l withadaptive design, multiple arms , and a shared placebo arm, aiming tolaunch on or about July 1. FDA is strongly supportive. The Moderna,Sanofi, and JnJ vaccines are likely to be included - might Pfizer alsojoin?----------------- CbH4> - I trust that compound is 0 n the list of therapeutic candidates that the Clinical Therapeutics WGof ACTIV is reviewing? They are supposed to put forward a tentativelist for the Wednesday Leadership Group meeting. Ditto with the(b)(4 option!Looking forward to catching up soon!Best, FrancisFrom: Dolsten, Mikael ---------- (b)(6) 1> Sent: Sunday, May 3, 2020 12:06 PM ----- -== To: Collins, Francis {NIH/OD} [E] ------- (b)( > Subject: Re: [EXTERNALR] E:O K to contact Joe Menetski to discussopportunities for alignment/ collaboration on ACTIV activities?Hi FrancisI trust you are well but likely working too many hours as we all experience inthe difficult Covid t imes.In the vaccine space we have progressed rapidly and are already in phase 1/2studies dose escalation phase testing multiple format of mRNA vaccine . Keyfor us is (b) (4 .-How are things going w ACTIV.Any issues to discuss ?I hope our PFE representatives in ACTIV are helping out wellPis let me know if there is anything particular to discuss or I can help youwithBest personal regardsMikaelSent from my iPhoneOn May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E](b) (6)> wrote:Hi Morten,Thanks for your note. It would be great to have thisconnection - but let me suggest that you start with DavidWholley (cc'd here), as he oversees all four of the ACTIVworking groups. Joe is the program lead for the group onpreclinical therapeutics/repurposing.Best, FrancisFrom: Sogaard, Morten ----------- (b)(6) Sent : Sunday, May 3, 2020 10:46 AMTo: Collins, Francis (NIH/OD) [E] _____ --,;C.b.H,.=,6. )Cc: Dolsten, Mikael (b)(6); Prof TrevorM Jones CBE FMedSci (b)( >;Sogaard, Morten Cb) (6)>Subje ct: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?Francis,(b) (4)I hope you are having a good weekend .Quick question: Would you be OK if I/we reached out to JoeMenetski, who I understand leads many of the ACTIV efforts.We have come to know Joe very well as a great collaborator onthe AMP gene therapy initiative and It would be very easy Ithink working informally with Joe to look a bit more under thehood and identify/ map opportun it ies for alignment with theother initiatives.All the Best,MortenFrom:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElMon, 4 May 2020 10:53:14 +0000Haskins, Melinda (NIH/NIAID) [ElRE: EOP/OMB Alert: May Hearing GuidanceWhat does this mean for the May 12 Senate Hearing?From: Haskins, Melinda (NIH/NIAID) [El (b)(6)Se nt: Monday, May 4, 2020 6:20 AM -----~~ To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: Billet, Courtney {NIH/NIAID) [E] (b)(6)>Subject: EOP/OMB Alert: May Hearing GuidanceI have highlighted in yellow the fundaments of the 0MB guidance below.MelindaFrom: Hallett, Adrienne (NIH/OD) [E] (b)( >Se nt: Sunday, May 3, 2020 9:54 PMTo: OD-OLPA-Leg Contacts <00-0LPA-LegContacts@OD .NIH.GOV>Subject: Fwd: May Hearing GuidanceFYI. New 0MB hear ing guidance.From: Yaworske, Jason A. EOP/OMB ------------ (b) (6)> Sent : Sunday, May 3, 2020 9:06 PM Cc: Ueland, Eric_ M_. EO _P/_WH;_O_ -- -=--=---=-~====~(b)(~6=)> ;- -Hodgson, Christophe r ( o v p. e op.gov) (b)(6)Subject: May Hearing GuidanceImportance: HighAgency legislative affairs teams,(bX5)-PCIThank you, and please let us know if you have any questions .JasonJason YaworskeAssociate Director for Legislative Affa irsOffice of Management and Budget(b)(6) ( 0)(b)(6) (c)From:Sent :To:[ElCc:Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 00:50:18 +0000Collins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID)Tabak, Lawrence (NIH/OD) [E];Parker, Ashley (NIH/OD) [E]Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?We need to find out precisely what he is ta lking about when he says "vaccine formats" and"refined formats". I really do not know what he is talking about. (b)(4),(b)(5)John/Cliff:Let us discuss this at our morning meet ing .Thanks,TonyFrom: Collins, Francis (NIH/OD) [El (b)(6)>Sent: Sunday, May 3, 2020 8:03 PMTo: Mascola, John (NIH/VRC) [E]_ _____ --,;(-b")('"=6");' Lane, Cliff (NIH/NIAID) IE]-------- (b)( ; Fauci, Anthony (NIH/NIAID) [E] (b)( > Cc: Tabak, Lawrence {NIH/OD) [E) (b)(6J>; Parker, Ashley (NIH/OD) [E)(b)(Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Hi John, Cliff, and Tony ,See note below, where Mikael Dolsten indicates Pfizer is planning to CbH4>. He intends to discuss our master protocol possibility with Kathrin Jensen.am not qu ite sure what he means by "several vaccine formats".Does this timetable sound realist ic?Any suggestion about a response?FrancisFrom: Dolsten, Mikael ---------- (b)(6)Sent: Sunday, May 3, 2020 6:26 PM -----~~ To: Collins, Francis (NIH/OD) [E] ------- (b)(6)Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Hi FrancisWe certainly enjoy taking part in ACTIVI will check if we did get our drugs on the lists belowI will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats thatis less advanced or a refined format of our most advanced in the master protocol etcIf we can agree about shared key endpoints , we can include that cross all studies Whether masterprotocol or more advanced sponsor trials which helps comparisonHappy to discuss w you and welcome your adviceMikaelMikael Dolsten, M.D., Ph.D.Chief Scientific Officer and President,Worldwide Research, Development and MedicalPfizer Inc.235 East 42nd StreetNew York, NY 10017On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]MatsHi Mikael,-------- (b)(6) wrote :Thanks for your note and this update on exciting progress on several fronts. ACTIVis moving forward with gratifying speed and commitment. With regard to vaccines,tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase11/11tr1ia l wi th adaptive design, multiple arms, and a shared placebo arm, aiming tolaunch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, andJnJ vaccines are likely to be inc lud ed - might Pfizer also join?(b) (4)------------------ (b)( 4)- I trust that compound is on the list 0 f therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing?They are supposed to put forward a tentative list for the Wednesday LeadershipGroup meeting. Ditto with the CbH4> option!Looking forward to catching up soon!Best, FrancisFrom: Dolsten, Mikael ----------- (b)( Sent: Sunday, May 3, 2020 12:06 PMTo: Collins, Francis (NIH/OD) [E] ______ .(,b,.")("=6")Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?HI FrancisI trust you are well but likely working too many hours as we all experience in the difficultCovid times.How are things going w ACTIV.Any issues to discuss?I hope our PFE representatives in ACTIV are helping out wellPis let me know if there is anything particular to discuss or I can help you withBest personal regardsMikael(b) (4)(b) (4)Sent from my iPhoneOn May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] -------- (b)(6) wrote :Hi Morten,Thanks for your note. It would be great to have this connection - butlet me suggest that you start with David Whalley (cc'd here), as heoversees all four of the ACTIV working groups. Joe is the program leadfor the group on preclinical therapeutics/repurposing.Best, FrancisFrom: Sogaard, Morten ----------- (b)(6)> Sent: Sunday, May 3, 2020 10:46 AMTo: Collins, Francis (NIH/OD) [E] ------=- (b) '""(=6)>Cc: Dolsten, Mikael (b)( ; Prof Trevor M Jones CBEFMedSci (b)(6); Sogaard, Morten------!=======; (b:);(:c:6");=;----Subject: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Francis,I hope you are having a good weekend.Quick question: Would you be OK if I/we reached out to Joe Menetski, who Iunderstand leads many of the ACTIV efforts. We have come to know Joe verywell as a great collaborator on the AMP gene therapy initiative and It wouldbe very easy I think working informally with Joe to look a bit more under thehood and identify/ map opportunities for alignment with the other initiatives.All the Best,MortenFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:45:43 +0000Greg Folkers (b)( 6) );Doepel, Laurie (NIH/NIAID) [ElPitt and INCAttachments: Commenc ement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for5-08-2020 (videos) .docxSee attachment with remarks for UPitt and UNC. I have left the tracked changesshowing so that you can see what I have done . Please accept these and thenproof it. It is now marked FINAL (tracking needs to be accepted) in the ODfolder . Thanks .Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail : (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:28:33 +0000Greg Folkers (b)(6) ;Doepel, Laurie (NIH/NIAID) [ElUSUHSCommencement Remark s, USUHS 2-min -FINAL- for 5-16-2020 (Vid eo).docxSee attachment with USU HS remarks . I have left the tracked changes showingso that you can see what I have done. Please accept these and then proof it. It isnow marked FINAL {tracking needs to be accepted) in the OD folder . Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent:To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:21:04 +0000Greg Folkers (b)(6) );Doepel, Laurie (NIH/NIAID) [ElAMACommencement Remarks, AMA 3-min - FINAL - fo r May 2020 (Video).docxSee attachment with AMA remarks. I have left the tracked changes showing sothat you can see what I have done . Please accept these and then proof it. It isnow marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.Anthony S. Fauci , MODirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 20:58:32 +0000To: Doepel, Laurie (NIH/NIAID) [E);Greg Folkers ______(b)_( ...)_ .Subject: UCSFAttachments : Commencement Remark s, UCSF SOM - FINAL - for May 2020 (Video) .docxGreg/Laurie:I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the ODfolder. However, I have left in the tracked changes fo r you to see what I did.Please accept the changes and then go over it one last time . I like it the way it isand so please no trivial corrections.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent:To:Subject:Attachments :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 20:11:08 +0000Doepel, Laurie (NIH/ NIAID) [E);Greg Folkers (b)( )Holy CrossCommenc ement Remarks, Holy Cross - FINAL - for 05-22-2020 (video) .docxThe Holy Cross video script is in the OD File mar ked as "FINAL". I have left thetracked changes showin g so tha t you will know w hat I have done. Please acceptthe changes and take a final look. I am also attaching for your look.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 18:34:28 +0000To: Tromberg, Bruce (NIH/N IBIB) [E);'Sharpless, Ned-----------, (b=~=(6)) 'Cc:Subject:Thanks, Bruce.Anthony S. Fauci , MDDirectorConrad, Patricia (NIH/N IAID) [E)RE: 2 quick pointsNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: _ __,. ,_, (b)( 6)The information inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Tromberg, Bruce (NIH/NIBIB) [E) ---------- (b)( 6)>Sent: Sunday, May 3, 2020 2:28 PM- -------, a-s-r,= To: Fauci, Anthony (NIH/NIA ID) [E) (b)( ; 'Sharp less, Ned(b)( 6)Cc: Conrad, Patr icia (NIH/NIAID) [E] ______ (b) <_ >Subject: Re: 2 quick pointsHi Tony,Thanks! Hope you are doing well.This is basically exactly wha t we are working to facilitate with our RADx and digita l health (app) platforminitiatives ... greatly expanding test ing and creating a digita l backbone to provide people with ways toaccess tests and interpret results . For expanding test ing platforms, see https://www.nibib .nih.gov/news events/newsroorn/nih-mobil izes-national-innovation -initiative -covid-19-diagnostics We have > 700applicat ions that have been started in just a few days. For the digital health (e.g. app) platform we'veput a lot of thought into the design and are hoping a contractor wil l be able to launch a pilot study ofhealthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institute sas stakeholders in the coming weeks.Best,BruceBruce J. Tromberg, Ph.D.DirectorNational Institute of Biomedical Imaging and BioengineeringNational Institutes of HealthBuilding 31, Room 1C14Bethesda, MD 20892-2281(b)(6)301-480-0679 - FAX(b)(6)http://www.nibib.nih .govFrom: "Fauc i, Anthony (NIH/ NIAID) [E]" <- -------- (b)(6)Date : Sunday, May 3, 2020 at 1:55 PM --------------------------~~ To: "'Sharpless, Ned ~~~":""":"'.~========~;---------(-b)(-6)- 11 T ro m berg, Bruce (NIH/N IBIB) [E]" (b)(6)> ~-=========~ Cc: "Conrad , Patric ia (NIH/NIAID) [E]" ________ Cb _H_6JSubje ct : FW: 2 quick pointsNed/ Bruce:I t hought that I would pass this on to you in case you have int erest. Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)(6)>Sent: Saturday, May 2, 2020 8:23 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [El- ------- (b)( > Subject: 2 quick pointsDear Tony,l. I had planned to wr ite to thank you for giving an interview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it.was waiting for the chaos around you to subside before writing but... ..2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6)As his email says, (b)(6) with Samsung's venture capital group, which hasan idea for a future , comprehensive surveillance system for COVID-19 (b)(4)It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-orien ted individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out Cb)<_ , and certainly nothing is more important these days than COVID-19 and the outstanding wor kyou are doing to manage it .All the very best,-EricFrom: Warren, John [mailto (b)(6)] ------------ Sent: Thursday, April 30, 2020 6:52 PMTo: (b)(6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up --------(b)(6)but I'm writing because it might yet bring at least the two of us together.------(b)(6)Samsung'sv enture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has ident ified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optimal ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MD 21201(b)(6)From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Sun, 3 May 2020 17:56:39 +0000NIAIDODAMSubject: RE: Dr. Antho ny Fauci & Avi Schiffm an/The Webby Awards????? Who is this person?Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Auchincloss , Hugh (NIH/NIAID) [El- ---------- (b)(6)> On Behalf Of Fauci, Anthony (NIH/NIAID) [ElSent : Sunday, May 3, 2020 1:55 PMTo: NIAID OD AM <NIAIDODAM@niaid .nih .gov>Subject: FW: Dr. Anthony Fauci & Avi Schiffman/T he Webby AwardsFrom: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>Sent: Friday, May 1, 2020 12:13 PM -------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby AwardsHI Dr FauciI just wanted to follow up on below regarding Avi and The Webby Awards. Would be wo nderful if youcould be a part of this moment for him.Thanks so muchLesleyOn Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy .com>wrote :<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>Dear Dr. Fauci,I hope you and the family are all safe and healthy dur ing these challenging times. Hailedby The New York Times as "the Internet's highest honor," The Web by Awards has been t hepremiere award for on line excellence for over two decades, honor ing the companies andpeople who have crit ically shaped digital techno logy and culture.This year, due to the impact of the coronavirus The Webby Awards are moving theirrenowned award show to an online experience. On May 19th, 2020, the 24th AnnualWebby Awar ds wi ll bring together Webby Winners from around the world in an InternetCelebration which wi ll showcase the artists, organi zations, and creators using th eirplatforms to imagine a bette r tomorrow th rough informa t ion, educatio n, movement,comedy, all while inspiring audiences to take action to enact posit ive change.The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Personof the Year to recognize his creation of ncov2019.liv e to track the spread of COVID-19across the world. We would be honored if Dr. Fauci would "virtually" present Avi withhis award .As we collectively navigate the severe impact of COVID-19 on the world and late calls fornation-wide social distancing, the Internet has become the lifeblood for people lookingfor accurate information about the novel coronavirus. Since launching the site onDecember 29th , Avi Schiffmann's tracking site was a necessary tool that sounded thealarm on the novel coronavirus and its spread, notably calling attention to its severitylong before many global officials. By providing over 100 million visitors with real-timedata on the virus' spread, Schiffmann has helped people around the globe understandCOVID-19 and the necessity of upgrades to current health care systems and measures toflatten the curve.For having the fore sight to track the global spread of COVID-19 and for creating awebsite to provide real-time data about the virus to people everywhere, it is our greatprivilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. Thecelebration will highlight the important work Avi and his fellow winners are doing, andwill mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci'spresenter speech could be recorded on his phone and we can send you through a scriptfor him to review, edit and details for format and deadline.This year's Webby Awards will also take action, t he impact of COVID-19 and govern mentresponses around the world, has brought the importance of vot ing into sharp focus. TheWebby Awards has partnered with Vote.or and aim to check the voter registration statusof 1 million voters in the United States, promoting the importance of voting to help ensurevote r turnout this November is the highest it has ever been. This partnership will integrateinto all elements of this year's on line celebration.Our thoughts are with all of you in this difficult time.BestLesley Cahill Roy(b)(6)From:Sent:To:(NIH/NIBIB) [ElCc:Subject:Attachments :Ned/ Bruce:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:55:14 +0000'Sharpless, Ned- ----------- (b)(6)';Tromberg, BruceConrad, Patricia (NIH/NIAID) [E)FW: 2 quick pointscovid contact tracing.pdfI thou ght that I wou ld pass thi s on to you in case you have int erest . Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)(6)Sent: Saturday, May 2, 2020 8:23 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] ______ Cb _H_ >Subject: 2 quick pointsDear Tony,1. I had planned to wr ite to thank you for giving an interview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. Iwas waiting for the chaos around you to subside before writing but .....2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b)(6)As his email says (b)(6) Samsung's venture capital group, which hasan idea for a future, comprehensive surveillance system for COVID-19 (b)( 4). It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-oriented individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) ~- and certainly nothing is more important these days than COVID-19 and the outstanding workyou are doing to manage it.All the very best,-EricFrom: Warren, John [mailto ----------- (b)(6)Sent: Thursday, April 30, 2020 6:52 PMTo: (b)(6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up (b)( ut I'm writing -------- because it might yet bring at least the two of us together.(b)(6)Samsung's ------ venture capital group and his team has what I th ink is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has identified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optima l ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MD 21201(b)(6)From:Sent :To:Subject:Eric:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:53:55 +0000Eric OttesenRE: 2 quick pointsThanks for your note . No problem . I will forward this to people here at NIHwho are pursuing such approaches. I hope that all is well with you.Best regards ,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)( >Sent: Saturday, May 2, 2020 8:23 AM -------~~ To: Fauci, Anthony {NIH/NIAID) [E] ---------(b)(6) Subject: 2 quick pointsDear Tony,1. I had planned to write to thank you for giving an inte rview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it .was waiting for the chaos around you to subside before writing but .....2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b)(6)As his email says, (b)(6) Samsung's venture capital group, which hasan idea for a future, comprehensive surveillance system for COVID-19 (b)(4). It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-oriented individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) ~_ , and certainly nothing is more important these days than COVID-19 and the outstanding workyou are doing to manage it.All the very best,-Ericl=rom: Warren , John [ma ilta (b)(6)] ----------- Sent : Thursday, April 30, 2020 6:52 PMTo: (b) (6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up (b)(6l b ut I' m wri.t.in gbecause it might yet bring at least the two of us together. ------------(b)(6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has identified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optima l ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MO 21201(b)(6)From:Sent :Auch incloss, Hugh (NIH/NIAID) [E] on behalf of Fau.ci, Ant hony (NIH/ NIAID) [E]Sun, 3 May 2020 17:52:37 +0000To: NIAIDODAMSubject:Importance:FW: INVITE- American College of Cardiolog yHighFrom: Kim, Jonathan Ho-Youn (b)(6)Sent: Friday, May 1, 2020 3:09 PM ------ ..,.....,..-= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)Cc; Ryan Meye r (b)(6) Roby n Snyde ------- (b)(6) Subject: Re: INVITE- American College of CardiologyImportance: HighDr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalfof the American College of Cardiology as noted below. We were hopeful we could stealjust an hour of your t ime in June for an important discussion on COVID-19 and exercisetraining. This is part of a virtual agenda for one of our national conferences (Care of theAthletic Heart) with outreach around the world given this is a part of the ACCeducational platform.We hope th is is something you have the bandwidth for, and simply appreciate yourconsideration. I hope to hear from you and thank you for all your service once again.My best, Jonathan KimJonathan H. Kim MD, MSc, FACCChief of Sports CardiologyDepartment of Medicine, Division of CardiologyDepartment of OrthopedicsEmory UniversityAdju nct Assistant ProfessorDivision of Applied PhysiologyGeorgia Inst itute of TechnologyTeam Cardiologist for Emory Athlet ics, Georgia Tech Athletics , Atlanta Falcons, Atlanta Hawks, AtlantaBraves, and Atlanta DreamOffice Phone: Cb) (6)Research Profile: http: // medicine .emorv .edu/cardiology/emory-first- facultydjrectory/profi le.htmi?f=JKIM10Email Cb) (6)From: Kim, Jonathan Ho-YounSent: Thursday, April 16, 2020 3:46 PMTo: (b)(6) Cc:- R-y-an-M =e=ye=r ===;--C--b)-( ·>; Robyn Snyder_ ____ C_>b_<_,>Subject: INVITE- American College of CardiologyDr. Fauci-On behalf of the American College of Cardiology (ACC), first I would like to thank you for yourtremendous service throughout your incredible career and certainly during these present andchallenging times. We are indebted to your service and thankful everyday we have you to helpguide public health measures through the COVID-19 pandemic .I am a member of the Sports and Exercise Council for the ACC and the Course Chair for ourannual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACCHeart House in Washington DC. I am also faculty at Emory University and direct our sportscardiology program in Atlanta.Of course, we have made the difficult decision to cancel our live meeting in June, but myselfalong with the staff at ACC are working very hard transitioning the course to a virtual courseand agenda. This course will be a much shorter version and the agenda will all be pre-recordedand distributed as a 'live simulated version' on June 20, 2020.With the impact of COVID-19 on all aspects of life and society, in our academic world of sportscardiology, we are dealing with how COVID has impacted exercise and athletes. As you canimagine, there are a multitude of different issues and questions that colleagues are raising.One new session for our virtual agenda that we think will generate a lot of interest and is ofhigh importance will be a panel discussion on sports, exercise, and COVID-19. We would like toget additional expertise on the panel from the ID/pub lic health and Sports Medic ine arenas, inaddition to sports cardiology. Of course, there is no one that carries the expertise you do fromthe ID and publ ic health perspective and we would be extremely honored if you could be a partof this one session and join our faculty for the course.Before getting into more details and a formal invite from the ACC, I wanted to first see if youhad the bandwidth for this. Understanding you are as busy, if not busier, than anyone in theworld right now. This session would be pre-recorded and we would certainly work to be flexiblewith anytime you had for this in early June to record.I hope this is something that could work- again we would be honored to host you virtually.Many thanks for considering, and hope to hear from you soon. Best, Jonathan KimJonathan H. Kim MD, MSc, FACCChief of Sports CardiologyDepartment of Medicine, Division of CardiologyDepartment of OrthopedicsEmory UniversityAdjunct Assistant ProfessorDivision of Applied PhysiologyGeorgia Institute of TechnologyTeam Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, AtlantaBraves, and Atlanta DreamOffice Phone: (b) (6)ResearchP rofile: http://medicine.emory.edu/cardiology/emory-first-faucltydirectory/profile. html?f=JKIM 1 OEmail (b) (6)This e-mail message (including any attachments) is 'or the sole use oflhe intended recipient(s) and may contain confidential and privilegedinformation. If the reader of this message is not the Intendedrecipient, you are hereby notified that any dissemination distributionor copying of this message (including any attachments) is strictlyprohibited.If you have received this message in error, please contactthe sender by reply e-mail message and destroy all copies of theoriginal message (including attachments).From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:50:45 +0000Jon LaPookSubject: RE: Today's segment on CBS Sunday MorningJon:Tenific piece on ":No time to abandon science"! Keep up this great work . We need to stay on course.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and lofectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Jnslirutes of HealthBethesda, MD 20892-2520Phone: (b)(6)f AX: (301) 496-4409E- mail: (b) (6)The informa1ion in this e-mail and any of its a1tachmen1sis confidential and may contain sensitive infom1ation. Itshould not be used by anyone who is not the original intended recip ient. If you have received this e-mail in errorplease inform the sender and delete it from your mailbox or any other storage devices. The National Institute ofAllergy and Infectiou s Disease s (NIAID) shall not accept liability for any statements made that are the sender's ownand not express ly made on behalf of the NlAID by one of its representatives.-----Original Message-----From: Jon LaPook.------ (=b)-..(=.6.,,),,(b) (6)>Sent: Sunday, May 3, 2020 I :31 PMTo: Fauci, Anthony (NIH/NlAfD) [E) ...,.._,.-,---,-----Subject: Today's segment on CBS Sunday MorningDear Tony,l hope (though would not bet my life that) you are getting at least a modicum of down time today.Here's a I ink to the segment l told you about. No commercial!htt:ps://www .youtube.com /watch?v-OjCohlBICgO[http://img.y outube.com /vi/OjCohlBICgO/O.jpg]<https: //www .yout ube.com/watch?v=OjCoh lBICgO>Dr. Jon LaPook: No time to abandon science - YouTube<https://www.youtube.com/watch?v=OjCohlBICgO>www .youtube.comAs we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health expertssay they should, Dr. Jon LaPook notes thatthis ...JonJonathan LaPook, M.D.Chief Medical Correspondent, CBS Even ing News Professor of Medici ne NYU Langone Health(bXS) - PCP.(bX5) -PCIFrom:Sent:To:Cc:Subject:Dr. Dama:Fauci, Anthony {NIH/N IAID) [E]Sun, 3 May 2020 17:23:12 +0000Paola DamaConrad , Patricia (NIH/N IAID) [E)RE: White House Coronav irus Task ForceThank you for your note. I am attaching a slide of the members of the USA TaskForce and as you can see, Dr. Antonio Giordano is not a member.Best regards,A.S. FauciWhite House Coronavirus Task Force -Announced Jan. 29, 2020Chair: VP Mike PenceResponse Coordinator: Deborah Birx■ Jerome Adams■ Alex Azar■ Stephen Biegun■ Robert Bla ir■ Ben Carson■ Ken Cuccinelli■ Kelvin Oroegeme ier■ Anthony Fauci■ Joe GroganAnthony S. Fauci, MDDirector■ Stephen Hahn■ Derek Kan■ Larry Kudlow■ Chris Liddell■ Steven Mnuch ln■ Robert O'Brien■ Matthew Pott inger■ Robert Redfield■ Joel SzabatNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MO 20892-2520Phone: (b) (6)FAX: (301 496-4409E-mail: (b)(6)■ Seema Verma■ Robert WllkleThe information in this e-mail and any of its attachments is confidentia l and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If you havereceived th is e-mail in error please inform the sender and delete it from your mailbox or any otherstorage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statements made that are the sender's own and not expressly made on behalf of theNIAID by one of its representatives.From: Paola Dama (b)(6)>Sent : Sunday, May 3, 2020 10:55 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: White House Coronavirus Task ForceDear Dr. Fauci,I hope to find you well with this ema il.I take the liberty to write you because I have some concern about the misinformationthat can discredit you r task and honors.On many occasions in tv and press, Antonio Giordano , Director of Sbarra Institute in Philadelphia,Keeps saying that he is a member of the USA Task Force.I'm wondering if it's true.I work in UK, but I'm originally from Naples (Italy).I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.Currently I'm a research fellow at University of Sussex.I apologize if you find this email inopportune, the time is unfortunate, I grant you .I don't like t he idea that some people might take advantage of this very unpleasant moment for all the world.So I wish that I made a mistake this time.I'm also wondering if you are willing to release a brief in te rview.I stand with you and USA that I miss very muchI really appreciate your timeThank youKind RegardsCiaoOPaola Dama, Ph DMolecular Oncology and PharmacologyUniversity of SussexSchool of Life SciencesJohn Maynard Smith (JMS) BuildingRoom 4B13Falmer, Brighton BNl 9QG-------- (b)(6) (USA)Email: (b)(6)Skype : -----(b)(6)website www .taskforcepandora .comFrom:Sent :Subject :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 15:44:23 +0000Great photo of Mommy and me in this article(b)( 6)https://ww w.usatoday.com/story/ne ws/nation/2020/05/03/coronavirus-white-house -expert -dranthony-fauci-americans-trust/3042991 001/Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (301) (b)( 6)FAX: (301) 4 6~09E-mail: .__....,.,___ (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please info rm the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: (b)(6)Sent: Sun, 3 May 2020 10:30:04 -0400To: Collins, Francis (NIH/OD) [E)Cc: Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID) [E);Wholley, David (FNIH)[Tl;Tabak, Lawrence (NIH/OD) [El;Denny, Joshua (NIH/OD) [E);Gebo, Kelly (NIH/OD) [Gl;lowy, Douglas(NIH/NCI) [El;Devaney, Stephanie (NIH/OD) [E];Adam, Stacey (FNIH) [T);Santos, Michael (FNIH)[T];Freire, Maria (FNIH) [T)Subject: Re: crazy ideaOn May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E](b) (6) >wro te:Hi John, Cliff, and Tony,(b) (5)As we contemplate ways to stand up a master protocol that could enroll 50 - lOOKpart icipants in a multi-arm COVID-19 trial th is summer, I wondered if (b)(5)See below ---------------------- (b) <5 . What do you think?FrancisFrom: Denny, Joshua (NIH/OD) [El -------- (b)(6)>Sent : Saturday, May 2, 2020 11:22 PM -----~~ To: Collins, Francis (NIH/OD) [El (b)(6)Cc: Tabak, Lawrence (NIH/OD) [El --------- (b)(6)>Subject: Re: crazy ideaHi Francis,This is exciting to hear! Fabulous to hear we may be approaching such a trial.Best,JoshSent from my iPhoneOn May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]------- (b) (6J>wrote:Hi Josh,-(b)(5)(b) (5lFrancisFrom:Sent :To:Cc:Subject:Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 12:31:13 +0000Handley, Gray (NIH/NIAID) [ElConrad, Patricia (NIH/NIA ID) [ElRE: form Jorge Perez IPK CubaThanks.From: Handley, Gray {NIH/NIAID) [E] ________ Cb _H_Sent: Saturday, May 2, 2020 11:04 PMTo: Fauci, Anthony {NIH/NIAID) [El -------:a- (b.H,.=.6..J>Cc: Conrad, Patricia (NIH/NIAID) [El- -------- (b)(6)•> Subject: RE: form Jorge Perez IPK CubaWill send a reply tomorrow morn ing.I have spoken to State Department and have approved response . Someone will listen in.Will copy you.GrayFrom: Fauci, Anthony (NIH/NIAID) [E] -------- (b) (6Jr>Sent: Saturday, May 2, 2020 3:18 PMTo: Handley, Gray {NIH/NIAID) [El -------'='"'""'=Cc: Conrad, Patricia {NIH/NIAID) [El --------- Subject: FW: form Jorge Perez IPK CubaGray:Wou ld you please handle this .Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Perez Avila, Jorge (b)(6)Sent : Friday, May 1, 2020 12:13 PM To: Fauci, Anthony (NIH/NIAID) [E] -_-_-_-_- -~~ CbC>6)>Subject: form Jorge Perez IPK CubaDear Dr. FauciHello from Cuba.Have been a long time we haven't been in touch.Now the whole world is facing a new epidemic and in Cuba we are working in order to controling. Wewill like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference inorder to exchange ideas to have a better understanding to control the epidemic. This conference will beheld from Cuba next tuerday 05/05/2020 at 4:30pm Cuban time. In douse I am sending the topics. Wewill like to have you and Dr. Handley in th is activity if it is possible to attend this conference. If you are inagreement we will like to know by answering this email and them we will you any other detail.If you have any other person to contact in order to participate will be helpful! for us.Waiting for your answer.Dr. Jorge PerezIPKCubaPreliminary programObjectives:Updating COVID-19 situation at global, regional and mainly in Cuba and USATo sharing data of how our two countries are facing this emergency including research studies , etcTopics for the discussion:• The main strategies that both countries are developing to face COVID-19 .• Diagnostic strategy• Clinical management in adults and children• Innovative Cuban biotechnology products incorporated into the treatment models used in thedifferent stages of treatment• Some other research studies• DiscussionEvents and courses at the following address :http://instituciones.sld.cu/ipk/From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [ElSat, 2 May 2020 20:17 :31 +0000Cassetti, Cristina (NIH/NIAID) [ElRE:ThanksAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Cassetti, Cristina (NIH/NIAID) [E] --------- Sent: Saturday, May 2, 2020 4:10 PM --------= ~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)> ~======:=:!~= Cc: Erbelding, Emily (NIH/NIAID) [E]- --------- (b)(6)>; Conrad, Patr icia (NIH/N IAID) [El (b)(6)Subject: RE:Hi,I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him todiscuss th is propos al.I will let you know t he outcome.Kind regards,CristinaFrom: Fauci, Anthony (NIH/NIAID) [ElSe nt: Saturday, May 2, 2020 3:39 PM(b)(6))-------~~ To: Cassetti, Cristina {NIH/NIAID) [E] (b)(6)> ';========~ ~ Cc: Erbelding, Emily {NIH/NIAID) [El CbH6>C1o;n rad, Patricia (NIH/N IAID) [E] __________ ,(b)(6)Subj ect: RE:Import ance: HighCristina:It would be a good idea for you to show this to a couple of other NIAID peoplefor their opinion, and then out of courtesy to get back to Dr. Bolognesi one wayor another.Thanks,TonyAnthony S. Fauci, MDDirec torNational Institute of Alle rgy and Infectious DiseasesBuild ing 31, Room 7A -0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confiden t ial and may contain sens itiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Inst itute of Allergy and Infectious Diseases (NIA ID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its represen tatives.From: Cassetti, Cristina (NIH/NIAID) (E]Sent: Thursday , April 30, 2020 11:36 PMTo: Fauci, Anthony (NIH/NIAID) [E]------ (=b)""('=6)>(b)( >Cc: Erbelding, Emily (NIH/NIAID) [E) ---------(b)(6)> Subject: RE:Dear Dr. Fauci,I reviewed this proposal (b) (5)(b) (5). (b) (4)(b) (5), (b) (4l------------------------------- (b)(5) informative to discuss the project directly with them. Wou ld you like for me to put together a small group at NIAID(with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?Kind regards,CristinaFrom: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6) Sent : Thursday, April 30, 2020 7:58 PM --------=-=-= To: Cassetti, Cristina (NIH/NIAID) [E] ..!=======(~b)(6~) Cc: Erbelding, Emily (NIH/NIAID) [E] (b)(6)>Subject: FW:Importanc e: HighCristina :Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/ AIDSinvestigators from a few years back . He is a serious scientist. Let me know what you think.Thanks,TonyFrom : Eisinger, Robert (NIH/NIAID) [E] (b) (6)> On Behalf Of Fauci, Anthony(NIH/NIAID) [E]Sent : Monday, April 27, 2020 6:57 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Dani Bolognesi, Ph.D.- --------- (b)(6) Sent : Monday, April 27, 2020 6:09 PM ------~~ To: Fauci, Anthony (NIH/ NIAID) [E] _____ C_)b(6J>; Barasch, Kimberly (NIH/NIAID) [C](b)(6)Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together with you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4). (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opport unity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D ." ----------- (b)(6)Date: Monday, April 27, 2020 at 2:53 PM To : "Matthias Gromeier, M.D." ---------------------~- - (b)( > Subject : Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows:(b) (4). (b) (5)(b) (4), (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you. As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best,DaniBest,DaniSent from Dani BolognesiThe information in this electron ic mail is sensitive, pro tected inform ation int ended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmed iate ly by return electr onic mail, and to delete it without further reading or retention . The information is not to beforwarded to or shared un less in compliance with Duke Health policies on confidentiality and/or with the approva l of thesender.From:Sent :To:Fauci, Anthony (NIH/NIAID) [ElSat, 2 May 2020 19:08:58 +0000Lerner, Andrea (NIH/NIAID) [ElSubject:viral loadFW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2Please take a look at this and respond if appropriate.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: ldonae Lovetrue (b)(6)>Sent: Friday, May 1, 2020 2:25 PM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Beigel, John (NIH) [E] CbH ; Booth, Mason (NIH/NIAID) [C]--------- (b)(6) Kim, Sonnie (NIH/NIAID) [E] (b)(6) Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2v iral loadDear Dr . Fauc i,I'd like to share with you that the recent clinical trial results on remdesivir have validated ourprediction of the remdesivir-specific post -treatment viral rebound in human COVID -19 patients.More details can be found in our off icial announcement https ://b it. ly/RRemdesivir.This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (4)(b)(4)We appreciate and respect all the efforts your have made towards the COVID-19 pandemic.Best regards,ldonaeldonae Lovetrue I CEO, Demiurge Technologies AG, Switzerlandwww.demiurge. technologyThis email and any attachments thereto may contain private, confidential. and privileged material for the sole use of theintended recipient. Any reV1ew, copying, or distribution of this email (or any attachments thereto) by others is strictly(b) (4)prohibited. If you are not the intended recipient, please contact the sender immediately and pe, manently delete the original andany copies of this email and any attachments thereto. This email is intended for information purposes only and is providedwithout any warranty of any kind, either expres1ed or implied. While some mformat1on used on this document may have beenobtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neitherguarantees 1t5 ac..cur"cy 01 completene55 nor accepts liability for any direct or comequential lo5se5 arning from its use.ThankyouFrom:Sent:To:Subject:Ninio:Fauci, Anthony (NIH/NIAID) [E)Sat, 2 May 2020 19:00 :06 +0000Fetalvo, Ninio J. EOP/OVPRE: Back to CMSThanks for all your good work in the White House . Stay safe and well.Best regards,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (301) 496-4409E-mail : Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Fetalvo, Ninio J. EOP/OVP ----------- (b)( Sent: Friday, May 1, 2020 3:12 PMTo: (b)(6); Fetalvo, Ninio (CMS/OC} ----------- (b)(6)Subject: Back to CMSAll,Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to cont inuesupporting the Trump Adm inistration's response to the coronavirus . It has been an incredible honorserving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you . Ilook forward to our ongoing work together .Best,NinioNinio J.H. FetalvoPersonal: ------ (~b)-(6~) I Cb()6 )CMS: _______ C_~bC6)I __ C~b_C_6 )From: Fauci, Anthony (NIH/NIAID) [ElSent: Sat, 2 May 2020 18:27 :23 +0000To : Johnson, Martin S. (NIH/NIAID) [E];Auchincloss . Hugh (NIH/ NIAID) [E];NIAIDOCGR Leg;McGowan, John J. (NIH/NIAID) [E];Erbelding, Emily (NIH/NIA ID) {E];tane-, Cliff (NIH/N IAID)[E];Rotrosen, Daniel (NIH/N IAID) [E];Crum, Wayne (NIH/NIAID) [El ;Harper, Jill (NIH/NIAID) [ElCc: Eisinger, Robert (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia(NIH/NIAID) [El;Mar ston, Hilary (NI H/ NIAID) [El;Lerner, Andrea (NIH/N IAID) [E];Doepel, Laurie(NIH/NIAID) [El;Gilles, Sharon (NIH/NIAID ) [E];Routh, Jennifer (NIH/N IAID) [E];Stover, Kathy (NIH/NIAID)[E];Law, Kim (NIH/NIAID) [E];Lee, Kun-Lin (NIH/NIAID) [E];Bushar, Nicholas (NIH/NIAID) [E];Schneider,Johanna (NIH/NIAID) [ElSubject: RE: FY 2020 - COVID-19 - Actua l and Forecasted Spending - Weekly ReportEnding 4/24/ 20Thanks, Mart in.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail : (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:J ohnson, Martin S. (NIH/NIAID) [E] ________ C>bC_6 )Sent: Friday, May 1, 2020 7:40 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El --------- (b)( ; Auchincloss , Hugh (NIH/NIAID) [El ":'--.-~""."""'.~===(b=)(-6.)>.;.; _N-IA_I,D,, O:-C=G\R L eg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (N_.IH:./..N..IA_I.D..). :[_El: ~==:e=,:;-----~--- (b)( >; Erbelding, Emily (NIH/NIAID} [El--:--"""".'"":"""'.":== (b=)=( 6=)-.>..;_:L_an .e.,._:c_1i"f f"~( =NIH / NIA ID) [El (b)( ·; Rotrosen, Daniel(NIH/NIAID) [El (b)( >; Crum, Wayne (NIH/NIAID) [El <wcrum@niaid .nih .gov>;Harper, Jill (NIH/NIAID) [El (b)( >Cc: Eisinger, Robert {NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6) >; Conrad, Patricia (NIH/NIAID) [El (b)(6); Marston, Hilary(NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/N IAID) IE] Cb)(Doepel, Laurie (NIH/NIAID) [El CbH6)>; Gilles, Sharon (NIH/N IAID) [ElCb)( >; Routh, Jennifer (NIH/NIAID ) [El CbH6)>; Stover, Kathy(NIH/NIAID) [El (b)(6}; Law, Kim (NIH/NIAID) [El (b)(6) >; Lee, Kun-Lin ======e:="':;----' (NIH/NIAID) [El (b)(6)>; Bushar, Nicholas {NIH/NIAID) [El (b)(6)v>;Schneider, Johanna (NIH/NIAID) [E] (b)(Subject: RE: FY 2020 - COVI0-19 -Actual and Forecasted Spending - Weekly Report Ending 4/24/20Tony,YTD spending is $110.8M, increasing $24.lM from last week.Spending driven by implementation of3 epidemiological studies, ramp up of resources necessary forvaccine candidate testing and vaccine candidate development.MartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, April 24, 2020 7:11 PM --------=-:~ To: Fauci, Anthony (NIH/NIAID) [El (b)( >; Auch incloss, Hugh (NIH/NIAID) [El--:-:-:--.:-:-:-:-:-::-:-(-b):(-6:)>:;" .N:.I:A:I:D:: O:~=C =G=RL =eg-. <;.N_IA--ID. OCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El--.--~~===:.:....._.(.b:)(.6.)_; _L.a;n_e_, C_l.if.f; ,(N IH/NIAID) [E] (b)( >; Rotrosen, Daniel(NIH/NIAID) [E] (bH6l>; Crum, Wayne (NIH/NIAID) [E] (b)(6);Harper, Jill (NIH/NIAID) [E] (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6); Marston,Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [El------~~==:!....:(.b,).( 6)>; _D oe_p;e_l,. .L.:a.u.r.i.e. ~(N IH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)> ;Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicho las (NIH/NIAID) [El---------- (b)(6J> ; Schneider, Johanna (NIH/NIAID) [E) (bH ,> Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20Tony,YTD spending is $86.7M, an increase of $8.3M from last week.Spending driven by foundat ional research including the characterizat ion of factors associated withsevere disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins . Small awards tosupport vaccine and therapeutic discovery.MartinFrom : Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, April 17, 2020 6:15 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)( ; Auch incloss, Hugh (NIH/NIAID) [E]"":"--.----:-:--.:.::::::=(b=)(6=); =N:I;A._ID- -O~-C, GRL eg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. {NIH/NIAID) (El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El-------- (b)(6)> ; Lane, Cliff {NIH/NIAID) [E] (b)(6); Rotrosen, Daniel(NIH/NIAID) [El (bH6l>; Crum, Wayne (NIH/NIAID) [El (b)(6)>;Harper, Jill (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6); Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)>; Marston,Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [El(b)(6); Doepel, Laurie (NIH/NIAID) [E] (b)(6); Gilles, Sharon ":"--.--.-:-.:-::====:...-_;_~~(NIH/NIAID) [E] (b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)Stover, Kathy (NIH/NIAID) [E] (b)(6); Law, Kim (NIH/NIAID) [E] (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicholas (NIH/NIAID) [E]---------- (b)(6)>; Schneider, Johanna (NIH/NIAID) [El (b)(6)> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/17 /20Tony,YTD spending is $78.4M, an increase of $10.9M from last week including costs to evaluate the rapeuticsin humans and NHPs, manufacture of a protype virus-like vaccine candidate developed byTaubenberger/Memoli, and spending to accelerate discovery of new therapeutics , vaccines anddiagnostics .Martin(b)(5)From: Johnson, Martin S. (NIH/NIAID) [ElSent : Friday, April 10, 2020 8:22 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)( >; Auchincloss, Hugh (NIH/NIAID) [El...-..- ---:-:-:-:-:;(b:):(6:)>=; =NI=AID= O=CG~R-L e-g~ <N~IA IDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6); Erbelding, Emily (NIH/NIAID) [ElCbH61>); Lane, Cliff (NIH/NIAID) [El Cb)( >; Rotrosen, Daniel":":""'-.-:-:-:----:-:-::--:;::::::="="".!_(NIH/NIAID) [El CbH6); Crum, Wayne (NIH/NIAID) [El CbH6);Harper, Jill (NIH/NIAID) [E) (b)(6)Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6)>; Marston,Hilary (NIH/NIAID) [E] (b)(6)::>; Lerner, Andrea (NIH/NIAID) [El(b)(6)>; Doepel, Laurie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)(6); Routh, Jennifer (NIH/NIAID) [El (b)(6)Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [El----------(b)(6); Schneider, Johanna (NIH/NIAID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 4/10/20Tony,YTD spending is $67 .SM, unchanged* from last week . A summary is attached .I have also attached an updated budget plan reflecting our projected spending by research category byfiscal year. We are updating this weekly as we receive updates from the divisions on the timing ofclinical trials, observat ional studies, natural history studies and research resource needs.We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.Martin• The reason that we have reported no weekly increase is to match our reported spending with thefinancial information that the Department is now extracting from our accounting system. We havealways included spending from our regular appropriat ion, as directed by the Department. Now theguidance from the Dept. has been updated to report only spending from the supplemental COVID-19 appropriations.From : Johnson, Martin S. (NIH/NIAID) (E]Sent: Friday, April 3, 2020 8:54 PMTo: Fauci, Anthony (NIH/NIAID) [E] ,r------- (=b)- c='>; Auchincloss, Hugh (NIH/NIAID) [E](b)(6J>; NIAID 0CGR Leg <NIAIDOCGRLeg@mail.nih.gov >; McGowan, John J.":":'"'."."."'.'"':"."".".""'."".":"":"7:":'--.:====::::....;.---::-,~(NIH/NIAID) [E] (b)( >; Erbelding, Emily (NIH/NIAID) [E]CbH6J;> Lane, Cliff (NIH/NIAID) [E] CbH6J>R; otrosen, Daniel(NIH/NIAID) [E] (b)(6l>; Crum, Wayne (NIH/NIAID) [E] (b)(6)Harper, Jill (NIH/NIAID) [E] (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (NIH/NIAID) [E](b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6J>; Marston,Hilary (NIH/NIAID) [E] CbH6l>; Lerner, Andrea (NIH/NIAID) [El(b)(6)>; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Gilles, Sharon"("N.""".l'".H.""-/"N:.'"."l'"A.""'~I.D"'.)""'[.:""E~'.]===..:....-:..,_ :(:b:.)-,(.=., >; Routh, Jennifer (NIH/NIAID) [E] (b)(6);Stover, Kathy (NIH/NIAID) [E] (b)(6)>; law, Kim (NIH/NIAID) [E] (b)(6);lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicho las (NIH/NIAID) [E]--------- CbH6;J Schneider, Johanna (NIH/NIAID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/3/20Tony,YTD spending is $67.SM, a weekly increase of $45.9M mostly for initial funding for set-up ofclinical tria ls for eva luat i.on ofremdesivir in patients with ear ly disea se stage and a placebocontrolledclinical trial of intravenous hyperimmune immunoglobu lin (IVIG) in patients withCOVID-1.9.I've provided a summary spending plan the team worked on and a table for the $ l .532B that wehave received in supplemental appropriations• $826M NIAID received 3/5/20 - the Coronavirus Preparedness and ResponseSupplemental Appropriation s Act• $706M NIAID received 3/25/20 - the Coronavirus Aid, Relief , and. Economic Security(CARES) ActIn the last document I've also included narrative summarizing activities funded by the $249MOther NIH Institutes received in the CARES ActMartinFrom: Johnson, Martin S. (NIH/NIAID) [E]Sent : Friday, March 27, 2020 7:39 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] CbH6l>A; uch incloss, Hugh (NIH/NIAID) [E]---:---~====:::(b:)!(6.):; N.-IA-ID~ 0~CG R l eg <NIAIDOCGRLeg@mail.nih .gov>; McGowan, John J. (NIH/NIAID) [E] (b)( >; Harper , Jill (NIH/NIAID) [E] (b)(6)>;Crum, Wayne (NIH/NIAID) [E] CbH6l>; Erbelding, Emily (NIH/NIAID) [El(b)(6); Lane, Cliff (NIH/NIAID) [E] (b)( >; Rotrosen, Daniel"(:N"-':l'"H."/-":N.-"' .I"A"'.l"'D":'".:)'"- -[~:E:]-====-_;__...;. ("b'")~'(6l>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [E]--------- (b)(6)· Conrad, Patricia (NIH/N IAID) [E] CbH6l>;M arston,Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [EJ(b)(6) 1 ; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Gilles, Sharon(NIH/NIAID) [E] (b)(6); Routh, Jennifer {NIH/NIAID) [E] CbH6J> ;Stover, Kathy (NIH/NIAID) [El (b)( >; Law, Kim (NIH/NIAID) [El CbH6J> ;Lee, Kun-Lin {NIH/NIAID) [E] CbH6J>B; ushar, Nicholas (NIH/NIAID) [El--------- (b)(6J; Schneider, Johanna (NIH/NIA ID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 3/26/20Tony,YTD spending is $2 1.6M, a weekly increa se of $4.0M for clinica l trial site set-up fortherapeutics, further vaccine development, small animal development, and therapeuticdevelopment (mAhs) and basic research.Most of the $50M-$60M we listed last week we expect to be awarded before March 31. In manycases contractors have begun work without the award so as to not stall work.Early next week I' 11 prov ide a summary spending plan for the addi tional $706M that NIAIDrece ived in the suppl ementa l appropriation signed by the President today.MartinFrom: Johnson, Mart in S. (NIH/NIAID) [ElSent: Friday, March 20, 2020 4:54 PM -----~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6J>; Auchincloss, Hugh (NIH/NIAID) [El":"---:-----:-~=(b=)(6=)>;= NI=AID! .O-C:G.-Rl- e~g <=N IAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper, Jill (NIH/NIAID) [E] (b)(6J>; Crum,Wayne (NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [E]--------- (b)(6)>; Lane, Cliff(NIH/NIAID) [El (b)( > Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El---:-----===(:b!)(6.J:; .C,__on r_ad_, P_a_tric:ia~ (~NIH /NIAID) [El (b)(6J>; Marston, Hilary (NIH/NIAID) [El (b)( >; Lerner, Andrea (NIH/N IAID) (El (b)(6);Doepel, Laurie (NIH/NIAID) [El (b)(6) ; Gilles, Sharon (NIH/NIAID) [El(b)(6J>; Routh, Jennifer (NIH/NIAID) [El CbH >; Stover, Kathy(NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>; Lee, Kun-Lin(NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [E] (b)(6)Schneider, Johanna (NIH/NIAID) [E) CbH6J>Subject: RE: FY 2020 - COVID-19 -Ac tual and Forecasted Spending - Weekly Report Ending 3/19/20Tony ,YTD spending is $ l 7.6M, a weekly increase of $3.SM for clinica l trial site set-up, therapeuticdevelopment (mAbs ) and basic research.We greatly appreciate all your hard work.MartinFrom: Johnson, Martin S. (NIH/NIAID) [E]Sent : Friday, March 13, 2020 6:45 PMTo: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auchincloss, Hugh (NIH/NIAID) [E](b) (5)---:---~-==== (=b)=(6~)>..;._.N:.IAI_D_O~C~GR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.(NIH/NIAID) [E] (b)(6)>; Harper, Jill (NIH/NIAID) [El (b)(6);""."":""::-'."."'"-:-=":--:-:"::.======-..;-~~Crum, Wayne (NIH/N IAID) [El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El(b) (6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)( ; Marston,Hilary (NIH/NIAID) [El (bH6l>; Lerner, Andrea (NIH/NIAID) [E)~~~~~== (=b)=(6::):>.:.=;:_,,o_o_e;p_e_l,:.:L.-a,.=.u,rie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)( >; Routh, Jennifer (NIH/NIAID) [E) (b)(6)> ;Stover, Kathy (NIH/NIAID) [E] (b)(6)>; Law, Kim (NIH/NIAID) [E] (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [E] (b)(6); Bushar, Nicholas (NIH/NIAID) [E]--------- (b)(6)>; Schneider, Johanna (NIH/NIAID) [E) (b)( > Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/12/20Tony,Since we our last report we have increased spending on the COVID-19 response by $1.SM for atotal YID spending of $14.lM.The $ I .SM increase is for the following:$ 1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptableRCT of rerndesivir.$0.4M supported data analysis of rhesus animal model and grant to gain understanding of thehost pathways that regu late viral gene expression and viral subversion of the host immunesystem.$0. lM funded vaccine development at VRC and DIRMartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, March 6, 2020 5:31 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auchincloss, Hugh (NIH/NIAID) [El---:----:-~===(=b)(6:)!>;. .N.I:A.I-D- O~CG~R l eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [E] (b)(6)>; Harper , Jill (NIH/NIAID) [El (b)( >;Crum, Wayne (NIH/NIAID) [El (b)(6)Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6J>; Conrad, Patricia (NIH/N IAID) [E] CbH ; Marston,Hilary (NIH/NIAID) [E] CbH6l>L;e rner, Andrea (NIH/NIAID) [ElCbH6JD;o epel, Laurie (NIH/NIAID) [E] (b)(6) Gilles, Sharon-(:N--::l-:H:-:/"-;N""..I'"A-':.1-"-D::--:)- :[:E':":]-.===::;.___;,~ (,b.).-.(.:6,-.=)>; Routh, Jennifer (NIH/NIAID) [El (b)(6);(b) (5)Stover, Kathy (NIH/NIAID) [El CbH6JL; aw, Kim (NIH/NIAID) [El CbH6J>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/5/20Tony,Since we our last report we have increased spending on the COVID-19 response by $0.2M for atotal YTD spending of $12.6M.The $0.2M increase is for vaccine candidate development at NIAID Intramural Labs includingRML. Costs are mostly for staffing and overhead and include a preclinical immunogen icitystudy designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study willmeasure the immune response to this vaccine in an animal model in anticipat ion of clinical test inhumans.MartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, February 28, 2020 11:57 AM To: Fauci, Anthony (NIH/NIAID) [E] -------------~-~ CbH6>>A;u chincloss, Hugh (NIH/NIAID) [E] ---:---~---::==(=b)(=6)>:;: N!IA..ID.. O..C:G.R-L -e~g <~NI AIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper, Jill (NIH/NIAID) [E] (b)(6);Crum, Wayne (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E (b)(6)>; Marston,Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [E)(b)(6)>; Gilles, Sharon (NIH/NIAID) [E] (b)(6)1>; Routh, Jennifer(b) (5)(NIH/NIAID) [El CbH6>>S;to ver, Kathy (NIH/NIAID) [El CbH6>>L;a w,Kim (NIH/NIAID) [El CbH6>>L;e e, Kun-Lin (NIH/NIAID) [E] (b)(6)Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27 /20Tony,Since we our last report we have increased spending on the COVID- 19 response by $2.3M for atotal YTD spending of $12.4M.A recap of the $2.3 million spent in the last week is as follows:• $1.9M to set-up a Phase I trial (45 subjects) of the VRC/Modema mRNA platformcandidate at Kaiser Pennanente Washington Health Research Institute (One of theVTEUs )• $0.3M that supported University of Hong Kong research ers in the development of a RTPCRtest to detect SARSCo V2 from human samp les. The group has now shared the testsand relevant reage nts with over 30 labs globally to enable diagn osis of COVID- 19.• $0.lM vaccine candida te development at NIAID Intramura l LabsMart inFrom : Johnson, Martin S. (NIH/NIAID) [ElSent : Friday, February 14, 2020 3:56 PMTo: Fauci, Anthony (NIH/NIAID) [E]_ _____ "("b".~.,c=..6)>;A uch incloss, Hugh (NIH/NIAID) [El-----.~~===~.(.b:)(6_)>_; -N-IA~ID OCGRl eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper , Jill (NIH/NIAID) [E] (b)(6)>;Crum, Wayne (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)> ; Marston,Hilary (NIH/NIAID) (E] (b)(6)> ; Lerner, Andrea {NIH/NIAID) (E)-------- (b)(6)>; Gilles, Sharon (NIH/NIAID) [E] (b)(6) Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20Dr. Fauci,Attached is a narrative we are updating weekly for NIAID's COVID-19 response.The accomp anying spreadsheet summar izes the figures and includes a summary of oursupplemental request.We' II provide an update by Thursday of next week.Martin(b)(5)Resource Planning and Mission Integration Branch (RPMIB) - NIAIDNIH Bldg. 31 Room 7A47Tel: (b)(6)From:Sent :To:Fauci, Anthony (NIH/N IAID) [ElSat, 2 May 2020 18:22 :37 +0000Fauci, Anthony (NIH/N IAID) [ElCc: (b)(6)Subject: RE: RE:Zeke:Thanks for your note. CbH6a) nd I would love to get together with you allfor dinner. Let us try to do so within a reasonab ly soon time frame.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Eisinger, Robert (NIH/NIAID) [E] ---------- (b)( > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]Sent: Saturday, May 2, 2020 7:24 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: RE:Email from Zeke Emanue l.Robert W. Eisinger, Ph.D.Special Assistant for Scie ntific ProjectsImmediate Office of the DirectorNat iona l Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone : (b)(6)Email: (b)(From: Emanuel, Ezekiel J -------- (b)( >Sent: Friday, May 1, 2020 8:04 PMTo: Fauci, Anthony (NIH/NIAID) [E] ------ ~=Cc: ------------------- Subject: Re: RE:TonyYou are national--internationa l --treasure . And we are depending upon your sanity and smarts.We can have you and CbH6)over for dinner on the porch and order in fromsomething. Anytime you are ready.Ezekiel .J. Emanuel, M.D., Ph.D.Vice Provost of Global Initi ativesChair, Departmen t of Medical Ethics and Hea lth PolicyLevy University ProfessorCo-Director , Heal thcare Transformation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone: Cb(>6 )(b)(6) --------From: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Friday, May 1, 2020 6:55 PMTo: Emanuel , Ezekiel JCc:(b)(6)(b)(6) ------------------- Subject: RE: RE:Zeke:Cb()6 ) orThanks for the note. Indeed, we do agree.- I look forweard tochatting with you some time soon.Best,TonyFrom: Emanuel, Ezekiel J -------- (bH >Sent: Thursday, April 30, 2020 6:37 PM To : Fauci, Anthony (NIH/NIAID) [E] -------------- -(=b)(=6)>, Subject: Re: RE:(b)(6)Sorry for misreading what you said--1 think maybe I overin tepreted- -lots of f inance peoplecalled and seemed like I was a downer compared to you. But I think we agree.Are you and --(-b)(6) doing okay?Ezekie l J. Emanuel, M.D., Ph.D.Vice Provost of Global Initi ativesChair, Department of Medical Ethics and Health PolicyLevy University ProfessorCo-Director , Heal thcare Transform ation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone: (b)(6) -----------(b)(6) --------From: Fauci, Anthony (NIH/NIAID) [E] _____ (b)_C_6>)Sent: Thursday, April 30, 2020 5:33 PMTo: Emanuel, Ezekiel J (b) ~ >Subject: RE:Zeke:I did not "strongly " endorse it. I specifically said tha t it was not a knockout drugand was only a baby step in the direction of develop ing more and better drugs. Isaid that it was important because it proved in a well-powered, randomized ,placebo-contro lled clinical tria l tha t one can suppress the virus enough to see aclinical effect, as modest as the effect was. I do not think I forced anything.Happy to chat with you about it.Best,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301) 496-4409E-mail : -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Emanuel, Ezekiel J -------- (b)(6)>Sent: Thursday, Apr il 30, 2020 2:12 PM --------=-=~ To: Fauci, Anthony (NIH/NIAID) [E]_ _____ C>b<_>Subject:Tony ,I hope you and (b)(6) are doing well. You are doing an amazing job under difficultcircumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!I am a bit perplexed by your seeming strong endorsement of remdesivir . Was it just a bitforced?My reading was the data were weak and in normal times for norma l disease it is not enough toto approve. And very unlikely to really impact COVID-19 disease pattern --regardless of supplyissues.Stay safeEzek iel J. Emanuel , M.D., Ph.D .Vice Provost of Global InitiativesChair, Departm ent of Medical Ethics and Health Policy -------- Cb)< )Levy Unive rsity Profe ssorCo-Director, Healthcare Transformat ion InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone : (b)(6)From :Sent :To :Subje ct:Thanks, Natalie !Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Sat, 2 May 2020 18:00 :31 +0000Hurst , Natalie R. EOP/OVPRE: Update - Whi te House Coronavir us Task Force Meet ingNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb) (6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .(bX5)-PCEFrom:Sent:To:Cc:Subject:Faud,Anthony (NIH/N IAID) [E)Sat, 2 May 2020 17:57 :11 +0000Conrad, Patricia (NIH/NIAID) [E)B~rasch, Kir,1bt?rly (NIH/NIAID) [C]FW: Greetings from IndiaLet us discuss.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Prof. Chirantan Chatterjee (b)(6)>Sent: Saturday, May 2, 2020 11:47 AM -------::-::-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)> ----====!---~~= Cc: Deepak Bhatt Manager - Communications (b)(6) _______.._. _Subject: Greetings from IndiaDear Dr Fauci,My greetings from India. I am a health econom ist and management professor at the Indian Institute ofManagement, Ahmedabad, India's premier management school. Also, i am a avid fan of your work evenfrom pre-covid19 days.I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. Thescience and policy ecosystem in India i think would immensely benefit if you can offer your thoughts onwhat should be India's 12-month strategy going forward for COVID-19.We have done some recent podcasts relate dly and they are listed her(https://m .soundcloud.com/healthcastbycmhs/l.If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the emailwill arrange the zoom logistics and make it as seamless as possible for you.We will also go per your t ime zone conveniences and do this over webex/hangout/skype or phone call ifthat helps.It would be a delight Dr. Fauci if you can j oin us in the conversation, loo king forward to hearing fromyou. Our respectful namaste g from India for all the brave work you are doing.My best, Chirant anCh Iran tan Chatterjee (PhD, Carnegie Mellon ) 11 Associate Professor (Economics & Business Polley) & ICICI Bank Chair In Strategic Managemen t 11Chairperson, Center for Managemen t of Health Services at IIMA 11 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller Nati onal Fellow,Hoover Inst itu tion, Stanford University 11 Office Address Wing lS F, Indian Institu te of Management 11 Ahmedabad, 380 015 Gujarat, India ! I Skvpe:--- ~"-"'~ 11 Email: ____ _. =--= ____ _,_!?}-® I I Hoover Inst it ution Website I IIMA Official WebsiteWhat is laid down, ordered, factual is never enough to erobroce the whole truth: life always spills over the rim of every cup. - Boris Pasternak in Bridges toInfi nity: The Human Side of Mathematics (1983) by Michael GuillenFrom: Fauci, Anthony (NIH/NIAID) [E)Sent : Sat, 2 May 2020 12:08 :00 +0000To: Conrad, Patricia (NIH/NIAID) [E)Cc: Billet, Courtney (NIH/NIA ID) [E);Haskins, Melinda (NIH/NIA ID) [E]; Barasch,Kimberly (NIH/NIAID) [CJSubject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virt ualTown Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at7:00 PM CDTAttachments : Dr. Anthony Fauci - Town Hall lnvite.pdfPlease take a look at this . We obviously will have to get clearance through HHS and WhiteHouse Leg. This is for Th ursd.iy .ind so we would need to submit soon.From: Coney, Lillie ------------ (b)(6)>Sent: Friday, May 1, 2020 11:23 PM To: Fauci, Anthony .(,N;I,H_/N__IA ;I_D_)_ [;E,] ,-.-.-;;-_--:---=-=--=-=--=~==, ;:~;-:-----:-(:b):( -::---.:===-===-==---- Cc: Rushing, Glenn ----------- (b)( ; Coney, Lillie ---------- (b)(6) Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meetinghosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDTMay 1, 2020Dr. Anthony Fauci, M.D.Director of the National Institute of Allergy and Infectious DiseasesDepartment of Health and Human Services5601 Fishers LaneBethesda, MD 20892-9806Dear Dr. Fauci:Thank you for your tremendous steadfast leadership during this pandemic andhealth crisis. Our nation has not faced a crisis of this magnitude since the 1918Spanish Flu, but we will travel this journey together and defeat this virus . In the end, thenation will become stronger and more prepared.Your participation is requested in a Virtual Town Hall meeting hosted byABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PMCDT. This town hall meeting will focus on testing and guidelines for re-openingour nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houstonis the fourth largest city in the country and your knowledge and expertise would be mosthelpful in our fight to keep our infection and fatality rates low for this entire region andthe State of Texas .My office has been pushing testing and setting up testing sites since the firstnotification of the coronavirus . We currently have seven active testing sites andexpanding each week to get to the mass testing necessary to flatten the infection rate.Thank you for your consideration of this request and I look forward to participatingwith you in the Virtual Town Hall meeting. Again, thank you for your leadership. PleaseRSVP or if you have questions regarding this request with Glenn Rushing, my Chief ofStaff at .__ ____, CbH6) and Lillie Coney, my ChiefPolicy Advisor a CbH6)Regards,Lillie ConeyPolicy DirectorVery truly yours,JSheila Jackson LeeMember of CongressCongre sswoman Sheila J ackson Lee (TX-18)2079 Rayburn HOBWashingto n , DC 205 15(b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Sat, 2 May 2020 12:01 :04 +0000(b)(6)FW: RE:Let us try to do this next weekend.From: Eisinger, Robert (NIH/NIAID) [E]..._ ________ ~90n Behalf Of Fauci, Anthony(NIH/NIAID) [E]Sen t: Saturday, May 2, 2020 7:24 AMTo: Fauci, Anthony {NIH/NIAID) [E]------ -(-b=)(-=6)Subject: FW: RE:Email from Zeke Emanuel.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone : (b)(6)Email: (b)(From: Emanuel, Ezekiel J -------- (b) ( >Sen t: Friday, May 1, 2020 8:04 PM ------~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: ------------------- (b)( 6)> Subject: Re: RE:TonyYou are national--internationa l --treasure. And we are depending upon your sanity and sma rts.We can have you and CbH6)ovefro r dinner on the porch and order in fromsometh ing. Anytime you are ready.Ezekiel J. Emanuel , M.D., Ph.D .(b)(6) orVice Provost of Global InitiativesChair, Departm ent of Medical Ethics and Hea lth Policy ______ C_>b<'6j)Levy University ProfessorCo-Dir ector, Hea lthcare Transformation Institut ePerelman School of Medicine and The Wharton SchoolUniver sity of Penn sylvaniaPhone: (b)(6)From: Fauci, Anthony (NIH/NIAID) [E] (b) (6lv> _______ ,....Sent: Friday, May 1, 2020 6:55 PMTo: Emanuel , Ezekiel J (b)(6)>Cc:- ----------------- (b) ( > Subject : RE: RE:Zeke:Thanks for the note . Indeed, we do agree.- I look forweard tochatting with you some time soon.Best,TonyFrom: Emanuel, Ezekiel J -------- (b)( >Sent: Thursday, April 30, 2020 6:37 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: Re: RE:(b)(6)Sorry for misreading what you said--1 think maybe I overin t epreted-- lots of finance peoplecalled and seemed like I was a downer compared to you. But I think we agree.Are you and ---C-bH6Jdoingo kay?Ezekiel J. Emanuel, M.D., Ph.D.Vice Provost of Global InitiativesChair, Depa1tment of Medical Ethics and Health Policy ______ C_>b<)Levy University ProfessorCo-Director , Healthcar e Transform ation Institut ePerelman School of Medicine and The Wharto n Schoo lUniver sity of PennsylvaniaPhon e: (b)(6) -----------From: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Thursday, April 30, 2020 5:33 PMTo: Emanuel, Ezekiel J (b) ( >Subject: RE:Zeke:I did not "strongly" endorse it. I specifically said tha t it was not a knockout drugand was only a baby step in the direction of develop ing more and bette r drugs. Isaid that it was important because it proved in a well-powered, randomized ,placebo-controlled clinical tria l tha t one can suppress the virus enough to see aclinical effect, as modest as the effect was. I do not think I forced anything.Happy to chat with you about it.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Emanuel, Ezekiel J --------- (b)(6) Sent: Thursday, April 30, 2020 2:12 PM ------- == To: Fauci, Anthony (NIH/NIAID) [E] --------- (b)( 6) Subject:Tony,I hope you and ---(b)-(6) are doing well. You are doing an amazing job under difficult circumstances. And ju st know we prefer the "real" Tony to the Brad Pitt version!!!I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bitforced?My reading was the data were weak and in normal times for normal disease it is not enough toto approve. And very unlikely to really impact COVID-19 disease pattern--rega rdless of supplyissues.Stay safeEzekiel J. Emanu el, M.D., Ph.D.Vice Provost of Global InitiativesChair , Departm ent of Medical Ethics and Health Policy -------- Cb)< )Levy University ProfessorCo-Director, Healthcare Transformation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of Penn sylv aniaPhone:- ---------....C1b(>6 )From: Fauci, Anthony (NIH/NIAID) [ElSent : Sat, 2 May 2020 02:04:00 +0000To: Selgrade, Sara (NIH/NIAID) [ElCc: NIAID OCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/N IAID)[E];Conrad, Patricia (NIH/NIAID) [E]Subject:HearingAttachments :changes.docxRE: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELP2020 .05.12 NIAID Senate HELP testimony COVID 19 - with Fauci trackedI am attaching the document with minor tracked edits. Nice jo b! Thanks.From: Selgrade, Sara (NIH/NIA ID) [E) (b)(6)>Sent: Thursday, April 30, 2020 5:24 PMTo: Fauci, Anthony (NIH/ NIAID) [E] <f -----~ Cb-H=6J>Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [ElCbH6J>F; olkers, Greg (NIH/ NIAID) [E (b)( >; Conrad, Patricia(NIH/ NIAID) [E] (b)(6)Subject: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELP HearingDr. Fauci:In preparat ion for the upcoming May l ih COVID-19 hearing of the Senate Health,Educa tion , Labor, and Pens ions Committee (Chair: Sen. Lamar Alexander, R-TN),we have drafted the attached NIAID te stimon y, bu ilding on your prior te stimonyon COVID-19. Dr s. Giroi r, Hahn, and Redfield also have been invited to thehea ring.We expect that your te stimon y will be included as an insert to an HHS-widetestimony. At the request of NCH OD, we have incorporated into the draft COVID-19 activ ities across NIH .The testimon y has been reviewed by the Divi sions and Dr s. Lane , Harpe r,Marston, and Lerner , as well as Courtney Billet , Greg Folkers, Martin Johnson ,and Laurie Doepel.NIH OLPA has asked to receive your testimony for clearance by tomorrow, ifpossi ble .Thank you for your help.SaraSara Selgrade, Ph.D.Sect ion Chief for Legislative ActivitiesLegislative Affairs and Con-espondence Management BranchOffice of Communications and Government RelationsNIAJD/NIH/DHHSBldg. 31,Room 7Al7, MSC 2520Bethesda, MD 20892-2520Phone: (b) (6)(b)(6)Disclaimer:The i11for111atio11 in this e -111ail and a.11y of its altac/1111c11ts is co ,!fide:ntial and ,nay c:ontai n sensitive i11fon11,1tio11. it ,-,·l,ou/d not beused by anyone who is not the original intended recipienl. lf you have rr?ceived this e-mail i11 error please inform the sender anddelete it from y our mailbox or any other storaw; devices. National Institute ofA!lerf!)' and Infectious Dise,ases shall not acceptliabili(v,(ora ny slatements made !hat are sender's own and not e,xpresslym ade 011b ehalf of ,he NJAID by one o/ilsrepresentatives ,From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [ElFri, 1 May 2020 15:28:23 +0000Routh, Jennifer (NIH/NIAID) [ElRE: cl ipsThanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Routh, Jennifer (NIH/ NIAID) [E] (b)( >Se nt : Friday, May 1, 2020 8:56 AM --------, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Cc: Billet, Courtn ey (NIH/NIA ID) [E] (b)(6); Conrad, Patricia (NIH/NIAID) [E]---------(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( > Subject: RE: clipsDr. Fauci-I have requested the full clips from our clipping service . I found the following on line in the meantime:Today Show:https://www .today .com/video/ d r-a ntho ny-fa uci-rem d esivir-is-a-very -i m port a nt -fi rst-step-in-fighti ngcoronavirus-82800 197863CNN Town Hall (clip discussing federal "reopening" guidel ines):https://twitter .com/CNN/status/1256023483638669313CNN Town Hall (clip discussing vaccines):htt ps:// twitter .com/CNN/ status / 1256044817093558272Thanks,JenJennifer Routh [E]News and Science Writing BranchOffice of Commu nications and Government RelationsNational Institute of Allergy and Infectious Diseases (NIAID)NIH/HHS31 Center Drive Room 7 A 17CBethesda, MD 20892Direct: (b) (6)(b)(6)Disclaimer : The information in this e-mail and any of its attachments is confidential and may contain sensit ive information. It should not beused by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for anystatements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.From: Fauci, Anthony (NIH/NIAID) [E] --------- (b)(6)Sent: Friday, May 1, 2020 7:44 AM To: Routh, Jennifer (NIH/NIAID) [E]-- --------------=---(-b)(: ->= Subject: clipsJen:Can we please make sure that I get the lips from yesterday from NBC TodayShow and CNN Town Hall with Sanjay and Anderson.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation_ It should not be used by anyone who is not the orig inal intended recipient_ If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices _ The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives_From:Sent :To:Subject:Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:26:55 +0000Fauci, Anthony (NIH/NIAID) [E)FW: (b)( 4)Another email from Andre Kalil.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone (b)(6)Email: (b)(From: Kalil, Andre C (b)(6)>Sent : Thursday, April 30, 2020 8:12 PMTo: Beigel, John (NIH) [El--:-:-::-:--:.=======.:.'"""'""-:-= (b)( ;Davey, Richard (NIH/NIAID) [El (b)( ; Lane, Cliff (NIH/NIAID) [El(b)(6)>; Proschan, Michael (NIH/NIAID) [E] (b)(6l>; Marston, Hilary(NIH/NIAID) [E] (b)( ·>; Fauci, Anthony (NIH/N IAID) [El (bH >Subject: RE: (b) (4)(b) (4)Thanks,AndreAndre Kalil, MD, MPH, FACP, FIDSA, FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transplant ID ProgramAssociate Editor. CMI. Official Journal of ESCMIDEditorial Board. CCM. Official Journal of SCCMl' UNMC.-,- t(JltUt.•University of Nebraska Medical Center985400 Nebraska Medical Center. Omaha. NE 68198-5400(b)(6) I fax 402.559-5581(b)(6)UNMC I Facebook I Twitter I You Tube I~"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditional probabilit ies. Giving due weight to the prior probabilities ... "Robert Ludlum - The Amb ler WarningFrom : Beige!, John (NIH) (E] -------- (b)( >Sent : Thursday, April 30, 2020 5:25 AM ------ --,;-,,= To: Dodd, Lori {NIH/NIAID) [E] (b)(6)>; Kalil, Andre C ~====~(b~)(6) >; Davey, Richard (NIH/NIAID) [E] (b)(6) ; Lane, Cliff (NIH/NIAID) [E] (b)( >; Proschan,Michael (NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [E](b)(6); Fauci, Anthony (NIH/NIA ID) [E] (b)( >Subje ct: Re: ------------- (b)( 4Non-UNMC email(b) (4)John Beige), M.D.Associate Direc tor for Clinical ResearchDivision of Microbiology and Infectious Disea~esNational Institute of Allergy and Infectious Diseases (NIAID)From: Lori Dodd CbH6)>Date : Thursday , Apr il 30, 2020 at 6:05 AMTo: John Seigel (b)(6)>, Andre Kalil (b)(6)>, Richard Davey(b)( >, Cliff Lane (b)(6), Michael Proschan =========~(b~)(6) >, Hilary Mars ton ---------- (b)(6)> , "Fauci, Anthony (NIH/ N IAI D) ,;I.E.-=]'-.'. ::====== (b)=C:6:) --=-:-.,.,,,,Subject: RE:- ------------- (b)(4)Andreilike what you wrote, and partic ularly like the first two sentences.From: Beigel, John (NIH) (E] (b)( >Sent: Thursday, April 30, 2020 5:53 AMTo: Kalil, Andre C (b)(6)> ; Davey, Richard {NIH/NIAID) [E] (b)(6)>; Lane,Cliff {NIH/NIAID) [El (b)( >; Dodd, Lori (NIH/NIAID) [El (b)(6)> ;Proschan, Michael (NIH/NIAID) [El (b)(6); Marston, Hilary (NIH/NIAID) [El(b)(6)>; Fauci, Anthony (NIH/NIA ID) [El (b)( >Subject: Re: (b) (4Andr e,We too are open for further editsJohnJohn Beige), M.D.Associate Director for Clinical ResearchDiv ision of Microbiology and Infectious DiseasesNational Institute of Allergy and Infectious Diseases (NIAID)Phone:email::=.=====:: ~=(b) (4)From: Andre Kalil (b)(6)>Date : Thu rsday, April 30, 2020 at 3:19 AMTo: John Seigel CbH6J>R, ichard Davey CbH >, Cliff Lane(b)(6), Lori Dodd CbH6)>M, ichael Proschan ~=======~~ (b)( >, Hilary Marston (b)(6)>, "Fauci, Anthony "':'---:--:-:--:--:-::.====:::;_;,--=.. ;...,; (NIH/NIA ID) [E)" CbH6)>Subject: -------------- (b) (4)Please let me know your t hough ts and suggestions.AndreAndre Kalil, MD, MPH, FACP, FIDSA, FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transp lant ID ProgramAssociate Edito r, CMI , Official Journal of ESCMIDEditorial Board, CCM, Official Journal of SCCM~ UNMc·~ f<)\U:,_.University of Nebraska Medical Center985400 Nebraska Medical Center , Omaha , NE 68198-5400___ (b_) (_6,) I fax 402.559-5581(b) (4)(b)(6)UNMC I Facebook [facebook.com) I Twitter (twitter.com) I You Tube [youtube.com) I Flickr [flickr.coml"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditiona l probabilit ies. Giving due weight to the prior probabil ities ... "Robert Ludlum - The Ambler WarningThe information in this e-mail may be privileged and confidential, intended only for the use of theaddressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you havereceived this e-mail by mistake, please delete it and immediately contact the se nder .The information in this e-mail may be privileged and confidential, intended only for the use of theaddressee(s) above. Any unauthorized use or disclosure of this informat ion is prohibit ed. If you havereceived this e-mail by mistake, please delete it and immediately contact the sender.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:25:50 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From : Dani Bolognesi, Ph.D.- ---------(b)(6) Se nt: Thursday, April 30, 2020 8:13 PM -------=-:-:= To: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6)> Subject: RE:TX Tony. Nice touch reminding fo lks of how AZT propelled the pharmas and great to see things movingwith this beast!Sei un campione !DaniFrom: Fauci, Anthony (NIH/NIAID) [E]Sent : Thursday, April 30, 2020 7:58 PM(b) ( >------~~ To: Cassetti, Cristina (NIH/NIAID) [E:] ,.=!:====== (=b)~(6;)',>.=Cc: Erbelding, Emily (NIH/NIAID) [E).__ _______ Cb _H_6JSubject: FW:Cristina:Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/ AIDSinvest igators from a few years back . He is a ser ious scientist. Let me know what you th ink.Thanks,TonyFrom: Eisinger, Robert (NIH/NIAID) [E) ----------- (b) (6J> On Behalf Of Fauci, Anthony (NIH/NIAID) [E]Sent : Monday, April 27, 2020 6:57 PMTo: Fauci, Anthony (NIH/NIAID) [E].__ _____ (b_H"""v"'>"'"Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7 A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Dani Bolognesi, Ph.D. ---------- (b)(6)>Sent : Monday, April 27, 2020 6:09 PM ------~= To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)>; Barasch, Kimberly (NIH/NIAID) [C] (b)(6)Subject: FW:Kimberly: Please see that t his reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getti ng together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows :(b) (4), (b) (5)(b) (4). (b) (5)We are prepared to discuss this with you and your team at any time that is convenien t for you . As youmay know, we are locked down here in the Research Triangle unt il May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opport unity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D."Date: Monday, April 27, 2020 at 2:53 PM(b)(6 )>To: "Matthias Gromeier, M.D." ------------------------=- -:(b-)(6=) , Subject : Please review th is draft email to Tony --TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows :(b) (4). (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you . As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best,DaniBest,DaniSent from Dani BolognesiThe information in this electronic mail is sensiti •,e, protec ted information intended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmed iately by return electronic mail, and to delete it without further reading or retent ion . The informat ion is not to beforwarded to or shared unless in compliance with Duke Health policies on confidentiality and/o r with the approva l of thesender.From:Sent :To:Subject:Importance:Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:10:09 +0000Fauci, Anthony (NIH/NIAID) [E)FW: ACTT pub licationHighAnother email from Andre Kalil.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email (b)(From: Kalil, Andre C (b)(6)>Sent : Friday, May 1, 2020 2:59 AM ------~~ To: Seigel, John (NIH) [El (b)( >; Davey, Richard (NIH/NIAID) [E]======~~(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6l; Dodd, Lori (NIH/NIAID) [E] (b)(6)>; Proschan, Mic hael {NIH/NIAID) [E) (b)(6) Marston , Hilary(NIH/NIAID) [E] (b)( ; Fauci, Anthony (NIH/N IAID) [El (b)(6)Subject: FW: ACTT publicationImport ance: HighNot my first choice, but I want to share the invitation email below with you.AndreAndre Kalil, MD, MPH, FACP, FIDSA , FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transp lant ID ProgramAssociate Edito r, CMI , Official Journa l of ESCMIDEditoria l Board , CCM , Official Journal of SCCM If UNMC--.ut1BIUGHl !'MIA.·Uni vers ity of Nebr aska Medi ca l Center985400 Nebraska Medical Center , Omaha , NE 68198-5400(b)(6) I fax402.559-5581===~ (b:).(.6=:c)UNMC I Facebook I Twitter I YouTube I Flickr"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditional probabilit ies . Giving due weight to the prior probab ilities ... "Robert Ludlum - The Amb ler WarningFrom: (b) (4) ------------------ Sent : Thursday, April 30, 2020 1:03 PMTo: Kalil, Andre C (b)(6)Subject: ACTT publicationImportance: HighNon-UNMC emailDear Dr. Kalil,(b) (4)From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Fri, 1 May 2020 11:38:53 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: FW: int erview request by Greek newspaper EthnosFYIAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone (b) (6)FAX: (301)4 96~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representative s.From: ru.:.,pyo<h; a¢u5ac; <gskafidas@ethnos.gr>Sent: Friday, May 1, 2020 6:07 AM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: inte rview request by Greek newspaper EthnosDear Dr. Fauci,my name is George Skafidas and I'm a journal ist working for the Greek nationa l weekly ETHNOS(www.ethnos.g r).We would be very much interested in doing an interv iew with you, to be published in theSunday edition of the paper, regarding the developments surrounding the COVID-19pandemic.Best regardsEG>NOEGeorge SkafidasSenior editor, World Affairstel: +30 210 6510550mob: (b)(6)o, n>-ripocpopiE<;n ou nEp1txovT01 aE OUTOT O μ~vuμo 11>-E><Tpov1KTooux uopoμEiou (e-mail) KoOw~ KOi aE Tuxov ouv11μμtvoEiVOIE μmOTEUTIKEK<O; i npoopi~OVTOyI 10 XPrt<Jro noKAEIOTIKCoIn e>T O OUVKEKplμEVnOo poArimr, (-E<;). o, nAr,pocpopiE<O; UTE<;μnopEi VO KOAUnTOVTOonI 6 EnlXEIPrJOIOKrOi 6 >>.oo n6pprJTOr i oAAouc;v 6μouc; KOi OEVE nlTpEOETOVIO OVOKOIVW9ou<vJ Eono1ovo,;noTE TpiTo. !E nEpimwori nou OEV EiOTE o nopoAr'lnTric; Tou μrivuμoroc; ri ro npoawno nou Eivo1 opμ6o10 y,o TrJVnopooooii TOU OTOVn opo>-r'lnTfJ, anoyopt:U€TOI VO TO OVOKOIVWO"E:TOtV, TIYPOljJE:"ToE,o:,v ciμE:"TEr:i OIOTrJPriOE:TEE:V: 6 Awv ri EVUEPEI.From:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Fri, 1 May 2020 11:38:08 +0000(b)(6)Subject: RE: Coronavir us: Covid 19Ato:Thank you for you note . We will know soon whether hydroxychloroquine hasany beneficial effec ts as the results of randomized, controlled trials becomeavailable. The pathogenesis of COVID-19 is sti ll an open question . You are correctin that ther e is a more recent tendency to use ventilators only as a very last resortsince oxygenation rathe r than ventilation appears to be key to recovery.Best regards,TonyAnthony S. Fauci, MDDirec torNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Inst itutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: gabriel stephens ---------- (b)( Sent: Friday, May 1, 2020 4:53 AM ------~= To: Fauci, Anthony {NIH/ NIAID) [E] (b)(6)> _______ _.Subject: Coronavir us: Covid 19Hi Dr Fauci,Please find an audio attached of a doctor descr ibing the experience with regards to covid 19 in thehospital. She seems to suggest covid 19 is a virus tha t rather attacks the blood cell, leading to respi ratoryand other organ comp lications, hence they need to loom at tre atme nt in a differ ent light. In the UKsome hospitals have moved away from using ventilators due to the high death rate of those onventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results aremuch much better compared to invasive ventilatorsThere are some anecdotal observations I have also made. The infection rate in most African countriesseem to be comparatively low, which could possibly due to the rate of testing being conducted.However t he death rates are also comparative ly very low. From in itial informat ion with regards tohydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were allegedto have had some benefits had mild symptoms of covid 19. I know some clinical trials have shownhydroxychloroquine not to be effect ive in the treatment of covid 19 in very ill patients. However, myhypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevelant in Africa,and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the lowdeath rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintendedbenefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, makingpeople less susceptible to covid19 .As I said, this is based on anecdota l observations.Yours sincerelyAto StephensFrom:Sent :To:Cc:Bee:Subject:Fauci, Anthony (NIH/N IAID) [ElThu, 30 Apr 2020 23:58 :07 +0000Cassetti, Cristina (NIH/NIAID) [ElErbelding, Emily (NIH/NIAID) [ElDani Bolognesi, Ph.D.FW:Attachment s: Brown et al submitted .pdf, NIH Presentation final.pptx,prepr ints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdfCristina :Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/A IDSinvestigators from a few years back. He is a serious scientist. Let me know what you think.Thanks,TonyFrom: Eisinger, Robert (NIH/NIAID) (El (b)(6)> On Behalf Of Fauci, Anthony(NIH/NIAID) [ElSe nt: Monday, April 27, 2020 6:57 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)>Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room ?A-03Bethesda MD 20892Telephone (b)(6)9Email (b)(From : Dani Bolognesi, Ph.D._ _______ C_>b_<_6>)Sent : Monday, April 27, 2020 6:09 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El ______ CbC>_6>); Barasch, Kimberly (NIH/NIAID) [C](b)(6)>Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4), (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15 . If it makes sense, we couldarrange a WebEx as an initial step .Many thanks for the opportunity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D." (bH6J>Date : Monday, April 27, 2020 a-t 2-:5-3- P-M- ------,; ~ To: "Matthias Gromeier, M.D." (bH >Subject: Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows :(b) (4), (b) (5)We are prepare c!Tciaiscuss this wit h you and your tea at any time tnaf 1s convenient for you. As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best ,DaniBest,DaniSent from Dani BolognesiThe information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmediate ly by return electronic mail, and to delete it without further reading or retention. The information is not to beforwarded to or shared unless in compliance with Duke Health polic ies on confidentiality and/or with the approva l of thesender.From:Sent:To:Cc:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:35 :34 +0000Jeremy Farrar ;Dzau, Victor J.;George GAORichard(b)(6);Hannon, Emma;Conrad,......". ""'.""":--:'~~:--"'""":""':'".':""'."~-"'."-:".~----------===~~"'.:"""""---:"'-.--Patricia (NIH/NIAID ) [E];Teresa Miller de Vega;- ---(b-)( 6);Rebeka Yasmin - CEPl;ben.t inker@cnn .com;Amanda.Sealy@cnn .com;Neel.Khairzada@turner.com;T ia.Miller@turner .com------- (b)(6)McGinnis, J. Michae l;Balatbat, Celynn e;Mun , Jenny; CbH ;Redfield, Robert R. (CDC/OD)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regard ing yourSaturday April 25 part icipat ionJeremy:Many thanks for the update. Please continue to keep me informed.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:J ere my Farrar _________ C_>b_<6 )Sent: Tuesday, April 28, 2020 10:39 Arvl -------, ~= To: Fauci, Anthony (NIH/NIAID) [E]- -------- (b)( ; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b)(6) >Cc: Richard Hatchett (b)(6)(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia"':'-""."'."":-'.'"-:-'.'-:-:"::.:=======:;....,.= (NIH/N IAID) [E] (b)(6); Teresa Miller de Vega (b)(___ C_b>_<_6); Rebeka Yasmin - CEPI (b)(6) ; ben .tinker@cnn .com; ----- ~= Amanda .Sealy@cnn.com ; Neel.Khairzada@turner .com; Tia.M iller@turner. com; (b)( 6)McGinnis, J. Michael (b)(6)>; (b)( >; Mun, Jenny<JMun@nas.edu> (b)( ; Redfie ld, Robert R. (CDC/OD) (b)( 6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25participationQuick updateUpdate in confidenceEuropean network from this morning:16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonalKD or TSSBarcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now whohave large coronary aneurysms, as have one child South London and one in Bristol.Most UK PICU have 1-2 of these type of casesPhenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees ofheart invo lvement and inflammation ++ - several have had their normal appendix whipped outMost negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSHearly case has seroconverted, but had immunog lobu linWe are establishing database UK and Europe and trying to define what the clinician features areand agree investigat ions.Notably , none in US reported (just 0/W Boston childrens who have been running sharedinternational COVID experience web calls) and none in Rome, unsure about rest of Italy yetDoes seem BAME preponderance-?? immune related or social phenomenon, in terms ofdeprivation prevalence and ability to isolateFrom: "Fauci, Anthony (NIH/NIAID) (E]" CbH6)Date: Monday , 27 April 2020 at 12:36To: Jeremy Farrar (b)(6) , Victor Dzau <VDzau@nas.edu> , George Gao(b)(6) >Cc: Richard Hatchett Cb()6 )Patricia (NIH/NIAID) [E]""Hann on, Emma " <EHannon@nas.edu> , "Conrad ,CbH6)T, eresa de VegaCb) (6) Rebeka Yasmin - CEPI---------- Cb)( 6) , "ben. tinker@cnn.com" <ben. tinker@cnn.com>, "Amanda.Se al y@c nn. com" <Amanda.Sealy@cnn.com >, "Neel.Kbairzada(a),turner.com"<Neel.Khairzada@turner.com> , "Tia.Miller@turner.com " <Tia.Miller @turner.com> ,Cb)(6) "McGinnis, J.Mic hael" <MMcGinnis@nas.edu> ,CbH>6,) ''Mun, Jenny" <JMun@nas.edu >,---------- CbH6l, "Redfield , Robert R. (CDC/OD)" (b)( >Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 participationJeremy:Thanks for the heads up. Is there any more detail ed description of the preciseclinical manifestations? They describe a "mult isystem infl ammatory state 11• It isvasculitis or anything more specific? Could be an infectiou s agent that hasnothing to do with SARS-CoV-2in fection even though some children arecircum stanti ally infected with SARS-CoV-2or it could be a post-SARS-CoV-2inflammatory syndrome, perhaps a Kawasaki syndrome- like disease. Please keepme inform ed if you hear any further inform ation .Best regards,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone· (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender 's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jeremy Farrar --------- (b) (6)>Sent: Monday, April 27, 2020 7:13 AM To: Fauci, Anthony (NIH/NIAID) [El-- ----------=---=---=(b=)(6 )>; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b)(6)>(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia(b)(6) >; Teresa Mil ler de Vega(b)(6)· Rebeka Yasmin - CEPI (b)( t>; ben.ti nker@cnn.com ; ____ _,,(b)(6);Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b) (6)McGinnis, J.Michael< MMcGinnis@nas.edu>; (b)(6)>; Mun, Jenny<JMun@nas.edu> (b)(6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25participationTo be aware of- news over night so a huge amount of uncertainty - important for COVID19 now, and apotentia l concern for how we view immunity, prot ection, post-infectiou s immunopathology.https://www.hsj.eo.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-beemerging-in-children/7027496 .articlehttps://t .co/Bj6YH U8ziFrom: "Fauci, Anthony (NIH/NIAID) [E]" CbH6>)Date : Sunday , 26 Ap1i l 2020 at 19:52To: Victor Dzau <VDzau@nas.edu >, George Gao CbH L---------~ =Cc: Jeremy Farrar CbH , Rich ard Hatchett CbH6)(b)(6) -----------"Hannon,Emma" <EHannon@nas.edu >, "Conrad , Patricia (NIH/NTAJD) [E]" Cb)( >,Teresa de Vega CbH>6), RebekaYasmin - CEPI (b)(6) "ben.tinker@cnn.com " <ben.tinker@cnn .com>,"Amanda.Sealy@cnn .com" <Amanda.Sealy@cnn.com> , "Neel.Khairzada@turner.com "<Neel.Kh airzada@tumer.com >, "Tia.Miller@tumer.com " <Tia.Miller@tumer.com> ,(b)(6) "McGinnis, J.Mic hael" <MMcGinn is@nas.edu >,(b)(6) "Mun, Jenny" <JMun@nas.edu >,(b)(6)Subject: RE: NAS Annual Meeti ng Sess ion on COVID- 19 -- Information regarding yourSaturday Ap ril 25 participationIt was a real pleasure to join all of you on this impor ta nt session. Many tha nks forinviting me.Anthony S. Fauci, MDDirectorNational Institute of Alle rgy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipie nt. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J. <VDzau@nas.edu>Sent: Saturday, Apr il 25, 2020 3:59 PMHannon,Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIA ID) [El ----------------- (b) ( ; rebeka.yasmin-@-ce-pi.-ne-t; -be-n.-tink-er-@cnn.com ; Amanda.Se a I y@ c n n. com ; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)McGinnis, J.Michael< MMcGinnis@nas.edu >; (b)(6)>; Mun, Jenny------ (b)(6)>; haja.bally@cepi.net Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25part icipationDear Jeremy, Tony, Sanjay, George, Susan and Richard,Thank you so much for your superh contri hutions. Tt was a spectacu lar session- a trnly inspi ringone. I am grateful to all of you.Hope to see you soon.Warm est regards,VictorOn Apr 25, 2020 , at 1: 22 PM, George GAO- ------ CbH6)w rote:I am waiting for being connected and will use s lides which were sent to your officeGeorge'&.§ it IYi:Pl honet£ 2020~4 ~ 24 B . 0 I :49, Dzau, Victor J. <VDzau@nas.edu>'.ij'.~ :Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really looking forward to this panel on COVID-19 at the NAS AnnualMeeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendousexcitement and enthusiasm, and registrat ion is through the roof.I am sending this note to do a last minute check to see if there is anyt hing youneed from me. I also want to check whether you are planning to use slides.Wi ll you be sending your slides to us to project or use the share screenfeature to advance your own slides? Regardless, it would be helpful to me ifyou could send me your slides for my preparation.I would greatly appreciate it if you wou ld respond to this email.Best,VictorPS,- -----(b)(6) ,· m y special assistant, will be sending you additional information about the session logistics shortly.From: Dzau, Victor J. <VDzau@nas.edu>Sent : Thursday, Apr il 9, 2020 11:01 AM ------~~ To: Mun, Jenny <JMun@nas.edu >, (b)(6); 'ben.tinker@cnn .com' <ben.tinker@cnn.com >;'Amanda.Sealy@cnn .com' <Amanda.Sealy@cnn.com >;(b)(6)'Neel . Khai rzada@turner.com' <Neel .Khai rzada@tumer.com >;'Tia.Mi ller@turner.com' <Tia. M iller@turner.com >; _____..._.Subject: RE: NAS Annual Meeting Session on COVID-19 -- Informationregarding your Saturday April 25 participationDear all,Thank you for agreeing to participate in a special late breaking sessionon the COVID-19 pandemic at the NAS annual meeting. Knowing howbusy you are, l am sending this email in lieu of a call to prepare for thesession.As you know , this is a 90 minute session which aims to provide ouraudience with deeper insights into the latest developments in theCOVID-19 response. I plan to hold an engaging discussion that coversthe whole experience on dealing with this pandemic - from US tointernational, to preparedness and response, the biology of the vims, thestate of diagnostic , treatment and vaccine development, and theimportance of commun ication.I will begin the session by providing brief ( ~3 min) opening remarksdescribing the circumstances of the pandemic . Then, I will introduce thepanelists and you will each have 7 minutes to provide remarks. Youmay use a limited number of slides for illustration. I hope that eachpanelist will provide their own perspective and speak to the issuesproposed below.• Jeremy Farrar will discuss the global response to the pandemic,drawing from his experience as a globa l leader, the chair of theScientific Advisory Group for the WHO's R&D Blueprint and asa member of the Global Preparedness Monitoring Board.• Tony Fauci will discuss the US pandemic and provide hisperspective as a member of the White House Corona virus TaskForce addressing the 2019-20 coronavirus pandemic.• George Gao will discuss China's response to the pandem ic andlessons learned for the rest of the globe .• Susan Weiss will discuss the viral characteristics of SARSCOV2 , insights into its pathobiology, immunity anddevelopment of a pan-Co V antiviral.• Richard Hatchett will discuss the development of new vaccinesand treatments against COV ID-19 .• San jay Gupta will comment on the health system response to thepandemic and challenges related to communication and publicengagement in responding to COVID-19.Following remarks from each panelist, we will have a moderateddiscussion amongst ourselves - I will ask you a set of questions ( 15mins) and then we will take questions from the web (25 mins). Toprepare me to be your moderator, please send me any questions youwould like me to ask you. For those of you who would like to have aprep call, please let me know and I will set it up.Best,VictorFrom: Mun, JennySent: Wednesday, April 8, 2020 10:56 AMben .tinker@cnn .com'; 'Amanda.Sealy @cnn.com'; 'Nee l.Khairzada@turner .com'; 'Tia.Miller@turner.com'Subject: NAS An nual Meeting Session on COVID-19 -- Information regardingyour Saturday April 25 participationDear Speakers:I am the logistical contact for the COVID-19 session that will be held as part ofthe Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT.Thank you for agreeing to participate in this session. To help you with yourplanning, I have provided additional details below.Please note that the session will be live webcast and the general public willalso be able to watch the session. Video from the session will also beuploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting . We willneed to obtain signed speaker release forms for your participation in thissession. I have attached the speaker release form for your review andsubmission. Please return the signed speaker release form by Monday, April13.Session speakers are asked to connect 30 minutes prior to the session starttime (by Saturday, April 25 at 1:30 pm EDT) to allow the technical staff tocheck connections and prepare for the session. Details on how to connect willbe sent before the meeting .We will list you in our promotional materials as noted below . If this isincorrect, please let me know .Anthony S. Fauci, Director, National Institute of Allergy and InfectiousDiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control &PreventionSanjay Gupta, Chief Medica l Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microbiology, Perelman School of Medicine,University of PennsylvaniaSince many of us have moved to remote work environments, you mayalready be proficient with Zoom and other online meeting/collaborationapplications. I am attaching a 'speaker guidelines' file in case you have anyquestions on how best to prepare for and stage your remote talk . We havetechnical staff available to help you become familiar with Zoom and itssettings - such as "sharing your screen" (if you have slide presentations thatneed to be shown during your talk) . We can arrange for a training session thisweek or next week. If you would like to schedule a session, please let meknow as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If youhave any other questions, please let me know.Regards, JennyJenny MunMembership DirectorNational Academy of Sciences(b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:19 :19 +0000Alexander PattersonRE: (b)(6) made a Video Game of Yo: "Fauci's Revenge"Thanks, Alex! Much apprecia t ed.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Alexander Patterson <alex.patterson@beatthebomb .com>Se nt: Thursday, April 30, 2020 11:26 AMTo: Fauci, Anthony (NIH/NIAID) [E) (b)(6)>Cc: Daniel La hart <dlahar t@r egis.org>Subject: (b)( made a Video Game of Yo: "Fauci 's Revenge"Dear Dr. Fauci -My name is Alex Patte rson and I'm (b)(6) I made a v ideo game about you called Fauci 'sRevenge. Link to play: https://beatthebomb .com/beatthevirusWe are stream ing the Finals of a tournament live tonight at 8 PM EST on Twitch , FB, and YouTube.Twitch Stream Link (free to watch): https://www .tw itch.tv/beatthebomb1000Also available on:Facebook : https://www.facebook .com/ BeatTheBomb/YouTube: https ://www.youtube .com/channel/UCOyh7vo1knuKuaaCKUssAzAPlease watch the Twitch Stream if you can! Otherw ise I will follow up tomorrow w ith a video!Media coverage of the Fauci's Revenge in the News:• NBC New YorkSpectrum NY1 NewsTimeout New YorkNews 12 New YorkBushwick DailyFox 5 Good Day New YorkTo date we've raised over $6,150 for New York City's Public Health System (NYC Heal th +Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We'vedonated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields toMaimonides Medical Center. Men for others!Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!Best,Alex Patterson~Alex PattersonCEO BEAT THE BOMBwww.beatthebomb.comFollow us on instagram: @beatthebomb247 Water Street, Suite 106, Brooklyn, 11201work : 718-643-0200 I I cell: (b)(6)From:Sent:Attachment s:Yikes!Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 22:18 :45 +0000(b)( 6) Grad made a Video Game of Vo: "Fauci's Revenge"Fauci's Revenge Game Logo.pngNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409(b)( 6)E-mail: .___,. __., (b)( 6)The information in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Alexander Patterson <alex.patte rson@beatthebomb .com>Sent : Thursday, April 30, 2020 11:26 AlvlTo: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid .nih.gov>Cc: Daniel La hart <dlahar t @regis.org>Subject: (b)(6) made a Video Game of Yo: "Fauci's Revenge"Dear Dr. Fauci -My name is Alex Patterson and I'm (b)(6) I made a video game about you called Fauci'sRevenge . Link to play : https:/Jbeatthebomb.com/beatthevirusWe are streaming the Finals of a tournamen t live tonight at 8 PM EST on Twit ch, FB, and YouTube.Twitch Stream Link (free to watch): httos://w ww.twitch.t v/beatthebom b1000Also available on:Facebook: https://www.facebook.com/BeatTheBomb/YouTube: https:// www.yout ube.com/channel/UCOyh7vo1knu KuaaCKUssAzAPlease watch the Twitch Stream if you can! Otherwise I will follow up tomorrow w ith a video!Med ia coverage of the Fauci's Revenge in the News:• NBC New YorkSpectrum NY1 NewsTimeout New YorkNews 12 New YorkBushwick DailyFox 5 Good Day New YorkTo date we've raised over $6,150 for New York City's Public Health System (NYC Health +Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We'vedonated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields toMaimonides Medical Center. Men for others!Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!Best,Alex Patterson Cb) (6)Alex PattersonCEO BEAT THE BOMBwww.beatthebomb.comFollow us on instagram : @beatthebomb247 Water Street, Suite 106, Brooklyn, 11201work: 718-643-0200 I I cell: (b)(6)
From: Fauci, Anthony (NIH/NIAID) [E)Sent: Thu, 30 Apr 2020 22:14 :57 +0000To: (b)( 6)Cc: Tromberg , Bruce (NIH/NIBIB) [E];Sharpless, Norman (NIH/NCI) [E];Birx, DeborahL. EOP/NSC;Redfi eld, Robert R. (CDC/OD);Collins, Francis {NIH/OD) [E) ( CbH6>1C1)o;nrad,Patricia {NIH/NIAID ) [E]Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up AmericaAgain"Attachments: 4.28.20 NDHS Overview Slides-Rusty -Fauci_ 1.pptxRod:Great to hear from you. Thanks very much for sending this . Very impressive! Iwill forward this to Bruce Tromberg and Ned Sharple ss who have been working onCOVID-related apts. In addition, I have cc'd Deb Birx {Coordinator of the WhiteHouse COVID-19 Task Force) as well as CDC Director Bob Redfield and FrancisCollins. I hope that all is well with you. Stay well and safe.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Pett igrew, Roderic ISent: Thursday, Apr il 30, 2020 4:20 AM ---------- ~= To: Anthony S. Fauci {NIH/NIAID) (b)(6)Subject: Stanford Nat ional Daily Health Survey for COVID - "Open Up America Again"Hi Tony ,Greetings from Houston, wher e the numb er of cases peak ed ~2 w eeks ago, dropped 35 -40%and seemed to have plateaued since. Grea t to see you on TV and see t he nat ion (includi ng BradPitt©) get to know the rigorously informed, keenly rationale and consistent ly clear Tony yourcolleagues have long known.(b) (4), (b) (5)Thank you , Tony . Very proud to know you. Kind regards ta ---(b-)( -.RodRoderic I Pettigrew , PhD, MDCEO EnHealth I Health Science Center and College of EngineeringRobert A Welch Professor and Executive Dean EnMed I Colleges of Medicine, Engineering and Houston MethodistHospitalTexas A&M University ALKEK Building I Suite 11032121 W Holcombe Blvd I Houston , TX 770?/Jwww.enmed.tamu.eduPh:_ __ .C..>b_ < .-~1- ____ C...>b_ < ..~..MAKING WHAT IF POS SIBLE I whatif.tamu.eduFrom: Hofmann, Lawrence, M .D. (b)(6)Sent: Tuesday, April 28, 2020 11:19 AtvlTo: Pettigrew, Roderic I (b)(6)Cc: Pelc, Norbert J (b) (6)Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"Best,RLawrence "Rusty" Hofmann , MDProfessor and Chief, lntervent ional RadiologyMedical Director, Digital Health IntegrationMedical Director, Cardiac and lnte rventional Services@rustyhofmannMD(ml CbH6lAssistant:(b)(6)(b)(6)(b) (4), (b) (5)From:Sent :To:Cc:Fauci, Anthony (NIH/N IAID) [ElThu, 30 Apr 2020 22:05 :19 +0000Barillas, Carolina (NIH/NIAID) [ElAuchi ncloss, Hugh (NIH/NIAID) [E]RE: (b) (5) --------------------------Carolina:Thanks for se nding thisBest regards,TonyAnthony S. Fauci, MDDirector(b) (5) ------National Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone Cb()6 )FAX: (301 496-4409E-mail: (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Baril las, Carolina (NIH/NIAID) [E] ---------(b)(6)Sent : Thursday , April 30, 2020 11:25 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)> ~-=======---~= Cc: Auchinclo ss, Hugh {NIH/ NIAID) [E] (b)(6)Subject: (b) (5)Dear Tony,(b) (5)All the best,Carolina(b)(S)(b)(5From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 21:47 :05 +0000(b)(6)Subject: FW: Autopsy data suppor t ing Remdesivir trialTake a look at the Figures in the manuscript.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)(6)FAX: (301 496-4409(b) (5)(b) (4)E-mail,___,,. __ _, (b)(6)The in ormation in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Timothy Schacker (b)(6)Se nt: Thursday, April 30, 2020 1:10 PM -------~ = To: Fauci, Anthony (NIH/NIAID) [E] ---------- (b)(6l!> Subject: Autopsy data supporting Remdesivir trialTony., __________________________________ ~=(b) (4)Stay well (please) and thank you for all you are doing!TimTimothy Schacker , M.D.Vice Dean for Research , Medical SchoolDirector, Program in HIV MedicineUniversity of MinnesotaMail:MMC250420 Delaware Street SEMinneapolis, MN 55455FedEx/UPS:Mayo C688420 Delaware Street SEMinneapolis, MN 55455Phone: Cb()6 )Fax: 612-626-5599email: (b)(6) -------(bX5) -PCI(bXS)- PCPFrom:Sent:To:Cc:Fauci, Anthony (NIH/NIAID) [ElThu, 30 Apr 2020 14:17:43 +0000Conrad, Patricia (NIH/NIAID) [E)Billet, Court ney (NIH/N IAID) [ElSubject: FW: May the Official Nobel documentary program at Swedish Television get aninterv iew with you Dr Fauci about Covid-19 before May 7th please?Please get clearance and set it up if possible.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: .___,. ,. , (b)(6)The information in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Johan Bergendorff <johan.bergendorff@svt.se>Sent: Thursday, April 30, 2020 9:56 AM ------ ::;..,..-,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) ICJ________ C_>b_C_6>) ; Stover, Kathy (NIH/NIAID) [El (b)(6)Subject: May the Officia l Nobel documentary program at Swedish Television get an interview with youDr Fauci about Covid-19 before May 7th please?Dear Dr . Fauci,I had the honor to interview you in april 2016 about the zika ep idem ic at your off ice for aprogram for national Swedish radio as their global health cor respondent. I hope I may have theho nor again now Sir?I am now working as science corresponden t for the nat ional Swedish Te levis ion (noncommercial public service, half the populat ion as daily viewe rs) in our official Nobel prizelaureau te documentary program "Vetenskapens Va rid" (the World of Science) and wonder ifyou have any chance to give us a 10 minute interview by web video before May 7th please?I would like to ask you two questions: What is most crucial now to suceed with an covid-19pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr.Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy,what is your view)?In this one hour program aired on May 11th we will have other prominent scientists as welltalking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. BengtHolmstrom MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean UniversityHongkong etc.Here you can see the reports I did from my earlier interview with you about the zika epidemicin 2016 (in Swedish). News report: https://sverigesrad io.se/artikel/642089120 mindocu men ta ry: https ://sverigesrad io.se/ avsn itt/712016One option is that I send you a link for a web video Conference call. Another option is that I callyou on the phone and your media department may have the oportunity to record a video ofyour anseers with HD quality that is better to air.Please let me know if you are available and when.Best regards,Johan BergendorffScience correspondent, Swedish Television(b)(6)From:Sent :To:Cc:Subject:resultsJuli e:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 13:31 :50 +0000Julie.Steen huysen@thomsonreuters .comGreg Folkers Cb) (6)FW: Fauci says leak concerns fueled his White House revelation of Gilead drugYou did a good job in reporting our conversati on last night . Thanks.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) [E] (b)(6J>Se nt: Thursday, April 30, 2020 8:59 AMTo: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAIDOD AM <NIAIDODAM@niaid.nih .gov>Subject : Fauci says leak concerns fueled his White House revelation of Gilead drug resultsHealth NewsApril 30, 2020 / 1:07 AM/ Updated 4 hours agoFauci says leak concerns fueled his WhiteHouse revelation of Gilead drug resultsJulie Steenhuysen5 Min ReadCHICAGO (Reute rs) - Concerns over leaks compelled the top U.S. infectious disease of fi cial to reveal dataon Gilead Sciences Inc's experimental drug remdesiv ir, the first in a scientifically rigorous clinical tr ial toshow benefit in t reating COVID-19.National Institute of Allergy and Infectious Diseases Director Dr. Ant hony Fauci attends a coronavirusresponse meet ing between U.S. President Donald Trump and Louisiana Governor John Bel Edwards inthe Oval Office at the White House in Washington , U.S., April 29, 2020. REUTERS/Carlos BarriaThe dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concernsamong scientists that the Trump administration was raising hopes about a coronav irus treatment beforesharing the full data with researchers.As a cautionary example of inflating the potential value of a therapy, some pointed to President DonaldTrump's repeated endorsements of malaria drug hydroxychloroquine as a treatment , with no evidencethat it works .Newer data suggests the malaria treatments may carry significant risks for some sufferers of therespiratory disease caused by the virus.Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running thetrial, said he took the first opportunity to get the word out that patients taking a dummy treatment orplacebo should be switched to remdesivir in hopes of benefiting from it .He expressed concern that leaks of partial information would lead to confusion . Since the White Housewas not planning a daily virus briefing, Fauci said he was invited to release the news at a newsconference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Faucitold Reuters in a telephone interview."I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have asituation where the ethical concern about getting the drug to people on placebo dominates theconver sation ."An independent data safety and monitoring board, which had looked at the preliminary results of theNIAID trial, determined it had met its primary goal of reducing hospital stays.On Tuesday evening, that information was conveyed in a conference call to scientists studying the drugglobally."There are literally dozens and dozens of investigators around the world/' Fauci said. "People werestarting to leak it." But he did not give details of where the unreported data was being shared.Several scientists interviewed by Reuters felt the White House sett ing seemed inappropriate for therelease of highly anticipated government-funded trial data on the Gilead therapy .They had expected it to be presented simultaneously in a detailed news release, a briefing at a medicalmeet ing or in a scientific journal, allowing researchers to review the data.Informat ion from various trials of remdesivir has been leaked to media in recent weeks. In a statementon Wednesday, Gilead said the NIAi D's much anticipated trial had met its primary goal, but gave nodetails .Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patientswho got the drug had a 31 percent faster t ime to recovery than those who got a placebo, cuttinghospital stays by four days.The trial also came close to showing the drug helped people survive the disease, but the data fell justshort of statistical significance."I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk.I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academicofficer at the Cleveland Clinic."Am I encouraged from what I've heard? Yes, I'm encouraged . But I want to get a full understanding ofwhat happened here, and not get it via a photo opportunity from the Oval Office ."Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomesbetween those receiving therapy and those who did not .Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were releasedin the British medical journal the Lancet after review by a peer group of scientists ."That's the only thing I'll hang my hat on, and that was negative ," said Dr. Eric Topol, directo r andfounder of the Scripps Research Translational Institute in La Jolla, California.He was unimpressed by remdesivir's modest benefit ."It was expected to be a whopping effect," Topol added . "It clearly does not have that ."At the Oval Office news conference, Fauci compared the study findings to AZT, the fi rst drug to show anybenefit against HIV, decades ago."We know that was an imperfect drug. It was the first step," Fauci said in the interview."Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of betterdrugs that will come in and be able to treat people with COVID-19.11(This story has been refiled to correct spelling of "clinical 11 in paragraph one)Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Clarence FernandezOur Standards :The Thomson Reuters Trust Principles.Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those of NIAlD , NIB, HHS, or the U.S. government.From:Sent:To:Cc:Subject :Bill:Fauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 10:20:32 +0000STEWART SIMONSO Cb)(Masur, Henry (NIH/CC/CCMD) [E);STEWART SIMONSONRE: COVID-19 and Haiti(b)(6) Work --------------------------------- with him. As per our prior conversation and as you know better than anyone, Haiti is strugglingand I know that Stewart wi ll do whatever he can to assist you.Warm regards,'TonyFrom: STEWART SIMONSON (b)(6) ------------ Sent: Thursday, April 30, 2020 5:44 AMTo : (b)(6)Cc: Fauci, Anthony (NIH/NIAID) [E. ,,_~~~-===(b)=(6) =M-a-su~r~, H enry (NIH/CC/CCMD) [E] ------- (b)(6)>; STEWARTS IMONSON (b)(6) Subject : COVID-19 and Hait iDear Dr. Pape:I lead the World Health Organization (WHO) delegation to the United Nations and know of you throughTony Fauci and Henry Masur, (b)(6). For nearly 5 years immediatelypreceding my appointment at WHO,, I was an technical advisor at Hop ital Sacre-Cawr in Milot andremain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed byMSPP to coordinate COVID-19 preparedness and response activities. If you have some time available onFriday, it would be good to talk via Zoom or Webex. I can arrange th is and would plan to have thePAHO deputy director as well as other PAHO officials on the line. Would you be available Fridayafternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on ourend.Thanks so much for considering t his.With best regards,Stewart SimonsonSTEWART SIMONSONWashington, DC/ New YorkCb) (6) or(b)(6)Cb) (6)1S)IS)------ (Switzerland)From:Sent :To:Subject:Please respond.Fauci, Anthony (NIH/NIAID) [ElThu, 30 Apr 2020 01:24:46 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Has anyone tried palivizumab (Synagis)From: Rich May (b)(6)Se nt: Wednesday, April 29, 2020 10:21 AM To: Fauci, Anthony {NIH/NIAID) [E] ----------~-=- -- (b)(6) Subject: Has anyone tried palivizumab (Synagis)Good morning Dr. Fauci,Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?Thank you for your time,Richard May, MD, PhD, D.H.Sc- -(-b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElWed, 29 Apr 2020 22:42:24 +0000Lerner, Andrea (NIH/N IAID) [ElFW: NAO repl etion for Covid-19Please t ake a look and respond if approp riateAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Mel Cohen (b)(6)Se nt: Wednesday, April 29, 2020 1:52 PM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: NAD repletion for Covid-19Import ance: HighDear Dr. Fauci,Recent research has shown that SARS-CoV-2 plays havoc with NAO function wit hin cells.Coronavirus Infect ion and PARP Expression Dysregulate the NAO Metabolome: A Potentially ActionableComponent of Innate Immunity:http s://www .bio rxiv.org/content/10 .1101/2020.04.17.047480v3The Molecular Story of COVID-19; NAD+ Depletion Add resses All Questions in th is Infection :https://www.preprints.org/manuscript/202003.0346/vlOther research has shown that NAD+ levels decline from aging and obesity, both significant factors inCovid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oraladministration of nicotin amide ribo side (NR) and nicotinamide mononucleotide (NMN). NR in particularhas had several human studies demonstrating its safety and efficacy, and roughly 50 human studieslisted on clinicaltrials.gov fo r all manner of disorders.There is at least one anecdotal repo rt of dramatic improvement in a Covid-19 patient afteradministration of NMN.NMN shows great promise in case studies of humans with COVID-19:https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-casestudies/?utm campaign=NMN%20for%20covid%20%28TqFTyz%29&utm medium=email&utm source=Main%20List& ke=eyJrbF91bWFpbCl61CJtZWx/l2.GlzdHJpYnVOZWwuY2EiLCAia2xfY29tcGFueV9pZCl61CJSbWROWFoifQ%3D%3DThat article begins with the disclaimer, "There are no human trials that prove effectiveness of any NAO+boost ing suppfements for preventing or curing COV/0-19."That is a problem . When I see the resources that have been wasted pursuing hydroxychloroquine, I amsaddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatmentregimen for Covid-19. Can you do anything about getting such a study done?Regards,Mel Cohen(b)(6)From:Sent:Fauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 22:01:22 +0000To: Folkers, Greg (NIH/NIAID) [E);NIAID OD AMSubject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEWIN ODNow FINAL in the OD fo lder. Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) [E] (b)(6)>Sent: Wednesday, April 29, 2020 5:03 PMTo: NIAID OD AM <NIAIDODAM@niaid .nih.gov>Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD• This is a zoom call.• I think you will be able to use slides.• I have put in OD a draft "curtain-raiser" set that you could show to kick things off - oruse them as TPs if you prefer.• I will update any epi or other numbers tomorrow night• The "ask" is belowFrom: Silverberg , Kristen <K5ilverberg@brt .org>Sent: Tuesday, April 14, 2020 4:11 PM ------~ = To: Fauci, Anthony (NIH/NIAID) [E] (b)( >Subject: invitation from BRTDr. Fauci,First, thank you for everyth ing you are doing . I have always been grat eful for yo ur public service, butfeel part icular ly indebted to you these days.To add to the debt ... Josh and I wanted to see if you would be willing to join a call with BusinessRoundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm . Typically,about 100-125 CEOS of large, U.S.-based firms will join. They are all managing and planning for difficultissues around employee and customer safety . They would love to hear from you directly and to ask afew questions . It might also be a good place to deliver any messages you want them to hear.We completely understand if it isn't doable, of course. If you are able, we would love to host yousometime between 1:30pm -2:30pm this Friday (or any Friday on which your schedule wou ld allow it).Best,KristenFrom:Sent:To:Subject:Attachments :Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 15:09:44 +0000Antho ny FauciFW: Potential slides fo r Remdesivir presentationRemdesivir bullet slides - FAUCI - FINAL.pptxNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Fauci, Anthony (NIH/NIAID) [E]Sent : Wednesday, April 29, 2020 11:02 AM --------~~ _T_o_ : Short.,.; _M __a_r_c T. EOP-/-O(bV')"P(~'6" )'>_ ________ (b)(6_)_, ; 'Mi ller, Katie R. EOP/OVP'Subject: Potential slides for Remdesiv ir presentationMarc/Katie:Here are 3 slides that I might use in the press briefing. If necessary, I couldmake the presentat ion without them, but it might be clearer to have them just incase.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892 -2520Phone Cb) (6)FAX: (301 496-4409E-mail: --------- (b)( 6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [E)Wed, 29 Apr 2020 14:18:44 +0000Billet, Courtney (NIH/N IAID) [E]RE: two thingsThanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Billet, Courtney (NIH/NIAID) [E (b)(6)Sent: Wednesday, April 29, 2020 9:16 AM ------ --=-= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Folkers, Greg (NIH/NIAID) [El (b)(6);; Conrad, Patricia (NIH/NIAID) [El(b)(6) >; Stover, Kathy (NIH/NIAID) [El CbH ; Routh, Jennifer"'.".---:------:-~~==~_;_-- ~~(NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [El CbH >Subject: ASF: two thingsTalked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had inthere about an EUA. Our release has been updated (attached) with the sentence highlighted below .ALSO: Bill Hall called me to ask if you had alerted the Secretary to th is (so the press release clearanceprocess isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps youwish to now?As part of the U.S. Food and Drug Administration's commitment to expediting the developmentand availability of potential COVID-19 treatments, the agency has been engaged in sustained andongoing discussions with Gilead Sciences regarding making remdesivir available to patients asquick ly as possible , as a_p_propriate.From: Fauci, Anthony (NIH/NIAID) [ElSent: Wed, 29 Apr 2020 10:45:24 +0000To: Billet, Courtney (NIH/NIAID) [ElCc: Folkers, Greg (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary(NIH/NIAID) [El;Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [El;Lane, Cliff (NIH/NIAID)[El;Erbelding, Emily (NIH/NIAID) [ElSubject: RE: please read, Gilead statementLooks fine. Thanks.From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>Sent: Wednesday, April 29, 2020 6:43 AMTo: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>Cc: Folkers, Greg (NIH/NIAID) [El <gfolkers@niaid.nih .gov>; Conrad, Patricia (NIH/NIAID) [El<conradpa@niaid .nih.gov>; Marston, Hilary (NIH/NIAID) [El <hilary .marston@nih.gov>; Routh, Jennifer(NIH/NIAID) [El <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [El <kathy .stover@nih .gov>; Lane,Cliff (NIH/NIAID) [El <clane@niaid.nih.gov>; Erbelding, Emily (NIH/NIAID) [El <emily .erbelding@nih.gov>Subject: ASF: please read, Gilead statementFYI - this will go out before markets open this morning:GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGINGFROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUSDISEASES' STUDY OF REMDESIVIRFoster City, Calif., April 29, 2020 - Gilead Sciences. Inc. (Nasdaq: GILD) is awareof the positive data emerging from the National Institute of Allergy and InfectiousDiseases' (NIAID) study of remdesivir. We understand that the trial has met itsprimary endpoint and that NIAID will provide detailed information at an upcomingbriefing.In addition to the NIAID trial, Gilead expects to share additiona l remdesivir datafrom the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-dayduration of therapy may have similar efficacy and safety as the 10-day treatmentcourse evaluated in the NIAID trial and other ongoing tria ls. Gilead expects data atthe end of May from the second SIMPLE study evaluating the 5- and 10-day dosingdurations of remdesivir in patients with moderate COVID-19 disease.Gilead will continue to discuss with regulatory authorities the growing data setregarding remdesivir as a potential treatment for COVID-19.From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 03:09:03 +0000Berkowitz, Avrahm J. EOP/WHORE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises TopCoronav irus Task Force ExpertThanks , A vi.-----Original Message-----From: Be rkowitz , Avrahm J. EOPfWHO (b)(6)Scot : Tuesday , April 28, 2020 I 0:00 P-M- ----. ;;-s-r;o= To: Fauci , Anthony (N1H/NIAlD) [E] CbH >Subject: Jar ed Kushn er Defends Dr . Fauc i After Fox News Host Criticises T op Coronavirus Task Force ExpertJust wanted to share an article- all the best!Avihtt:ps: //www .newsweek. conv'j ared-kushner-defends-dr-fauc i-fox -news-host-Ii ttle-tough-I 5003 3 9Sent from my iPhoneFrom: Fauci, Anthony (NIH/N IAID) [E)Sent: Wed, 29 Apr 2020 03:08:36 +0000To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E);Routh, Jennifer(NIH/NIAID) [El;Erbelding, Emily (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID) [El;Marston, Hilary (NIH/NIAID)[ElCc: Conrad, Patricia (NIH/NIA ID) [E)Subject: RE: DRAFT NIAID statement on remdesivir , ACTT 2Attachments: SHORTENED NIAID statement NEW NEW -with Fauci edits .docxSee my minor edits. (b)(5)From: Billet, Courtney (NIH/NIAID) [El (b)(6)>Sent: Tuesday, April 28, 2020 10:40 PM ------~ = To: Folkers, Greg {NIH/NIAID) [E) (b)( •>; Fauci, Anthony {NIH/NIAID) [E)CbH6>>R; outh, Jennifer (NIH/NIA ID) [E] CbH6)E; rbelding, Emily(NIH/NIAID ) [E) CbH6l>; Lane, Cliff (NIH/NIAID ) [E) (b)(6)>; Marston,Hilary (NIH/NIAID) [El (b)( >Cc: Conrad, Patricia (NIH/NIAID) [El (b)(6)Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2From: Billet, Courtney (NIH/NIAID) [ElSent: Tuesday, April 28, 2020 10:02 PM ------- -== To: Folkers, Greg {NIH/NIAID) [El (b)(6); Fauci, Anthony (NIH/NIAID) [El(b)(6)v>; Routh, Jennifer (NIH/NIAID) [El (b)(6)>; Erbeldlng, Emily(NIH/NIAID) [E) CbH6)>L;a ne, Cliff (NIH/NIAID) [E] CbH6>; >Marston , Hilary (NIH/NIAID) [E] Cb)( >Cc: Conrad, Patricia (NIH/NIAID) [E) Cb)( v>Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2(not sure what happened with spacing). Cliff- I got your suggestion too . I'll blend yours, mine, andGregs and send a clean new one shortly.From: Billet, Courtney (NIH/NIAID) [E]Sent: Tuesday, April 28, 2020 10:01 PM -------~ = To: Folkers, Greg (NIH/NIAID) [El (b)( >; Fauci, Anthony (NIH/NIAID) [E](b)(6b ; Routh, Jennifer (NIH/NIAID) [El< CbH6)>E; rbelding, Emily(NIH/NIAID) [El (b)(6)>; Lane, Cliff (NIH/NIAID ) [El (b)(6);Marston , Hi la ry_(NI H./.,N-IA-1D. ..) . .[.-E )-::::::===:::!...:~___.:.~ (~b)~( >Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2I took a crack at a revision as well. We can blend these.From: Folkers, Greg (NIH/NIAID) [El (b)(6)Sent: Tuesday, April 28, 2020 9:57 PMTo: Fauci, Anthony (NIH/NIAID) [El .e-f----~ (b~)( =6J; Routh, Jennifer (NIH/NIAID) [E](b)(6)>; Billet, Courtney (NIH/NIA ID) [El (b)(6); Erbelding, Emily(NIH/NIAID) [El (b)(6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6); Marston,Hilary (NIH/NIAID) [E] (b)(6):,.Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2Here is my suggested edit to the short version.From: Fauci, Anthony (NIH/NIAID) [E] ------- Sent: Tuesday, April 28, 2020 9:21 PM ------~~ To: Routh, Jennifer (NIH/NIAID) [El (b)(6); Billet, Courtney (NIH/NIAID) [El(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( >; Erbelding, Emily(NIH/NIAID ) [El (b)(6)>; Lane, Cliff (NIH/NIAID) [E] ------- (b)(6); Marston , Hilary (NIH/NIAID) [El (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [El (b)( >Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThanks for all your work.this.From: Billet, Courtney (NIH/NIAID) [El -------- (b)(6)Sent: Tuesday, April 28, 2020 7:29 PM -------= = To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: Routh , Jennifer {NIH/NIAID) [El (b)(6)>; Stover, Kathy (NIH/NIA ID) [Elange(b)(6)>; Conrad , Patricia (NIH/NIAID) [El (bH >; Folkers, Greg(NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [El (b)(6)>;'.":"":":"::-'.'::"":-:-:::":--:::====--~~Lane, Cliff (NIH/NIA ID) [E] (b)(6)>; Marston, Hilary (NIH/NIAID) [El(b)(6)Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElWed, 29 Apr 2020 01:53:28 +0000Lane, Cliff (NIH/NIAID) [ElRE: BulletsRendesivir bullet slides - FAUCl.pptxI added another bullet.From: Lane, Cliff (NIH/NIAID) [El _______ Cb _H_6)Sent: Tuesday, April 28, 2020 9:51 PMTo: Fauci, Anthony {NIH/NIAID) [El_ _____ "("b"")"(="6")Subject: Re: BulletsGraph inserted.From: Anthony Fauci (b)(6)>Date: Tuesday, April 28, 2020 at 9:47 PM -------=-:~ To: "Lane, Cliff (NIH/NIAID) [E]" -------- (b)(6) ,> Subject: RE: BulletsI made some minor changesFrom: Lane, Cliff (NIH/NIAID) [El -------- (b)(6)Sent: Tuesday, April 28, 2020 9:27 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El- -------- (b)(6J>Subject: BulletsFor commentFrom:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElWed, 29 Apr 2020 01:50:16 +0000Lane, Cliff (NIH/NIAID) [ElRE: DRAFT NIAID statement on remdesivir, ACTT 2ACTT 2 NIAID statement CB KS EE HM HCLl - with minor edits.docx(b) (5) I made some minor edits.From: Lane, Cliff (NIH/NIAID) [E] ______ (_b)_(_ >Sent: Tuesday, April 28, 2020 9:44 PMTo: Fauci, Anthony {NIH/NIAID) [E] ------ -(-b==)-(=6)Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2Attached for consideration.From: Anthony Fauci (b)(6)>Date: Tuesday , April 28, 2020 at 9:21 PM ------- -== To: "Routh, Jennifer (NIH/NIAID) [E]" (b)(6)>, "Billet, Courtney (NIH/NIAID)[E]" (b)(6)>, "Folke rs, Greg (NIH/NIAID) [El" (b)(6)"Erbelding, Emily (NIH/NIA ID) IE]" (b)(6), " Lane, Cliff (NIH/NIAID) [E]"(b)(6)>, Hila ry Marston --------- --========:e:=~ Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b)(6)>Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Thanks fo r all your work. (b) (5)(b) (5)-------------------------- (b)( 5) Please change t his.From: Billet, Courtn ey (NIH/NIAID) [El ------- (b)(6)>Sent: Tuesday, April 28, 2020 7:29 PM ------= = To : Fauci, Anthony {NIH/NIAID) [El (b)(6)>Cc: Routh, Jennifer (NIH/NIAID) [E] (b)(6) ,; Stover, Kathy (NIH/NIAID) [E](b)(6)>; Conrad, Patricia (NIH/NIAID) [El (b)(6); Folkers, Greg(NIH/NIAID) [El~---:~-=== (=b)=(6::)!>....;:.E. ~rb_el~ding, Emily (NIH/NIAID) IE] (b)(6);Lane, Cliff (NIH/NIAID) [E) (b)(6); Marston, Hilary (NIH/NIAID) [El(b)(6)Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From: Fauci, Anthony (NIH/N IAID) [E)Sent: Wed, 29 Apr 2020 01:21:27 +0000To: Routh, Jennifer (NIH/NIAID) [E);Billet, Courtney (NIH/NIAID) [E];Greg Folkers(GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [El; Lane, Cliff (NIH/NIAID) [El;Marston , Hilary(NIH/NIAID) [ElCc: Conrad, Patricia (NIH/NIA ID) [E)Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement .docxThanks for all our work. HoweverCb) (5). Please change --------------------------- this.From: Billet , Courtney (NIH/NIAID) [El --------- (b)(6) Sent: Tuesday, April 28, 2020 7:29 PM -------=-:-= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Routh, Jennifer (NIH/NIAID) [E) (b)(6h; Stover , Kathy (NIH/NIA ID) [E)(b)(6)>; Conrad, Patricia {NIH/NIAID) [E) (b)(6); Folkers, Greg":'----:-------:--:--:-.:==~(NIH/NIAID) [E)~-~-==== (b=)(=6l->:; ..E~..r.be~lding, Emily {NIH/NIAID) [E) (b)(6)>;Lane, Cliff (NIH/NIAID) [E] Cb)( >; Marston, Hilary (NIH/NIAID) [E)(b)(6)>Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From:Sent :To:Subject:Attachme nts:Fauci, Anthony (NIH/NIAID) [ElWed, 29 Apr 2020 00:56:02 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Coronavirus info about a program that can help.BCA_id_Vl (wecompress.com) .pdfPlease take a look and respond if appropria te-----Original Message-----From: Alex Holbus .:-------- (b~)~(=6)Scot: Tuesday , April 28, 2020 6:59 PM- ----- --,;;..,....,-= To: Fauci , Anthony (N1H/NIAlD) [E] CbH >Subj ec t: Cor onavirn s info about a pr ogram that can he lp.Dear Dr Faucilt's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or exYugoslavia.l am a Economist and Humanitarian. I can talk about my Biography but. at this time the subject I want to share withyou I much more important.ln January 2016 1 sent a letter to Mr Trump (b) (6) telling him that 1 was happy that hewill bring change to America and the world and that ifhe needed my expertise that I wou ld help your count ry andthe world. As 1 have not got any responses from him nor his people I can see that he might not be interes ted. But as Ihave been following you over the media and be read ing about your carrier as a Doctor I believe you know what yourdoing and would like to take this opportuni ty to help you and your country at this time when it's the worst then everbefore in the modem world. I have a program that can help with the coronavirus in the way of identifying peopleand following there movement that can help you collect data faster and more suffic ient. The progr am is based on anapp so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has madeit mandatory that all member state, need to use it and the future members like Serbia. So you will see attached apresentation about the program and if you or your country is interes ted please let me know and I will put you incontact with the company making this program. I did not send this email to you so we make money on people it's tohelp I ju st wanted to help. I will be contacting my contacts in the USA from Thursday morning but first 1 wanted totalk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. Tfnothing comes back from you anyway my friend and contact in the USA will talk with the white house but l wantedto do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus .Anyway wish you and your country all the best and that the world will become a better place after this epidemic isover.Jt's one life one world one human we arc all one on this planet no one is bigger or better the all of us as human ity asone.Kind regardsAlex HolbusDirector at Real Five Compan y.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Tue, 28 Apr 202017 :41:52 +0000(b)(6)Subject: RE: worrisomeYes. Please call to th eir att ention.a nasa l swab___________ C_b>_<6> It is merelyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From : (b)(6) ------------------- Sent : Tuesday, April 28, 2020 10:32 AMTo: Fauci, Anthony (NIH/NIAID) [E] -------= (b=)(=6)Subject: worrisomeFrom today's Medscape.https://www.medscape.com/viewarticle/929407?nlid=135287 5653&src=wnl newsalrt daily 200427MSCPEDIT&uac=71367AK&impl0=2361940&faf=1Older adults with COVID-19, the illness caused by the coronavirus , have several "atypical " symptoms,complicating efforts to ensure they get time ly and appropriate treatment, according to physicians.COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortnes s of breath.But older adults - the age group most at risk of severe complications or death from t his cond ition -may have none of these characte ristics.Instead, seniors may seem "off" - not acting like themselves - early on afte r being infected by thecoronavirus . They may sleep more than usual or stop eating. They may seem unusually apathetic orconfused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniorsstop speaking or simply collapse.(b)(6)From:Sent :Fauci, Anthony (NIH/NIAID) [ElTue, 28 Apr 2020 17:39:34 +0000To:Subject:Janet Tobias;Conrad, Patricia (NIH/NIAID) [ElRE: Riding along tomorrow amOKAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Janet Tobias <jane t @ikanamedi a.com>Sent: Tuesday, April 28, 2020 12:46 PMTo: Fauci, Anthony (NIH/NIAID) [El -------------- (=b)(6)•1>; Conrad , Patr icia (NIH/NIAID) [El (b)(6)Subject: Riding along tomorrow amHi Tony and Patty:Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get thereearly to do one more paper throw. And last night was great!JanetFrom: "Fauc,i Anthony (NIH/NIAID) [E]" <_ _____ Cb<>6>)Date: Sunday, April 26, 2020 at 4:30 PMTo: Janet Tob ias <janet@ ikanamedia.com >Subject: RE: Quick questionMy work with the Coronavirus Task Force and the large volume of incomingemails precludes me or my staff from answering each individual message. I wouldencourage you to visit www.coronavirus.gov for the latest information andguidance related to COVID-19.Thank you, and best regards.Anthony S. Fauci, M.D.From:Sent :To:Subject:Attachme nts:I don't think so.From: Elizabeth HaenleAuchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]Tue, 28 Apr 2020 15:50:24 +0000NIAIDODAMFW: Invitation from the Investment CommunityLetter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf--------- Sent: Tuesday, April 28, 2020 11:36 AM To: Fauci, Anthony (NIH/NIAID) [El -------------- -(b=H6~J> Subject: Invitation from the Investment CommunityDear Dr. Fauci,I am the co-founder of SAGE Wor ldwide, a global speaker and consulting company. I am reaching out onbehalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitationto join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18.Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At thiscritically important time in our nation's history, the investment community wants to help our nationfight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. Theyalso are thinking through how to help our nation's businesses going forward. Your expertise isimportant to this conversation .By way of background, I served in the White House for eight years in the Bush Administration as theSocial Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range ofdiscussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, webring that level of excellence to our business partners as we help curate discussions that have an impacton public awareness and investor sentiment, which is part icular ly impor tant as the U.S. responds toCovid-19.Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals andhealthcare research and are the businesses on the frontline of the Covid-19 healthcare response.Attached please find an invitat ion from UBS with further details of the event. I welcome the opportunityto hear from you at your earliest convenience, and thank you for your important work and dedication toour country's well being over the course of your distinguished career and service at NIAID.Warmest regards,Elizabeth HaenleCo-Founder, SAGE WorldwidePhone: (b)(6)Attachment 1Elizabeth Haenle CmH!l.Co-founder and PresjdeotM: -------(b)(6)E:- -------- (b)(6)W: SAGEworldwide.comcotmThis email and any files transmitted with it are confidential and intended solely for the use of theindividual or entity to whom they are addressed. If you have received this email in error please notifythe system manager. This message contains confidential information and is intended only for theindividual named. If you are not the named addressee you should not disseminate, distribute or copythis e-mail. Please notify the sender immediately by e-mail if you have received this e-ma il by mistakeand delete this e-mail from your system. If you are not the intended recipient you are notified thatdisclosing, copying, distributing or taking any action in reliance on the contents of this information isstrictly prohibited.From:Sent :To:Subject:For discussionAuchincloss, Hugh (NIH/ NIAID) [E] on behalf of Fauci, Ant hony (NIH/NIAID) [ElTue, 28 Apr 2020 14:46:56 +0000NIAID ODAMFW: HIGH SCHOOL MUN CONFERENCEFrom: Dane Cohn (b)(6)>Sent: Tuesday, April 28, 2020 10:44 AM -----~= To: Fauci, Anthony (NIH/ NIAID) [El (b)( >; Barasch, Kimberly (NIH/ NIAID) [C](b)(6); Conrad, --:---:----:----:--:--:-;::::::::::c.:..._ _ Patricia (NIH/NIAID ) [El (b)(6) ; Fauci, ___,:__~=Ant hony (NIH/ NIAID) [E] (b)( 6)Subject: HIGH SCHOOL M UN CONFERENCEDear Dr. Anthony Fauci,My name is Dane Cohn, and I am an (b)( 6). I have oftenlistened to your inspiring words on the news and followed your assiduous work to helpus through this pandemic. Our school participates in Model UN, an event in which highschool studen ts represent various countries in debates on international issues from thepast and present. Colorado's final Model UN conference was canceled , so our school----------- (bH6) ) decided to host an online conference for the whole state of Colorado and beyond . Our team would like to formally invite you to give a shortaddress (be it pre-recorded or live online) to the students during our openingceremony .We hope that our conference will inspire the youth of our nation and the world to standup and fight for our futu re rather than resign their aspirations to lockdown . We host thisconference because we see the importance of keeping our academ ic passions goingwhile staying safe within the confines of our homes. We host this conference becausewe want to contribute to the fight against COVID-19 - money raised from ourconference will go towards buying masks, food, and other resources for those who needit most.This is why we ask you , a hero during this troubling time, to speak to the students of ourconference, who not only include the youth of Colora do , but also the youth of ourcountry and world. Any type of address would be greatly and wholeheartedlyappreciated. If your address is pre-recorded , we would appreciate it if we could receiveit by May 1st, as our conference is the morning of May 2nd . We believe you can bringtrue inspiration into our hearts and minds . We know you are very busy, but if it were atall possib le to share with us even a short 2-3 minute pre-recor ded greeting andmessage to the students participating in this Model UN conference , it would be trulyinspirational. Thank you so much for your time , we hope to hear from you soon .Most Respectfully,Dane Cohn and the entire --------- (b)( 6) Model UN TeamFrom:Sent :To:Cc:Fauci, Anthony (NIH/N IAID) [ElTue, 28 Apr 202011 :25:09 +0000Haskins, Meli nda (NIH/NIAID) [ElConrad, Patricia (NIH/NIA ID) [ElSubject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 68:30 AM would be good. Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Haskins, Mel inda (NIH/NIA ID) [El ---------- (b) ( '> Sent: Tuesday, April 28, 2020 7:08 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6):>Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wed nesday, May 6Let me know when you 'd like me to call please.From: Fauci, Anthony (NIH/NIAID) [E] CbH >Sent : Tuesday, April 28, 2020 7:04 AM ------- -,a-s-r= To: Haskins, Melinda (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6Let us chat by phone t his morningOn Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E]wrote:(b) ( >We do not know if the Dela uro hearing would be remote. The Senate HELP one would bein person with some form of social distanc ing.Sent from my iPhoneOn Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIA ID) [E)-------- (b) (6) wro te :E should make sure that we schedule it at a time of day that does notconflict with the COS visit.From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>Se nt: Monday, April 27, 2020 8:20 PM ------ --=-<= To : Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6This is the day of the VIP visit-whoever it is. VP or COS. Pis advise. And notsure if these are I person or not. I suspect remote right??Sent from my iPhoneBegin forwarded message:From: "Haskins, Melinda (NIH/N IAID) [E]"(b)(6)Date: Apri l 27, 2020 at 8:10:52 PM EDTTo: "Conrad, Patricia (NIH/NIAID) [E]"(b) ~ >Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, " Billet ,Courtney (NIH/NIAID) [E)" (b)( , "Harper, Jill(NIH/NIAID) [E]" (b)(6)Subject: Please advise LHHS Hearing w/ Dr. Fauci -Wednesday,May 6Patty,See below . Another hearing.Thank you,MelindaSent from my iPhoneBegin forwarded message:From: " Hallett, Adrienne (NIH/OD) [E]"(b)(6)Date: April 27, 2020 at 7:57:36 PM EDTTo: "Haskins, Melinda (NIH/NIAID) [E]"(NIH/NIAID) [E)" (b)(6)>,"LaMontagne, Karen (NIH/OD) [E]"(b)(6)>, "Higgins, Lauren-( N- I-H-/:0--D"').-"[:"E--]: ,-': -:=:===~ (b~) ~( > -------- Subject : Fwd: LHHS Hearing w/ Dr. Fauci -Wednesday,May 6Guess they really are coming back.Begin forwarded message:From: "Steigleder, Stephen"(b)(6)>Date: April 27, 2020 at 7:41:56 PMEDTTo: "Hallett, Adrienne (NIH/OD) [E]"(b) ( >Subject : LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6Hi Adrienne,I hope you're doing well.I'm reaching out because ChairDelauro would like to invite Dr. Faucito a hearing next Wednesday, May 6,with the House LHHS appropriationssubcommittee . The focus of thehearing, not surprisingly, would beCOVID-19. Members of thesubcommittee wo uld very much liketo hear from Dr. Fauci on anythingrelated to COVID-19, but I think themain topics would be:• Mitigation and Testing; and• Progress on vaccines,therapeutics, anddiagnostics, as well asnecessary preparations tomanufacture anddisseminate a vaccine once itis ready.Chair Delaura is flexible about astarting time for the hearing onWednesday , so she would be happyto accommodate a t ime that worksfor Dr. Fauci's schedule.Please let me know as soon aspossible, so we can plan accordingly.Thanks so much,StephenStephen SteiglederHouse Appropriations CommitteeLabor/HHS/Education SubcommitteeFrom:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/NIAID) [E)Tue, 28 Apr 2020 00:22:50 +0000(b)(6)FW: Remdesivir--good news20-0006 _DSMB _primary _analysis_report_for _OMI D.pd fFrom: Erbelding, Emily {NIH/NIAID) IE] _______ C>b<_>Sent: Monday, April 27, 2020 8:05 PMTo: Fauci, Anthony {NIH/NIAID) [E] _____ ("b"~""(6=) >Subject: Remdesivir--good newsTon'l,,_ ______________________________ --~(b) (5)EmilyEmily Erbelding, M.D., M.P.H.Director, Division of Microb iology and Infectious DiseasesNIAID/N IH5601 Fishers LaneRockville, MD 20852Tel: (b)(6)From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 22:56:59 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW:Attachme nts: Brown et al submitted .pdf, NIH Presentation final.pp tx,prepr ints202002.0147.v2 (1) .pdf, Mosaheb et al 2020.pdfEmail from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific Project sImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From : Dani Bolognesi , Ph.D. ---------- (b)(6)>Sent : Monday, April 27, 2020 6:09 PM To: Fauci, Anthony (NIH/NIAID) [E] ---------------= C=bH6 l;B arasch, Kimberly (NIH/NIAID) [C] (b )( 6)Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4). (b) (5)(b) (4), (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opportun ity to share this with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D." (b)(6)>Date: Monday, April 27, 2020 at 2:53 PM -----------~~ To: "Matthias Gromeie r, M.D." (b)(6)Subject: Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows:(b) (4). (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you . As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step .All the best,DaniBest,DaniSent from Dani BolognesiThe infor matio n in this electronic mail is sensitive, protected information inte nded only for the addressee(s). Any othe r person,including anyone who believes he/she might have received it due to an address ing error, is requeste d to notify the senderimmediate ly by return electronic mail, and to delete it without further reading or retention . The information is not to beforwarded to or shared unless in compli ance with Duke Health policies on confidentiality and/o r with the approva l of thesender.From:Sent :Fauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 22:17:19 +0000To:Subject:Folkers, Greg (NIH/NIAID) [E);NIAID OD AMRE: COVID/Transportation ImpactsOk. Let us discuss forwarding to CDC>Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 3 I, Room 7 A-0331 Center Dri ve, MSC 2520Nationa l Ins titutes of HealthBet hesda , MD 20892-2520Phone: (b) (6)FA X: (301) 496-4409E-mail (b) (6)The informati on in this e-ma il and any of its attachme nts is confidential and may contai n sensitive infom1ation. Itshould not be used by anyone who is not the original intended recipie nt. lf you have received this e-mail in erro rplease inform the sender and delete it from your mai lbox or any other storage devices. The Nationa l Inst itute ofAllergy and Infectio us Diseases (NlAI D) shall not accept liability for any stateme nts made that are the send er's ownand not expressly made on behalf of the NlAID by one of its representatives.-----Original Message-----From: Folkers, Greg (NlH/NlAID) (E] ---------(b)( Sent: Monday , April 27, 2020 6:15 PM --------= To: Fauci, Anthon y (NTH/NlAID) [E] ---------(b)( ; NJAID OD AM <NIAJD0DAM @niaid.nih.gov > Subject: RE : COYID/fransportation Impactsthis seems like CDC issueThey address some of the issues here:What Ridesbare, Tax i, Limo, and other Passenger Driv ers -for-Hire Need to Know about COVJD - 19https://www.cdc.gov / coronavi ms/20 I 9-ncov /community / orga nizati ons/ ridesbare-drivers -for-h ire.htm ICommunication Too lkit for Transpo1tat ion Parto el'S to Inform Road Travelers Monday, April 27, 2020https: //www .cdc.gov / coronav irus/2019 -ncov / travelers /transportat ion-toolkit.htm lCleaning and Disinfect ion for Non-eme rge ncy Transpo rt Vehicles Tuesday, April 14, 2020https: //www .cdc .gov/ coronav i ru s/? 019-ncov / community /organizations / d isi n fectinQ.-transport-vch icles. h tm I-----Original Mcssage-----F[Ero]m : Conrad, Patricia (NIH/NIAID) [E] ....__ ____ (b_)(_6_) , On Beha l f OfF auci, Anthony (NIH/NIA ID)Sent: Monday, Apri l 27, 2020 6:05 PMTo: NIAID OD AM <NIAID0DAM @niaid.nih.gov >Subject: FW: COVID/Transportation Impacts-----Original Message-----From: Anthony Foxx (b)(6) >Sent: Monday, April 27, 2020 4:39 PM- ------~~ To: Fauci , Anthony (NIH/NIATD) [E] --------- (b)( Subject: COVID/Transportation ImpactsDr. Fauci:This is Anthony Foxx, immediate former US Transportation Secretary, and T great ly enjoyed our interactions (briefthoughts they were) during my time in the last Admi nistrat ion.I write to request your help in advising the transportation community about how to manage through the presentcrisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/ A, whichcould be valuable for rideshare companies (b) (6l), transit agencies, airlines etc. I wouldthink that a I 0-15 minute chat would do wonders. That said, I know you are terribly busy and have so many thingsto do but would appreciate any opportunity to help you get important infonnation out.This could be pulled together rapidly and done within the next week or so,Thanks for your attention to this matter. All my best,Anthony.Sent from my iPhoneFrom :Sent :To :Subject :FYIAnthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 22:00:13 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Update - White House Coronavirus Task Force Mee t ing - 4.28.20National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent :To:Fauci, Anthony (NIH/N IAID) [ElMon, 27 Apr 2020 21:57:57 +0000Lusso, Paolo (NIH/N IAID) [ElSubject: RE: Covid t hrombiThanks, Paolo.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Lusso, Paolo (NIH/NIAID) [E] ---------(b)(6)Sent: Monday, Apri l 27, 2020 12:34- P-M- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6) -~"."':=======~~ Cc: Kovacs, Joseph (NIH/CC/CCMD) (E] (b)(6) Masur, Henry (NIH/CC/CCMD) [E](b)( ; Lane, Cliff (NIH/':N':"".I"A':."l'"D:'".:)'-[":"E':.:]'. ====::- .(.b,.,)...(..,6.:,);>;, -------- Subject: Re: Covid thrombiDear Tony,I talked with Dr. Viecca this morning who shared additional info rmation about his protocol. They startedfrom the pathologica l observation that all patients dying of Covid-19 pneumo nia had diffuse pulmonarymicrothrombosis . Since th ey detect ed almost exclusively white th rombi, they reasoned that they had toblock platelet activation/aggregation, whi le heparin would be ineffective at that stage. Thus, theyt reated a first group of five critica l pati ents with potent anti-aggregant therapy (Tirofiban/ Aggrastat) andapparen t ly in all of them the p02 started to rise within less than 2 hours, they got off the vent ilators andwent on to full recovery. Viecca is an intervent ional cardiologis t (b)( 4)I sent copy of his protocol and contact information to Joe.Let me know if I can be of any further help. All the best,PaoloPaolo Lusso, M.D., Ph.D.Chief, Section of Viral PathogenesisLaboratory of lmmuno regulationBldg. 10, Rm. 6AllNIAID, NIHBethesda, MD 20892Phone: (b)(6) (personal)(b)(6) (lab)Fax: (301) 480-5291E-mail: (b)(6) --------The information in this e-mail and any of its attachments is confident ial and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If you havereceived this e-ma il in error please inform the sender and delete it from your mailbox or any otherstorage devices. The Natio nal Institute of Allergy and Infect ious Diseases (NIAID) shall not acceptliability for any statement made tha t are the sender's own and not expressly made on behalf of theNIAID by one of its representatives.******************************~From:Sent:To:Cc:Subje ct:Attachment s:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 21:57:23 +0000 -----~~ Collins, Francis (NIH/OD) [El- ------ (b)(6) Mascola, John (NIH/VRC) [E)FW: Revised SlidesVaccine Development Slides Revised Draft 042720.pptxPleas respond for both of us. I already cc'd you on an email that I sent to Johnwith a minor comm ent about slide #2.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone (b) (6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Marks, Peter- --------- (b)(6) Sent: Monday, April 27, 2020 1:14 -P-M- ---~~ To: Fauci, Anthony (NIH/NIAID) [El- ------- (b)( >; Collins, Francis (NIH/OD) [El (b )( 6)Cc: Mascola, John (NIH/VRC) [E] -------- (b)( >Subje ct : Revised SlidesDear Francis and Tony,Apologize that t he prior slides were too busy. John conveyed that message. Please see these versionsthat may be more along the lines that you are looking for . (b) (5)Best Regards,PeterFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 21:54:37 +0000Schwetz, Tara (NIH/OD) [ElSubject: RE: Flagging NIH Media Product for Release TomorrowYou could play the role in the movie of my medical school girl friend, which wou ldgive you the possibility of working with Brad Pitt QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail : (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Schwetz, Tara (NIH/OD) [E] (b)(6)Sent: Monday , Apri l 27, 2020 5:49 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Subject: Re: Flagging NIH Media Product for Release TomorrowNow, you also have the answer to who would play you in a mov ie! ©Tara A. Schwetz, PhDActing Director, NINRAssociate Deputy Director, NIHA: Building 1, Room 138 P: (b)(6) I M: ---------(b-)(,6;) -,-=From: "Fauci , Anthony (NIH/NIAID) [E]" CbH6)Date : Monday, April 27, 2020 at 5:46 PMTo: Tara Schwetz (b)(Subject: RE: Flagging NIH Media Product for Release TomorrowThanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pittlooked "exact ly like me". That stateme nt made my year. (Q)Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveInformation. It should not be used by anyone who Is not the orig inal Intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Schwetz, Tara (NIH/OD) [El (b)( >Sent : Monday, April 27, 2020 5:11 -PM-- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Marston , Hilary (NIH/NIAID) [E] (b)(6) ; Conrad, Patricia (NIH/NIAID ) [E](b)(6)>; Barasch, Kimberly (NIH/NIAID) [CJ (b)(6) Myles,Renate (NIH/OD) [El (b)( ; Walsh, Elizabeth (NIH/OD) [El (b)(6)Subject: Flagging NIH Media Product for Release TomorrowTony,Please see below and attached a ti me-sensit ive COVID-19 item for your awareness and sharing wit h t herema inder of the Task Force, as appropriate. The plan is to release this tomorrow.Item 1: Title : Rapid Acceleration of Diagnostics (RADx) InitiativeActivity Type : Funding of new research programSummary: With a (b)(5) investment from fede ral st imulus fund ing, RADx initiat ive will infusefund ing into early innovation techno logies to speed deve lopment of rapid and widely accessibleCOVID-19 tes ting. At the same time, NIH will seek opportunit ies to move more advanceddiagnost ic technolog ies swiftly through the development pipeline towa rd commercialization andbroad availabil ity. As part of the init iat ive, NIH is urging scientists and inventors with a rapidtest ing technology to compete in a nat ional COVID-19 test ing challenge for a share of up to $500million over all phases for further developmen t. The goal is to add tens of millions per month ofaccurate and easy-to-use tests to all Americ ans by Fall 2020.Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, andcommercializ ati on of innovative new testing methods that can be deployed in point-of-care andhome settings. These technologies are urgently needed to guide and inform safe return to work,schoo l, and life activities.Office : National Institute of Biomedical Imaging and BioengineeringAction Date: Solicitation announcement April 28, 2020Type of Action: Research Program AwardPotential for Press Coverage: Mainstream PressPress Release in Development? : YesDo let me know if you have any questions.(Also, Brad Pitt?! Wow, that was a real ly nice shout out/thank you.)Best,Tara A. Schwetz, PhDActing Director, NINRAssociate Deputy Director, NIHA: Building 1, Room 138 ---~~ P: (b)(6) I M: (b)(6)From :Sent:To:Cc:Subject :Att achment s:Deb:Fauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 21:48:46 +0000Birx, Deborah L. EOP/NSCRedd, Stephen (CDC/DDPHSIS/OD);Hahn, StephenFlagging NIH l'vledia Product fo r Release Tom orrow2020-04-27 COVID-19Week lyReport _ NIBIB OD_tas.docxAs an FYI. This is an initia tive from NBIB/N IH on development of POCdiagnost ics for SARS-CoV-2.Best,TonyAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 21:39:57 +0000Stover, Kathy (NIH/NIAID) [E)Cc:(NIH/N IAID) [ElSubject:Billet, Courtney (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, PatriciaRE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in childrenLooks fine. Thanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail,___,,. __ _, (b)(6)The in ormation inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Stover, Kathy (NIH/NIAID) [El (b)(6)>Sent: Monday, Apri l 27, 2020 4:57 PM ------= = To: Fauci, Anthony (NIH/NIAID) [El (b)(6)>Cc: Billet, Courtney {NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El_______ Cb>C_6,); Conrad, Patricia (NIH/NIAID) [E) (b)(6)>Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in childrenHi Dr. Fauci,Please find attached fo r your review a draft release about the launch of t he HumanEpidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determinethe percentage of children infected with SARS-CoV-2 and the percentage of infected childrenwho develop COVID. In addition , the study will examine whether rates of SARS-CoV-2 infectiondiffer between children who have asthma or other allergic conditions and children who do not.Your draft quote is as follows :110ne interesting feature of this novel coronavirus pandemic is that very few childrenhave become sick with COVID-19 compared to adults," said NIAID Director Anthony S. Fauci,M.O. "Is this because children are resistant to infection with SARS-CoV-2, or because they areinfected but do not develop symptoms? The HE ROS study will help us begin to answer theseand other key questions."Thanks much,KathyKathy StoverBranch ChiefNews and Science Writing BranchNational Institute of Allergy and Infectious Diseases (NIAID)Office of Communications and Government RelationsNational Institutes of Health/HHS31 Center Drive, Room 7Al 7EBethesda, MD 20892Phone: (b)(6)E-mail (b) (6)NIAID Media Line: (301) 402-1663From :Sent:Fauci, Anthony (NIH/N IAID) [E)Mon, 27 Apr 2020 21:04:24 +0000To: ---------~~ Auch incloss, Hugh (NIH/N IAID) [C) ----------- (b)( 6) Cc: Conrad, Patricia NIH/NIA ID [E);Jean W PapeSubject :Attachment s:Hugh:Than ks,To nyAnthony S. Fauci , MDDirec torPlease t ake care of it.National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)(b) (4)(b) (6), (b) (4)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From : (b)(6) ---------------- Sent: Monday , April 27, 2020 3:01 PM To: Fauci, Anthony (NIH/NIAID) [E] ---------------=---=-(b)-(6-) :-= Subject : (b) (4)To ny,(b) (4), (b) (6)Best,BillJEAN WILLIAM PAPE, MDHoward and Carol Holtzmann Professor of Clinical Medicine,Center for Global Health, Division of Infectious Diseases, Department of Medicine,Weill Cornell Medical College, New York, New York, USA402 East 67th Street, New York, NY 10065Tel (Office) (b)(6)Director,Les Centres GHESKIO,33, Blvd. Harry Truman, Port-au-Prince, Ha'iti.Tel (Office): (b)(Voip: (b)(6)From:Sent:To:Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 16:09:04 +0000NIAIDODAMSubject: FW: The National Organization of Ital ian Americans in Film & Television(NOIAFT) - Int erview RequestPatricia L. ConradPublic Health Ana lyst andSpecial Assistant to the Direc torNational Inst itut e of Allergy and Infectious DiseasesThe National Institutes of Heal th31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The informat ion in this e-mail and any of its attachments is confidentia l and may conta in sensi tive information. It should not be usedby anyone who is not the original intended recipient. If you have rece ived this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID ) shall not acceptliab ility for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.From: Taylor Taglianetti <taylor@noiaft.org>Sent: Monday, April 27, 2020 12:03 PM -------~~ To: Fauci, Anthony (NIH/NIAID) [El .:=========~~ Cc: Fauci, Anthony (NIH/NIAID) [El ________ ...Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - InterviewRequestDear Dr. Fauci,I hope this email finds you wel l. My name is Taylor Taglianetti and I am the founder of the Nationa lOrganization of Italian Americans in Film & Television (NOIAFT).Our organization is so very proud of the work you are doing for our country and sends tremendousthanks for the hope and reassurance you have instilled during these trying times.It would be an honor to conduct a short inte rview with you. Our organization includes many youngItalian Americans breaking into the entertainment industry and with the coronavirus dramaticallyimpact ing our field, I'd love to ask you a few questions about what the future of theentertainmen t business looks like. We'd be happy to send the questions in advance for your approval. Ifyou don't have time for a phone call, the questions can be answered via email at your leisure .Thank you for your time and consideration.Sincerely,Taylor TaglianettiFounder, The National Organization of Italian Americans in Film & Television (NO/AFT)(347) 686-4968www.noiaft.orgtaylor@noiaft.org
(bX5)-PCl1(bX5) -PCP.(bXS) - PCP.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 14:19:38 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: RE: Media query: CNN, re: ASF's NAS web briefing on SaturdayI was referring only to animal (macaque) models. I never said that it looked goodin humans. Human clinical trials are ongoing to answer t hat question . Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Sent: Monday, April 27, 2020 9:30 AMTo: Fauci,A nthony (NIH/NIAID) [E]------= (b")"(=6J>Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on SaturdayPis adviseSent from my iPhoneBegin forwarded message:From: "Leifman, Laura (NIH/NIAID) [E]" --------- (b) (6),>Date: April 27, 2020 at 9:27:13 AM EDT -------~~ To: "Conrad, Patricia (NIH/NIAIO} [E]" ----------- CbH6J>N, IAID FOG <fog@ niaid .nih.gov>Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquir ies<mediainquiries@niaid.nih.gov>Subject: Media query: CNN, re: ASF's NAS web briefing on SaturdayElizabeth CohenCNNElizabeth.Cohen@turner.comTopic: Statement by ASF during Saturday NAS web briefingDeadline: urgentHi Patty,Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesiv irduring his NAS web briefing on Saturday. The transcribed segment of the talk that she isfocused on says:"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at itin a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good.There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 inrhesus macaques."She wants to clarify what Dr. Fauci meant by looking at remdesivir " in a prophylactictherapeutic model in MERS"-whether this means in an animal model or something else. Itsounds like that phrase is referring to the RML study in which remdesivir successfullyprevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAIDmedia availability pasted below . Is that correct?Best,LauraRemdesivir Prevents MERS Coronavirus Disease in MonkeysResults Support Testing Antiviral Against 2019 Novel CoronavirusFebruary 13, 2020The exper imental antiviral remdesivir successfully prevented disease in rhesus macaquesinfected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to anew study from National Institutes of Health scientists. Remdesivir prevented diseasewhen administered before infection and improved the condition of macaques when givenafter the animals already were infected.The new report from NI H's National Institute of Allergy and Infectious Diseases (NIAID)appears in the Proceedings of the National Academy of Sciences.MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously knownas 2019-nCoV) that has grown to be a global public health emergency since cases were firstdetected in Wuhan, China, in December.Remdesivir has previously protected animals against a variety of viruses in labexperiments . The drug has been shown experimentally to effectively treat monkeysinfected with Ebola and Nipah viruses. Remdesivir also has been invest igated as atreatment for Ebola virus disease in people.The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton,Montana. The work involved three groups of animals: those treated with remdesivir 24hours before infection with MERS-CoV; those treated 12 hours after infection (close to thepeak time for MERS-CoV replication in these animals); and untreated control animals.The scientists observed the animals for six days. All control animals showed signs ofrespiratory disease. Animals treated before infection fared well: no signs of respiratorydisease, significantly lower levels of virus replication in the lungs compared to controlanimals, and no lung damage. Animals treated after infection fared significantly betterthan the control animals: disease was less severe than in control animals, their lungs hadlower levels of virus than the control animals, and the damage to the lungs was lesssevere.The scientists indicate that the promising study results support additional clinical trials ofremdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Severalclinical trials of remdesivir for COVID-19 are under way in China, and other patients withCOVID-19 have received the drug under a compassionate use protocol.The Biomedical Advanced Research and Development Aut hority (BARDA), part of the U.S.Department of Health and Human Services, also provided support for this study . GileadSciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in theresearch.MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World HealthOrganization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3).Because about one-third of MERS-CoV cases spread from infected people being t reated inhealthcare settings, the scientists suggest that remdesivir could effectively prevent diseasein other patients , contacts of patients , and healthca re workers . They also note the drugmight help patients who are diagnosed with MERS or COVID-19 if given soon aftersymptoms start.ARTICLE:Ede Wit et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesusmacaque model of MERS-CoV infection. PNAS DOI: 10.1073/pnas .1922083117 .WHO:NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator inNIAi D's Laboratory of Virology, are available to comment on this study.From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 14:11:59 +0000Lerner, Andrea (NIH/N IAID) [ElFW: Coronavirus Antigen Mi croarrayPlease t ake a look and handle.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Anderson, Cassandra (NIH/NIDDK) [E] ------------(b) (6)•> Sent: Monday, Apri l 27, 2020 8:17 AM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: Coronavirus Antigen MicroarrayGood morning Dr. Fauci,I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.Thank you for all the information you have provided to our nation . I also want to say you are doing aterr ific job in handl ing the COVID-19 virus, without you and your staff I don't know wher e our countrywould be.I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sentthis email, but I tho ught of you and your staff . Please see the email below .Thank you again for all that you are doing to help keep us safe!Stay safe!Cassandra AndersonAdmin istrative ProfessionalBldg. SO Room 4133301-402-7845From: Yufei Jiang <yufei.jiang@sinobio logical.info>(b)( >Sent : Monday, April 27, 2020 8:04 AMTo: Anderson, Cassandra (NIH/NIDDK) [E) ------------- Subject: Coronavirus Antigen MicroarrayHi Cassandra,Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigenMicroarray (CoVAM) which belongs to our Sinommune™ Mu ltiplex Antigen Microarray product line. Youmay get more details from the following link:https ://www. sinobio logica I .com/ research/virus/ coronavi rus-arrayCurrently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each arraythere are 65 antigens related to the viruses that can cause upper respiratory tract infections includingthe most recent SARS-CoV-2T. he list price is $3,200/slide . Please contact me for how to place the orderif you are interested or need more information.So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19infect ion, and 2) Evaluating antibody reactiv ity in animals (monkeys and mice) after vaccination . Pleasebe advised that our array is for research use only (RUO), not for the diagnostic purpose which needs theFDA approval.After you run the samples on the slide, you may read the slide on the following compatible machines:https://www.innopsys .com/en /lifesciences-products/m icroarrays/innoscanhttps://www.moleculardev ices.com/produc ts/additional -products/genepix-microarray-systemsscanners#grefhttps://www.agilent .com/en /produ ct/cgh -cgh-snp-microarray-platform/cgh- cgh-snp-microarrayscanners-equipment/surescan-m icroarray-scanne r-228493Thanks.-YufeiYufei Jiang, PhDManager, NY, MD, DC, VASales & Business DevelopmentSino Biological US Inc.1400 Liberty Ridge Dr., Suite 101Wayne, PA 19087Celli (b) (6)Email: yufei jiang@sinobiological.comwww.sinobiological.comFrom:Sent :To:Subject:Let us discuss.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 14:11:06 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Otto e Mezzo - Ita lian ShowNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representative s.From: Torchia Patrizia <Patrizia.Torchia@la7.it>Sent: Monday, Apri l 27, 2020 8:05 -AM-- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] --------- (b)(6) Subject: Otto e Mezzo - Italian ShowDear Mr. Fauci,I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show Otto e Mezzo,hosted daily by journa list Lilli Gruber on La7 channel.I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explorein more depth the challenges Coronavirus has forced the world to face. Can make this happen?Below is Lilli Grube r's bio and a brief descript ion of the show.WHO :Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto emezzo", airing on prime-t ime on La7 TV. She's received Italy's most prestigio us journalism awards forher work and was the first woman to ever conduct the prime-time News broadc ast in Italy (RAI TV,1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall ofthe Berlin wall to 9/11 to the Iraq war. Beside her te levision work, Ms. Gruber wrote eleven bestsellerbooks including "Eredita", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruberwon a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to theEuropean Parliament. There, among other appointments, she was the Head of the EU Delegation to theGulf States and Yemen and a member of the EU Delegation to Iran."Otto e mezzo"Italy's most influential political daily ta lk show shown on prime-time on La7 TV. Through interviews withelected political figures and candidates for office, commentators, and journal ists, the show focuses oninternational political news and economy wi th a special focus on Italy and Europe. Beginning in2008 "Otto e Mezzo" became Lilli Gruber's way to keep her commitment to holding those in poweraccountable by asking questions and touching on topics citizens are curious about. Otto eMezzo airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's newscolumn "II Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest ratedissues in an agenda. During the current season Otto e Mezzo has become Italy's most watched politicaltalk show reaching an average of 7.3% of share wi th 2.5 million viewers per day.Production location( s): La7 studios, via Umberto Navaro 32, Rome, ItalyPresented by: Lilli GruberOriginal network: La 7Executiv e produ cers: Stefania BucciarelliDirected by: Lorenzo Fontanawww.live.la7.itwww.ottoemezzo.la 7 .itTwitter: @OttoemezzoTW)Facebook : Ottoemezzola7)Thank you in advance for the considering. Looking forward to hearing from you.Patty TorchiaOtto e Mezzo(b)(6)From:Sent :To:Subject:Not really.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Mon, 27 Apr 2020 14:08:24 +0000Conrad, Patricia (NIH/NIAID) [E)RE: Fauci and PayPalNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Conrad , Patricia (NIH/NIAID) [E] ----------(b)(6) Sent: Monday, Apri l 27, 2020 9:54 AMTo: NIAID OD AM <NIAIDODAM@niaid .nih.gov>Subject: FW: Fauci and PayPalPatricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496 -4409 faxDisclaimer:The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID ) shall not acceptliab ility for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.From: Fetalvo, Ninio J. EOP/OVP (b)(6) _________... __Sent : Monday, April 27, 2020 9:51 AM -------- == To: Conrad, Patricia (NIH/NIAID) [E] ---------- (b)(6) Subject: FW: Fauci and PayPalFYI-Defer to you on this.From: Miller , Amanda <amanmiller@paypal.com >Sent : Monday, April 27, 2020 9:18 AMTo: Fetalvo, Ninio J. EOP/OVP_ _________ ("b"~'"'(=6)Cc: Walters, Lindsay <Lindsay.Walte rs@edelman.com >Subject: [EXTERNAL] Re: Fauci and PayPalHi Ninio,We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO andPresident Dan Schulman to talk about safety measures, health and science tied to COVID-19. We wou ldair the conversation during a global employee all hands to our 23,000 employees and then we couldsyndicate parts of it externally on our social channels.Thanks for any help in reaching Fauci's team .Thanks,AmandaAmanda Christine Mill erSenior Director, Corporate Communications408.219.0563@PayPalNews• PayPalFrom:Sent:To:Fauci, Anthony {NIH/NIAID) [E]Mon, 27 Apr 2020 14:07:40 +0000Lerner, Andrea {NIH/NIAID) [E]Subject : RE: ------------------------ (b) (4)Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: {301 496-4409E-mail: (b)(The info rmation in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intend ed recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Lerner, Andrea {NIH/NIAID) [E) --------- (b)( >Sent: Monday, April 27, 2020 10:05 AMTo: Fauci, Anthony {NIH/NIAID) [E) ------ -(=b-)s(-=r6)Subject: Re: ------------------------ (b)(4I will make sure they get a response!From: "Fauci, Anthony (NIH/NIAID) (E]" ---------(b)(6) >Date: Sunday, April 26, 2020 at 8:43 PM To: "Lerner, Andr ea (NIH/NIAID) [E]" ----------=-:C-b):(6-) =Subject: FW: Update: -------------------------- (b)(4Please respond to this person. Thanks.From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>Se nt: Wednesday, Apr il 22, 2020 9:41 AM --------~~ To: Coomes, Stephanie {NIH/NIAID) [E) _________ CbH_6)>; Fauci, Anthony {NIH/NIAID) [E)(b)(6)Cc: '-:-""'."""".~-:----::== (b=)=(6:)::;: :K.:..:i:.r.:c:.:..h::~e. .i:s..:.D::.r;...: .:R..::a..l;.f: .<...R:=K=i=rc=h=ei=s:@=::s::y:::n:::t=:a=c:o::1::1:::d.::::e::>_. ___ ,.._,,._,Subje ct: Update: (b)( 4) ------------------------ 1 mp o rt an c e: HighDear Dr. Fauci,dear Dr. Coomes,thank you for your reply from 13. April with the notice that the information has been shared with NIAID'sCOVID-19 research team.Has the project already been initially evaluate d by the team?Are there any questions or need for additional information?Looking forward to hearing from you.Kind regards,RalfMit freundlichen Gru~en / Kind regardsDr. Ralf KircheisDirector R&DResearch & DevelopmentMail: RKircheis@syntacoll.dePhone: +49 9441 686048s~ntacollSyntacoll GmbH, Donaustrasse 24, 0·93342 Saal a. cl. DcnauTel: +499441 / 68 60 0, Fax: +49 9441/6860 30Handelsregister : Amtsgericht Regensburg - HRS 1612USt- JdNr. DE 128580796Gesch3ftsfuhrerin: Dr. Alexandra Dietr ichUnsere Hinweise zum Datenschutz, insbesondere zu den Jhnen zustehenden Rechten, finden Sie unterwwws votacond.eJdatenschutz(b) (4)Von: Coomes, Stephanie (NIH/NIAID) [El -------------- (b)(6) Ge send et : Montag, 13. Apri l 2020 02:37An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>Betr eff: RE: ___________________ Cb _H_4) _,CbH_5)Dear Dr. Kircheis,Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division ofMicrobiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases(NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleasedto respond .I want to thank you for reaching out to share this informat ion and let you know that your mes:;age ha:;been shared with NIAi D's COVID-19 research team .Sincerely,StephanieStephanie M. Coomes, Ph.D.Health Scientist AdministratorOffice of Scientific Coordinat ion and Program OperationsDivision of Microbiology and Infectious DiseasesNational Institute of Allergy and Infect ious DiseasesNational Institutes of Health5601 Fishers Lane, Room 7G68Rockville, MD 20892(b)(6)(b)(6)Disclaime r: The informat ion in this email and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inally intended recipient. If you have received th isemail in erro r, please inform the sender and delete it from your mailbox or any ot her storage devices. The Nationa lInstitu te of Allergy and Infectious Diseases shal l not accept liability for any statements made that are the sender 'sown and not express ly made on behalf of NIAID by one of its represe ntatives .From: Kircheis Dr. Ralf ') (b)( ~ >Sent: Wednesday, Apr il 8, 2020 2:49 AMTo: Fauci, Anthony (NIH/NIAID) [El ..------ --,.(b.)._c=- >; Billet, Courtney (NIH/NIAID) [El-------- (b)(6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov> Cc: Fischer, Elizabeth (NIH/NIA ID) [El (b)(6>i>; Foster, Erin (NIH/NIAID) [El(b)(6) Foster, Sarah {NIH/NIAID) [El CbH >; Vasilenko, Olga{NIH/NIAID) [El (b)( >; Vasquez, Aurelio (NIH/NIAID) [El---------- CbH >; Vostal, Alexander (NIH/VRC) [Fl (b)(6J>;V azquez- Maldonado , Nancy (NIH/NIAID) [El (b)( >; Austin, James (NIH/NIAID) [ElCbH '>; Agulto, Liane (NIH/NIAID) [E] CbH6JD; eckhut, Alison(NIH/NIA ID) [El (b)(6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>Subject: WG: ------------------------ (b) (4), (b) (5) 1 mp o rt an c e: HighDear Dr. Fauci,dear Madams/Sirs,(b) (4), (b) (5)I want to bring to your attension some pote nt ially impo rtant experimenta l data and a new proposa l fortreatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry forthe broad distribution but I wanted to make sure tha t my message reaches you.(b) (4), (b) (5)Please forward this mail to the colleages you consider relevant for evaluation, discussion andconsideration for your clinical strategy for COVID-19.Please let me know if additional informations are necessary.(b) (4). (b) (5)To my person: I have MD PhD degree and have many years experience in phar maceutical development{Boehringer lngelheim ), Biotech {lgeneon , Aphton , Virolog ik GmbH) {for reference see also PubMedKircheis r) currently leading R&D activities at Syntacoll {part of lnnocoll). I am providing this informationpersonally in order to help to find a treatment for COVID-19 patients .Looking forward to getting feedback from you,With kind regards,Ralf Kircheis {MD PhD)(b)(6)rkircheis@svn ta coll .de(b) (4), (b) (5)Mit freundlichen Grur..en / Kind regardsDr. Ralf KircheisDirector R&DResearch & DevelopmentMail: RKircheis@syntacoll.dePhone: +49 9441 686048s~ntacollSyntacoll CmbH, Donoustrasse 24, D 93342 Saa l a. d. DcnauTel: +49 9441 / 68 60 O, Fax: +49 9441 / 68 60 30Handelsregister: Amtsgericht Regensburg - HRB 1612USt-ldNr DE 128580796Gescha~sfuhrenn: Dr . Alexandra Dietr ichUnsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unterwww.syntacoll .de/da tenschutz(b) (4). (b) (5)
(bX5) -PCP.
From:Sent :Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 12:33:44 +0000To: Jeremy FarrarSubject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 part icipati onThanks, Jeremy. I saw the report in the Post from Saturday. These children hadmostly respiratory disease and diarrhea . I wi ll check with the docs at DCChildren's Hospital about the presence of " mult isystem inf lammatory state". Thiscould just be the advanced stage of their disease compatible with advancedSARS-COV-2Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892 -2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and dele te it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Jeremy Farrar _______._... _ (b)(6)Sent : Monday, Apri l 27, 2020 7:38 AMTo: Fauci, Anthony (NIH/NIAID) [E] _____ --,a(b.~,.c=..6)>; Dzau, Victor J.<VDzau@nas.edu>; GeorgeGAO (b)(6)>(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia ========-=-~ (b)( >; Teresa Miller de Vega (b)( >;(b)(6); Rebeka Yasmin - CEPI (b)(6); ben.tinker@cnn.com; ---- -----~= Amanda.Sealy@cnn.com; Neel.Khairzada@turner .com; Tia.Miller@turner.com; (b) (6)McGinnis, J. Michael <MMcGinnis@nas.edu>; (b)(6) Mun, Jenny<JMun@nas.edu>; (b)( Redfield, Robert R. (CDC/OD) (b)( '>Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25participationThanks Tony- have asked for that and wi ll share as soon as I can.I believe the re have been reports in the Washington Post.https://www .washingtonpost .com/local/new-dc-hospital-numbers-suggest-kids-do -face-some-riskof-coronavi rus-hospitalization/2020/04/25/Se 78c268 -86fe-11ea-878a-86477 a 724bdb story.htmlFrom: "Fauci, Anthony (NIH/NIAID) [E]" <f CbH>6 )Date: Monday, 27 April 2020 at 12:36To: Jeremy Farrar (b)(6) , Victor Dzau <VDzau@nas.edu >, Geo rge Gao(b)(Cc: Ric hard Hatchett (b)(6)" ann n, Emma" <EHannon@nas.edu>, "Conrad,Patricia (NIH/NIA ID) [E]" Cb)< >, Teresa de Vega------------- Cb>< , Rebeka Yasmin - CEPI ---------- (b) (6 ) "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda. Sealy@cnn .com" <Amanda.Sealy@cnn.com >, "Neel. Khairzada@turne r.com"<Neel.Khairzada@turner.com >, "Tia.Miller@turner.com " <Tia .Miller@turner.com >,(b)(6) "McGinnis, J.Mic hael" <MMcGinn is@nas.edu >,(b)(6) "Mun, Jenny" <JMun@nas.edu>,CbH6") Redfield , Rob ert R. (CDC/OD)"(b)(6)r------------Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 participationJeremy:Thanks for the heads up. Is there any more detailed description of the preciseclinical manif estation s? They describe a "mul tisystem inflammatory state 11• It isvasculitis or anything more specific? Could be an infectious agent that hasnothing to do with SARS-CoV-2 infection even though some children arecircumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2inflammatory syndrome , perhaps a Kawasaki syndrome-like disease. Please keepme informed if you hear any further information.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: Cb()6 )FAX: (301) 496-4409E-mail --------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jeremy Farrar ________ (b _)_(6)>Sent: Monday, April 27, 2020 7:13 AM ------- ~= To: Fauci, Anthony (NIH/NIAID) [E] _______ (b_H_6); Dzau, Victor J.<VDzau@nas.edu>; GeorgeGAO (b)(6) >Cc: Richard Hatchett (b)(6) --=====~--~--~--~:----:--~ "':""""-:---"".'"":"-:.:======H=a-n~no~n , Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b)(6) Teresa Miller de Vega (b)(6) ;(b)(6)· Rebeka Yasmin - CEPI (b)( >; ben.tinker@cnn.com; ____ _,,Amanda.Sealy@cnn.com: Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6);McGinnis, J.Michael< MMcGinnis@nas.edu>; (b)(6)> ; Mun, Jenny<JMun@nas.edu>; (b)(6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25pa rtici pat ionTo be aware of - news over night so a huge amount of uncertainty - important for COVID19n ow, and apotenti al concern for how we view immunity, protection, post-infect ious immunopathology.https://www .hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-beemerging-in-children/7027496.articlehttps://t.co/Bj6YH U8ziFrom: "Fauci, Antho ny (NIH/NIAID) [E]" (b)(6)Date: Sunday, 26 April 2020 at 19:52To: VictorD zau <VDzau@nas.edu >, George Gao ______ ...- -------~ =Cc: Jeremy Farrar (b)( 6} , Rich ard Hat chett _________ (b><6 )"Hanno n,Emma" <EHannon@ nas.edu >, "Conrad , Patricia (NIH /NIA ID) [E]" (b) (6)>,Teresa de Vega (b) (6)>, RebekaYasmin - CEPI (b)( , "ben. tinker@cnn.com " <ben. tinker@cnn.com >,"Amanda.Sealy@cnn.com " <Amanda.Sealy@cnn.com >, "Neel.Khairzada@turner.com "<Nee l.Khairzada@turner .com>, "Tia.Miller@turner.com" <Tia .Miller@turner.com >,---------------- (b)( 6) "McGinni s, J.Mi chael" <MMcG innis@nas.edu >,CbH>6,) "Mun, Jenny" <JMun@nas.edu>,(b)( 6)Subject: RE: NAS Annual Meeting Sess ion on COVID-19 -- Information regarding yourSaturday April 25 participationIt was a real pleasure to join all of you on this important session. Many thanks forinviting me.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb()6 )FAX: (301) 496-4409E-mail -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and dele te it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J.< VDzau@nas.edu>Sent: Saturday, April 25, 2020 3:59 PMTo: George GAO (b)(6)Cc: Fauci, Anthony (NIH/NIA ID) [E] ----------------~~Emma <EHannon@nas.edu >; Conrad, Patricia (NIH/NIA ID) [El; Hannon,------------------------- (b) (6) ben.tinker@cnn .com; Amanda.Se a I y@ c n n. com; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)McGinnis, J.Michael< MMcGinnis@nas.edu >; (b)(6J>; Mun, Jenny------ (b)(6); haja.bally@cepi.net Subject: Re: NAS Annual Meet ing Session on COVID-19 -- Informat ion regarding your Saturday April 25participationDear Jeremy, Tony, Sanjay, George, Susan and Richard,Thank you so much for your superb contributions. It was a spectacular session- a tmly inspiringone. I am grateful to all of you.Hope to see you soon .Warm est regards,VictorOn Apr 25, 2020 , at 1: 22 PM, George GAO -------CbH6>) wrote:I am waiting for being connected and will use slides which were sent to your officeGeorge~ § ilt 1¥-JiPhone1± 2020~4 Fl 24 B . 0 l :49, Dzau , Victor J. <VDzau @nas.edu>~Ji:Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really looking forward to this panel on COVID-19 at the NAS AnnualMeeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendousexcitement and enthusiasm, and registrat ion is through the roof.I am sending this note to do a last minute check to see if there is anything youneed from me. I also want to check whether you are planning to use slides.Will you be sending your slides to us to project or use the share screenfeature to advance your own slides? Regardless, it would be helpful to me ifyou could send me your slides for my preparation.I would greatly appreciate it if you wou ld respond to this email.Best,VictorPS, (b)(6) my special assistant, will be sending you additionalinformation about the session logistics short ly.From: Dzau, Victor J.< VDzau@nas.edu>Sent: Thursday, Apr il 9, 2020 11:01 AM---------- (b)(6); 'ben .tinker@cnn.com ' <ben.tinker@cnn.com >; 'Amanda.Sealy@cnn.com ' <Amanda .Sealy@cnn.com >;'Neel. Khai rzada@turner .com' <Neel.Khairzada@turner.com >;'Tia.Miller@turner .com' <Tia.Miller@turner .com>; 'hujr@chinacdc.cn'(b)(6)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Informationregarding your Saturday April 25 part icipa t ionDear all,Thank you for agreeing to participate in a special late breaking sessionon the COVID-19 pandemic at the NAS annual meeting. Knowing howbusy you are , I am sending this email in lieu of a call to prepare for thesession.As you know, this is a 90 minute session which aims to provide ouraudience with deeper insights into the latest developments in theCOVlD-19 response. I plan to hold an engaging discussion that coversthe whole experience on dealing with this pandemic - from US tointernational, to preparedness and response, the biology of the virus, thestate of diagnostic , treatment and vaccine development , and theimportance of commun ication.I will begin the session by providing brief ( ~ 3 min) opening remarksdescribing the circumstances of the pandem ic. Then , I will introduce thepanelists and you will each have 7 minutes to provide remarks. Youmay use a limited number of slides for illustration . I hope that eachpanelist will provide their own perspective and speak to the issuesproposed below.• Jeremy Farrar will discuss the global response to the pandemic,drawing from his experience as a global leader, the chair of theScientific Advisory Group for the VvHO's R&D Blueprint and asa member of the Global Preparedness Monitoring Board .• Tony Fauci will discuss the US pandemic and provide hisperspective as a member of the White House Coronavirus TaskForce addressing the 2019- 20 coronavirus pandemic.• George Gao will discuss China 's response to the pandemic andlessons learned for the rest of the globe.• Susan Weiss will discuss the viral characteristics of SARSCOV2, insights into its pathobiology, immunity anddevelopment ofa pan-CoV antiviral.• Richard Hatchett will discuss the development of new vaccinesand treatments against COVID-19.• Sanjay Gupta wtll comment on the health system response to thepandemic and challenges related to communication and publicengagement in responding to COVID-19.Following remarks from each panelist, we will have a moderateddiscussion amongst ounelves - I will ask you a set of questions ( 15mins) and then we will take questions from the web (25 mins). Toprepare me to be your moderator , please send me any questions youwould like me to ask you. For those of you who would like to have aprep call, please let me know and I will set it up.Best,VictorFrom: Mun, Jennysent: Wednesday, April 8, 2020 10:56 AMTo:(b)(6)'ben .tinker@cnn .com' ; 'Amanda .Sealy@cnn.com'; 'Neel.Khairzada@turner.com'; 'Tia.Miller@turner .com'Subject: NAS Annual Meeting Session on COVID-19 -- Information regardingyour Saturday April 25 participationDear Speakers:I am the logist ical contact for the COVID-19 session that will be held as part ofthe Ann ual Meet ing (online) program on Saturday, Apri l 25 at 2:00 pm EDTThank you for agreeing to participate in this session. To help you with yourplanning, I have provided additional details below .Please note that the session wi ll be live webcast and the general publ ic willalso be able to watch the session. Video from the session will also beuploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting. We willneed to obtain signed speaker release forms for your participation in thissession. I have attached the speaker release form for your review andsubmission. Please return the signed speaker release form by Monday , April13.Session speakers are asked to connect 30 minutes prior to the session starttime (by Saturday , April 25 at 1:30 pm EDT) to allow the technical staff tocheck connect ions and prepare for the session. Details on how to connect willbe sent before t he meeting .We will list you in our promotional materials as noted below . If this isincorrect , please let me know.Anthony S. Fauci, Directo r, National Institute of Allergy and InfectiousDiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control &PreventionSanjay Gupta, Chief Medical Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microbiology , Perelman School of Medicine,University of PennsylvaniaSince many of us have moved to remote work environments, you mayalready be proficient with Zoom and other on line meeting/collaborationapplications . I am attaching a 'speaker guidelines' file in case you have anyquestions on how best to prepare for and stage your remote talk. We havetechnical staff available to help you become familiar with Zoom and itssettings - such as "sharing your screen" (if you have slide presentations thatneed to be shown during your talk). We can arrange for a training session thisweek or next week. If you wou ld like to schedule a session, please let meknow as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If youhave any othe r questions , please let me know.Regards, Jenny********************~***********Jenny MunMembership DirectorNational Academy of Sciencesjmun@nas.edu(b)(6)From:Sent:Subject:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 18:45:27 +0000SNL revi ew(b)(6)OKAY, so here is something even better than having Brad Pitt portray me onSNL. It is a recent review of Pitt 's performance in which the TV reviewer said :" Kicking things off, the Oscar winner dropped jaws during the cold open withhis monologue about President Donald Trump's recent (and concerning)comments about COVID-19."Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and lookednearly identical to the director of the Nationa l Institute of Allergy and InfectiousDiseases."Someone said Pitt looked "nearly identical" to me. Yikes!! QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: Cb()6 )FAX: (301 496-4409E-mail: (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 18:37:57 +0000Barnes, FreddieSubject: RE: Appr eciationFreddie:Many thanks fo r your kind note . It is much appreciated .Best regar ds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301) 496-4409E-mail : Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barnes, Freddie <freddie.barnes@ncdps.gov>Sent: Sunday, April 26, 2020 10:48 AM ------~~ To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Subject: AppreciationDr. Fauci I just wanted to express my profo und appreciat ion to you for your work during this COVID-19pandemic. I especially appreciate how you have spent considerable time and capital reaching out to theBlack and brown communities. I saw exerts of your snapchat with Will Smith and saw nearly all of yourinterview on the Breakfast Club. I regret I have to send an email to you re this matter. But t his is theday we live in. Minority communities continue to be over-looked in crises and the impact of such criseson their respective communities. For you to be int entional about keeping the minor ity communities inthe loop is commendable, especially since these communities will be absorbing the disproport ionateshare of the sicknesses and deaths coming from COVID-19.Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on thefacts, data, and truth.Take care and "Cover your six."Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to thirdparties by an authorized state official.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 13:29:53 +0000To:(HHS/OASH)Cc:Adams, Jerome (HHS/OASH)-- ---------------~-~ CbH61G) iroir, Brett(b)(6)Subject : RE: High touch points(b) (5)From: Adams, Jerome (HHS/OASH) ---------(b) ( ">Sent : Sunday, May 3, 2020 7:37 AM ------ ~= To: Fauci, Anthony (NIH/NIAID) (E] (b)(6J>; ----------(b)( ; Giroir, Brett (HHS/OAS H) (b)(6)>Cc: CbH6JSubject: Fwd: High touch pointsPlease see short thread below. Senator Young reached out to me about this and I forwarded to CDC. AsJeromeVADM Jerome Adams20th US Surgeon GeneralBegin forwarded message:From: "Adams, Jerome (HHS/OASH)" --------- (b)( > 0 ate: May 3, 2020 at 7:32:46 AM EDTTo: "Jernigan, Daniel B. (CDC/DDID/NCIRD/1D)" __ .;._.:...::~~---Cc: "Schuchat, Anne MD (CDC/OD)" (b)(6)(b) (6)>Subject: Re: High touch pointsThank ou.(b)(5(b) (5)(b) (5)Please keep me posted . And should I refer the senator to you or someone at CDC to closethe loop?Thanks!JVADM Jerome Adams20th US Surgeon GeneralOn May 2, 2020, at 7:08 PM, Jernigan, Daniel B. {CDC/DDID/NCIRD/ID)------(b)(6)> wrote :ADM Adams:Thanks for sending this. There has been a lot of guidance on disinfection andcleaning, notably some very recent collaborative work we have done withEPA (https://www .cdc.gov/coronavirus/2019-n cov/communi ty/ reopenguidance.html) . Attached are two documents focused on re-opening Americawith emphasis on cleaning and disinfection, including high-to uch surfaces.Also below are a number of websites that address cleaning and disinfectionwhich point out the importance of disinfecting high-touch locations likedoorknobs. They give guidance how to clean them, but they don't addressmethods for using a paper towel or Kleenex to first turn the knob and thendiscard the towel. (b)(5)ThanksDan.Daniel B. Jernigan, MD MPHDirector, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 ResponseCaptain, USPHS (RET)National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention1600 Clifton Rd NE, Atlan ta, GA 30329Phone (b) (6) , Cell (b) (6)------- (b) (6) www.cdc.gov/fluhttps://www.cdc.gov/coronavirus/2019-ncov/community/disinfectingbuildi ng-facil ity. htmlhttps://www.cdc.gov/coronavirus/2019-ncov/prevent-gettingsick/disinfecting-your-home.htmlhttps://www.cdc.gov/ coronavirus /2019-ncov / community/disinfectingbui ldi ng-facil ity-H.pdfFrom: Adams, Jerome (HHS/OASH) --------- (b) (6)>Sent : Friday, May 1, 2020 5:35 PMTo: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) __.:. ._~~~---Cc: Schuchat, Anne MD {CDC/OD) (b)( >Subject: High touch pointsDr. Jernigan,I got a message from a Senator asking why we didn't have specific reopeningrecommendations for "high touch" points like door knobs/ handles/ elevatorbuttons . The Senator stated that (b) (5)JeromeVADM Jerome Adams, M D, MPH20th U.S. Surgeon General<Reopening_America_Guidance.pdf><ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>From:Sent :Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:37 :05 +0000To :Subject:Hahn, Stephe n;Debi Birx;Redfie ld, Robert R. (CDC/OD);Verma, Seema (CMS/OA)RE: Serology Studies in GermanyThanks, St eve !Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"44 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Hahn, Stephen (b)( •>Sent: Thursday, April 30, 2020 6:34 PMTo: Debi Birx (b)(6l>; Redfi eld, Robert R. (CDC/OD) ---------(b)( , Seem a (CMS/OA ) (b)( >; Fauci, Anthony (NIH/NIAID) [E)(b)(6)Subject: Fwd : Serology Studies in GermanyInteresting information from GermanyFrom: Shuren, Jeff ---------(b) (6)>Date : Apr il 30, 2020 at 5:46 :27 PM EDT_To_: H_a hn.,. .S.te:p,h_en_ :...,__..!(:b):(6:J=>, ~Sh~ah~, A--n-a-.n.d. .....!=====~(~b)(-6J->-, Lenihan , Keagan (b )( >, Guram, Jeet (b)( >, Rom, Colin======== (b~)(~6)~>--Subject: Serology Studies in GermanyFYSA regarding serology studies being conducted in Germany, including status of tests to be used forthose studies. This is the follow up to what I sent you last week . (b)( 5From: Hoshi, Ryan (b)(6)Sent: Thursday, April 30, 2020 3:17 PMTo: Shuren, Jeff (b)(6)Cc: Nalubola, Ritu (b)(6); louati, Claudia (FSN)* .:=:::::========~~ .;.....!:::========~;;-" O'Leary, Brendan (b) < >; Torres, Melissa A ----------- Stenz e I, Timothy (b) ( >Subject: FW: PLEASE REVIEW» Meeting Notes - Call with (b)(5(b)(5)(b)(S )Thank you,RyanRyan A. Hoshi , Ph.D.Internat ional Po licy Analyst I Center for Devices and Radiological Health I ______ .C.,.b).,.(.6,.)., I phon e(b) (6)1 mobil e Cb) (6) .,__ ____U.S. FOOD & DRUGADM IHISTUTIONExcellent customer service ,s ,mporta~t to usPlease take a moment to provl:fe feedback regarding the customer service you have receivedclick here for survey(b) (5)From: Fauci, Anthony (NIH/NIAID) [E)Sent : Mon, 27 Apr 2020 14:14:36 +0000To: Halkovich, Townshend ConnieSubject: RE: Appr eciation to my hero --Dr. Fauci--our country 's voice of reason in th eseunsett ling, uncertain t imes--We NEED YOU!!!! Please don' t leave us now wh en we need you most!!!Connie:Many t hanks fo r you r kind note . Mu ch appreciated .Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Halkovi ch, Townshend Connie (b)(6)Sent : Monday , April 27, 2020 9:04 AMTo: Fauci, Anthony (NIH/NIAID) [E] _____ ("b"~'""('6=)>Cc: Halkovich , Tow nshend Connie (FDA/OC) (b)(6)Subject: RE: Appreciat ion to my hero--Dr. Fauci--our country 's voice of reason in these unsett ling,uncertain t imes--We NEED YOU!!!! Please don 't leave us now when we need you most!!!Where is Dr. Fauci?I know where Dr. Fauci is-I saw him on SNL- remarkably he looked like Brad Pitt - except [to many ofus] Dr. Fauci is better looking . Smile, wink Why? We look with our heartsI remember someone asked Dr. Fauci [in jest ] who would he like to represent him in a movie ... Dr. F. saidBrad Pitt. Well - Dr. F. Your dream suggestion came t rue. But, in many of our hearts- NO ONE can takethe place of our beloved, we ll respected, honored Dr. Anthony Fauci !!! !God Bless Amer ica, God Bless Dr. Fauci ! ! !From: Halkovich, Townshend ConnieSe nt: Friday, March 13, 2020 11:06 AM(b) (6)>To: 'anthony .fauci@nih.gov ' (b)(6)Cc: Halkovich , Townshend Connie <Constance.Halkovich@fda.hhs.gov>Subject: AppreciationDear Dr. Fauci:1st & foremost - please keep you rself healthy .... get more rest than 3 hrs/nigh t.© Why? We need you!THANK YOU for all your very informat ive updates . YOU are voice of reason ... in t ime of coronavirusfear ... you give us hope ... saying that action is what is needed ... not fear!You are someone we can be proud of ... you provide service we can count on!!!!God bless You & Your Family!! !Warmest Regards from:Connie Leigh Townshend Halkovich, Management Analyst, 410-867 -0878,#FDA OIMT D10 Proud: Peo le & Service ou can count on!©(b)(6)My Wish 4 U: Peace, Love. Laugher -blessed Z work with U ALL! Abe Lincoln: "folks are as happy as they choose 2be" -Bhappy all circumstances -H ope all well with you, yours--ifnot, pretend it is.FDA M ission: Responsible for protecting public hea lth by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med.devices, aur nation 's food supply, cosmetics, & products that emit radiation.D10 Mission: -Provide excellent implementation, aperatian , maintenance of IT {equipment, services} to promote FDA's PublicHealth Mission.D/0 Vision: Provide state -of-the -art IT services-inclusive of surrounding policy, planning, customer service, in tegration, &oversight necessary to make the mission successful & sustainable.From: Fauci, Anthony {NIH/NIAID) [E)Sent : Tue, 5 May 2020 22:26:27 +0000To: Foikers, Greg (NIH/NIAID) [E);Billet, Courtney (NIH/ NIAID) [E];Stover, Kathy(NIH/NIAID) [E);Routh , Jennifer (NIH/N IAID) [E];Awwad , David (NIH/NIAID) [C]Cc: NIAID OD AMSubject:Attachment s:0RE: ASF RE: Dr. Fauci video reque st: Public Service Recognit ion WeekASF pub lic service recognition - w ith tracked edits -05-0 5-2020 .docxSee minor tr acked changes.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301) 496-4409E-mail Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/ NIAID) [E] CbH >Sent: Tuesday, May 5, 2020 6:16 PMTo : Billet, Courtney (NIH/NIAID) [E] -----~ Cb ~H=6)>; Stover, Kathy (NIH/NIA ID) [E]CbH6J;> Routh, Jennifer {NIH/ NIAID) [E] CbH6>1A; wwad,David (NIH/NIA ID) [C] CbH6J>Cc: NIAID OD AM <NIAIDODAM@niaid.n ih.gov>Subject: ASF RE: Dr. Fauci v ideo request: Pub lic Service Recognition Wee kASFHereis a short script for Public Serv ice Recognition Week. We agreed to do a short videoASF - can u tweak as needed?David, could u record in some format that is easy? Cell phone or other I just learned they want by COBtomorrow<< File: ASF public service recogn ition.docx >>From: Seigfreid , Kim (NIH/OD) [E] CbH6J>Sent: Monday, Apri l 27, 2020 4:30 PM --------=-~ To: Billet, Courtney (NIH/NIAID) [E] (b)(6J>; Stover, Kathy (NIH/NIA ID) [E]--------- (b)(6)>; Routh, Jennifer (NIH/NIAID) [E] (b)(6)> Cc: Fine, Amanda (NIH/OD) [E] Cb)( >; Polimeni, Lydia (NIH/OD) [E](b)(6)Subject: Dr. Fauci video requ est: Public Service Recognition WeekHi there,Please see below. HHS is taking over the Partnership for Public Service IG accoun t next week for PublicService Recogn ition Week . They asked if Dr. Fauci would be willing to do a short 30-second or less prerecordedvideo thanki ng public servants for their work . It would be featured during the takeover , and alsoon NIH's other sm handles next week . It can be taken on a cell phone as sm does not require higherresolution . Let me know if you would like to accept or decline the request.Many thanks ,KimKim SeigfreidSocial Media LeadNIH Office of Communications and Public Liaisonph: (b)(6)(b)(6)From: Muhammad, Janell (HHS/ ASPA) (b)(6),Sent : Monday, Apri l 27, 2020 4:10 PM ---------~~ To: Seigfre id, Kim (NIH/OD) [E] CbH6J>; Channer, Amber (OS/OASH)---------- CbH6J>;F oster, Timothy (OS/ ASPA) CbH6)> Cc: Palczewski, And rew (HHS/ASPA) CbH6J>; Pratt, Michael (OS/ASPA)--------- (b)(6J>; Sherman, Jennifer (HHS/OASH) (b)(6) Wi lker, Michael (HHS/ASPA) (b)(6); Dine, Brooke (HHS/ASPA)(b)( 6)Subject: Public Service Recognition WeekHello All,Hope eve ryone is holding up well !OHR is taking over the Partnersh ip for Public Service (PPS) lnstag ram account during PublicService Recognit ion Week (May 3-9, 2020). The OHR team has reached out about want ing todevelop a senio r leade r "mashup " video -perhaps including the DepSec. TThey asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci andthe SG doing a pre-recorded video thank ing public servants for their work.I wanted to gather the troops so we can identify what all is being planned for this week ofrecognition and provide a POC for OHR if the request is feasible.Happy to set up a call, if tha t is needed to discuss further .Thanks,JanellJanell MuhammadASPA Digital Engagement (Team Lead)U.S. Department of Health and Human ServicesEmail: (b) (6)Office: (b) (6)iPhone: Cb()6 )HHS on Facebook I HHS on Twitter I HHSLatinoFrom:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [E)Tue, 5 May 2020 21:58:55 +0000Adams, Jerome (HHS/OASH)RE: Update on Sara AlertWhat do you mean by ------------------------ (b) (5)Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Adams, Jerome (HHS/OASH)- --------(b)( > Sent : Tuesday, May 5, 2020 2:49 PMTo: Birx, Deborah L. EOP/NSC -------- "C"'.bH.,.".6."J"'; Fauci, Anthony (NIH/NIAID) [E)(b)(6)>Subject: FW: Update on Sara AlertImportance: HighJeromeVADM Jerome Adams, MD, MPH20th U.S. Surgeon GeneralFrom: Jarris, Paul (b)(6J>Sent: Friday, May 1, 2020 7:29 P-M- -----~~ To: Adams, Jerome (HHS/OASH) CbH6)> ...;..::=======-~:a;-Cc: Wright, Janet (HHS/OASH)- --------- CbH6)(b) (5)Subject: Update on Sara AlertImportance: HighDear Jerome,I hope you are well. Thank you for all you are doing to represent public health and our nation. It is verycomforting knowing you are informing the nations COVID-19 response.I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. SaraAlert is being provided free of any costs and deployed in state, tribal, and local health departments tosupport public health in contact tracing and active monitoring of individuals in isolation and quarantine.We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMSplatform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictionsincluding Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It isalso being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are gettingready to launch in additional jurisdictions over the next couple of weeks.We have recently responded to questions we were told came from the White House so I wanted tomake sure you have background materials. I imagine you are the person that the President and VicePresident would turn to for information. I am happy to arrange any briefing mater ials or demo thatwould be helpful for you to respond.As I mentioned previously, Sara Alert is a standards-based, open source tool that automates the processof monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) - andwi ll serve as an enduring national resource to contain disease. Sara Alert is free for use by public healthorganizations.Best wishes to you. Stay healthy for all of us.PaulABOUT SARA ALERTIn response to the COVID-19 pandemic, the MITRE Corporat ion, a not-for-profit that works in the publicinterest, developed Sara Alert, a standards-based, open source tool in partnership with national publichealth organizations. Sara Alert automates the process of monitoring individuals exposed to or infectedwith COVID-19 (or any disease, it's configurable) - and will serve as an enduring national resource tocontain disease. Sara Alert is free for use by public health organizations .• Sara Alert allows public health officials to import and enroll individuals (or households) at risk ofdeveloping or infected with COVID-19.• Individuals enter their symptoms daily via web, text, email or phone, allowing public healthofficials to focus on high risk and non-reporting individuals .• The web-based tool enables increased efficiency in tracking cases, leading to earliercontainment of the virus and reduction of burden on public health resources.• Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighte rcontact tracing.Sara Alert launched on April 3 and is now supporting multiple jurisdictions .Sara Alert YouTube Video : https://youtu.be/lQxAuNsg-RAPaul E. Jarris, MD, MBAChief Medical AdvisorHealth Transformation CenterMITRE Corporation(b) (bJj-=-=-=-=-;:((bb:))( ~(66))] ] OMfofbicieleFrom:Sent :To:Cc:Subject:Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 17:45:26 +0000Lane, Cliff (NIH/NIAID) [El;Collins, Francis (NIH/OD) [ElLowy, Douglas (NIH/NCI) [E);Mascola, John (NIH/VRC) [ElRE: Gallo and OPV(b) (5)National Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Lane, Cliff (NIH/NIAID) [El -------- (b) ( >Se nt: Sunday, May 3, 2020 1:22 PM -----~~ To: Collins, Francis (NIH/OD) [El (b)( >Cc: Lowy, Douglas (NIH/NCI) [El (b)(6) ; Fauci, Anthony (NIH/NIAID) [El-------- (b)(6) >; Mascola, John {NIH/VRC) [El (b)(6)> Subject: Re: Gallo and OPVFrancis,(b)( 5)CliffOn May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [El _______ Cb _H_6) wrot e:Hi all,I'm a bit at a loss to know how to respond to Bob Gallo.FrancisFrom: Gallo, Robert- --------- (b)( > Sent: Sunday , May 3, 2020 12:07 PM ------~~ To: Collins, Francis (NIH/OD) (E] ..._ _____ Cb_) _(6)Subject: RE: Your query to Dr. KadlecDear Francis,It was a pleasure to hear from you, and yes, it has been a long time since we met oreven spoke. Moons ago I was set to write to you after reading your wonderfulbook, but I ended up instead speaking with others about it. I should add at thispoint that I did not quickly respond to your email of a few days ago because Isimply missed it.It is true that I strongly suggest that OPV be quickly (already it is not quickly)brought forward for induction of a strong innate immune response to prevent ormarkedly reduce SARS-CoV-2in fection and/or severity until the field obtains aproven safe and efficacious vaccine producing a long lasting, adaptive immunity .OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use andcompletely safe in a vaccinated population), simple, cheap, rather obvious, yetunique among the massive number of vaccines many (maybe most) of which arethe same or at least if not exactly the same aiming at the same mechanism(targeting the spike and searching for the putative correlate of neutralizing Abs.).OPV should work for a few months and possibly longer. Also it should be workingmultip le times so I think could cover more than a few months, giving us time for aproven vaccine of adaptive immunity, which might be very long lasting as is hoped.In the main the WHO comments are correct. Of course we sought and have lettersof support from them as well as from many others . Though they are againsupportive in their notes to you, there is one item that surprises me. They addthat there was no clinical efficacy results as yet. They know or certainly shouldknow that there is plenty of clinical data for this concept with BCG, OPV, and liveMeasles vaccine. Needless to say this is what turned me on during our regularGlobal Virus Network (GVN)conference calls. (Incidentally GVN is an organization Ihave thought of bring ing to your attention. I th ink you would find it impressive anduseful). I would be happy to share with you the clinical observations with OPV ifyou wish.I would like to take a small diversion, but I suspect you are aware of these things.My colleagues and I respect the WHO because of its representation and becausewe have colleagues/friends there as well. However, sometimes bureaucracy of amassive degree leads to inaction or even much worse-- political expediency. I won'tbother you with details of these unless you ask, but I had such experiences withHTLV-1 which we discovered in 1980 as the 1st human retrovirus and which causenot only the highest incidence of cancer(% of infections) of any virus and otherfatal diseases as well but mainly in less developed countries (plus Japan) and againwith HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in thefuture because a few at WHO took a position to remove OPV (Sabin) in favor of IPV(Salk) in their polio eradication scheme. It was a huge failure. As my FDAcollaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he savedOPV and saved the day and in so doing has produced a still better OPV.There is indeed data also for BCG as well as live Measles though I know less of thelatter. BCG is less available, requires injection, harder to make, not as safe, and wethink unlikely to be as effective as OPV. Nonetheless, we favor its use too. Themechanisms will be similar.You asked whether monkey trials are planned. For several reasons definitely not -thoughwe are planning some monkey experiments, but not large enough for"clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousandsor millions have received OPV safely and in our collective view (and we know thestudies pretty well) protection has been clinically shown; 3) In a pandemic wewished to move quickly (so far we must say that has not been achieved). A typicalmonkey vaccine study will take time, but 4) in this case it would be a huge amountof lost time as monkeys require great doses of polio for infection and monkeyshave to be trained to drink their orange juice. It would be hard to imagine that suchstudies would even give us useful information.On a final digression Francis I have had 36 years of on/off experiences withglycosylated spike proteins-their analyses immunologically and especiallyregarding use in vaccines and developing neutralizing Abs. I believe it will be amistake to put most eggs in that basket. The risks: shortened antibody half life; 2)protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them.Admittedly, they might work, but I trust and hope that not everything is going inthis bag. If you wish to discuss this again I will be available.Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19disease, but I am very happy to learn this.Thanks.Bob GalloFrom: Collins, Francis (NIH/OD) [E] (b)( >Sent: Thursday, April 30, 2020 5:00 PMTo: Gallo, Robert Cb) (6J>Cc: Disbrow, Gary (OS/A SPR/BARDA) CbH6J>K; adlec, Robert(OS/ASPR/I0) Cb)( >; Tabak, Lawrence (NIH/OD) [E)CbH6J>S;h uy, Bryan (OS/ASPR/I0) Cb)( >; Johnson,Robert (OS/ASPR/BARDA) Cb)( >; Mascola, John (NIH/VRC) [E)--------- (b)(6b ; Lane,C liff (NIH/NIAID) (E] (b)(6J>Subject: Your query to Dr. KadlecCAUT ION; Tbis message 01iginnted from II oon UMB, UMSOM, FPI , or UMMS cmnil sys tem . Wheth er thesender is known or not known, hover over any links before c]jcking and use caution opening attachments.Dear Bob,It's been quite a while since we've chatted. Bob Kadlec asked me to respond toyour query about the possible use of OPV to activate innate immunity and provideCOVID-19 protection. Has this been tested in a non-human primate model? I notethe recommendation below that says a clinical trial is planned - can you tell memore about that?As you can imag ine, we are all flat out on the vaccine development pathway!Franc isThe use of oral polio vaccine( OPV) to prevent SARS-CoV2(P olio EradicationCampaign)There is no evidence that ora l poliovirus vaccine (OPV) protects people againstinfection with COVID-19 virus.A clinical trial address ing this question is planned in the USA, and WHO willevaluate the evidence when it is available.In the absence of evidence , WHO does not recommend OPV vaccination for theprevention of COVID-19. WHO continues to recommend OPV as part of essentia limmunization services to prevent poliomyeli tis and as part of global polioeradication efforts.There are experimental signals from various studies over the years that OPV hasnon-spec ific effects on the immune system. These effects have not been wellcharact erized and the ir clinical relevance is unknown. Such non-specific effects maynot be limited to OPV, as other live vaccines have also been associated with nonspecificprotective effects (such as BCG vaccine against tuberculosis). Non livevaccines in contrast do not seem to have the same effects.The exact mechanism of non-specific protection induced by live vaccines needs tobe elucidated f urther. Clinical studies could begin immed iately because thevaccines in question are licensed and have an excellent safety record. Clinical tria lsinvolving off-label use of various drugs licensed for other indications are currentlyunderway. The existing scientific rationale suggests that the same should be donefor OPV and other live vaccines. A study is currently being discussed with variouspartners and vaccine manufacturers, including the US FDA, the outcomes of whichwill be carefully assessed to determine potential use in the context of the spread ofSARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.From: Kadlec, Robert (OS/ASPR/10) (b)(6)Sent : Thursday, April 30, 2020 10:28 AMTo: Gallo, Robert CbH6l; Collins, Francis (NIH/OD) IE](b)(6); Tabak, Lawrence (NIH/OD) [E] (b)( >; Shuy,Bryan {OS/ASPR/10) (b)( >Subject: Re: ResponeDr Gallo thank you for your note and I appreciate you reaching out to me. I have copied DrCollins and Dr Tabak to consider the ACTIV forum they have created to br ing industryacademia and government to consider scientific base approaches That you havedescribed. Dr Collins has organ ized a vaccine group and I assess could be the best andfastest place to discuss your concept. I am sure they will connect with you soonestBestBob Kadlec.Sent from my iPhoneOn Apr 30, 2020, at 10:02 AM, Gallo, Robert ---------- (b)(6)>wrote:Dear Dr. Kaldec ,I have not heard from you in over a week. You mentioned getting backto me in a day or two. l ime is passing. I am asking you to look at OPV 1plus 3 serotypes as a bivalent, completely safe vaccine with powerfulstimulation of innate immunity lasting several weeks, which can begiven a second or third time, and with a historical track record ofpreventing other infections from entirely different RNA viruses (such asprotecting against influenza). Therefore, it should be really helpful forsome months, and I think get us past a second wave of SARS-CoV-2,and help people return to work safely. I don't understand delays orapparent lack of interest . Who can possibly be against this? If you hearof hypothetical prob lems we can show you that these are false. Justask the questions, and we can give you the evidence.However, no answer from you suggests no interest and must quicklymake alternative pathways. I am though quite surprised and fear youare receiving "fake news" if you will pardon the expression . Some havebeen against th is who defend their old and fai led position on polioeradication with their promotion of the use of the inactivated poliovirus vaccine. Please note that in the US between 1962 and 1985 wereceived (safely) the oral polio (OPV). Moreover, if vaccinated alreadythere has not been a single case of a complication and BILLIONS havereceived it . No it will not last long as innate immunity is short lived, butwe strongly believe that we can break the back of the SARS-CoVID-2spread. Also note that this is what Bill Gates is doing now in India andmuch of the Eastern hemisphere .There are countries outside the US wanting to move fast on th is. Weare waiting for your reply .Robert GalloDirector, Institute of Human Virology,Professor of Medicine and Professor of Microbio logy,UMB, School of Medicine , Baltimore,AndCo-founder and International Science Advisor of the Global VirusNetwork (GVN)From:Sent:Fauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 15:17:01 +0000To :[ElCollins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID)Cc: Tabak, Lawrence (NIH/OD) [ElSubje ct: RE: ResponeFrancis:Thanks for the not e. I will let Cliff speak for himself, (b) (5 '(b) (5)--------- Cb>5>< but I will let him speak for himself . We can discuss further if you wish.Best,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MO 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in er ror please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Collins, Francis (NIH/OD) [El ------- (b)(6)>Sent : Thursday, April 30, 2020 10:58 AM ------~~ To: Mascola, John (NIH/VRC) [El (b)( >; Lane, Cliff (NIH/NIAID} [El--------- (bH ; Fauci, Anthony (NIH/NIAID) [El (b)(6)•> Cc: Tabak, Lawrence (NIH/OD) [El (b)( >Subject: FW: ResponeHi John, Cliff, and Tony,Ignore the silly part of the message below, where -:-~===========(b)=( 5) ~ . But let me ask you guys whetherFrancisFrom: Collins, Francis (NIH/OD) [E]Sent : Thursday, April 30, 2020 10:55 AM -------..,,.,..., = To: Kadlec, Robert (OS/ ASPR/10) ~======~~ Cc: Tabak, Lawrence (NIH/OD) [El >; Shuy, Bryan (OS/ASPR/10)(b)(6); Disbrow, Gary (OS/ASPR/BARDA) (b)( >; Johnson, Alfred(NIH/OD) [El (b)(6)Subject: RE: ResponeBob,I I I I . : .. • • • • I I • I I I • I I• (b) (5). . • • IFrancisFrom : Kadlec, Robert (OS/ASPR/10) (b)(6)Sent: Thursday, April 30, 2020 10 :28 AMTo: Gallo, Robert (b)(6)>; Collins, Francis (NIH/OD) [El -------- (bH6J; Tabak, Lawrence (NIH/OD) [El (b)(6)> ; Shuy, Bryan (OS/ ASPR/10)(b)(6)Subject: Re: ResponeDr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins andDr Tabak to consider the ACTIV forum they have created to bring industry academia and government toconsider scientific base approaches That you have described. Dr Collins has organized a vaccine groupand I assess could be the best and fastest place to discuss your concept. I am sure they will connectwith you soonestBestBob Kadlec.Sent from my iPhoneOn Apr 30, 2020, at 10:02 AM, Gallo, Robert- --------- (b) (6)> wrote:Dear Dr. Kaldec,I have not heard from you in over a week. You ment ioned getting back to me in aday or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as abivalent, completely safe vaccine with powerful stimulation of innate immunitylasting several weeks, which can be given a second or thi rd time , and with ahistorical track record of preventing other infections from entirely differen t RNAviruses (such as protecting against influenza). Therefore, it should be really helpfulfor some months, and I think get us past a second wave of SARS-CoV-2, and helppeople return to work safely . I don't understand delays or apparent lack of inte rest.Who can possibly be against this? If you hear of hypothetical problems we canshow you that these are fa lse. Just ask the questions, and we can give you theevidence .However , no answer from you suggests no interest and must quickly makealternative pathways. I am though quite surprised and fear you are receiving "fakenews" if you will pardon the expression. Some have been against this who defendtheir old and failed position on polio eradication wit h their promotion of the use ofthe inactivated polio virus vaccine. Please note that in the US between 1962 and1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated alreadythere has not been a single case of a comp lication and BILLIONS have received it.No it will not last long as innate immunity is short lived, but we strongly believethat we can break the back of the SARS-CoVID-2 spread. Also note that this is whatBill Gates is doing now in India and much of the Eastern hemisphere.There are countr ies outside the US wanting to move fast on this. We are wait ing foryour reply.Robert GalloDirector, Institute of Human Virology,Professor of Medicine and Professor of Microbiology,UMB, School of Medicine, Baltimore,AndCo-founder and International Science Advisor of the Global Virus Network (GVN)From:Sent :To:(b)(6)Wed, 29 Apr 2020 13:39:44 -0400Billet, Courtney (NIH/NIAID) [E]Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statementAttachments : 4 29 20 remedesivir.docx, ATTOOOOl.htmCann ot do right now. Go without meBegin forwarded message:From: "Billet, Courtney (NIH/NIAID) [E]" (b)(6)Date: April 29, 2020 at 1: 11: 19 PM EDTTo: "Fauci, Anthony (NIH/NlAID) [E]" --------=-::-:-=Cc: "Routh , Jennifer (NIH/NIAID) [E]" (b)(6) , "Stover, Kathy(NIH/NIAID) [E]" (b)(6) "Lane, Cliff (NIH/NIAID) [E]"(bH6) >, "Marston, Hil ary (NIH/NIAID) [E]"(bH6) >, "Conrad, Patricia (NIH/NIAID) [E]"(b)( >, "Folkers , Greg (NIH/NIA.ID) [E]"(b)(6) >Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statementFrom: Fritz, Craig (NIH/OD ) [E] (b)(Sent : Wednesday, April 29, 2020 10:38 AMTo: Billet, Courtney (NIH/NIAID) [El -------= (b")"(""6=>"r>; Stover, Kat hy (NIH/N IAID) [El-------- (b)(6) Routh, Jennifer (NIH/N IAID) [El (b)( > Cc: Burklow, John (NIH/OD) [El (b)( ; Myles, Renate (NIH/OD) [El(b)(6) ; Fine, Amanda (NIH/OD) [El (b)(6)>; Wojtowicz,Emma (NIH/OD) [El (b)(6)>; NIH News Clearance (NIH/OD)<NIHNewsClearance@mail.nih.gov>Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statementImportance: HighHi all - please let us know if you have any comments to the attached.Thanks !CraigFrom: Brennan, Patrick ( OS/ ASPA) (b)(6)>Sent: Wednesday, April 29, 2020 10:33 AMTo : Fritz, Craig (NIH/OD) [El CbH6J>; Burklow, John (NIH/OD) [El(b)(6)>; Myles, Renate (NIH/OD) [El (b)(6); Fine,Amanda (NIH/OD) [El CbH >; Wojtowicz, Emma (NIH/OD) [El(b)(6)>; Charrow, Robert (HHS/OGC) (b)(6)Cc: Pence, Laura (HHS/ASL) (b)(6J>; Hall, Bill (HHS/ASPA)(b)(6);,; Pratt, Michael (OS/ ASPA) (b)(6);,; Blakeman,Scott (05/ASPA ) (b)(6)>Subject: For review ASAP: draft Sec. Azar Remdesivir statementNIH and Mr . Charrow,Below and in the attached is a draft statement from the Secretary regarding theRemdesivir trial - please let me know as soon as you can if this looks OK. (I pulled thefrontmatter from the NIH press release.) Thank you!- PatrickPatrick BrennanDirector of SpeechwritingDepartment of Health and Human ServicesOffice: Cb) (6) I Cell Cb) (6)(b) (5)Frmn:Sent:To:Fauci, Anthony {NIH/NIAID) [E)Wed, 29 Apr 2020 01:56:42 +0000(b)(6)vEi ubject:Attachments:FW: DRAFT document for WH Briefing TomorrowDevelopment-Medical-Countermeasures-WH-B riefing 29 Apr il.pptxHere it is.From: Collins, Francis (NIH/OD) [E] Cb)( '>Sent: Tuesday, April 28, 2020 8:08 PM To: Fauci, Anthony {NIH/NIAID) [E) ------ =(bH= >Subject: FW: DRAFT document for WH Briefing Tomo rrowHi Tony,FrancisFrom: Mango, Paul (HHS/1OS) CbH6)>Sent: Tuesday, April 28, 2020 7:2-6- -PM-- --::-,--:=, To: Collins, Francis (NIH/OD) [E] CbH6)>; Kadlec, Robert (OS/ASPR/1O)CbH6)>; Fauci, Anthony (NIH/NIAID) [E] Cb)( >; Marks,Peter {FDA/CBER) CbH6);W oodcock, Janet (FDA/CDER) --------~~ ----------- CbH >; Tromberg, Bruce (NIH/NI BIB) [E] CbH6) Subject: DRAFT document for WH Briefing TomorrowThank you all for your timely responses for contributions to this today. Please give this a lookand let us know if there is anything glaringly out of place. We will have time to address editsdu ring and after our 930am check in tomorrow. The Secretary may or may not use page 1du ring his introdu ctory remarks.From: Fauci, Anthony (NIH/NIAID) [E)Sent: Sun, 26 Apr 2020 18:14:04 +0000To: Gibbo ns, Gary(NIH/NHLB I) [E]Cc: Koroshetz, Walt er (NIH/NINOS) [E); (b)(6) ;Auch incloss, Hugh(NIH/N IAID) [CJ (b)(6) ;Coll ins, Francis (NIH/OD) [E) (b)(6) ;Tabak,Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/N IAID) [E);Barasch, Kimberly (NIH/NIAID) [C]Subject: Thrombotic phenomena in COVID-19Gary:In follow -up of our recent conversation regarding the growing evidence that theextremely catastrophic course of many patients with COVID-19 seems to mepathogenically associated with the find ings of microthrombi in the lungs andoften a multisystem process resembling DIC. In addition, there have beengrowing numbers of cases of indiv iduals (some young and otherwise healthy)who have had unexplained strokes, only to find out that they actually haveCOVID-19. I (bH 5~I- ----- (bH 5l Thanks. Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phon e: (b) (6)FAX: (301 496-4409E-mail: (b)(6)(b)( 5)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:I wou ldn't think so.Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [ElSun, 26 Apr 202017 :42:12 +0000NIAIDODAMFW: Invitation to Webinar as keynote speaker.From: Secretary ARP (b)(6)>Sent: Saturday, Apr il 25, 2020 2:07 PM ------- ~= To: Fauci, Anthony (NIH/NIAID) [El- -------- (b)(6) Subject: Invitation to Webinar as keynote speaker.To,Anthony S. Fauci,Office of the Director,Nationa l Institute of Allergy and Infect ious Diseases,National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,Bethesda MD 20892Subject: Invitat ion to Webinar as keynote speaker.Dear Sir,On behalf of ASSOCIATIONO F REGISTEREDP HARMACIST( An association working for PharmacyProfession and having more than 2000 membe rs) in collaboration with Divine Internationa l, Gwalior (APioneer Pharmacy Institute) I am pleased to invite you to our Web inar having THEME "CHALLENGESA NDOPPORTUNITIESF OR PHARMACISTI N THE PRESENTE PIDEMIC COVID-19" that will be held from 2ndMay 2020 to 3rd May 2020. This Web inar is the get together of Pharma professionals through the web.The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in ourcountry to th is epidemic COVID-19 for present and future aspect and exports more real istic ideas andpresent scenario of this epidemic COVID-19.You are one of the legends of Pharma Expert of our country, it is a great pr ivilege for us to see if youshare your experience with us, we really expect and want that you join our Web inar and share with usthe great exper ience of your life, we want to learn something from you so that we can create a greatideas, opportunity, and roll of Pharma professional for our country in th e present scenario.We wou ld be pleased to have you present at th is point at this web inar to listen to what the role andimportance in the Pharmacist advancement and thei r impact on our society and daily life we would alsolove to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacyfraternity .Therefore you are requested to send your recorded Lecture/ presentation of 30-40 minSincerely,ThanksRajesh Singh JadonSecretary (National)Association of Registered PharmacistsGwalior MPMob: (b)(6)From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Sun, 26 Apr 2020 15:43:25 +0000(b)(6)Subject: REAttachments :From: ------------------- (b) ( > Sent: Sunday, April 26, 2020 11:32 AMTo: Fauci, Anthony {NIH/NIAID) [E] _____ "("b"")"("=6")Subject: FW: ---------------(b)(6), (b)(4)To work on at homeFrom: Ulrich, Connie M (b)(6)Sent: Saturday, Apr il 25, 2020 2:35 PMTo: Cynda Rushton (b)(6)>;Subject (b) (6), (b) (4)Hi Christine and Cynda,(b) (6), (b) (4)(b) (6), (b) (4)(b)(6)I finished my section and unfortunately have to keep changing the COVID numbers! I will add somethoughts to the last section . Not sure how much we can add there but maybe some reflections wouldbe helpful. Enjoy the sunshine today! IBest.ConnieFrom:Sent :To:Cc:Bee:Subject:Francis:Fauci, Anthony (NIH/N IAID) [ElSun, 26 Apr 2020 02:57:3 1 +0000Collins, Francis (NIH/OD) [ElTabak, Lawrence (NIH/OD) [E] -----~~ Mascola, John (NIH/VRC) [El- ------ (b)(6) RE: agenda for Kadlec et al., Sun noon meetingSorry that I took so long to respond . (b) (5)1,,.,(b) (5)(b)(5) [ et us connectby phone first th ing in the AM>Thanks,TonyFrom : Collins, Francis (NIH/OD) [ElSe nt: Saturday, Apr il 25, 2020 2:55 PM(b) (6)·>-----~~ To: Fauci, Anthony (NIH/NIAID) (El '°.._ _____ C_Hb_~ ; Tabak, Lawrence (NIH/OD) (E](b)(6)>Subject: RE: agenda for Kadlec et al., Sun noon meet ingFrom: Collins, Francis (NIH/OD) (ElSent : Saturday, Apr il 25, 2020 2:49 PM ------~~ To: Fauci, Anthony (NIH/NIAID) (El- ------- (b)(6)>; Tabak, Lawrence {NIH/OD) [E) (b )( 6)Subject: agenda for Kadlec et al., Sun noon meetingHi Tony and Larry,(b) (5)For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks,and us three), I would propose the following framework :(b) (5)(b)( 5)Thoughts? Tony , should --------------------- (b) (5)FrancisFrom:Sent :To:Cc:Subject:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 01:22:2 1 +0000Corey MD, LarryConrad, Patricia (NIH/NIAID) [ElRE: (b)( --------------Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.From: Corey MD, Larry _______ Cb_) _(6)Sent: Saturday, Apr il 25, 2020 5:36 PMTo: Mascola, John {NIH/VRC) [E] ______ --,;(b"H"'="' >Cc: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)!; Collins, Francis (NIH/OD) (E] (b)(Subject: Re: --------------- (b)(6)Agree. ______________ Cb><_6lSent from my iPhoneOn Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E)wrote:------ (b)(6) seem reasonableSent from my iPhone(b)(6)>On Apr 25, 2020, at 15:54, Corey MD, Larry --------- (b)(6) wrote:A do have to say I am surprised . but okFrom: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Saturday, April 25, 2020 12:53 PMTo: Corey MD, Larry (b)(6l; Mascola, John (NIH/VRC) [E)(b)(6)>Cc: Collins, Francis {NIH/OD) [E] (b)(6)Subject: Fwd: New England Journal of Medicine 20-13479Let us discuss next stepsBegin forwarded message:(b)(6)From:Sent :To:Cc:(b)(6)Sat, 25 Apr 2020 13:05 :04 -0400Collins, Francis (NIH/OD) [E)Tabak, Lawrence (NIH/OD) [E]Subject: Re: White House Task Force Briefing Monday(b) (5)On Apr 25, 2020, at 11 :42 AM, Collins, Franc is (NIH/OD) [E](b) (6):FCFrom: Collins, Francis (NIH/OD) [E)Se nt: Saturday, April 25, 2020 10:36 AMTo: (b)( (OS/IOS) (b)(Cc: Tabak, Lawrence---(-N:"-':.l":H".'"./""07':..:"D:"-.):-:[~E:].====--------=- (b-):(--6:-)=; Fauci, Anthony (NIH/NIAID)[E] (b)(6)>; Pence, Laura (HHS/ASL) (b)( ; Harrison,Brian (HHS/10S) (b)(6J>; Wood, Gretc hen (NIH/OD) (E]-------- (b)(6) McManus, Ayanna (NIH/OD) [E] (b)(6J Subject : FW: White House Task Force Briefing MondayHi Mr. Secretary,Francis(b)(5)-PrnGlad to speak with you about how best to handle, if(b)(6)(b)(5)-PCE
(bX5)-PCI
From:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 14:25:16 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Italy Covid-19La Stam pa is one of the two most important newspapers in Ita ly.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Mastro lilli Paolo <Paolo .MASTROLILLl@lastampa.it>Sent: Friday, April 24, 2020 10:08 AM -------- To: Fauci, Anthony (NIH/NIAID) [EJ(Subject: Italy Covid-19 1--,------Dear Doctor Fauci,My name is Paolo Mastro lilli, I am the US Bureau Chief for the Italian daily La Stampa.I am writing because we would appreciate very much the opportunity to have a phone orwr itten Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficultsituation Italy is experiencing, the help President Trump is sending to Italy, and the plan to openAmerica again, it would be very helpful for Italy to hear from your experience and competenceto address the Covid 19. We think that your advices would be very helpfu l to help our countryand our citizens in dealing with the pandemic .We understand that you are very busy and this request has no deadline.La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of FiatChrysler as well.I am also a contributor for the Vatican Radio and the official news portal of the Holy See, Iwould share the interview with them as well, if you like.My cellphone number ief CbH6YPlease let me know if you need any further information.Best regardsPaolo MastrolilliII presente messagglo (inclusi gli allegati) contiene informazloni riservate esclusivamente al destinatario/ai destlnatari lndicato/i nel messaggio, ed eprotetto dalla legge. La diffusione, distribuzlone e/o la copia del contenuto del presente messaggio da parte di qualsias i soggetto diverso daldestinatario e severamente vletata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei datl personali . Se non siete idestinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediala comunicazione inviando un messaggio di ritorno all'indirizzoe-mail del mittente.This message (including any attachments) contains confidential information intended only for the reclpient(s) named above, and is protected by law.Any disclosu re, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art616 c.p, and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately aboutthe deletion by sending a message lo the sender's e-mail address.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 10:33:49 +0000Holland, Steven (NIH/NIA ID) [E]Cc:Subject:Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]RE: Successful Submission of a Manuscript to Science (abc4208)Thanks, Steve.-----Original Message-----From: Holland , Steven (NIWNIAID) [E] --------- (b)( Scn t: Thur sday, April 23 , 2020 11: 48 P-M- ---- --:a-,-= To: Fauci, Anthony (N1H/NIAlD) [E] ':======= (=b~-~(6~)Cc: Marston , Hilary (NIH/NJ AID) [E] (b)( ; Lerner , Andr ea (NIH/NT AID) [E](b)(6)Subject: FW: Successful Submission of a Manuscript to Science (abc4208)This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to besure about the results but some of the authors (Not the NI AID one) balked and have gone elsewhere. Just keepingyou in the loop.SteveDirector, Divisi on of Intramural Research Nat ional Institu te of Allergy and Infectious Diseases National Institute s ofHea lthBldg. IO/ l IN248 MSC 1960Bethesda, MD 20892-1960(b) ( voice.3,..0.,-l.-..4.,"8.'"0,.-..4...."5,".0,'.7., .fax(b)(6)Assistant lab: Eva Portillo(b)(6)(b)( voice ____ _,,Assistant to SD: Beth Schmidt(b)(6)(b) (6) voice ____ _,,On 4/23/20, 1: 59 PM, "Lionakis, Michail (Nll-1/NIAID) [E]" ________ (b)_(6_J> wrote:Attached the submitted paper, which will be deposited to MedRx iv.org today I think.Mihali sOn 4/23/20, I :34 PM, "science_editors@aaas.org"< science:..e_ditors@aaas.org> wrote:Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19Author: LionakisManuscript Number: abc4208Dear Dr. Lionakis:You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.According to Science policy, all authors must have seen and approved the submission of their manuscript. If youhave seen the manuscript and approved its submission, no action is necessary.Tfyou have not read this paper or do not approve its submission to Science, please let us know as soon aspossible. Please refer to the manuscript number listed above in any correspondence (you can just reply to thismessage) .You can see the status of your manuscript at any time by logging into your account at the Science JournalsSubmission and lnfonnation Portal at https://cts.sciencemag.org.If you do not yet have an account, please go to https://cts.sciencemag.org/scc /#/ forgot-password and use theemail at which you received this correspondence because that is linked to your manuscript. Then, follow the promptsto set your password and login. After login, you can access your manuscript and monitor its status.Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitatesthe correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit theirsite at: http ://orcid.org.Your manuscript is now undergoing an initial screening to detennine whether it will be sent for in-depthreview. If the manuscript is sent to review, its status will change to "To Review".Sincerely ,The EditorsScienceFrom:Sent :Fauci, Anthony (NIH/N IAID) [E)Fri, 24 Apr 2020 01:58:36 +0000To: Greg Folkers (b)(6)Subject: FW: HIVR4P postponed to 17-21 January 2021FYI. See yellow highlighted request.From: HIVR4P- Secretariat <secretariat@hivr4p.org>Se nt: Thursday, April 23, 2020 11:23 AM -------~= To: Fauci, Anthony {NIH/NIAID) [E]Cc: Conrad, Patricia (NIH/NIAID) [E~) =======~ =; Dieffenbach, Carl (NIH/NIAID) [E](b) (6) >Subject: HIVR4P postponed to 17-21 January 2021Dear Dr. Fauci,HIV RESEARCHFOR PREVENTIONCb.PET OWN SOUTHA FRICA·1 7-21J ANUA'.-l2V0 21As the research community responds to the global challenges of the COVID-19 pandemic, HIV preventionscience matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P)conference remains the safety and wellbeing of all participants .After careful consideration, we have decided to postpone the HIVR4P conference to 17-21 Janua ry2021 . Updated details for the session(s) are listed below:Session title: HIV prevention 2020 - Where are we now and where are wegoing?Session type: Opening plenarySuggested presen tation Much accompl ished; Much to do -An overview on HIVtitle/topi c: prevention researchSession descr ipt ion: Today's plenary sets the stage for the conference week ahead,outlining the big-picture chal lenges we face in research, productdevelopment and access to prevention. Speakers will providediverse perspectives on the state of the field today, theopportunities and obstacles ahead and priorities for actionmoving forward .Session date and time: Monday, 18 January 2021 -16:00-18:00Meet the Experts lunchesWe invite you to host an informal table discussion at a Meet the Experts lunch on 20 January 2021 ,12:00-13:00. Daily meet the experts lunches provide early-ca reer investigators and community advocateswith valuab le opportunities for informal, in-depth exchange with experts represen ting a cross-section ofresearch issues, implementation challenges and HIV-affected communities.Please reply to this email by Wednesday, 6 May if you are still available to deliver this importantpresentation and, if so, please also include a photo and a brief biography.We are acutely aware many researchers and research organizations with critica l studies and submissionsto HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing theconference , rather than presenting it virtually in October, will allow for the broadest participation to fosterknowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P isknown for.Thank you for your consideration.Sincerely,HIVR4P - SecretariatHIV Research for PreventionW: -------(b)(6) Avenue de France 23 I CH-1202 Geneva I SwitzerlandHIVR4P Conferenc e 117-21 January 2021 I Cape Town , SouthAfri caHIVR4P.org 0 @HIVR4PxFrom : HIVR4P- SecretariatSen t: 21 February 2020 16:57To: (b) (6)0 /HIVR4PCc: Bargavi Thyagarajan ---------------------- (b)(6) Subject: HIVR4P 2020 - Invitation to presentDear Dr. Fauci,HIV RESEARCHFOR PREVENTIONUF>i OWN. ~JTH Af~ICA · 11-·& OCTOB~ 2020We are writing with great pleasure to invite you to present at the 4th HIV Research for PreventionConference (HIVR4P 2020 ) in Cape Town, South Africa, from 11-15 October 2020. HIV Research forPrevention is the only global scientific conference focused exclusively on the challenging and fastgrowingfield of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange onHIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well astheir related social and behavioura l implicat ions.Details for the session(s) are listed below:Session title:Session type:Suggested presentationtitle/topic:Session description:Session date and time:Meet the Experts lunchesHIV prevention 2020 - Where are we now and where are we going?Opening plenaryMuch accomplished ; Much to do - An overview on HIV preventionresearchToday 's plenary sets the stage for the conference week ahead,outlining the big-picture challenges we face in research, productdevelopment and access to prevention. Speakers will provide diverseperspectives on the state of the field today, the opportunities andobstacles ahead and priorities for action moving forward.Monday , 12 October 2020 - 16:00-18:00We invite you to host an informal table discussion at a Meet the Experts lunch on 14 October 2020,12:00-13:00 . Daily meet the experts lunches provide early-career investigators and communityadvocates with valuable opportunities for informal, in-depth exchange with experts representing across-section of research issues, implementation challenges and HIV-affected commun ities.As an invited-speaker , you would be eligible to receive:• Complimentary conference registration ;• Roundtrip economy airfare arranged through the HIVR4P travel agency; and• Accommodation at one of the hotels pre-blocked by the conference secretar iat.To accept this invitation, please reply to this email by Thursday, 27 February and include a photoand a brief biography . Please find also attached for your record the official invitation signed by theHIVR4P 2020 Co-Chairs.We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org .Thank you for your consideration. We look forward to you joining us in Cape Town!Sincerely ,From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Fri, 24 Apr 2020 01:30:49 +0000blonda quir icoSubject: RE: estimation of dynam ics of COVID-19 in USA new simulations at 23 Apri l 2020Thanks.From: blonda qu irico (b)(6bSe nt: Thursd ay, Apr il 23, 2020 5:02 PM ------ To : Fauci, Ant hony {NIH/NIAID) [E] -------- (~b)(=6)> ; COPPIETERS'TW ALLANT Yves (b) (6)>Subject: est imat ion of dy namics of COVID-19 in USA new simulations at 23 Apri l 2020Tony,We send you our simu lations.Best regards.QuiricoLe mercred i 22 avril 2020 a 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E)ecrit:Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)(b)(6) > aThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: blonda quirico Cb) (6)Sent: Tuesday , April 21, 2020 11 :18_A_M__ __ ~~To : Fauci, Antho ny (NIH/N IAID) [E] Cb)( ; COPPIETERS'T WALLANT Yves(b) (6)>Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020Tony,Professor COPPIETERS and I, we send you our new simulations :In summary, the USA COVID-19epidemic model says :- the final size of epidemic= more than 85061 0 people infected and detected;- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day duringthis peak - about +/- 35520;- end of epidemic=+/- 19-28 June 2020 (we use two methods) ;- mortality at the end of epidemic :** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate= 5%)** if death rate 10% = +/- 85.060 deceased peopleYou reached 91, 1 % of the theorical logist ic curve .Best regards .Quirico00 32 475 48 68 42Le dimanche 19 avril 2020 a 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E]ecrit:Quirico :Cb)( > aThanks again! Please keep this information coming to me.Best regards,TonyFrom: blonda quirico Sent: Sunday . April 1-9, 2-02-0 5-:04- A--M- ----- -=-<'"= To: Fauci, Anthony (NIH/NIAID) [E] CbH >; COPPIETERS'T WALLANT Yves(b)(6) -------Subject: Re: estimation of dynamics of COVI D-19 in USA new simulations at 18 April 2020Tony,We send you our new simulations.In summary, the USA COVID-19 epidemic model says:- the final size of epidemic = more than 779000 people infected and detected;- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day duringthis peak - about +/- 35063;- end of epidemic=+/- 4-13 June 2020 (we use two methods);- mortality at the end of epidemic :** if dead rate 5% = +/- 40000 deceased people** if dead rate 10% = +/- 80.000 deceased peopleYou reached 8 7 .5 % of the theorica I logistic curve.Best regards.Quirico00 32 475 48 68 42Le lundi 6 avril 2020 a 03:32:35 UTC+2, Fauci , Anthony (NIH/NIAID) [E]_ _____ C>bC_6>) a ecrit:Dr. Bionda:Thank you for sending me this information. I appreciate it.Best regards,TonyFrom: blonda quirico (b)( .....,,.,=-e-..,,....,,-,,--,:,-,-,---- ....Sent: Sunday , April 5, 2020 9:23 PM-- ---~~ To : Fauci, Anthon NIH/NIAID) [E] (b)( >; COPPIETERS'T WALLANT Yves(b)(6)> -------Subject: estimat ion of dynamics of COVID-19 in USAProfessor Anthony F AUCY,Sorry to disturb during the COVID-19 in USA.But I would you inform about the COVID-19 in USA.I'm medical doctor in Belgium.With my teacher Professor Yves COPPIETERS ( Ecole de sante publique - ULB -Brussels) , we make simulations about the COVID-19 for many countries.In summary, the USA COVID-19 epidemic model says:- the final size of epidemic=+/- 462760 people infected and detected;- date of epidemic peak = +/- 1- 2 April 2020 with theorical new cases - in one dayduring this peak - about +/- 28390;- end of epidemic = +/- 15 May 2020;- mortality :** if dead rate 5% = +/- 23140 deceased people** if dead rate 10% = +/- 46275 deceased peopleIf you are interrested by our simulations, you can contact us.Best regards.Dr Quirico BLONDA(b)(6)From:Sent :Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 00:50:12 +0000(b)(6)Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whosedrugstore our family relied on back in the 1950s.You have got to read this!!!From: Folkers, Greg {NIH/NIAID) [E] ---------(b)(6)>Sent: Thursday, April 23, 2020 7:21 PMTo: NIAID COGCORE <COGCDRE@mail.nih.gov> ; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAIDOD AM <NIAIDODAM@niaid.nih .gov>Subject: The Tablet I find myself thinking back to his fathe r, Stephen Fauci, whose drugstore our familyrelied on back in the 1950s.https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/~ I 0,A™F uz, I jiQ!ftACi vsTHE~LETNt:WS O.PINIO.N PJUUSHa SCHOOLS SPORl'S AIIOUNI> THC OIOCES£CCIIIONAVUtU.SOnly in Print; Dr. Fauci's Roots in Dyker Heights:.,,,, a 2Q'20D CJSCJDI A/IIIIOllyF auci mlH!l$ •!II Rf9,$ H,O,, Stl'>OONI udelltS a1t11,,ucll00P/fl~ FJU>er~ Ill U ~an$ J ,,t 20•l l 4uc• ,_.,,_ t;,m ty OWNld• ,,..g1,bomood pl,.rmKf ,n Oy/(fl' i-.gt,ta/ IS a 19$4 f}<8<1,;atecltl>t Jew.I WtOOI (Phelo COIIIWf of FIM:I t;Jm#f)CATHOLIC NEWS SERVICERiMQIOUStO Ucallon COfflinUtsi n dlffnntfOffllalOu!lnQ Pllldem.tC81$hop" ,~ ~ IJ•Qt Peru to QU4td tnaigenou$Plil<l3 du!ln g pano.m1cFrom the Neighborhoodby Frank DerosaFrank DeRosa retired as Associate Publisher of TheTablet and director of the Diocesan PublicInformation Office in 2008When I see Dr. Anthony Fauci on the TV screenexplaining expertlyeverything we need to know about thecoronavirus pandemic, I find myself thinkingback to his father, Stephen Fauci, whosedrugstore our family relied on back in the 1950s.Steve Fauci was the neighborhood pharmacist.The Fauci Pharmacy stood on the southwestcorner of 13th Ave. and 83 rd St., in the DykerHeights section of Brooklyn, diagonally acrossfrom the Shrine Church of St. Bernadette. Welived two blocks away on 85 th .Long ago parishioners like me remember whatthe store looked like, thesoda fountain that ran along the right wall, thetelephone booths at the left close to theentrance and the counter straight ahead downthe center.Whenever my mother sent me there, Mr. Fauciwould be behind thecounter, but it was a family enterprise. Theylived in an apartment above the store, and if thepatriarch wasn't serving you, his wife, Eugenia,or daughter, Denise, was there. Young Anthony,I've since learned, pitched in too, his fathersending him out on his bike to deliver items tocustomers.I've never met the man who has become themost important medical voice in the country. Norhave former parishioners that I've spoken toabout him in recent days, like boyhood palsAnthony LoFrisco, from80th St., now in Connecticut, and Bob Orlando,who lived on 84th, now a New Jersey resident,as well as Bishop Gerald Barbarito of the PalmBeach Diocese, from 11th Ave. But eachremembers the pharmacy as a Dyker Heightsinstitution.While we don't know him personally, in a sensehe's become everyone'sfriend. With his steady television presence, he'simparted his vast knowledge andstraightforward advice in a trademark,sometimes gravelly or raspy, Brooklyn accentthat has endeared him to people far and wide.You can't be anything but proud of someone ofhis prominence who came from the parish.Anthony became known as Tony, as he tells it,when Father Flanagan,principal of Regis High School, decided to callhim that on his first day as a freshman. Thename stuck.Tony took buses and trains to the Jesuit schoolin Manhattan, including the old Sea BeachExpress. He traveled 70 minutes each way, didthree hours of homework, captained thebasketball team and excelled in the classroom.I remember hearing that when Tony was a highschooler, he had a parttimejob working in St. Bernadette's rectory,answering the phone and doing whatever elseparishioners wanted him to do to put them intouch with one of the parish priests. In thosedays, the rectory had a priestly bonanza. Therewere four of them.Because St. Bernadette's School had not yetbeen established, Tony went to Our Lady ofGuadalupe School, where he was taught byDominican Sisters. It was, and is, St.Bernadette's neighboring parish.Like most kids, he loved sports. He played CYObaseball and basketball. At Dyker Park on 86thSt., he and his friends developed skills inimitation of their heroes. A Yankee followerliving in the midst of Brooklyn Dodgers fans whoadored The Boys of Summer, he's said hisfavorite players were Joe DiMaggio and MickeyMantle.Tony's father and mother married at 18, afterthey graduated from NewUtrecht High School. Steve went on to Columbiato study pharmacy.Sometime after he opened his pharmacy, hebecame friends with Father Al Varriale, one of St.Bernadette's beloved parish priests. At onepoint, Steve, as a parent, and the priest knownas Father V, who directed the parish's robustCYO sports program for youths, shared aconcern. It was the easy availability of indecentand immoral publications that they knew was athreat to the moral development of youngpeople.So, with the approval and support of the Dioceseof Brooklyn, together they formed a diocesancommission against pornography. Both men arenow long gone, and so is the commission, but itwas a good idea, though it did not survive them.Remarkably, just a few houses up the block fromwhere Steve established his pharmacy, lived thePellegrinos, another family of St. Bernadette'sparishioners that produced a renowned medicalprofessional. The eldest son, Edmund, became abioethicist, a "preeminent" one, as onenewspaper described him after he died. But hewas more. He helped develop medical programsat Kentucky, Stony Brook and TennesseeUniversities. Later, he took on the presidency ofThe Catholic University of America. Then, aftercompleting his tenure there, he became, asphysician and philosopher, the director of theKennedy Institute of Ethics at GeorgetownUniversity.Though years apart in age, both Dr. Fauci andDr. Pellegrino becameHippocratic stars, nurtured on the same block.Only in Brooklyn, I say, not without bias.Steve Fauci was known by members of hisextended family and friends for his personality,kindness, sense of humor and wit, and for tellinggood stories. So they said in comments after hedied in 2008.Tony appears to have inherited Steve's gene forlightheartedness. Hisdaughter once told the Washington Post that herdad could be a "goofball ... he works hard anddoes his thing, but he comes home and he'ssinging opera in the kitchen and dancingaround."That kind of calm can help a man maintain hisbalance as he deals with the pressure of talkingto millions of people every day about thecomplexity of a global pandemic.As one newsman said, "When Fauci appears onthe screen, you turn up the volume."He once said the Jesuits at Regis and HolyCross College taught him theimportance of "precision of thought andeconomy of expression."That's what he delivers every day: accurateinformation given concisely.That's Tony Fauci, now a national treasure. Andto think, he came from the neighborhood.Dr. Anthony FauciTOSLOWEADHe graduated from RegisHigh School and theCollege of Holy Cross.He graduated numberone in his class atCornell Medical Schoolin 1966.He completed hismedical residency atNew York HospitalIn 1984, he becamedirector of NationalInstitute of Allergy andInfectious Diseases, aposition he holds today.Front row, kneelingU.it1lc Cr~ l\ or r-,,,.,,St~\, was on<c known as th< chmp ut ysprmta nov. he u .tl' ls H lhc cla:.; K"~t J, . 1.-rA r.?guhr fellow w11h ., re3dy <n,tl~ ,1td fullot ~pun You could ilJ"ns count on St~\C bt:-1n,: p:.•stnt .it cv~r\· cli-,5 .tnd sdmol affairDisclaimer: Any third-part y material in this email has been shared for internal use under fair use provi sionsof U.S. copyright law, without further verification of its accuracy/veracity. lt does not necessa rily repr esentmy views nor those ofNIAlD, NTH, HHS, or the U.S. government.From:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [ElFri, 24 Apr 2020 00:35:33 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Another PossibleT ool in The Fight Against SARS-CoV-2?Pleas take a look and figure out where to send it.From: Gary Radin <GRadin@dhs.lacounty.gov >Sent: Thursday, April 23, 2020 8:31 PM ------ ~= To: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6)> Subject: Another Possible Tool in The Fight Against SARS-CoV-2 ?Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out toyou but I don't really KNOW any other way!I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed inthe Anatomic Pathology department at LA County-USC Medical Center here in SouthernCalifornia.But I have been reading a lot- -- and in my own exploration I have come across several articleswhich suggest the possibility of using a class of agents calledSPHINGOSINE-1-PHOSPHATER ECEPTORA GONISTSi n combination with antivirals likeoseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsibl e for thecurrent pandemic as well as the runaway immune response of the host leading to the oft fatalcytokine storms.Apparently these compounds have been approved for flare-ups of multiple sclerosis, and haveeven been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But thesepapers that I have cited for you below seem to indicate that structural analogs of thiscompound could be important in damping down the dysregulated pro -inflammatory cascadeswhich seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leaksyndrome and ultimately the multiple organ failure that is killing an unacceptably high numberof people.The fly in the ointment Dr. Fauci here is that these 5-1-PR agonists have only beendemonstrated to be effective in non-human primates and other mammals. And much of thesestudies on these compounds has been done not on coronaviruses but on influenza viruses .So it would be a gamble. But is that not how we have learned much about human health anddisease is by the gracious sacrifice of our anim al cousins? And might it not be a general effectthat these sphingosine derivat ives have on viral sepsis so that maybe what works for influenzamight work for the coronavirus?In the dire situation that many of the most critically ill COVID 19 patien ts find themselves, itseems they are on the precipice of a rapid demise once they begin to show certain keylaboratory resu lts---(sp ikes in 0-DIMER, C-Reactive Protein, Serum Ferritin, prolongation ofprothrombin and APTT, increased card iac troponin 1, surges in IL-6, IL-7, monocytic andmacrophage chemo-attractant cytokines etc) .With pat ients isolated by these aberrant lab values, the window may be narrow but it may be atime where application of antiviral compounds in combination with these inflamma torymod ulat ors could have a striking impact on mort ality? Indeed maybe even TWO differentantivirals with diff ering mechanisms of action in combination with these S1-PR Agonists wouldeven be better. And the possibilit ies of other combinat ions of course would be there forfurther exploration .Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least themedical rat ionale is sound for the inclusion of these agents into the possible arsena l oftherapeutics for the more severe COVID 19 patients.Please refer below to the st udies I found particularly helpful or promis ing. Perhaps you can puttogether some 'teams ' to further explore investigate these opt ions??We all appreciate everyt hing you have done, and continue to do !Gary Radinhttps://www .sciencedirect.com/science/article/pii/S0140673620303056https ://www.pnas.org/ conte nt/108/29 /12 018https://www .clinical key .com/# !/con tent/p layContent/1-s2. 0-S0042682214000063 ?return url=http s:%2 F%2Fli nkinghu b.elsevier .com%2 Fretrieve%2Fpii%2FS0042682214000063%3Fshowall%3Dtrue&referrer=Suppression of cytok ine storm with asphingosine analog prov ides protectionagainst pathogenic influenza virus IPNASHuman pandemic H1N1 2009 influenza virus rapidlyinfected millions worldwide and was associated withsignificant mortality. Antiviral drugs that inhibit influenzavirus replication are the primary therapy used to diminishdisease; however, there are two significant limitations totheir effective use: ( i) antiviral drugs exert selectivepressure on the virus, resulting in the generation of ...www.pnas.orghttps://www.thelancet.com / journals/lancet/article/PIISO l 40-6736(20)30566-3 /fu lltextClinical course and risk factors for mortality of adult inpatientswith COVI D-19 in Wuhan, China: a retrospective cohort study1 - The LancetThe potential risk factors of older age, high SOFA score, and d-dimer greater than 1μg/ml could help clinicians to identify patients with poor prognosis at an early stage.Prolonged viral shedding provides the rationale for a strategy of isolation of infectedpatients and optimal antiviral interventions in the future.www.thelancet.comhttps:/ /www.ncbi.nlm.nih.gov /pmc/articles/PMC317 6439 /Endothelial cells are centralorchestrators of cytoki neamplification duringinfluenza virus infection -PubMed Central (PMC)Cytokine storm during viral infection isa prospective predictor of morbidityand mortality, yet the cellular sourcesremain undefined. Here, using geneticand chemical tools to probe functionsof the S 1 P 1 receptor, we elucidatecellular and signaling mechanismsimportant in initiating cytokine storm.While S1 P 1 receptor is expressed onendothelial cells and lymphocyteswithin lung tissue ...www.ncbi.nlm.nih.govFrom: Fauci, Anthony (NIH/NIAID) [E)Sent: Thu, 23 Apr 2020 22:47 :07 +0000To: Billet, Courtney (NIH/N IAID) [E];Greg Folkers ---------- (b)(6} ;Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [ElCc: Barasch, Kimber ly (NIH/NIAID) [C]Subject:Attachments:FW: Sammies recognition th is year - congratulationsAFauci, NIH.pdfPlease take a look at this and let us discuss. Thanks.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Max Stier <msti er@ourpubl icservice.org>Sent: Thursday, Apr il 23, 2020 2:57 P-M- ------,;- = To: Fauci, Anthony (NIH/NIAID) [E) (b)( 6)>Cc: Barasch, Kimberly (NIH/NIAID) [C] _________ Cb _H_ ; Sammies<Sammies@ourpublicserv ice.org>Subject: Sammies recognition this year- congratulat ionsDr. Fauci:I hope you are healthy and well. The Partnership for Public Service is honored to inform you that wehave selected you as a fi nalist for the 2020 Samuel J. Heyman Service to America Medals, otherwiseknown as the Oscars of government service.You were nominated by Francis Collins for your outstanding career at NIAID and th e wor k you arecurrently doing on behalf of the American people to prepare, inform and protec t lives in our country andaround the wor ld during th is uncertain time . Your work truly embod ies the best of governm ent tha t westrive to recognize through the Sammies program.Attached, I've included the profi le we have drafted to summarize your work and accomplishments -both for recognizing you as a fina list and for having the selection committee vote for the awardrecipients . Should you have any edits or wish to add a personal quote, please send those to us at yourconvenience. We will be releasing your profile publicly with the rest of the final ists on Sunday, May 3.Again, thank you for the work you do on behalf of the NIH and our country.Best,Max StierPresident and CEOPartnersh ip for Public ServiceFrom: Fauci, Anthony (NIH/N IAID) [ElSent : Thu, 23 Apr 2020 22:37 :35 +0000To: Greg Folkers CbH6);Conrad, Patricia (NIH/NIAID) [ElSubject: FW: NAS Annual Meet ing Session on COVID-19 -- Information regarding yourSaturday April 25 part icipationFYIAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J. <VDzau@nas.edu>Se nt: Thursday, Apr il 23, 2020 1:49 PMTo: Fauci, Anthony (NIH/NIAID) [E] ----------------~~Cc: Hannon, Emma <EHannon@nas.edu>; Conrad , Patr icia {NIH/NIAID) [El (b) (6);(b)(6)'ben.t inker@cnn .com' <ben.t inker@cnn .com>;'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com> ; 'Neel.Khairzada@t urner .com-'- ----; ~,s, <Neel.Khairzada@turner .com>; 'Tia.Mille r@turner.co m' <Tia.Mi ller@turner .com>; (b) (>; McGinnis, J. Mic hael <MMcG innis@nas.edu>; (b)( =======~ -------- (b)(6) ; Mu n, Jenny <JMun@nas .edu>; (b)(6) Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regard ing you r Saturday April 25part icipationDear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really look ing for ward to th is panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25that 2:00 -3:30 pm ET. There is tremendous excitement and enthusiasm, and registr ati on is thr ough theroof .I am sending this note to do a last minute check to see if there is anything you need from me. I also wantto check whether you are planning to use slides. Will you be sending your slides to us to project or usethe share screen feature to advance your own slides? Regardless, it would be helpful to me if you couldsend me your slides for my preparation.I wou ld greatly appreciate it if you would respond to th is email.Best,VictorPS,- ----- Cb)~ , my special assistant, will be sending you additional information about the session logistics shortly.From: Dzau, Victor J. <VDzau@nas.edu>Sent: Thursday, April 9, 2020 11:01 AM ---------------~ ~---:---:-:--:-:--:-:---:-=(=b)(=6)>=; =Ha=nn:o.n.., ;E_m-m-a= <~EH annon@nas.edu>; 'conradpa@niaid.nih.gov ' (b)(6)>; 'T.MillerdeVega@wellcome.ac .uk'(b)(6)>; 'jsi@cepi.net ' (b)(6) 'rebeka.yasmin@cepi .net' =========.~;;;--:-:-- (b )( 6) >; 'ben.tinke r@cnn.com' <ben.tinker@cnn.com >; 'Amanda.Sealy@cnn.com' _____._. ___<Amanda.Sealy@cnn.com >; 'Neel.Khairzada@turner .com' <Neel.Khairzada@t urne r.com>;'Tia.Miller@turner .com' <Tia.Miller@turner.com >; (b)(6)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25participationDear all,Thank you for agreeing to participate in a spec ial late breaking session on the COVID-19pandemic at the NAS annual meeting . Knowing how busy you are, I am sending this ema il inlieu of a call to prepare for the session.As you know, this is a 90 minute session which aims to provide our audience with deeperinsights into the latest developments in the COVID-19 response . I plan to hold an engagingdiscussion that covers the whole experience on dealing with this pandemic - from US tointernat ional, to preparedness and response , the biology of the virus, the state of diagnostic ,treatmen t and vaccine development, and the importance of communication.I will begin the session by providing brief ( ~ 3 min) opening remarks describing thecircumstances of the pandemic. Then, I will introduce the panelists and you will each have 7minutes to provide remarks. You may use a limited number of slides for ilJustration. I hope thateach panelist will provide their own perspective and speak to the issues proposed below.• Jeremy Farrar will discuss the global response to the pandemic, drawing from hisexperience as a global leader, the chair of the Scientific Advisory Group for the WHO'sR&D Blueprint and as a member of the Global Preparedness Monitoring Board .• Tony Fauci will discuss tbe US pandemic and provide his perspective as a member of theWhite House Coronavirus Task Force addressing the 2019 - 20 coronavirus pandemic.• George Gao will discuss China's response to the pandemic and lessons learned for therest of the globe.• Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into itspathobiology , immunity and developmen t of a pan-CoV antiviral.• Richard Hatchett will discuss the deve lopment of new vaccines and treatments againstCOVID-19.• Sanjay Gupta will comment on the health system response to the pandemic andchallenges related to communication and public engagement in responding to COVID-19.Following remarks from each panelist, we will have a moderated discussion amongst ourselves -I will ask you a set of questions (15 mins) and then we will take questions from the web (25mins) . To prepare me to be your moderator, please send me any questions you would like me toask you. For those of you who would like to have a prep call, please let me know and I will set itup.Best,VictorFrom: Mun , JennySent: Wednesday, Apri l 8, 2020 10:56 AM(b) (6) ;--------------------------- (b)(6) 'ben.tinker@cnn.com'; 1 Amanda.Se a I y@ c n n. com'; 'Neel.Khai rzada@turne r.com' ; 'Tia.Miller@turn er.com'Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday Apri l 25participa t ionDear Speakers:I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting(online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in thissession. To help you with your planning, I have provided additional details below.Please note that the session will be live webcast and the general public will also be able to watch thesession. Video from the session will also be uploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting . We will need to obtain signedspeaker release forms for your participation in this session. I have attached the speaker release form foryour review and submission. Please return the signed speaker release form by Monday , April 13.Session speakers are asked to connect 30 minutes prior to the session start time (by Saturday, April 25at 1:30 pm EDT) to allow the technical staff to check connections and prepare for the session. Details onhow to connect will be sent before the meeting.We will list you in our promotional materials as noted below . If this is incorrect, please let me know .Anthony S. Fauci, Director, National Institute of Allergy and Infectious DiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control & PreventionSanjay Gupta, Chief Medical Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microb iology, Perelman School of Medicine, University of PennsylvaniaSince many of us have moved to remote work environments, you may already be proficient with Zoomand other online meeting/collaboration applications. I am attaching a 'speaker guidelines' f ile in caseyou have any questions on how best to prepare for and stage your remote talk . We have technical staffavailable to help you become familiar with Zoom and its settings -such as "sharing your screen" (if youhave slide presentations that need to be shown during your talk). We can arrange for a t raining sessionthis week or next week. If you would like to schedule a session, please let me know as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any othe r questions,please let me know .Regards, Jenny******************* *************Jenny MunMembership DirectorNational Academy of Sciencesjmun@nas.edu(b)(6)From: Fauci, Anthony (NIH/NIAID) [E)Sent : Thu, 23 Apr 2020 22:36:33 +0000To: ----- -=-a=Ca, ssetti, Cristina (NIH/N IAID) [E);Lerner, Andre a (NIH/NIA ID) [El (b)(6) ;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary (NIH/N IAID) [ElSubject: FW: New sheetAttachment s: COVID.docxAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-O331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail=--__,. __., (b)(6)The information inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Dani Bolognesi, Ph.D. (b)( 6)Sent : Thursday, April 23, 2020 1:01 PM ------- == To: Fauci, Anthony (NIH/ NIAID) [El ~=======-~ = Cc: Conrad, Patr icia (NIH/NIAID) [E]Subject: FW: New sheetHi Tony :I hesitate to bother you with th is as I am sure that you are inundat ed with requests of this sort over andabove everyth ing else you are doing which is tr uly magnific ent. I beli eve th at th ere is something ofpotentia l importance in what is commun icated below but you are in the best position to tell me whethe rit could fit in the toolb ox you are assembling for COVID 19 in both the short and longer term . I have toacknowledge our fr iend Bob Gallo for triggering this(b) (4)Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do notexpect you to review this but perhaps you can forward to one of your trusted colleagues.PPS. loved the interview with Coach K!Con un forte abbraccio IDani(b) (4)From:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 22:25 :14 +0000(b)( 6)Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before TrumpMin imized Coro navirus I MSNBC http s://bit. ly/2yynEPfI may have already sent this to you, but I do not think so. It is short (6 minutes)but it has a segment that shows me 37 years ago. Yikes!!! You will get achuckle.Anthony S. Fauci , MODirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone (b) (6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barasch, Kimber ly (NIH/NIAID) [CJ- --------- (b)(6) Sent: Thursday, April 23, 2020 9:04 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6) Subject: FW: MSNBC: See Dr. Fauci's Stunni ng Pandemic Warn ing - Long Before Trump Mi nimizedCoronavirus I MSNBC https ://b it.ly/2yyn EPfKim Barasch [ClOffice of the DirectorNational Institute of Allergy & Infectious Diseases(b)(6)(b)(6)From: Folkers, Greg {NIH/NIAID) [E)- ------- (b) (6)> Sent: Tuesday, April 21, 2020 11:06 PMSubject: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing- Long Before Trump Minim izedCoronavirus I MSNBC https :ljbit.ly /2yynEPfDisclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily representmy views nor those ofNTAID, NIB , HHS, or the U.S. government.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 22:14 :31 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject:Attachme nts:FW: A proposal to stop COVID-19 and reopen our schools and businessesScientists_to_Stop_COVID19_2020_04_23_FINAL.pdfEmail below from David Liu.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone (b)(6)Email: (b)(From: David Liu (b)(Se nt: Thursday, April 23, 2020 6:-0-1- P-M- -=-::-:-= To: Collins, Francis {NIH/OD) [E] (b)( >; Fauci, Anthony {NIH/NIAID) [E](b)(6); Lane, Cliff (NIH/NIAID) [El (b)( >; Austin, Christopher(NIH/NCATS) [E] (b)(6 )'>; Whalley, David (FNI_H_) [T:.] ...:......:..!::::====~~ (FNIH) [T] (b)(6); Tabak, Lawrence (NIH/OD) [El '.=========~-= = Cc: Michael Rosbash (b)(6)>; Ramnik Xavier (b)(6)>;EDWARD SCOLNICK (b)(6); Stuart Schreiber (b)(6)>; Michael Z Lin -----~=--- ":"'""~----(:b~ )( 6-) ->-; B-e:n.= Cr=av:a:tt. ...;.-=-:~ (b)(6J>; Thomas Cahil l (b)(6) R. Scott Kemp (b)(6)Subject: Re: A proposal to stop COVID-19 and reopen our schools and businessesDear Francis, Anthony , Cliff, Christopher, David, Maria , and Lawrence,I hope you are all well. Attached is the updated set of four proposals on:1) Rapid repurposing of antiviral drugs to treat COVID-19;2) Expedited development of neutralizing monoclonal antibodies to t reat COVID-19;3) Rapid COVID-19 vaccine development;4) Risk-reduced ways to reopen schools and businesses, and the healthcare system changes that areneeded to enable them.We hope you find these updated proposals useful , and would be happy to engage in any way that couldbe helpful.Sincerely yours,Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin(Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), EdScolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)David R. LiuRichard Merkin Professor and Director of the Merkin InstituteofTransformative Technolog ies in HealthcareDirector of the Chemical Biology and Therapeutic Sciences ProgramCore Institute Member and Vice-Chair of the Faculty, Broad InstituteInvestigator, Howard Hughes Medical InstituteThomas Dudley Cabot Professor of th e Natu ral Sciencesand Professor of Chemistry & Chemical Biology, Harvard Unive rsity75 Ames StreetCambridge, MA 02142On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] -------- (b)(6)> wrote:Dear David et al.,Thanks for forwarding this very thoughtful document, which presents a series ofimportant recommendations - most of which I agree with. I don't know if you sawFriday's announcement (attached) of the new public private partnership calledACTIV (for Accelerating COVID-19 Therapeutic Interve ntions and Vaccines), but ithas taken on most of the points you raise in sections 1- 3 of your letter. I shareyour hopes that remdesivir will show benefit, and the current large NIH-sponsoredRCT has completed enrollment and shou ld reveal results in about a month. But ofcourse we want to test multiple other interventions - both small molecules andantibody-based therapies, so we need our tria l system to be optimized like neverbefore. I will share your letter with the leaders of ACTIV, who are working withunprecedented speed to prioritize the next set of therapeutic candidates as well aspushing vaccine development programs to adopt exceptionally creative trialdesigns to test safety and efficacy (with full engagement by FDA).Best regards , FrancisFrom: David Liu Cb()6 )Sent : Sunday, April 19, 2020 5:20 PMTo: OD Labc (NIH/OD) (b)( •>; Collins, Francis (NIH/OD) [E](b)(6)--------...!::===~~----___(b,).( 6)>;R amnik X-a-v-i-e-r - ~=":'"":'~~---:::====== (=b):;(:~- ;~EDWARDS COLN_ICK--=====~~Schreiber (b)(6)>; Michael Z Lin CbH ; Ben Cravatt-----=== ('ab~:'s:(;6~)----Cc: Michael RosbashSubject: A proposal to stop COVID-19 and reopen our schools and businessesDear Francis,I hope you are well.I write on behalf of a group of citizen -scientists, most or all of whom you know. Motivatedsolely by our desire to help defeat the serious threat our nation and the world now faces,we wrote a set of four actionable, non-partisan proposa Is (attached) to produce safe andeffective COVID-19 therapeut ics and vaccines in the shortest possible timeframe, and toreopen our society in a manner that reduces the risk of future COVID-19 outbreaks .We hope you find these ideas interesting, and might be willing to share this set ofproposa ls with Dr. Tony Fauci, along with our willingness to discuss any part of theproposals with him if we can be helpful. We understand from our efforts to contact Dr.Fauci through emai l routes that his standard inbox may be too overwhelmed for ourproposa l to reach him.The four proposals attached describe: (1) How to rapid ly repurpose an ant iviral drug totreat COVID-19 patients; (2) How to expedite the development of human antibody drugs totreat patients and to provide short-term protect ion for healthy individuals; (3) How todevelop COVID-19 vaccines on an expedited t ime scale; and (4) How to reopen ourbusinesses and schools in a manner that reduces the risk of future outbreaks and deaths.Thank you for any help or thoughts you might be able to provide.Sincerely yours,Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT),Michael Lin (Stanford), David Liu (Harvard/Broad), Michae l Rosbash (Brandeis), StuartSchreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier(MGH/Broad)David R. LiuRichard Merkin Professor and Director of the Mer kin Instituteof Transformative Technolog ies in HealthcareDirector of the Chemical Biology and Thera peut ic Sciences ProgramCore Institut e Member and Vice-Chair of the Faculty, Broad InstituteInvestigator, Howard Hughes Medical Instit uteThomas Dudley Cabot Professor of the Natural Sciencesand Professor of Chemistry & Chemical Biology, Harvard University75 Ames StreetCambridge, MA 02142<NIH_ACTIV _Release_041720.docx>From:Sent:To:Cc:Subject :FYIAnthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 21:47 :13 +0000Conrad, Patricia (NIH/NIAID) [E)Barasch, Kimberly (NIH/NIAID) [C]FW: Whit e House Coronavir us Task Force Meet ing - 4.24.20National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent:To:Cc:Subject :Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 21:40 :33 +0000Conrad, Patricia (NIH/NIAID) [E)Barasch, Kimberly (NIH/NIAID) [C]FW: Update: White House Coronaviru s Task Force Meet ingHeads-up! Change in schedule for tomorrow.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.(bX5) -l'UFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 21:29 :50 +0000Fauci, Anthony (NIH/NIAID) [ElSubject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before TrumpMin imized Coro navirus I MSNBC http s://bit. ly/2yynEPfhttps://bit. ly/2yyn EPfAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barasch, Kimberly (NIH/NIAID) [C]- --------- (b)(6) Se nt: Thursday, April 23, 2020 9:04 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - Long Before Trump MinimizedCoronavirus I MSNBC https ://b it .ly/2yyn EPfKim Barasch [CJOffice of the DirectorNational Institute of Allergy & Infectious Diseases(b)( 6)(b)(6)From: Folkers, Greg (NIH/NIAID) [E] ---------(b)( 6)> Sent : Tuesday, April 21, 2020 11:06 PMSubject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning- Long Before Trump Minim izedCoronavirus I MSNBC https://bit .ly/2yynEPfDisclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily representmy views nor those ofNTAID, NIB , HHS, or the U.S. government.From: (b)(6)Sent :To:Subject:Thu, 23 Apr 2020 14:34:36 -0400Conrad, Patricia (NIH/NIAID) [E)Fwd: Thank you, and ...Attachments : image002.png, ATT0000l.htm, PasstheMic Expert Outreach.pdf, ATT00002.htmLet us discussBegin forwarded message:From: Gay le Smith <gayle.smith@one .org>Date : April 23, 2020 at 1 :49 :04 PM EDT To: "Fauci, Anthony (NIH/NlAID ) [E]" ----------=:--:-(b-)(:6)- =- _____._. ___Cc: Tom Hart <tom.hart@one.org>Subject: Thank you, and ...Dear Tony,I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. Asan American, a former colleague, a long-time admirer and student of your wisdom - thankyou. We are all safer because of you, and the world will be a better place because ofyou. Again.As you know, I am now leading the ONE Campaign. We've been quite active wi th theONEWorld Campaign, dedicated to the fight against this newest virus, and focused onAfrica . We've made some progress on debt, and next up is a focus on ensuring that avaccine, when it comes, is available to everyone.One of the things we want to do is educate people, in all of the places we work. It won'tsurp rise you that of particular urgency amongst our partners in Africa is that facts andinformation get to people across the continent, but we also know that more facts areneeded everywhere . So next month we are going to launch #PassTheMic, where every dayfor 19 days we will ask a celebrity to turn his or her social media channels over to an experton COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to ta lkabout the critical elements needed to flatten the curve and slow the spread. Or Idris Elbacould give up his lnstagram to the head of the African CDC so that he can illustrate theimpact COVID-19 will have across Africa and what that means for the rest of the world .We know artists want to be helpful right now, but that it is hard to know what to do. Andwe know there are experts like you out there who have the answers. We've thought aboutthis a lot at ONE and wanted to do something we felt would truly have an impact . As welook ahead we know COVID-19 does not know borders and until it is beaten everywherewe are not in the clear. We need a global response plan and we need it now. By turn ingover their platforms for the day, celebrity influencers will be donating one of their biggestassets - their followers - to YOU, giving you the platform you need (and we all need) to tellthe world why a global response is critical. Because none of us are safe until all of us aresafe.We wi ll work with each expert/celebrity pair to personalize the content to our and ourcelebrity partners' audiences - in North America, Europe and Africa, and help createcontent that both part ies are happy with . We are now confirming our talent partners, andso far are getting a terrific response.We know you're a busy man, so we've planned it so that the amount of time on your endwould be minimal. But the impact wou ld be maximal.I'm attaching more information about the campaign. Please let me know what you thinkand if you have questions. Ideally we would like to get this off the ground in early May, soare hoping to confirm folks by April 28th at the latest. Our team will be in touch with youroffice to follow up.Thanks as always for everything you do. All my best to you, Gayle
Gayle Smith I President & Chief Executive Officer I ------- (b)(6)ONE.ORG I Twitter I Facebook I lnstagramONE is a global movement campaigning to end extreme poverty and preventable disease by2030 so that everyone, everywhere can lead a life of dignity and opportunity .From: Fauci, Anthony (NIH/N IAID) [E)Sent:To:Subject:Thu, 23 Apr 2020 18:25 :56 +0000Simmons-Butler, Kirk (NIH/NIA ID) [C]Re: Thank you Dr. Fauci!Attachments : image001.png, image002.gifKirk:Thank you for yom· kind note. Much appreciated.Best regards ,TonyOn Apr 23, 2020, at 2:16 PM, Simmons -Butler , Kirk (NIH/NIAID) [C]Cb)( wrote:Greetings Dr. Fauci,I just wanted to take a moment to personally thank you for all of your support andleadership during these unprecedented times. I am proud to be a part of the NIAD familyand you represent us and the country well ! God continue to bless and keep you and yourfamily! Thank you again sir!Regards,KirkKirk D. Simmons-Butler, M.S.Assistant Facility Manager 14DNR. Charles River Laboratories Inc.NIH/NIA--I D-- ~~ (Office) (b)(6)(fax) (301) 761-6013Charles River website - www.criver.com<image00 1. png><image002. gif>The information in this e-mail and any of its attachments is confidential and may containsensitive information. It should not be used by anyone who is not the original intendedrecipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. The National Institute of Allergy andInfectious Disease (NIAID) shall not accept liability for any statement made that are thesender'so wn and not expresslym ade on behalf of the NIAID by one of itsrepresentatives.From: Fauci, Anthony (NIH/N IAID) [E] (b)( >Sent: Friday, March 27, 2020 11:55 AMTo: NIAID Announcements <NIAID-announce@niaid .nih.gov>Subject: Platelet Donations Down are Down Amid Coronavirus Outbreak -- Please DonateDear Colleagues:The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesavingplatelets to patients. The need for platelet donations is especially acute now with thecoronavirus pandemic. While social distancing and increased telework are necessary tocontain and slow the spread of coronavirus, we have seen a marked decline in platelet andblood donations for our patients.To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) areco-sponsoring a two-week Platelet Drive from March 30 -April 10. Platelet collections, aswell as whole blood and Double Red Cell donations, can only be made at the NIH BloodBank on campus in Building 10, Room 1(713 Monday through Friday from 8:00 am to 5:00pm. The Platelet Center at Fishers lane is temporarily closed and plate let collections arenow on the main campus through at least the next 30 days. This move helps to ensure thatblood donors are protected by visitor screening, minimizing possible exposure toindividuals at risk.What is a double red cell donation? A double red cell donation enables donors to donatetwo units of red blood cells in one visit. During a procedure called apheresis, whole blood isseparated through a cell separator and red blood cells are collected. The remainder of theblood components are returned to the donor along with saline to replace the lost volume.I encourage participation of all employees who are eligib le to provide a donation to benefitour NIH patients. I understand employees may be hesitant to participate under the currentconditions, but I would like to reassure you that blood donation is a safe process.Additiona l precautions have been put in place at our Blood Bank to help prevent thespread of infection and protect the health of donors and staff .Thank you to all who support our quarterly platelet drives. Your efforts provide a lifelinefor our patients . Those who participated in the last drive are now eligible to help onceagain. In appreciation of your dedication to helping others, NIAID grants administrativeleave to any NIAID federal employee who donates platelets at the NIH Blood Bank.Specifically, you will be granted 4 hours of administrative leave to be used immediatelyfollowing your platelet donation appointment. As always with such activities, please notifyyour supervisor for approval prior to donating at the NIH Platelet Center .. Contractoremployees should speak directly to their contract companies to determine what leaveoptions are available . Please contact the Donor Center at 301-496-4321 to schedule yourappointment. let the Donor Center staff know you are with t he NIAID Platelet/Double RedCell Drive. They will answer eligibility questions and provide information about thedonation process.Thank you for consider ing donat ing during t his stressful t ime. Best regards.Sincerely,A.S. FauciAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892 -2520Phone (b)(6)FAX: (301) 496-4409E-mail: (b)(6) --------The information in this e-ma il and any of its attachments is confidential and maycontain sensitive informat ion. It should not be used by anyone who is not theoriginal intended recipient. If you have received this e-mail in error please informthe sender and delete it from your mailbox or any other storage devices. TheNational Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statements made that are the sender's own and not expresslymade on behalf of the NIAID by one of its representatives.~CHARLERSI VERlABOAATORIES
From:Sent :Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 17:39 :48 +0000To: Auchincloss, Hugh (NIH/NIAID) [C)-- -------------~-~-- (b)(6) Subject: F W: Wellness Initiat ive ProposalAttachme nts: Wellness ln iti ative_POC_Sundar .zip, Wellness Initiative Proposal_Sundar .pdf,Managing Anxiety Around COVID-19 March 27 {007) .pdfPlease take a look at th is and handle.From: Sundar, Sachin {NIH/NIAAA) [F] --------- (b)( > Sent : Thursday, April 23, 2020 1:05 PM To: Fauci, Anthony (NIH/NIAID) (E]-- -------- ---- (~b)=(6) > Subject: Wellness Initiative ProposalDear Dr. Fauci,I have an idea regarding science commun icat ion and wellness . Here's a rough proposal and proof ofconcept . At fu ll effect , I think it could have noteworthy potential. (b) (5)Thank you for your time .Respectfully,Sachin SundarFrom:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 13:25 :22 +0000Stephen L. HoffmanSubject: RE: Follow Up ThanksThanks, Steve. I appreciate your note.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Stephen L.Hoffman<slhoffman@sanaria.com>Sent : Wednesday, April 22, 2020 9:56 PM -------::-::-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)( >Subject: Follow Up ThanksDear Tony,I hear continuously from people from all walks of life how grate ful they are for your presence on theCOVID-19 team . You are perform ing an incredible service to our country and the world.Thanks again,SteveStephen L. Hoffman, M.D.Chief Executive and Scientific OfficerSanaria Inc.9800 Medical Center Dr. ste 209aRockville MD 20850tel: (b)(6) (work)tel : (bH (mobile)fax: 301-770-5554E-Mail: slhoffman@sanaria.comwww .sanaria.comFrom:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 13:00 :55 +0000Redfield , Robert R. (CDC/OD)Cc:Subject:Attachments :All ison Arwady ;David Barr;Conrad, Patricia (NIH/N IAID) [E)FW: Dr. Fauci asked me to send Chicago questionWorkforce _Proposal_ Chicago April2020. pdfBob:Please take a look at this . This question evolved from a te leconference that Ihad 2 nights ago with people " in the t renches" including Alison Arwady(Chicago ). The question is what w ill be the relationsh ip between the publichealth workforces at the federal and local levels. Youi had spoken of the CDCpeople that will be assigned locally and that will help build up a local workforce.How will COD interact and relate to the locals. Is there any possibility of Federalfunding of their proposal (see attachment). If not, do you have any suggestionsfor them? I can discuss this with you today at the Task Force meet ing. Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb) (6)FAX: (301 496 -4409E-mail: Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The Nat ional Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E)Sent: Wed nesday, April 22, 2020 3:53 PM To: Fauci, Anthony (NIH/NIAID) [E)-- ------------- .(b.)(,6.) ....,...= Subject: FW: Dr. Fauci asked me to send Chicago questionPis advise.(b)(6)From: Allison Arwady (b)(6)Sent: Wednesday, April 22, 2020 3:42 PM To: Conrad, Patricia (NIH/NIAID) [E] -_-_-_-_--_- -~ C_>b_<=.,.>Subject: Dr. Fauci asked me to send Chicago questionDear Patty,Last night on his call with public health leaders from cities across the country , Dr. Fauci asked me tosend him/you my follow -up question from Chicago:How will the necessary public health workforce expansion (e.g. for wide-scale case investigation,contact tracing, linkage to care, community testing, and vaccination) be supported at the federallevel?Our understanding is that state or local ju risdictions will be able to develop their own workfor ces ratherthan supporting a single workforce at the federal level, and we agree with this approach , but it would bevery helpfu l to understand next steps and potential timelines, particularly as the reopening drumbeatgets louder.For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs,help address some of our underlying race and economic equity concerns, and build on our existingcommunity and clinical partnerships. We have shared it with some partners, but it is not at all clearhow/whether/when/how much funding might be available. Given the need to quickly expand ourworkforce and plan ahead, it would be very helpful to get a sense of:a. How much funding/support might be available, and how that will be determinedb. Whether funding might come through HHS/CDC (our preferred mechanism), FEMA, or anothermechanismc. Will support be available in weeks or months ... and for how long-we are strongly advocatingfor 5 years, similar to what was done for Ebolad. Any other information about how our local or state plans need to be adapted to fit into federalthinking on this approachThank you so much; I deeply apprec iate Dr. Fauci taking the time to meet with us directly and hear ourconcerns.AllisonAllison Arwady, MD, MPHCommissionerChicago Department of Public Health(b)(6)HEALTHYC H IC A GOFrom: David Barr (b)(6) ------------ Sent: Wednesday, April 22, 2020 8:47 AMTo: Al lison Arwady --:-:-:--:=====~~~(b)(-6)-; Percak, Jeffrey M ------- (b)(6)>; Fauci, Anthony (NIH/NIAID) [El (b)(6)>; Conrad, Patricia (NIH/NIAID) [El======~~-(b)(6)>; Demetre Daskalakis (b )( 6) >; Barasch, Kimberly (NIH/NIAID) [C](b)(6)>; Mushatt, David M(b) (6)>; Iyengar,Preetha (DO.H.). .:..=========~~----------------- (b)(6) Duch in, Jeff (b)(6)Subject: Notes from call with Dr. FauciHello - Thank s for all for a very informa tive and sobering discussion last night. I've providedbullets below to capture the main points. Please add or change as needed. I've kept this relativelyshort but can supply a full recording of the call if you want it.We will have another call next Tuesday.DavidPPE supplies:- whi le hospitals are in better shape than a few weeks ago, significant shortages remain at longtermcare facilitates , skilled nursing facilitates , outpatient settings like doctors' offices and urgentcare clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields arealso short. Doctors offices are closing for lack of PPE.- each city is trying to solve these shortages in a short-term , piecemeal way. They need a longe rtermsolution to stab ilize availability. Outpatient settings are looking to health departments toprovide supplies , something HDs are not set up to do.- testing in most places still requires PPE use (e.g. no avai lability of anterior nasal swabs) and thePPE shortages are severely limiting testing scale up.- even at hospitals , supply limitations make re-opening elective surgeries and other proceduresimpossible at this stage.- If considering re-opening businesses, this will drastically increase PPE needs to a whole newsecto r.TESTING challenges:- Each city reported that, despite improvements, a very limited number of tests are beingperfom1ed compared to need.- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents arethe biggest obstacles. Not clear where this is going to come from or who is responsiblefor addressing problems.- Private labs limit number of sample kits distributed each week. In places where publiclabs are available, there is a push to get providers to use the public labs. But manyplaces don't have public labs.- There is no clear guidance on how to prioritize who gets tested first. So, in some places, thatmeans that people at lower-risk are being testing but people at greater risk (due to symptoms ,exposure , high-risk living/work environment, etc) are not being testing. Guidelines are neededto help prioritize where testing resources are used first.- Public testing produces skewed results . Testing becomes available only to those whocan make an appointment and who can drive to the site. This means many lowerprioritypeople get tested but high-priority people do not. This skews understanding ofpositivity rates.- Some labs are underutilized - but the reason is that there are breakdowns in the supply chainthat make it difficult to test people and get tests to the labs. (e.g .) (b) <4)- Reimbursement is an obstacle. CMS offering to cover test costs ($100 per test) would help getlabs to do more testing. It would not solve the problem , but it would help.- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results,misinterpretation of what results mean ( e .g. telling people who test antibody positive that theymust quarantine for two weeks). Chicago spends a lot time shutting down these testing sites asthey make things harder and use up supplies.- there is increasing pressure to reach a target nwnber of tests performed each day in order to getto 're-opening'. But the number needed is contextual based on the environment, population -there isn't one 'right' number for everywhere.- Need better public messaging on difference between virology and serologic tests.- Current testing capacity is no where near what is needed to make informed decisions about reoperung.TESTING: reporting challenges- CwTent PoC tests have no link to provide results to health departments . Many outpatientfacili ties and SNFs have no system for reporting test results to HDs. Need electronic link forreporting PoC test results.- While aggregate positive tests may be reported, negative result'> are not.- Impossible to really understand population levels of infection because ( 1) number of testsperfom1ed is too low and (2) not testing the 'right' people- Every one is pushing for rapid scale up of antibody tests, but we still don't know what theresults of these tests mean and bow to apply them to policy development.- CDC and NIH will each coordinate sere-surveys. No details on CDC approach yet. NIH studyis up. Still not clear how to use the results of these studies , but useful to collect data now andapply it as knowledg e grows. Locally-coordinate aero-surveys can be helpful but only if tests arehighly validated .The Future:- How many tests should we being doing? How much PPB/testings /beds/staff will be needed inthe coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testingcapacity, how will we differentiate between the two?- What are the plans for contact tracing? Who will recruit and train? Is there a federal plan orguidelines for this? How will it be paid for? What do we do to effectively isolate those infected?This e-mail , and any attachments thereto , is intended only for use by the addressee(s) namedherein and may contain legally privileged and/or confidential information . If you are not theintended recipient of this e-mail ( or the person responsible for delivering this document to theintended recipient ), you are hereby notified that any dissemination, distribution, printing orcopying of this e-mail, and any attachment thereto, is strictly prohibited. If you have receivedthis e-mail in error, please respond to the individual sending the message, and permanently deletethe original and any copy of any e-mail and printout thereof.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Thu, 23 Apr 2020 12:53:24 +0000Stover, Kathy (NIH/NIAID) [E)Cc:(NIH/N IAID) [ElSubject:Billet, Courtney (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, PatriciaRE: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine /azithromycinstudyLooks fine.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Stover, Kathy (NIH/NIAID) [El (b)(6)Sent: Wednesday, April 22, 2020 3:56 PMTo: Fauci, Anthony (NIH/NIAID) [E) ------ --=-=·'======~~ Cc: Billet, Courtney (NIH/NIAID) [E) (b)( ·; Folkers, Greg (NIH/NIAID) [E)-------- (b)(6)>; Conrad, Patricia {NIH/NIAID) [E) (b)(6) Subject: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin studyHi Dr. Fauci,Please find attached for your review a draft press release describing the launc h of the ACTGhydroxychloroqu ine/azithromycin study for COVID-19. NIAID will issue the release after the firstparticipant(s) has enrolled, which is currently anticipated around May 1.The following is the quote we have drafted for you:"We urgently need a safe and effective treat ment for COVID-19. Repurposing existing drugs isan attractive option because these medications have undergone extensive testing, allow ingthem to move quickly into cli nical trials and accelerating thei r potential approval for COVID-19t reatment ," said NIAID Director Anthony S. Fauci, M .D. "Although there is anecdota l evidencethat hydroxychloroquine and azithromycin may bene f it peop le with COVID-19, we need soliddata from a large random ized, control led clinical trial to determ ine whether this experimentaltreatment is safe and can improve clinical outcomes. "Thanks much,KathyKathy StoverBranch ChiefNews and Science Writing BranchNational Institute of Allergy and Infectious Diseases (NIAID)Office of Communications and Government Relat ionsNational Institutes of Health/HHS31 Center Drive, Room 7A17EBethesda, MD 20892Phone: (b)(6)E-mai Cb) (6)NIAID Media Line: (301) 402-1663From:Sent:To:Cc:Subject:Attachments:Larry /John:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 11:54 :41 +0000Corey MD, Larry (b)( ;Masco la, John (NIH/VRC) [E]Conrad, Patricia (NIH/NIA ID) [E);Fauci, Antho ny (NIH/NIA ID) [E]NEJM manuscriptCOVID vaccine editoria l_ prefinal April2 1_7pm fsc - with minor Fauci edits. docxI have gone over the changes that Francis has inserted and I have edited someof them. Please accept his changes and my edits of them (or any additional editsthat you have) and then it is OK to send in . Please let me know if you have anyquestions.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 11:13 :29 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW: seeking your advice on a COVID-19 questionEmail from Pardis Sabeti.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Pardis Sabeti (b)(6) ---------- Se nt: Wednesday, April 22, 2020 9:47 PMTo: Fauci, Anthony (NIH/NIAID) [E)--------=- (b:)-(-=6: )>Cc: Collins, Francis (NIH/OD) [E] ------- (b)(6) Subject: Re: seeking your advice on a COVID-19 questionAwe, thank you, here for you two any time, and grateful for the enormous positive impact you have onthe world, PardisOn Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E] ------- (b)(6)> wrote:Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot.Warm regards,TonyFrom: Collins, Francis (NIH/OD) [E] ______ CbC>6)>Sent : Wednesday, April 22, 2020 8:44 PMTo: Pardis Sabeti (b)(6)>Cc: Fauci, Anthony (NIH/NIAID) [El -------- (b)( > Subject : RE: seeking your advice on a COVID-19 questionHey there Pardis,You are much too kind - but we are grateful for YOU and your team!It was fun to talk science for a litt le whi le. QBest, FrancisFrom : Pardis Sabeti (b)(6)>Sent : Wednesday, April 22, 2020 8:38 PM ------ == To: Collins, Francis (NIH/OD) [El (b)( >Cc; Fauci, Antho ny (NIH/NIAID) [El (b)(6)>Subject : Re: seeking your advice on a COVID-19 questio nDear Francis and Tony,Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left andtalked about how inspired we are by each of you and by the camaraderie between you two . Jacobadded those two are national treasure s, and Bronwyn and I whol eheartedly agreed.Grateful for you both,PardisOn Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E] -------- (b)(6):> wrote:Hi Pardis,See attached paper that argues there may be a significant difference in virulence of the COVI0-19clade that predominates on the west coast compared to the east coast. Tony Fauci and I would liketo kno (b) (5)Also attached is a MedRxiv preprint that describes major differences in pathogenicity of differentviral st rains. I just got this (b)(5)Can I talk with you later today after you have a chance to review this?Thanks, FrancisPardis Sabeti, MD, DPhilProfessor, Harvard University & Harvard T.H. Chan School of Public HealthBroad Institute of MIT and HarvardHoward Hughes Medical InstituteAssistant: (b)(6)Phone:_.!===~ (b~H~-----------Website: www .sabeti lab.orgPardis Sabeti, MD, DPhilProfessor, Harvard University & Harvard T.H. Chan School of Public HealthBroad Institute of MIT and HarvardHoward Hughes Medical InstituteAssistan,t. ..!:==~~:;:;;------------ Phone: (b)(6)CbH >------ Website : www.sabetilab.orgFrom:Sent:To:(b)(6)Thu, 23 Apr 2020 07:09 :44 -0400Conrad, Patricia (NIH/NIAID) [E)Subject: Fwd: invitation to New Zealand conversationSent from my iPhoneBegin forwarded message:From: Pat Brittenden <info@blindfi sh.medi a>Date: April 23, 2020 at 12:02: 13 AM EDT,------- --;;-~To: "Fauci , Anthony (NIH/NIAID ) [E]" -------- (b)( Subject: invitation to New Zealand conversationGood afternoon Dr Fauci,We are intere sted in seeing if you would be ava ilable for a chat via Zoom to NewZealand abou t COVID- 19The US is an essential part of the NZ economy contr ibuting between $1.5 and $2billion dollars annually from tourism alone and we would love to have aconversation about where the US is at, how COVID-19 is being dealt with, and thefuture of things that could lead up to opening our borde rs again.We're happy to have you for any length of time, but if you have 10-20 minutes thatwould be amazing.Thank you for what you are doing in this global event, I hope we can connectsometime soonSincer ely,Pat Brittendenwww. theDOC.nzwww .patbrittenden.com /abou t(b)(6)From:Sent :To:(b)(6)Thu, 23 Apr 2020 07:08:26 -0400Barasch, Kimberly (NIH/NIAID) [CJSubject: Fwd: Global Health Leaders Call, Thursday, 23 April, 14:30 CETSent from my iPhoneBegin forwa rded message:From: "KABIR, Sophia" (b)( >Date: April 23, 2020 at 6:54:46 AM EDTTo: SHOC <shoc@who.int >, Office of the Director-Genera l <DGOffice @who.int>,"Redfie ld, Robert R. (CDC /OD)" (b) (6)(b)( , "Felicity Harvey, "Chris.Elias"(b)(6)"Fauci, Anthony (NIH/NIAID) [E]''(b)(6)(b)(6). ,------ (b)(6)., "COX, Paul Michael""GREIN , Thomas"(b)("SCHWARTLANDER, Bernha rd F."Raman" ----------. "Conrad, Patricia (NIH/NIAID) [E]" --------. Jaouad" (b)( , "FALL, Ibrahima Soce", "MINHAS,(b)(6)(bH6) >, "MAHJOUR ,(b) (6), "Thomas(b)(6),--------(b)(6) , Preside nt I Resolve to Save LivesSHORBAn, Farah""DRURY, Patric k Anthony"(b) (6), "Amadou.SAL L"(b)(6) "AL(b)(6)1--c,~ Robynn Leidig (b) (6),(bH · , "Dr VAN KER.KHO VE, Maria"(b)(6)----------------- "GRAAFF , Peter Jan"CbH6), "POOLE, Marcia" Cb()6 ) , Tarik MohammedCb()6 ) CarlosNavarro Colorado, Ryan Morhard ------ ~ (b)(6)~"BRIAND, Sylvie" CbH6, )"MORGAN, Oliver' -------- (b)(6) "Ha JT i es, Jenny" CbH , "Awwad, David (NIH/NIAID)[C]" CbH6>), "SIMONSON, Stewart" CbH6)"SINGER , Peter Alexander" CbH , "Jayatunga , Wikum"(b)(6)"Julie.HA LL"RIOUX, "SHIN, Young-Soo""SMITH, Ian Michael"Raymond Bruce J."Cc: SHOC <shoc@who.int >, Office of the Director-General <DG0ffice @who.int> ,"SCHWARTLANDER, BernhardF." ....__ __ _,, CbH6") MAHJOUR,Jaouad" CbH , "FALL, Ibrahima Soce" CbH , "GREIN,Thoma s" CbH6>J, "MINHAS , Raman" CbH6, )"COX, PaulMichael" ____ CbH6J , "AL-SHORBAJI, Farah" CbH >,"POOLE , Marcia" CbH6l , "DRURY, Patrick Anthony"------ CbH · , "GRAAFF, Peter Jan" CbH6J, "Dr VAN KERKHOVE , Maria" Cb<>6 ,J "FARES, Christine Youssef'(b)(6)Subject: RE: Global Health Leaders Call, Thursday, 23 April, 14:30 CETDear colleagues,Apologies for the mistake in the below subject line.The meeting starts at 14.30 CET, as mentioned in the email.Kind regards,SophiaFrom: KABIR, SophiaSent : Thursday, April 23, 2020 10:51 AMTo: SHOC <shoc@who .int>; Office of the Director -General <DG0ffice@who.int>;(b)(6)(b)(6), ,TLANDER, Be rd F. (b)(6); MINHAS,"'.'--~==::!.....::..__ _____ .:_ ___ ..!::::======~ (b:):(-~=6);-MAHJOUR, Jaouad (b)(6); FALL, lbrahima Soce :..--.....:=======::;..,:-:-= ; 'Thomas R. Frieden' (b)( ; 'Elhadj SY' ======"=~ -------- (b)(6); 'Lynn Banks' (b)( ·; 'President I (b )( 6)ALnLeidig' (b)( ·; DRURY, ~-:-::-:-:::--:-:---:--;::::=====:::-,-;,.;.-.-s-= r VAN KERKHOVE, Maria (b)( 6)(b)(6) SMITH, Ian Michael (b)(Cc: SHOC <shoc@who.int>; Office of the Director-Gen eral <DGOffice@who .int>;SCHWARTLANDER, Bernhard F. (b)(6) ; MAHJOUR, Jaouad====~~(b)-(6)-r>; FALL, lbrahima- S-o-c-e -===~(b~)(6)~; G REIN,T homas ::::::==(=b)(=6J'=c; >M~IN-H=AS , Raman (b)(6); COX, Paul Michael (b)(6); Al -SHOR BAJ I, Farah (b)( ; POOLE, Marcia ====~~ ::::::===(b=)(6)= >;~ D~RU RY,P atrick Anthony (b)(6)·> ; GRAAFF,P eter Jan _____ (bJ~(6~);_Dr VAN KERKHOVEM, aria _______ (_b~_<_.·>; FARES,Christine Youssef (b)(6)Subject: Global Health leaders Call, Thursday, 23 April, 14:00 CETDear colleagues,Ahead of the Global Health leaders Call at 14.30 CET today, please find an epidemiologicalupdate and analysis attached , in addition to the "Consideration s in adjusting public healthand social measures in the context of COVID-19" inte rim guidance document, which waspubl ished on the WHO website on 16 April.Please find below, t he key questions for your consideration and input.1. What is your view on the latest epidemiology, virus transmission and severity inaffected countries?2. What are the emerging issues/challenges that you see as impo rtant?3. What should be the priorit ies for the 1-2 weeks?4. Any other issues you see as important?You will be able to connect via t he Webex connection below. If you experience anytechnical difficulties, please contact the WHO HQ EOC operator at: +41 22 79 15 533 or viaemail: shoc@who.int.Best,SophiaMeeting number (access code): ------ (b) (6), (b) (4)Meeting password ------- (b) (6), (b) (4)Thursday , April 23, 20202:00 pm I (UTC+02:00) Brussels , Copenhagen, Madrid, ParisJoin meetingJoin by phoneTap to call in from a mobile device (attendees only)(bH6JTZERLANDTo llSTollGlobal call-in numbersFrom:Se nt:To:Subject:Attachment s:2020.04.14 .. pdfAlice:Fauci, Anthony (NIH/NIAID) [E]Thu, 23 Apr 2020 02:16:12 +0000Alice ParkFW: Time follow upMedRxiv_ Mutat ions impact pathogenicity SARS-CoV-2_ Lanjuan Li et al.Here is another manuscript.TonyFrom:Sent:To:Subject:Lou:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 02:11:27 +0000Lou lgnarroRE: Greeti ngs- NOT urgentThank you for your kind note. It is much appreciated. I hope that you are well.Best regards,TonyFrom: Lou lgnarro (b)(sent: Tuesday, April 21, 2020 5:38 PMTo: Fauci, Anthony (NIH/NIAID) [E] -------= (b,.),(.=.6)Subject: Greet ings- NOT urgentHi Tony,This is Lou lgnarro from UCLA. You and I shared the stage in the "Shoe" at the OhioState University a few years ago, where you gave the Graduation Address to theundergraduate seniors . I was on stage with you, to receive an award for my basicbiomedical research which resulted in my being awarded the Nobel Prize in Medicinein 1998. I recall the nice conversations we were enjoying with Sanjay Gupta whilerobing for the event.Thanks for the tru ly spectacular job you are doing, regarding the coronaviruspandemic. We Nobel Laureates especially regard your work as the most importantduring our lifetime. Thank you and God bless.My best wishes,Lou lgnarroFrom:Sent :To:Cc:Subject:Attachments:Fauci, Anthony (NIH/NIAID) [E]Thu, 23 Apr 2020 01:50:03 +0000Conrad, Patricia (NIH/NIAID) [E]Barasch, Kimberly (NIH/NIAID) [C]FW: letter from the Governor of Puerto RicoDr. Anthony S. Fauci, MD[2].pdfHeads up for a call from the Puerto Rican Health Minister.From: Pablo L. Pena Antonmarch i <ppena@fortaleza.pr.gov>Sent: Wednesday, April 22, 2020 5:24 PMTo: Fauci, Anthony (NIH/NIAID) [E]------ (=b)""('=6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6):>; Barasch, Kimberly (NIH/NIAID) [CJ---------- (b)(6J>; Jennifer M. Storipan <jstoripan@prfaa.pr .gov>; Juan L. Negron < j neg r on@ p rf a a.pr .gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. PabonBatlle <apabon@forta leza.pr.gov>Subject : letter from the Governor of Puerto RicoImportance: HighDear Dr. Anthony Fauci:I am sending you for your attention a letter from the Governor of Puerto Rico Hon. WandaVazquez Garced.Cordially,Pablo L. Pena Antonmar chiExecutive AssistantLedo . Antonio Pabon BatlleChief of Staff OfficeLa Fortaleza. * ., LA PORTALEZANOTA DE CONFIDENCIALIDADE: sta transmisi6n electr6nica cont iene informaci6n perteneciente ala Oficina del Gobernado r, que es confidencial, privilegiada y/o privada bajo las leyes aplicables.Solamente podra ser util izada par la persona o entidad a la cual se dirige. Si usted no es eldestinatario intencional, se le notifica que se prohibe cualquier uso, disem inaci6n o copia de estacomunicaci6n. Si usted recibe esta comunicaci6n por erro r, favor de notificar al remit ente yeliminar este correo electr6nico de su sistema.CONFIDENTIALITYN OTE: This electronic transmission contains information belonging to theGovernor's Office, which is confidential , privileged and exempt from disclosure under theapplicable law. It is intended solely for the use of the individual or entity to which it is addressed. Ifyou are not the intended recipient, you are hereby notified that any use, dissemination, or copyingof the communication is strictly prohibited. If you have received this communication by error,please notify the sender and delete this e-mail from your system.From:Sent :To:Subject:Attachments :Alice:Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 01:40:52 +0000Alice Park;Conrad, Patricia {NIH/NIAID) [ElRE: Time follow upViral Clades Brufsky 42020 Accepted Final.pdfIt was great working w ith you today. Here is the reference. I believe that it will be in theJourna l of Medical Virology . It has been accepted, but is no yet in print.Best regards,To nyFrom: Alice Park <alice.park@time.com>Sent: Wednesday, April 22, 2020 6:30 PMTo: Fauci, Anthony (NIH/NIAID) [El <AFAUCl@niaid.nih.gov>; Conrad, Patricia {NIH/NIAID) [El<conradpa@niaid.nih.gov>Subject: Time follow upDear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of theTIME 100 Talks, which will go live tomorrow.In the meantime, I wanted to double check the reference to the study you mentioned about theeast and west coast strains and their potentia l difference in virulence. Realize it's preliminary,so just wanted to confirm any references we make to it. I checked the biorxiv and medrx iv butdidn't find the citation. Would appreciate the journal if it was pub lished . Many thanks! AlicePLEASE NOTE NEW PHONE NUMBERAlice ParkTIME(b)(6)a lice. park@time.com@aliceparknyFrom:Sent :To:Cc:Subject:Attachment s:Francis:Fauci, Anthony (NIH/N IAID) [ElWed, 22 Apr 2020 16:29:19 +0000 -----~~ Collins, Francis (NIH/OD) [El (b)(6)Corey MD, Larry CbH6lMascola, John (NIH/VRC) [ElFW: "final draft"COVID vaccine editorial _ prefinal April21_7pm.docxHere is the paper th at I mention ed to you and t hat we are plannin g to submit tothe NEJM. I have put you r name on it as the senior author. If you arecomfort able with th at, we will go wit h it. Please tak e a look at th e manu scriptand make any comment s or edits t hat you see fit.Thanks,TonyFrom:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Wed, 22 Apr 2020 14:41:09 +0000Billet, Courtney (NIH/N IAID) [E]Cc: Greg Folkers (b)( 6) ;Conrad, Patricia (NIH/NIAID) [ElSubject: RE: Request for Dr. Fauci+ Ryan Zimm erman Pros For Heroes I COVID-19 ReliefFundI was t hinking the very same t hing.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone (b) (6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Billet, Courtn ey (NIH/NIAID) [E) -------- (b)(6) >Sent: Tuesday, April 21, 2020 8:43 PM ------ ::;..,..-,= To: Fauci, Anthony (NIH/NIA ID) [El (b)(6)> ~======~ = Cc: Conrad, Patr icia (NIH/NIAID) [E] ---------- (b)( >; Folkers, Greg (NIH/NIAID) [E] (b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundPs - what do you want to bet you get invited to throw a first pitch next year?From: Billet, Courtney (NIH/NIAID) [E]Sent: Tuesday, April 21, 2020 8:38 PMTo: Fauci, Anthony (NIH/NIAID) [E)_ _____ "("b"..~',.c=.6)>Cc: Conrad, Patricia (NIH/NIAID) [E) (b)(6) •> ; Folkers, Greg (NIH/NIAID) [E)(b)(6)>Subject: FW: Request for Dr. Fauci+ Ryan Zimmerm an Pros For Heroes I COVID-19 R@lief FundWe're a "go" on this . I'll circle back with his rep tomorrow.On Apr 21, 2020, at 6:50 PM, Billet, Courtney (NIH/NIAID) [E] -------- (b) (6) >wrote :Hi guys - as a huge Nats fan, Dr. Fauci very much wants to do this chat with RyanZimmerman. Can I get a green light to work on this with them? I'll get the q's but it will bethe same general theme as with Steph Curry, YES Network, etc.From: Judee Ann Williams <judeeann.williams@caa.com>Se nt: Tuesday, April 21, 2020 5:54 PM --------=-s-= To: Billet, Courtney (NIH/NIAID) [E] (b)(6)Cc: Christine Lancman <christine .lancman@caa.com> ; Routh, Jennifer (NIH/NIAID) [E](b)(6)Subject: Re: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 ReliefFundAbsolute ly! We would 100% be able to work around that and avoid any association offund raising.We wou ld set this up however he will be most comfo rtab le, seed questions in advance, etc.and shed a light on what is most helpfu l.Will wait to hear and if you need anything else ju st let us know. Thank you so much!From: "Billet, Courtney (NIH/NIAID) [E]" --------- (b)(6) Date : Tuesday, Apr il 21, 2020 at 4:41 PMTo: Judee Williams <judeeann .will iams@caa.com>Cc: Christine Lancman <christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIA ID)[E]" (b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19Relief FundI *Exte rnal Sender*Hi - thanks for your message - we will check and someone will get back to you in the nextfew days. One caveat is that as a Federal official, Dr. Fauci cannot be associated withfundraising in any way . Please confirm that is someth ing you would be able to workaround?From: Judee Ann Williams <judeeann.williams@caa.com>Sent : Monday, Apri l 20, 2020 5:21 PMTo: Routh, Jennifer {NIH/ NIAID) [E] (b)(6)>; Billet, Courtney (NIH/N IAID)[E] (b)( >Cc: Christine Lancman <christ ine.lancman@caa.com >Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundJennifer & Courtney -Hello! Our fr iends fr om Steph Curry's team passed along your contact informat ion to usand we work at CAA where we represent Wor ld Series Champion, Ryan Zimmerman.Ryan wanted to express his grat itude first & fo remost to Dr. Fauci, the ent ire team and allthose behind the scenes working around the clock.Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30professional athle tes suppo rting and over $300,000 raised across 1,400 separate donat ions.(>www .prosforhe roes.org<). Since its launch last Tuesday, contribut ions from the Pros ForHeroes Fund have gone directly :awards PPE needs throug hout the I nova hospita l netw orkt hroughout the mid-Atlantic and have helped provide meals to those cr it ical care fron t -lineworkers - keeping these front -line heroes covered at work and comfortable at home .If Dr. Fauci was up to it, Ryan would love to host eithe r a short 15 minute Q&A on hisFacebook to continue raising awareness for how we need to be responding to the ongoingcrisis. Or even simply thank Dr. Fauci for the tire less work he is doing and shine a light onhow fo lks can support these critical fron t line workers.We are also open to what you th ink would work best ! Wou ld there any openings thatwould work best?We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we canever be support ive or help navigate anything in the world of pop cultur e, please do nothesitate to ask.Warmest wishes,Judee AnnJudee Ann Williams I Co-Head, CAA Social ImpactT: 212-277 -5294 I M: (b)(6) I Washington, DCNEW YORK - LONDON -NASHVILLE-MUNICH - LOS ANGELES -BEIJING - SHANGHAI>https://www .caa.com/<Pros For Heroes"Teamwork is the ability to come t ogether tow ards a common goal. We are looking forwardto at tracting as many supporters to help join this cause and give back as much as we can totho se who have given us so much," said Washington Nationa l All-Star, Ryan Zimmerman,the fu nd's fo under.Social Links:>https://www.instagram.com / prosforheroes/<>http s://twitter.com/prosforheroes<Today Show:>https://www.today.com/video/ryan-zimmerman-talks-pros-for -heroes-fund -for -feedinghealth-care-wor ke rs-82 2026935 77 <Washington Post Launch Article:>https://www.washingtonpost .com/sports/2020 / 04/ 14/nationals-ryan-zimmerman-startsfund-hea Ith-care-workers -with- lO0k-gift/ <This e-mail and any files transmitted with it are intended solely for the use of the individualor entity to whom they are addressed. If the reader of this e-mail is not the intendedrecipient or the employee or agent responsible for delivering the message to the intendedrecip ient, you are hereby notified that any use dissemination, forwarding, printing orcopying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients arefree to do their best work without experiencing harassment and want to ensure they havethe relevant resources they need. Clients can go to >https://www .caa.com/legal/sexual harassment-guidelines-caa-clients< to learn more about their rights, and how to reportviolations.This e-mail and any files transmitted with it are intended solely for the use of the individualor entity to whom they are addressed. If the reader of this e-mail is not the intendedrecipient or the employee or agent responsible for delivering the message to the intendedrecipient, you are hereby notified that any use dissemination, forwarding, printing orcopying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients arefree to do their best work without experiencing harassment and want to ensure they havethe relevant resources they need. Clients can go to >https://www .caa.com/legal/sexualharassment-guidelines-caa-clients< to learn more about their rights, and how to reportviolations.From:Sent :Fauci, Anthony (NIH/NIAID) [ElWed, 22 Apr 2020 00:29:33 +0000To: -----~~ Collins, Francis (NIH/OD) [El- ------ (b)(6) Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, andmutations affect dead liness of strains, Chinese study findsMore on mutationsFrom: Fauci, Anthony (NIH/NIAID) [E]Sen t: Tuesday, April 21, 2020 1:58 PMTo: Graham, Barney (NIH/VRC) [E)------- =(b=H=6)Subject: FW: SCMP: Coronavirus's ability to mutate has been vast ly underestimated, and mutat ionsaffect deadliness of strains, Chinese study findsNot peer reviewed, but what do you t hink?Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892 -2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender 's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Folkers, Greg {NIH/NIAID) [E] (b)( >Sent: Monday , Apri l 20, 2020 1:53 PMSubject: SCMP: Coronavirus's ability to mutate has been vast ly underestimated, and mutations affectdeadl iness of strains, Chinese study findsChina/ ScienceCoronavirus's ability to mutate has been vastlyunderestimated, and mutations affectdeadliness of strains, Chinese study finds• The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as theleast potent type• New York may have a deadlier strain imported from Europe, compared to less deadly viruseselsewhere in the United StatesStephen Chen in BeijingPublished: 10:41pm, 20 Apr, 2020Updated: 1:33am, 21 Apr, 2020A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possibleimplications for the pandemic . Photo: EPA-EFEA new study by one of China's top scientists has found the ability of the new coronavirus to mutate hasbeen vastly underestimated and different strains may account for different impacts of the disease invarious parts of the wor ld.Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patientsmany mutations not previously reported. These muta tions included changes so rare that scientists hadnever considered they might occur.They also confirmed for the first time with laboratory evidence that certain mutations could createstrains deadlier than others."Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity, " Li and hercollaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.Li's study provided the first hard evidence that mutation could affect how severely the virus causeddisease or damage in its host.Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolatedfrom 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, andthen tested how efficiently they could infect and kill cells.The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,while the milder strains were the predominant varieties found in parts of the United States, such asWashington state, according to their paper.A separate study had found that New York strains had been imported from Europe. The death rate inNew York was similar to that in many European countries, if not worse.But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang,two pat ients in their 30s and 50s who contracted the weaker strain became severely ill. Although bothsurvived in the end, the elder patient needed treatment in an intensive care unit.This finding could shed light on differences in regiona l mortality. The pandemic's infection and deathrates vary from one country to another, and many explanations have been proposed.Genetic scientists had noticed that the dominant strains in different geographic regions were inherentlydifferent. Some researchers suspected the varying mortality rates could, in part, be caused by mutationsbut they had no direct proof .The issue was further complicated because survival rates depended on many factors, such as age,underlying health conditions or even blood type.In hospitals, Covid-19 has been treated as one disease and patients have received the same treatmentregardless of the strain they have. Li and her colleagues suggested that defining mutations in a regionmight determine actions to fight the virus."Drug and vaccine development , while urgent, need to take the impact of these accumulating mutations... into account to avoid potential pitfalls," they said.Li was the first scientist to propose the Wuhan lockdown ,according to state media reports. Thegovernment followed her advice and in late January, the city of more than 11 million residents was shutdown overnight.The sample size in this most recent study was remarkably small. Other studies tracking the virusmutation usually involved hundreds, or even thousands, of strains.Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - werenew.They found some of these mutations could lead to functional changes in the virus' spike protein, aunique structure over the viral envelope enabling the coronavir us to bind with human cells. Computersimulation pred icted that these mutations would increase its infectivity.To verify the theory, Li and colleagues infected cells with strains carrying different mutat ions. The mostaggressive strains could generate 270 times as much viral load as the weakest type. These strains alsokil led the cells the fastest.It was an unexpected result from fewer than a dozen patients, " indicating that the true diversity of theviral strains is still largely underapprecia ted," Li wrote in the paper.--Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: XinhuaThe mutat ions were genes different from the earliest strain isolated in Wuhan, where the virus was firstdetected in late December last year.The coronavirus changes at an average speed of about one mutation per month . By Monday, more than10,000 strains had been sequenced by scientists around the globe, containing more than 4,300mutations, according to the China National Centre for Bioinformation.Most of these samples, though, were sequenced by a standard approach t hat could generate a resultquickly . The genes were read just once, for instance, and there was room for mistakes.Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of thevirus genome was read more than 100 times, allowing the researchers to see changes that could havebeen over looked by the conventional approach.The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-year-old patient , which was a rare event. Usually the genes mutated at one site at a time. This patientspent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeceswere infectious with living viral strains."Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li andcolleagues said in the paper .Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Informat ionScience and Technology at Tsinghua University, said ultra-deep sequencing could be an effectivestrategy to track the virus' mutation."It can produce some useful information," he said.But this approach could be much more time consuming and costly. It was unlikely to be applied to allsamples."Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the viruscame from, why it could kill some healthy young people while generating no detectable symptoms inmany others still left scientists scratching their heads."If there is a discovery that overturns the prevailing perception, don't be surprised."Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those ofNIAID, NIH, HHS, or the U.S. government.From:Sent :Fauci, Anthony (NIH/NIAID) [ElWed, 22 Apr 2020 00:16:44 +0000 To: Collins, Francis (NIH/OD) [El -----~~ (b)(6) ------- Subject: FW: For your attent ionAttachments : COVAX2020- A GLOBAL EFFORTfo r the ACCELERATEDD EVELOPMENT,PRODUCTIONa nd EQUITABLEA CCESSto COVID-19 VACCINES_16Apr2020_0RAFT.docxSee attachment that Hilary sent me.From: Marston, Hilary (NIH/NIAID) [El (b)(6) ________ _,Sent: Tuesday, April 21, 2020 7:44 PMTo: Fauci, Anthony (NIH/NIAID) [E]Subject: Re: For your attent ionFrom: Anthony Fauc i Cb)< >Date: Tue sday, April 21, 2020 at 7:30 PMTo: Hila ry Marston (b)( v>Subject: FW: For your attention(b)(6)(b) (5)Have you heard of this on any of the calls where you represent me??From: Collins, Francis (NIH/OD) (El (b)(6)Sent : Tuesday, April 21, 2020 7:28 PMTo: Fauci, Anthony (NIH/ NIAID) (El--------=- (b")"("= ; Lane, Cliff (NIH/N IAID) (El(b) (5)-------- (b)( ·; Tabak, Lawrence (NIH/OD) (El (b)(6)>; Freire, Maria (FNIH) (Tl <mfreire@fni h.org>; Wholley, David (FNIH) (T) <dwholley@fnih.org>Subject: FW: For your attentionHi all,See note below from Victor Dzau about a globa l effort on COVID-19. I can't tell if this is morethan a fund-raising effort. I know we have Gates reps on our ACTIV working groups- has any ofthis plan come up, David ?FrancisFrom: Dzau, Victor J. <VDzau@nas.edu>Sent : Tuesday, April 21, 2020 4:10 PMTo: Collins, Francis (NIH/OD) [El ------=- (b')"("=6' -)Cc: Kanarek, Morgan <MKanarek@nas.edu>Subject: For your attenti onDear Francis,Congratulat ions on your launch of Public Private Partnership to speed COVID 19 vaccine and treatmentoptions. This is very timely and much needed. Kudos to your leadership .I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics andtherapeutics. I have been part of the conversation and planning along with Jeremy Farrar, RichardHatchett , Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and EuropeanCommission have been leading the planning. This has advanced rapidly and is in the final stages indevelopment that wil l be soon announced. It has involved European Commission, Germany, Japan, UK,Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, GlobalFund, CEPI, GPMB and private sector industry . The initiative will begin with a Pledge conference for $8Bas a starting point. This will be led by President van der Leyen and is co-chaired by the above countryleaders. This will occur on May 4 . In addition by the end of this week or early next week there will be anannouncement on the global coordinating structure with will involve Gates, WHO etc.I am writing to be sure that you and the White House are aware of these upcoming events . Can youshare this information with the White House? Besides you, who else should I share this informationwith? I will be happy to send you background documents if you wish.Please call me anytime.Best,VictorFrom:Sent :To:Subject:Infect ionEisinger, Robert (NIH/ NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAID) [ElTue, 21 Apr 2020 23:10:36 +0000Fauci, Anthony (NIH/NIAID) [E)FW: Consideration of IM COVID Immune Globul in for Prevent ion of COVID-19Attachment s: Prophylact ic Intramuscular COVID-IG - Oxman.pdf, FURTHER ARGUM ENTS INFAVOR OF INTRAMUSCULAR COVID-IG Version 4 - Oxman.pdfEmail from Gary Noble, advisor to Bob Windom in the 1980s.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Off ice of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email : (b)(From : Gary Noble (b)(6)Sent : Tuesday, Apr il 21, 2020 4:56 PM -----~= To: Fauci, Ant hony (NIH/ NIAID) [E] (b)(6)>Cc: McGowan, John J. (NIH/ NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]-------- (b)(6J·; Oxman, Michael (b)( · Subject: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 InfectionDear Tony,I will always remember our amazing collaboration during the HIV/AIDS days inthe 1980s, when I served as AIDS Advisor to Bob Windom , the DHHSAssistant Secretary for Health during President Reagan's administration. Andnow, I am delighted and amazed to watch you so adroitly maneuver theCOVID-19 scientific policies and keep them front and center in the currentWhite House!!---------------- Cb><6M>\i,c hael Oxman, has worked with John Zaia at City of Hope, and a Mayo/Hopkins /Michigan Stateconsortium for a tria l of IM COVID-IG as a prefe rred method for treatmentand prevent ion of COVID-19.This week , Mike expects to complete the protocol for a placebo (normalIG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workerswho are engaged in direct patient care at UCSD, but they need a modicumof support. Mike asked if I would reach out to see if NIAID might provide ofsupport for this effort, using IM, as opposed to IV, COVID-IG.I've copied Mike, who has provided the attached background information.Tony , with all my respect and admiration for what you are doing for the U.S.and for all of us.GaryGary R. Noble, MD, MPH, MA (Oxon)From:Sent :To:Subject:Let us discuss.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 22:14:24 +0000NIAIDODAMFW: Invitation to Speak at UC Berkeley COVID-19 HackathonNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Saahil Chadha <saahil@calhacks.io>Sent: Tuesday, April 21, 2020 11:00- -A-M-- -~~ To: Fauci, Anthony (NIH/NIAID) [E]_ ______C bH6)> _,Subject: Invitation to Speak at UC Berkeley COVID-19 HackathonDear Dr Fauci,My name is Saahil , and I'm a director at Cal Hacks, a student organization at theUniversity of California, Berkeley. This upcoming weekend, we will be hostinghack:now ,a 36-hour global online hackathon to foster innovative and technical solutions to tacklethe challenges faced around the current COVI D-19 pandemic. We're projected to have1,500 participants from around the world. I'm reaching out to invite you to be ouropening ceremony speaker.Specifically , this Friday night, April 24, from 7-8pm Pacific Daylight Time, we're going tobe hosting the opening ceremony of our event. At this time, we want to inspire ourhackers to help solve global challenges related to health and community. We would beabsolutely honored if you would join us to speak at our opening ceremony forjust a few minutes to share your experiences with and response to the COVID-19pandemic. Your unique perspective and expanse of knowledge makes you the mostqualified person, and we would be humbled to include you as our opening ceremonyspeaker. Please let us know if you are able to accept this invitation.Stay safe,Saahil Chadha(b)(6)Calhacks .ioFrom:Sent :Fauci, Anthony (NIH/N IAID) [ElTue, 21 Apr 2020 22:06:57 +0000To:Subject:Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [ElRE: Message for Dr Anthony FAUCIOK. Please take care of this. Thanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Folkers, Greg (NIH/NIAID) [El --------- (b)(6) Sent: Tuesday, April 21, 2020 11:31 AMTo : Conrad, Patricia (NIH/NIAID) [El --------,;- (b")('"=6'"):'>; Fauci, Anthony (NIH/NIAID ) [El(b)(6)Subject: RE: Message for Dr Anthony FAUCII wou ld be extreme ly grateful to you if you can provide me with the most recent and pertinen t scientificand population data concerning covid-19. I know how extremely busy you are but maybe a collaboratorof yours whether he can send me the data via e-mail (b)(6)_Not exactly sure what he wants but I can send him some links that will get him the latest CoVinfo from pubmed, prepr ints, CDC etcFrom: Conrad , Patricia (NIH/NIAID) [ElSent: Tuesday, April 21, 2020 11:16 AtvlTo: Fauci, Anthony (NIH/NIAID) [E]-------= (b")"(=6' )>Cc: Folkers, Greg {NIH/NIAID) [El _______ CbCJ_6 )Subject: FW: Message for Dr Antho ny FAUCICan we direct her somewhere? Gray?(b) (6)>Patricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7 A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The information in this e-ma il and any of its attachments is confidentia l and may contain sensi tive information . It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statement made that are sender's own and not expressly made on behalf of the NIAIO by one of its representatives .From: Jean-Louis Touraine ------------------(b)( > Sent: Tuesday, April 21, 2020 11:06 AMTo: Conrad, Patricia (NIH/NIAID) [E] _______ ("b")'"("=6' )Subject: Potential SPAM :Message for Dr Anthony FAUCII wou ld be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.Many thanks.Sincerely yours,Pr Jean-Louis TOURAINE, Lyon and Paris, France.Dear Tony,You may remember, that we have met repeatedly and worked in parallel and in association, during theearly years of the HIV epidemic .You and I have been trained in immunoly. Both of us are much sollicitated to help facing and f ighting thecovid-19 epidemic .During the past years, as well as recently, I have followed with great interest and respect youraccomplishments and your advices in the fights against epidemics. I would be extremely grateful to youif you can provide me with the most recent and pertinent scientific and population data concerningcovid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can sendme the data via e-mail (b) (6) This will allow me to give moredocumented informations to the French President and Government. Cooperation between countries willbe crucial against covid-19 as it has been against HIV and other agents.I look forward to seeing you again in quieter times.Many thanks and very best personal regards.Jean-Louis TOURAINE, M.D., Ph. D., M.P.Ce message, ainsi que les pieces jointes, sont etablis, sous laseule responsabilite de l'expediteur, a !'intention exclusivede ses destinataires ; ils peuvent contenir des informationsconfidentielles . Toute publication, utilisation ou diffusiondoit etre autorisee prealablement.Ce message a fait l'objet d'un traitement anti-virus.11 est rappele que tout message electronique est susceptibled'alteration au cours de son acheminement sm Internet.Yous pouvez consulter le site de l'Assemblee nationale al'adresse suivante : http://www.assemblee-nationale.frFrom: Fauci, Anthony (NIH/N IAID) [ElSent: Tue, 21 Apr 2020 21:39:30 +0000 -----~~ To: Collins, Francis (NIH/OD) [El (b)(6)Cc: Myles, Renate (NIH/OD) [E);Burk low, John (NIH/ OD) [E);Billet, Courtney(NIH/N IAID) [E);Conrad, Patricia (NIH/NIAID) [E]Subject: FW: STAT: Director of U.S. agency key to helming vaccine developme nt leavesrole suddenly amid coro navirus pandemic https://bi t. ly/ 2XRZqKaAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail (b) (6)(b) (5)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/N IAID) [E)- ------- (b) (6) > Sent: Tuesday, April 21, 2020 3:01 PMSubject: STAT: Director of U.S. agency key to helming vaccine development leaves role sudde nly amidcoronaviru s pandemic ht t ps:// bit .ly/2XRZqKaDirector of U.S. agency key to helming vaccinedevelopment leaves role suddenly amidcoronavirus pandemicBy Nicholas Florko @NicholasFlorkoApril 21, 2020Rick Bright HHSWASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the directorof the Biomedical Advanced Research and Development Authori ty, is no longer leading the organization,officials to ld STAT.The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office,which invests in drugs, devices, and other technologies that help address infectious disease out breaksand which has been at the center of the government's coronaviru s pandemic response.Bright, whose departure was confirmed by th ree industry sources and two current Trump admin istrationsources, will instead move into a narrower role at the National Institutes of Health overseeing a similarbut lim ited public-pr ivate part nership aimed at vaccine development. Gary Disbrow, Bright's formerdeputy at BARDA, wi ll serve as the acting director of the office, an HHS spokesperson confirmed toSTAT.BARDA was expected to play an even larger role in the coming months; Congress more than tripledBARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in someof the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and ModernaTherapeut ics, both of which are developing potent ial Covid-19 treatments .Related:This tiny federal agency was built to respond to a crisis likecoronavirus. Now that it's here, is BARDA ready?BARDA has been plagued with management issues virtually since its creation in 2006, with much of thecriticism aimed at a contracting department that some say is unresponsive to industry partners. Theoffice has only had two permanent directo rs since its creation in 2006. Bright has led the organizationsince 2016.None of the sources articu lated the reason for Bright's departure, though several mentioned recentchafing between Bright and Bob Kadlec, the HHS Assistant Secretary for Preparedness and Response,which has oversight over BARDA.An HHS spokesperson confirmed that Bright will work on a recently announced NIH public-privatepartnership with 16 drug makers aimed at develop ing vaccines and treatments for Covid-19."Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA) to the [NIH) .... Dr. Brightbrings extensive experience and expertise in facilitating powerful public-private partnerships tha tadvance the health and well -being of the American people," the spokesperson said.Bright did not immed iately respond to requests for comment.Bright's career has largely centered around vaccine and drug development . His work at the Centers forDisease Control and Prevention focused on influenza viruses, antiviral drugs and tests . He has alsoworked in the biotechnology industry and served as an advisor to the World Health Organization. Beforebecoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division.Lev Facher contributed reporting.Disclaimer: Any third-party material in this email bas been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. It does not necessarily representmy views nor those of NlAID , NlH, HHS, or the U.S. government.From: Fauci, Anthony (NIH/N IAID) [E)Sent: Tue, 21 Apr 2020 21 :18:24 +0000To: Crawford , Chase (NIH/NIAID) [E);Auchincloss, Hugh (NIH/NIAID) [E);McGowan ,John 1. (NIH/NIAID) [E];Ha rper, Jill (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID)[E];John son, Martin S. (NIH/NIAID) [E);Marston, Hilary (NIH/NIA ID) [E];Billet, Courtney (NIH/NIAID) [E]Cc: Haskins, Melinda (N IH/NIAID) [E];Selgrade , Sara (NIH/NIAID) [E)Subject: RE: Atte ntion: COVID-19 legislative package bill text releasedThanks.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Crawfo rd, Chase (NIH/NIAID) [E] --------- (b)(6)> Sent: Tuesday, April 21, 2020 3:27 -PM- -----,;; = To: Fauci, Anthony (NIH/NIAID) [E) CbH >; Auchi ncloss, Hugh (NIH/NIAID) [E)(b)(6J> ; McGowan, John J. (NIH/NIAID) [E] "':"':"".".'.""."".~======-- =-J. i'1:"1:"(": N'""'..l"''H'.."'/"":.N""'':.I"'A":"."l'~D".:)- :[~E:]- :=: =~~--= (b=H~ >; Gill es, Sharon (NI H/N JAi D) [ E] >;"""-:--:-:--:-:::====:::::::......:..._~Lane, Cliff (NIH/NIAID) [E] (b)(6) ; Johnson, Martin S. (N IH/NIAID) [E] _ __;_ _ __;__,;___..;..:,~'=i-':-:----:-::-:--::-:-:" .(b)( ; Marston, Hilary (NIH/NIAID) [El (b)( ; Bille t,-C-o-ur-tn_e_y'"('.N' IH'"/'.N' IA-ID-:)-'"['.-E'-:l~!,;._--....,;_ _ _(;,b,.):~(6)Cc: Haskins, Melinda (NIH~/ "N."-I'A:.--::1-~D: ):-[:~E:l- :=:===--- ('"b")"''~6=); Selgrade , Sara (NIH/NIAID) [El(b)(6)Subject: Atte ntion: COVID-19 legislative package bill text releasedImportance: HighGood Afternoon,At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimousconsent on the "Paycheck Protection Program and Health Care Enhancement Act"(bill text attached). In particular please note that the legislat ive package includesthe following supplemental appropriations for diagnostic testing (pages 13-15 ofattached) :• NIH/OD - not less than $1B to develop, validate, improve, and implementtesting and associated technologies; to accelerate research, development,and implementation of point of care and other rapid testing; and forpartnerships with governmental and non-governmental entities toresearch, develop, and implement the activities outlined in this proviso.• funds in the preceding proviso may be transferred to the accounts of theInstitutes and Centers of the National Institutes of Health for thepurposes specified in the preceding proviso• the transfer authority provided in the preceding proviso is in addition toall other transfer authority available to the NIH• NCI - not less than $306M to develop , validate, improve, and implementserological testing and associated technologies for the purposes specifiedunder this paragraph in this Act:• NIBIB - not less than $S00M to accelerate research, development, andimplementation of point of care and other rapid testing related tocoronavirus:• CDC - not less than $1B for surveillance, epidemiology, laboratory capacityexpansion, contact tracing, public health data surveillance and analyticsinfrastructure modernization, disseminating information about testing, andworkforce support necessary to expand and improve COVID-19 testing• BARDA- not less than $1B for necessary expenses of advanced research,development, manufacturing , production , and purchase of diagnostic ,serologic, or other COVID-19 tests or related supplies, and other activitiesrelated to COVID-19 testing at the discretion of the Secretary• FDA-$22M to support activities associated with diagnostic, serological,antigen, and other tests, and related administrative activitiesWe will keep you updated on any developments related to this legislation. Pleaselet us know if you have any questions.Thanks,ChaseFrom:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 21:01:27 +0000Billet, Courtney (NIH/N IAID) [E]RE: Ryan ZimmermanIf cleared, I would love to.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )(b)(5)- PCThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Billet, Courtney (NIH/NIAID) [E] (b)(6)Sent: Tuesday, April 21, 2020 4:43 PM ------ == To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] CbH6l>; Routh, Jennifer (NIH/NIAID) [E](b)(6); Stover, Kathy (NIH/NIAID) [E] (b)( ·; Folkers, Greg"('.N -'"-1'-H/-:N--I-A--ID ~)-:[-E::]"=:'====:!.;___...;._ =(b)=(6~)Subject: Ryan ZimmermanWould you be interested in doing something with Ryan Zimmerman? Format TBD. We' ll pursue furtherdiscussion if you give the green light.From: Billet, Courtne y (NIH/NIAID) [E]Sent : Tuesday, April 21, 2020 4:41 PMTo: Judee Ann Wi lliams <judeeann.will iams@caa.com>Cc: Christine Lancman <christine. lancman@caa.com >; Routh, Jennifer (NIH/NIAID) [E)(b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundHi - thanks for your message - we will check and someone will get back to you in the next few days. Onecaveat is that as a Federal official , Dr. Fauci cannot be associated with fundrais ing in any way . Pleaseconfirm that is something you would be able to work around?From: Judee Ann Williams <jude eann.will iams@caa.com>Sent: Monday , April 20, 2020 5:21 PM -------~~ To: Routh, Jennifer (NIH/NIAID) [E] (b)(6); Billet, Courtney (NIH/NIAID) [E](b)(6)>Cc: Christine Lancman <christine. lancman@caa .com>Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundJennifer & Courtney -Hello ! Our friends from Steph Curry's team passed along you r contact info rmation to us and we work atCAA where we represe nt Wor ld Series Champion, Ryan Zimmerman .Ryan wanted to express his gratitud e first & fo remost to Dr. Fauci, the entire team and all those behindthe scenes working around the clock.Ryan recent ly launched the Pros for Heroes Covid-19 Fund last week, with more than 30 pro fessionalathletes supporting and over $300,000 raised across 1,400 separate donat ions.(www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fundhave gone direct ly towards PPE needs throug hout the I nova hospital netwo rk throug hout the midAtlanticand have helped provide meals to those critical care front -line wo rkers - keeping these front -lineheroes covered at wor k and comfo rtab eat home.If Or. Fauci was up to it, Ryan would love to host eit her a short 15 minute Q&A on his Facebook tocontinue raising awareness for how we need to be responding to the ongo ing crisis. Or even simply t hankDr. Fauci for the tir eless work he is doirg and shine a light on how folks can support th ese cr it ical fro ntlineworkers.We are also open to what you think would wo rk best I Would there any openings that would work best?We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever besupport ive or help navigate anyth ing in the world of pop culture, please do not hesitate to ask.Warmes t wishes,Judee AnnJudee Ann Williams I Co-Head, CAA Social ImpactT: 212-277-5294 I M (b)(6) I Washington, DCNEW YORK· LONDON -NASHVILLE· MUNICH - LOS ANGELES -BEIJING· SHANGHAIhttps://www.caa.com/Pros For Heroes"Teamwork is the ability to come together towards a common goal. We are looking forward to attractingas many supporters to help join this cause and give back as much as we can to those who have given usso much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.Social Links:https://www.instagram.com/prosforheroes/https ://twitter. com/prosforheroesToday Show:https://www.today .com/video/ryan-zimmerman-talks -pros-for -heroes-fund -for-feeding -health-careworkers-82202693577Washington Post Launch Article:https ://www. wash i ngton post. com/sports/2020/04/14/nationa ls-rya n-zi mmerma n-sta rts-fund-hea Ithcare-workers-with- lO0k-gift/This e-mail and any files transmitted with it are intended solely for the use of the individua l or entity towhom they are addressed. If the reader of this e-mail is not the intended recipient or the employee oragent responsible for delivering the message to the intended recipient, you are hereby not ified that anyuse dissemination, forwarding, printing or copying of this e-mail is strictly prohibited . CAA is committedto ensuring that clients are free to do their best work without experiencing harassment and want toensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexua lharassment-guidelines-caa -clients to learn more about their rights, and how to report violations .From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 20:44:40 +0000Conrad, Patricia (NIH/NIAID) [E)Cc:Subject:Billet, Court ney (NIH/NIA ID) [E);clane@niaid .nih .govRE: urgent: CNN requestCliff should do thi s.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E) --------- (b) (6):>Se nt: Tuesday, April 21, 2020 4:41 PM -------~= To: Fauci, Anthony (NIH/NIAID) [E]- -------- (b)(6) Subject: Fwd: urgent: CNN requestSent from my iPhoneBegin forwarded message:From: "Conrad, Patricia (NIH/NIAID) [E]" ---------(b) (6)>Date: April 21, 2020 at 4:31 :46 PM EDT ------~~ To: "Billet , Courtney (NIH/NIAID) [E]" -------- (b)(6)> Subje ct: Fwd: urgent: CNN requestSent from my iPhoneBegin forwarded message:From: "Billet, Courtney (NIH/NIAID) [E]"Date: April 21, 2020 at 2:49:39 PM EDT(b)(6)-------~~ To: "Conrad, Patricia (NIH/NIAID) [E]" (b)(6)Cc: "Routh, Jennifer (NIH/NIAID) [E]" ..:======= (~b)::(:6~;,)Subject: FW: urgent: CNN requestPatty - can you please check with Dr. Fauci if he'd like to speak to ElizabethCohen about the treatment guidelines.From: Lane, Cliff (NIH/NIAID) [E] ------- Sent : Tuesday, April 21, 2020 2:48 PM ------~= To: Billet , Courtney (NIH/NIAID) [E] (b)( ; Pau, Alice(NIH/NIAID) [E] (b)(6)>Cc: Doepel, Laurie (NIH/NIAID) [E] (b)(6); Masur, Henry(NIH/ CC/CCMD ) [E]_ .:...__..:....:_.:..== ("b')"::(:6"~')";-M_y_le-s,-R-e-na_te ,(_NI H/0 D) [ E](b) (6)>Subject: Re: urgent: CNN requestI think Dr. Fauci would want the option of first refusal. He has anticipated hewill be asked about these.From: "Bi llet, Courtney (NIH/NIAID) [E]"- --------- (b)(6) Date : Tuesday, Apr il 21, 2020 at 1:35 PMTo: "Pau, Alice (NIH/NIA ID) [E]" -------= Cb =H=6J>Cc: Laur ie Doepe l CbH6)>, "Masur, Henry(NI H/CC/CC MD ) [E'"]:-1:1::-.:::======;;, (b,);(:~:6:), " Lane, Cliff (NIH/NIA ID)[E]" CbH6)", Myles, Renate (NIH/OD) [E]".;....:.--=====~~-- (b )( 6) >Subject: RE: urgent: CNN requestHI Alice - thanks for sending this along. We will confer about how best tohandle media requests about the guidelines - we're calling them NIHguidelines and the press release came from NIH, so I'd like to involve the NIHmedia office in this, hence I've cc'd Renate Myles . I think it's sort of anunsettled question as to who the spokespeople will be. Drs. Lane and Masur- do you have a preference?Also, who is Claire? (The person who forwarded the CNN request to you andDr. Masur. Would be good to have a last name so we can confer with her asneeded going forward.)From: Pau, Alice (NIH/NIAID) [E] ------- (b)(6)>Sent : Tuesday, April 21, 2020 1:24 PMTo: Billet, Courtney (NIH/NIAID) [E] (b)(6) Cc: Doepel, Laurie (N_IH./.:_N..IA_ID..)....[::.E..:]...:.;!=.-::-:=:;=:---=--.="'."="".="9=(_~b)_C~~6 )Masur, Henry(NIH/CC/CCMD) [E] (b)(6)>; Lane, Cliff (NIH/NIAID) [E](b)(6)>Subject: FW: urgent: CNN requestHi Courtney,Please see below the request from CNN. Per Laurie, I will forwardother reques ts to you.Thanks, AliceFrom: COVID19 Treatment Guidelines<C0VID19TreatmentGuidelines@nih.gov >Date: Tuesday, April 21, 2020 at 1:06 PMTo: Henry Masur (b)(6), Alice Pau(b)(6)>Subject: Fw: urgent: CNN requestHi Henry and Alice,I am not sure how we want to handle interview requests like this.Would someone on the Panel want to/be allowed to speak to the pressabout the guidelines?I am happy to politely declin e if we want to handle it that way.It is nice to see that we are being picked up by the press alreadythough. I am glad peop le are already expressing interest.Just let me know!ClaireFrom: Nigam, Minali <Minali.Nigam@turner.com >Sent: Tuesday, April 21, 2020 4:03 PMTo: COVID19 Treatment Guidelines <C0VID19TreatmentGuidelines@nih.gov >Cc: Cohen, Elizabeth <Elizabeth.Cohen@turner.com >; Fine, Amanda (NIH/OD)[E] (b)( >Subjec t: urgent: CNN requestTo the NIH Covid- 19 Treatment Guidel ine Team:My name is Minali Nigam and I work with Elizabeth Cohen at CNNHealth. We wanted to reach out and request to speak with someoneover the phone involved with the NIH treatment guidelines for covid-19. Please let us know as soon as possible for an available time today.We appreciate your help, as we inform our viewers of important healthinformation.Best,MinaliDr. Minali NigamCNN Health(b)(6)(bXS) -PCl1(b)(5) - Pe l
(bX5) -PCI(bX5) -PCI(bX5)-PCI(bX5) -PCI
(bX5) -PCI(bX5) -l'U
From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202019 :42:03 +0000Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield , Robert R. (CDC/OD)FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, andmutations aff ect dead liness of strains, Chinese study findsSee belowAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (301) 496-2263FAX: (301) 496-4409E-mail: afauci@niaid.nih.govThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) (E] (b)(6)Sent : Monday, April 20, 2020 1:53 PMSubject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affectdeadl iness of strains, Chinese study findsChina/ ScienceCoronavirus's ability to mutate has been vastlyunderestimated, and mutations affectdeadliness of strains, Chinese study finds• The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as theleast potent type• New York may have a deadlier strain imported from Europe, compared to less deadly viruseselsewhere in the United StatesStephen Chen in BeijingPublished: 10:41pm, 20 Apr, 2020Updated: 1:33am, 21 Apr, 2020A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possibleimplications for the pandemic. Photo: EPA-EFEA new study by one of China's top scientists has found the ability of the new coronavirus to mutate hasbeen vastly underestimated and different strains may account for different impacts of the disease invarious parts of the world.Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patientsmany mutations not previously reported . These mutations included changes so rare that scientists hadnever considered they might occur.They also confirmed for the first time with laboratory evidence that certain mutations could createstrains deadlier than others."Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity," Li and hercollaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.Li's study provided the f irst hard evidence that mutation could affect how severely the virus causeddisease or damage in its host.Li took an unusual approach to investigate the virus mutation . She analysed the viral strains isolatedfrom 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, andthen tested how efficiently they could infect and kill cells.The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,while the milder strains were the predomina nt varieties found in parts of the United States, such asWashington state, according to their paper.A separate study had found that New York strains had been imported from Europe. The death rate inNew York was similar to that in many European countries, if not worse .But the weaker mutation did not mean a lower risk for everybody, according to Li's study . In Zhejiang,two patients in their 30s and 50s who cont racted the weaker strain became severely ill. Although bothsurvived in the end, the elder patient needed treatment in an intensive care unit .This finding could shed light on differences in regional mortality . The pandemic's infection and deathrates vary from one country to another , and many explanations have been proposed .Genetic scientists had noticed that the dominant strains in different geographic regions were inherentlydifferent. Some researchers suspected the varying mortality rates could, in part, be caused by mutationsbut they had no direct proof.The issue was further complicated because survival rates depended on many factors, such as age,underlying health conditions or even blood type .In hospitals, Covid-19 has been treated as one disease and patients have received the same treatmentregardless of the strain they have. Li and her colleagues suggested that defining mutations in a regionmight determine actions to fight the virus."Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations... into account to avoid pote ntial pitfalls," they said.Li was the first scientist to propose the Wuhan lockdown.accord ing to state media reports. Thegovernment followed her advice and in late January, the city of more than 11 million residents was shutdown overnight.The sample size in this most recent study was remarkably small. Other studies tracking the virusmutation usually involved hundreds, or even thousands, of strains.Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - werenew .They found some of these mutations could lead to functional changes in the virus' spike protein, aunique structure over the viral envelope enabling the coronavir us to bind with human cells. Computersimulation pred icted that these mutations would increase its infectivity .To verify the theory, Li and colleagues infected cells with strains carrying different mutat ions. The mostaggressive strains could generate 270 times as much viral load as the weakest type. These strains alsokilled the cells the fastest.It was an unexpected result from fewer than a dozen patients, "ind icating that the true diversity of theviral strains is still largely underappreciated," Li wrote in the paper.-Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: XinhuaThe mutat ions were genes different from the earliest strain isolated in Wuhan, where the virus was firstdetected in late December last year.The coronavirus changes at an average speed of about one mutation per month. By Monday, more than10,000 strains had been sequenced by scientists around the globe, containing more than 4,300mutations, according to the China National Centre for Bioinformation.Most of these samples, though, were sequenced by a standard approach that could generate a resultquickly. The genes were read just once, for instance, and there was room for mistakes.Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of thevirus genome was read more than 100 times, allowing the researchers to see changes that could havebeen overlooked by the conventional approach.The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patientspent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeceswere infectious with living viral strains."Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li andcolleagues said in the paper.Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for InformationScience and Technology at Tsinghua University, said ultra-deep sequencing could be an effectivestrategy to track the virus' mutation."It can produce some useful info rmation," he said.But this approach could be much more time consuming and costly. It was unlikely to be applied to allsamples."Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the viruscame from, why it could kill some healthy young people while generating no detectab le symptoms inmany others still left scientists scratching their heads."If there is a discovery that overturns the prevailing perception, don't be surprised."Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those ofNIAID, NIH, HHS, or the U.S. government.From:Sent :To:Subject :Jim:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202018:01:06 +0000Jim Yong KimRE: My art icleVery nice pape r! Thanks for sending it .Best,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)( 6)FAX: (301) 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jim Yong Kim <Jim.Yong.Kim@global -infra.com>Sen t: Monday, April 20, 20 20 3:00 PM ------- ~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6):>Subject: My articleTony,Hope you're well and thank you again for all that you are doi ng. I got this out today in the New Yorkerand I'll be ta lking to most of the Democratic caucus today about what we're doing in Mass and thedeveloping worl d.Hang in there and let me know if there is anything more I can do . Mass is tough but we're going to havea 1000 contac t tra cers very soon . Every day we learn so much, wh ich is why it's so im portant foreveryone to get started .JimFrom:Sent:To:Cc:(NIH/N IAID) [ElSubject:Attachment s:Ed:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202017 :43:2 1 +0000EDWARD SCOLNICKMascola , John (NIH/VRC) [El;Cassetti, Cristina (NIH/N IAID) [El;Marston , HilaryRE: for your considerationScient ists_to_Stop _COVID19_2020_04_15_FINAL.pdfThank you for your note and for sending this. The outline that you provide is exactly in sync with what we arealready doing and have definitive plans to do with regard to classic antivirals , monoclonal antibodies, and a varietyof vaccine candid ates. As you know, the candidate developed here at Nll-1 in collaboration with Moderna is wellinco phase I crials and at lease 2 ochers are encer ing into phase 1 trials.Best regard::;,TonyAnthony S. Fauci, MDDirectorNational Tnslitu te of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520Nat ional Tnslitutes of HealthBethesda, MD 20892-2520Phone : (b) (6)FAX : (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachmen ts is confidential and may contain sensitive infom1ation . Itshould not be used by anyone who is not the original intended recip ient. If you have received this e-mai l in errorplease infonn the sender and delete it from your mailbox or any other storage devices. The Nat ional Institute ofAllergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's ownand not express ly made on behalf of the NIAID by one of its representatives.-----Original Message-----From: EDWARD SCOLNICK (b)(6)Sent: Sunday, April I 9, 2020 5: 18 PM To: Fauci , Anthony (NIH/NIATD) [El- --T-""-'!-"'~~~-~!"" ' (b_) _C6,.).>_ _______ ~~Cc: David R. Liu (b)(6) ; Schreiber, Stuart (b)(6) ; Michael Rosbash_______ C_b)_(6_),> ; Ramnik Xav ier __________ C_b)_(6)Subject: for your consid erat ionTony . I hope your mail box is not so full that lhere is room for this. A group of concerned scient ists from differentparts of the country was organized to try to encap sulate and focus tbe national effott against Covid. This documenthas been shared with the White House although we are not sure if it has had any effect on their plans. It has alsobeen shared with The Gates Foundation and a few other business and academic leaders. We rhink we have beenfairly comprehens ive in our cons iderations and recommendations . I hope you will find this helpful. We wouldgreatly appreciate a conversation with you after you have had an oppo1tunity to digest the content of the proposal.lfthere is anything else we can do to help you in this National emergency, we stand ready to help. When I was atMerck ,we led the successfuleffort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the dmgs wemade ,and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The CovidPandemic Best wishes Ed scolnickFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [ElTue, 21 Apr 202015 :12:29 +0000Grady, Christine (NIH/CC/BEP) [ElFW: Thank youSee part about you. QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31 , Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (30 96~ 09E-mail: (b)(6)The information m t 1s e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Conrad, Patric ia (NIH/NIAID) (E]- -------- (b)( > Sent: Tuesday, April 21, 2020 11:07 AM ------~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6) ______.._...Subject: FW: Thank youThis is a cute note ... you can skip most of it and see highlight - that is the cute partPatricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The informat ion in this e-mail and any of its attachments is confidential and maycontain sensitive informat ion. It should not be used by anyone who is not theor iginal intended recipient. If you have received this e-mail in error please informthe sender and delete it from your mailbox or any other storage devices. NationalInstitute of Allergy and Infectious Diseases (NIAID) shall not accept liability forany statement made that are sender's own and not expressly made on behalf ofthe NIAID by one of its representatives .-----Original Message-------------,;- s--=, From: JOAN HUSSEY (bH6lSent: Tuesday, April 21, 2020 9:34 AM ---------=-:- = To: Fauci, Anthony (NIH/NIAID) [E] --------- (bH 6)> Subject: Thank youDear Dr. Fauci,I just wanted to say thank you for everything you are doing to educate us in thiscountry , and keep us safe during this horrendous coronavirus pandemic. I can'teven begin to imagine how difficult it is to maintain your composure andpersevere with your focus, being constant ly in the public eye and also trying toexpert ly guide a president who seems more preoccupied with his own image (andsound of his own voice), and political aspirations than with the actual well beingof his country's citizens.By now, it should be perfectly clear to us that we can't have a healthy economywit hout a healthy population.(b)(6)I (bH ~ We all have beendiligent about staying at home I (b)( ~ordering food and other t hings to be delivered to ourhouse (we all wash our hands 'religiously') . (b)(6) is the only one of uswho occasionally goes to a grocery store or drug sto re if necessary and then, healways wears a mask, gloves, and keeps at least six feet between himself andanyone else, and gets in and out as quickly as possible. In addit ion, (b)( 6)- are so intent on keeping me we ll and alive, we haven't even, any of us,physically visited with each other , in person, inside our house for months .In the past two months, I've been outside only four times - twice on our deck andtwice in my car, dropping off a couple of shopping bags at a friend's house and at-------- CbH6) group home - both times leaving the bags in the dr iveway, and then driving right back home.I'm so t hankful for FaceTime, but we miss hugs and kisses. I know all this mustsound extreme, and it is, but I'm terr ified of becoming a statistic so we're doingwhatever we can to stay healthy for ourselves and one another.------ CHb (i)jM y family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thankyou for your wisdom and advice, both grounded in years of experience.(b)( 6)I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. Imet you once, briefly , about 40 years ago(+/ -) in Bldg. 31's fitness room . I hadbeen working in the CC, in the Patient Activities Dep't. (on the POB out - and inpatientunits)at the time. I was incorrectly using a piece of equipment and youwere kind enough to come over and show me the correct way to use it. Irecognized you immediately , and have never forgotten that experience and howgracious you were .I'm well aware from the news that you are up against some very tough peopleand some very tough times but please know you also have an army of gratefulfollowers in this country who are comp letely convinced that what you areadvising is in their very best interest.Thank you again for all you've done for all of us over the years. My family and Iare more grateful than I can e><press .PS I read all about your wife who sounds amazing also. You two make an "AllStar"team .Be well.Gratefully, Joan ("Joanie") HusseySent from my iPhoneFrom:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202015 :11:29 +0000(b)(6)Subject: FW: Thank youJoanie:Many thanks for your kind note . It is much appreciated . Stay safe !Best,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail : (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.-----Original Message----- -------~= From: JOAN HUSSEY CbH6lSent: Tuesday, April 21, 2020 9:34 AM To: Fauci, Anthony (NIH/NIAID) [E] --------------~-~- -- CbH6) Subject: Thank youDear Dr. Fauci,I just wanted to say thank you for everything you are doing to educate us in thiscountry , and keep us safe during this horrendous coronavirus pandemic . I can'teven begin to imagine how difficult it is to maintain your composure andpersevere with your focus, being constan t ly in the public eye and also trying toexpertly guide a president who seems more preoccupie d with his own image (andsound of his own voice), and political aspirations than with the actual well beingof his country's citizens.By now, it should be perfectly clear to us that we can't have a healthy economywithout a healthy population.(b)(6)(b)( • We all have beendiligent about staying at home ------------------- (b)(6)1 ordering food and other things to be delivered to ourhouse (we all wash our hands 'religiously'). (b)(6) is the only one of uswho occasionally goes to a grocery store or drug store if necessary and then, healways wears a mask, gloves, and keeps at least six feet between himself andanyone else, and gets in and out as quickly as possible. In addit ion, (b)(6)- are so inten t on keeping me well and alive, we haven1t even, any of us,physically visited with each other, in person, inside our house for months.In the past two months , I've been outside only four times - twice on our deck andtwice in my car1 dropping off a couple of shopping bags at a friend's house and at-------------- (bH6l - both times leaving the bags in the dr iveway,and then driving right back home.I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this mustsound extreme , and it is, but I'm terr ified of becoming a statistic so we're doingwh af_e,ver we._c.a o_to_sia~he.aJtb.._v..fnr nu r.selve_c;_nad on e._a.noib e .__ ____ ~~(b)(6)------- (b)(6) My family is hearing what you're saying and taking your advice.1' m sorry this email is so long but my intention , more than anything, is to thankyou fo r your wisdom and advice, both grounded in years of experience.I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. Imet you once, briefly , about 40 years ago(+/-) in Bldg. 31's fitness room . I hadbeen working in the CC, in the Patient Activities Dep't. (on the POB out- and inpatientunits)at the time. I was incorrectly using a piece of equipment and youwere kind enough to come over and show me the correct way to use it. Irecognized you immediately , and have never forgotten that experience and howgracious you were.I'm well aware from the news that you are up against some very tough peopleand some very tough times but please know you also have an army of gratefulfollowers in this country who are completely convinced that what you areadvising is in their very best interest .Thank you again for all you've done for all of us over the years. My family and Iare more grateful than I can express.PS I read all about your wife who sounds amazing also. You two make an "All Star"team.Be well.Gratefully, Joan ("Joanie") HusseySent from my iPhoneFrom :Sent :To :Subject :Att achm ent s:Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/NIAID) [E)Tue, 21 Apr 202014 :52:49 +0000Barasch, Kimberly (NIH/NIAID) [C)FW: White House Coronavirus Task Force PowerPoint - 4.21.20PowerPoint April 21.pptxNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.(bX5)-PCIFrom:Sent:To:Subject :Att achment s:Here it is.Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 02:52:55 +0000Corey, Larrymanuscr iptCOVID vaccine editoria l_prefinal April20 wfigur e -with Fauci trac ked edit s.docxNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:(b)(6)Mon, 20 Apr 2020 19:24:58 -0400Mascola, John (NIH/VRC) [E]Subject: Fwd: COVID-19 vaccineLet us discuss. I am not sure how to answer Adrian.Begin forwarded message:From: Adr ian Hill (b)(6)Dat e: April 20, 2020 at 6: 16:30 PM EDT ------~~ To: "Fauci, Anthony (NIH/NIAID) [E]" ------. (b)(6J: Cc: Hildegund Ertl (b)(6) , Sarah Gilbert ----------- (b)( Subject: F,v: COVID-19 vaccineDear Dr Fauci(b) (4)Thank you for your consideration of this at an exceptionally busy time.Yours sincerelyAdrian HillProfessor Adrian V. S. HillDirector, The Jenner InstituteNuffield Department of MedicineUniversity of OxfordOld Road Campus Research BuildingOxford OX3 70QFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [E)Mon, 20 Apr 2020 20:43:18 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Update: White House Coronavirus Meeting - 4.21.20Yikes .......................... That wou ld make 4 days in a row without a Press Conf erencefor me - Saturd ay, Sunday, Monday and tom orrow Q QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Hurst, Natalie R. EOP/OVP (b)(6)Sent: Monday , Apri l 20, 2020 4:38 PMSubject : Update: Whit e House Coronavirus Meet ing - 4.21.20Importance: HighAll -There will be no Whit e House Coronavirus Task Force Me eting on Tuesday , April 21st.Enjoy your evening ,Natalie Hur stOperation s Coordin ator , White House Coronaviru s Task Force
From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Mon, 4 May 2020 21:05:39 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6Please see me about thi s.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Collins, Francis (NIH/OD) [E] (b)(6)>Sent : Monday, May 4, 2020 11:18 AMTo: ICDDIR-L@LIST.NIH.GOVCc: Parker, Ashley (NIH/OD) [E) (b)(6); Whalley, David (FNIH) [T](b)( >; Melencio, Cheryl (FNIH) [T) (b)(6J> ______ _,Subject: Invitation to join (virtua lly) the ACTIV Leadership Meeting 5/6Dear Colleagues,As you may be aware, the Accelerating COVID-19 Therape utic Interventions and Vaccines (ACTIV) publicprivatepartnership has been moving forw ard rapidly to address the global pandemic. We held ourinitial ACTIV leadership meeting on April 3rd including, NIH, FDA, BARDA, EMA, and industry heads ofresearch and development . Four work ing grou ps were formed out of this meeti ng to focus onprecli nical therapeutics, clinical therapeutics, clinical trial capacity, and vaccines.Although some ICs have representatives participating in t he working groups, we recognize there is aneed to keep everyone looped in to the various activities and prog ress of the partnership, particula rly inview of all of the concurrent IC projects about COVID-19. The ACTIV working groups will be deliveringt heir second report to the ACTIV Leadership Group on Wednesday, May 6, from 3:30-5:00 pm. I amwriting to invite the ICDs to listen-in on this meeting. There will be a lot to cover during the meet ing andthe members of the Leadership Group will be asking the questions . But to give a chance for us NI Hers todiscuss what has been presented, I am scheduling a separate ICD call for 5:05-5:30pm, immediatelyfollow ing the ACTIV leadership meeting.If you are available to take part, please send your responses to David Wholley and Cheryl Melencio ofFNIH (cc'd here) by noon tomorrow , May 5th . Once you confirm your attendance, Cheryl will send youa calendar invite for both the ACTIV leadership meeting and the ICD follow-up call.Best regards,FrancisFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 15:28:08 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: RE: Need your help Covid-19 CAS-1O685I do not know this person. We should refer him to Brett Giroir.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Conrad , Patricia (NIH/NIAID) [E] (b)(6) •>Sent: Monday, May 4, 2020 10:04 AM ------ -=-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: FW: Need your help Covid-19 CAS-10685Do you know this person?Patricia L. ConradPublic Health Ana lyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7AO3Bethesda, Maryland 20892(b)(6)301-496 -4409 faxDisclaimer :The informat ion in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.From: Harris, Kara (NIH/NIAID) [El (bH >Sent: Friday, May 1, 2020 8:38 AMTo: Conrad, Patricia (NIH/NIAID) [ElCc: Auchincloss, Hugh (NIH/NIAID) [El >; Billet, Courtney (NIH/NIAID) [El-------- (b)(6)>; Haskins, Melinda (NIH/NIAID) [El- --------- (b)(6) Subject: FW: Need your help Covid-19 CAS-10685Hi, Patty-This individua l states that he previously worked with Dr. Fauci and that he knows him. Please let meknow if you would like Public Inquiries to handle .Thanks,KaraFrom: Ray Rosa (b)(6)>Sent: Thursday , April 30, 2020 5:58 PMTo: NIAID Ocpostoffice (NIH/NIAID) <0CPOSTOFFICE@niaid. nih.gov>Subject: Need your help Covid-19I am working with a group of physicians whom need your guidance on Serum Covid-19 tests. I needsomeone to call me so I can ask specific questions . I worked with Dr Fauci back in 1998 when I was inthe Air Force. So he does know me. Ray Rosa is the name . Can you please call me.(b)(6) cellScot from AOL Mobile MailGet the new /\OL app· mail.mobile.aol.comFrom:Sent :Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]Mon, 4 May 2020 14:00:23 +0000To: NIAIDODAMSubject: FW: inquiryAnot her one that he will probably want to do.From:A ugustine M. K. Choi ---------- (b)( Sent: Monday, May 4, 2020 9:21 AMTo: Fauci, Anthony {NIH/NIAID) [E] ------ (=b)""('6=J>Cc: Conrad, Patric ia (NIH/NIAID) [E] ---------- (b)( > Subje ct; inquiryHi Tony,I can only imagine your schedule. Thank you for all you are doing for the country in our fight against thisvirus.Weill Cornell would like to invite you for a 3 min remarks to the Class of 2020 at their upcominggraduation if your schedule allows. The virtual graduation is on May 28th . We can tape your remarks atany time which fits your schedule, from now or up to right before May 28.If you able to accept this invitation, please let me know. If not, totally understandable and we wouldlove to have you back again after covid subsides.Thanks again!Augustine M.K. Choi, M.D.Stephen and Suzanne Weiss Dean, Weill Cornell MedicineProvost for Medical Affairs, Cornell UniversityWeill Cornell Medicine1300 York Avenue, Suite F-113 Box 83 I New York, NY 10065Telephone: 212-746-6005Fax: 212 -746 -8424Email: amc2056@med.cornell.eduFrom: Anthony Fauci (b) (6)Date: Monday, March 30, 2020 at 12:19 PMTo: Augustine Choi (b)(6)Subject: [EXTERNALR] E: all wearing masksMy work with the Coronavirus Task Force and the large volume of incomingemails precludes me or my staff from answering each individual message. I wouldencourage you to visit www .coronavirus.gov for the latest information andguidance related to COVID-19.Thank you, and best regards.Anthony S. Fauci, M.D.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 12:28:04 +0000To: Corey, LarrySubject: FW: [EXTERNAL] RE: OK to contac t Joe Menet ski to discuss opport unities foralignment/ col laborat ion on ACTIV activities?As an FYI for the 9:00 AM meet ing.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dolsten, Mikael (b)(6)>Sent : Monday, May 4, 2020 8:15 AM ------~ = To: Collins, Francis (NIH/OD) [E] ~ -;:::=====:::::.;.;,-s-r;,= Cc: Fauci, Anthony (NIH/NIAID) [E] >; Mascola, John (NIH/VRC) [E](b)(6)>; Lane, Cliff (NIH/N IAID) [E) CbH >; Lowy, Douglas (NIH/NCI) ":":"::-::=:======~ [E) (b)(6) ; Jansen, Kathrin (b)( >Subject: Re: [EXTERNAL) RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaborat ion on ACTIV activities?FrancisThanks for the responseWe appreciate the federal initiative and opportunity to influence it's design . I know Kathrin Jansen (ccdhere) from PFE is working w the team on t his.(b)(4 )CbH4> It 's great to be collaborating w NIH-FDA for the best of our nation and global ______._.... _health.In the master protocol, I hope the work ing committee is discussing (b) (5)(b)( 5)(b) (5)These are just two examples we can discuss on Wednesday in the leadership meeting of times permits.I look forward to the meetingBestMikaelSent from my iPhoneOn May 4, 2020, at 04:26, Collins, Francis (NIH/OD) [E] ______ (bH_6)> wrote:Hi Mikael,Wow, sounds like you are making fantastic progress with the vaccine program, andwe would certain ly not want to do anything to slow you down! I understand thatyou are evaluating several mRNA formats with BioNTech. If one of those turnedout to be ready for phase 11/111in late June, we would be most interested in thepossibility of includ ing that in the master protocol. Please keep Tony and me intouch with Pfizer's progress, including which mRNA format you choose to moveinto advanced development.Hope to hear your voice at the ACTIV Leadership Group meeting on Wednesday .There will be a lot to ta lk about!Best, Francis(b)(5)From: Dolsten, Mikael (b)(6)>Sent : Sunday, May 3, 2020 6:26 PM ------~ = To: Collins, Francis (NIH/OD) [El (b)( >Subject : Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?Hi FrancisWe certainly enjoy taking part in ACTIVI will check if we did get our drugs on the lists belowI will discuss w Kathrin Jansen if we may have an option to add one of our several vaccineformats that is less advanced or a refined format of our most advanced in the masterprotocol etc(b)(4)If we can agree about shared key endpoints, we can include that cross all studies Whethe rmaster protocol or more advanced sponsor trials which helps comparisonHappy to discuss w you and welcome your adviceMikaelMikael Dolsten, M.D., Ph.D.Chief Scientific Officer and President,Wor ldwide Research, Development and MedicalPfizer Inc.235 East 42nd StreetNew York, NY 10017On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [El-------- (b)(6)> wrote: MatsHi Mikael,Thanks for your note and this update on exciting progress on severalfronts. ACTIV is moving forward with gratifying speed andcommitment. With regard to vaccines, tomorrow the ACTIV vaccinesWG will be discussing a master protocol for a phase 11/11tr1ia l withadaptive design, multiple arms , and a shared placebo arm, aiming tolaunch on or about July 1. FDA is strongly supportive. The Moderna,Sanofi, and JnJ vaccines are likely to be included - might Pfizer alsojoin?----------------- CbH4> - I trust that compound is 0 n the list of therapeutic candidates that the Clinical Therapeutics WGof ACTIV is reviewing? They are supposed to put forward a tentativelist for the Wednesday Leadership Group meeting. Ditto with the(b)(4 option!Looking forward to catching up soon!Best, FrancisFrom: Dolsten, Mikael ---------- (b)(6) 1> Sent: Sunday, May 3, 2020 12:06 PM ----- -== To: Collins, Francis {NIH/OD} [E] ------- (b)( > Subject: Re: [EXTERNALR] E:O K to contact Joe Menetski to discussopportunities for alignment/ collaboration on ACTIV activities?Hi FrancisI trust you are well but likely working too many hours as we all experience inthe difficult Covid t imes.In the vaccine space we have progressed rapidly and are already in phase 1/2studies dose escalation phase testing multiple format of mRNA vaccine . Keyfor us is (b) (4 .-How are things going w ACTIV.Any issues to discuss ?I hope our PFE representatives in ACTIV are helping out wellPis let me know if there is anything particular to discuss or I can help youwithBest personal regardsMikaelSent from my iPhoneOn May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E](b) (6)> wrote:Hi Morten,Thanks for your note. It would be great to have thisconnection - but let me suggest that you start with DavidWholley (cc'd here), as he oversees all four of the ACTIVworking groups. Joe is the program lead for the group onpreclinical therapeutics/repurposing.Best, FrancisFrom: Sogaard, Morten ----------- (b)(6) Sent : Sunday, May 3, 2020 10:46 AMTo: Collins, Francis (NIH/OD) [E] _____ --,;C.b.H,.=,6. )Cc: Dolsten, Mikael (b)(6); Prof TrevorM Jones CBE FMedSci (b)( >;Sogaard, Morten Cb) (6)>Subje ct: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?Francis,(b) (4)I hope you are having a good weekend .Quick question: Would you be OK if I/we reached out to JoeMenetski, who I understand leads many of the ACTIV efforts.We have come to know Joe very well as a great collaborator onthe AMP gene therapy initiative and It would be very easy Ithink working informally with Joe to look a bit more under thehood and identify/ map opportun it ies for alignment with theother initiatives.All the Best,MortenFrom:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElMon, 4 May 2020 10:53:14 +0000Haskins, Melinda (NIH/NIAID) [ElRE: EOP/OMB Alert: May Hearing GuidanceWhat does this mean for the May 12 Senate Hearing?From: Haskins, Melinda (NIH/NIAID) [El (b)(6)Se nt: Monday, May 4, 2020 6:20 AM -----~~ To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: Billet, Courtney {NIH/NIAID) [E] (b)(6)>Subject: EOP/OMB Alert: May Hearing GuidanceI have highlighted in yellow the fundaments of the 0MB guidance below.MelindaFrom: Hallett, Adrienne (NIH/OD) [E] (b)( >Se nt: Sunday, May 3, 2020 9:54 PMTo: OD-OLPA-Leg Contacts <00-0LPA-LegContacts@OD .NIH.GOV>Subject: Fwd: May Hearing GuidanceFYI. New 0MB hear ing guidance.From: Yaworske, Jason A. EOP/OMB ------------ (b) (6)> Sent : Sunday, May 3, 2020 9:06 PM Cc: Ueland, Eric_ M_. EO _P/_WH;_O_ -- -=--=---=-~====~(b)(~6=)> ;- -Hodgson, Christophe r ( o v p. e op.gov) (b)(6)Subject: May Hearing GuidanceImportance: HighAgency legislative affairs teams,(bX5)-PCIThank you, and please let us know if you have any questions .JasonJason YaworskeAssociate Director for Legislative Affa irsOffice of Management and Budget(b)(6) ( 0)(b)(6) (c)From:Sent :To:[ElCc:Fauci, Anthony (NIH/NIAID) [E)Mon, 4 May 2020 00:50:18 +0000Collins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID)Tabak, Lawrence (NIH/OD) [E];Parker, Ashley (NIH/OD) [E]Subject: RE: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?We need to find out precisely what he is ta lking about when he says "vaccine formats" and"refined formats". I really do not know what he is talking about. (b)(4),(b)(5)John/Cliff:Let us discuss this at our morning meet ing .Thanks,TonyFrom: Collins, Francis (NIH/OD) [El (b)(6)>Sent: Sunday, May 3, 2020 8:03 PMTo: Mascola, John (NIH/VRC) [E]_ _____ --,;(-b")('"=6");' Lane, Cliff (NIH/NIAID) IE]-------- (b)( ; Fauci, Anthony (NIH/NIAID) [E] (b)( > Cc: Tabak, Lawrence {NIH/OD) [E) (b)(6J>; Parker, Ashley (NIH/OD) [E)(b)(Subject: FW: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Hi John, Cliff, and Tony ,See note below, where Mikael Dolsten indicates Pfizer is planning to CbH4>. He intends to discuss our master protocol possibility with Kathrin Jensen.am not qu ite sure what he means by "several vaccine formats".Does this timetable sound realist ic?Any suggestion about a response?FrancisFrom: Dolsten, Mikael ---------- (b)(6)Sent: Sunday, May 3, 2020 6:26 PM -----~~ To: Collins, Francis (NIH/OD) [E] ------- (b)(6)Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Hi FrancisWe certainly enjoy taking part in ACTIVI will check if we did get our drugs on the lists belowI will discuss w Kathrin Jansen if we may have an option to add one of our several vaccine formats thatis less advanced or a refined format of our most advanced in the master protocol etcIf we can agree about shared key endpoints , we can include that cross all studies Whether masterprotocol or more advanced sponsor trials which helps comparisonHappy to discuss w you and welcome your adviceMikaelMikael Dolsten, M.D., Ph.D.Chief Scientific Officer and President,Worldwide Research, Development and MedicalPfizer Inc.235 East 42nd StreetNew York, NY 10017On May 3, 2020, at 5:16 PM, Collins, Francis (NIH/OD) [E]MatsHi Mikael,-------- (b)(6) wrote :Thanks for your note and this update on exciting progress on several fronts. ACTIVis moving forward with gratifying speed and commitment. With regard to vaccines,tomorrow the ACTIV vaccines WG will be discussing a master protocol for a phase11/11tr1ia l wi th adaptive design, multiple arms, and a shared placebo arm, aiming tolaunch on or about July 1. FDA is strongly supportive. The Moderna, Sanofi, andJnJ vaccines are likely to be inc lud ed - might Pfizer also join?(b) (4)------------------ (b)( 4)- I trust that compound is on the list 0 f therapeutic candidates that the Clinical Therapeutics WG of ACTIV is reviewing?They are supposed to put forward a tentative list for the Wednesday LeadershipGroup meeting. Ditto with the CbH4> option!Looking forward to catching up soon!Best, FrancisFrom: Dolsten, Mikael ----------- (b)( Sent: Sunday, May 3, 2020 12:06 PMTo: Collins, Francis (NIH/OD) [E] ______ .(,b,.")("=6")Subject: Re: [EXTERNAL] RE: OK to contact Joe Menetski to discuss opportunities foralignment/ collaboration on ACTIV activities?HI FrancisI trust you are well but likely working too many hours as we all experience in the difficultCovid times.How are things going w ACTIV.Any issues to discuss?I hope our PFE representatives in ACTIV are helping out wellPis let me know if there is anything particular to discuss or I can help you withBest personal regardsMikael(b) (4)(b) (4)Sent from my iPhoneOn May 3, 2020, at 10:49, Collins, Francis (NIH/OD) [E] -------- (b)(6) wrote :Hi Morten,Thanks for your note. It would be great to have this connection - butlet me suggest that you start with David Whalley (cc'd here), as heoversees all four of the ACTIV working groups. Joe is the program leadfor the group on preclinical therapeutics/repurposing.Best, FrancisFrom: Sogaard, Morten ----------- (b)(6)> Sent: Sunday, May 3, 2020 10:46 AMTo: Collins, Francis (NIH/OD) [E] ------=- (b) '""(=6)>Cc: Dolsten, Mikael (b)( ; Prof Trevor M Jones CBEFMedSci (b)(6); Sogaard, Morten------!=======; (b:);(:c:6");=;----Subject: OK to contact Joe Menetski to discuss opportunities for alignment/collaboration on ACTIV activities?Francis,I hope you are having a good weekend.Quick question: Would you be OK if I/we reached out to Joe Menetski, who Iunderstand leads many of the ACTIV efforts. We have come to know Joe verywell as a great collaborator on the AMP gene therapy initiative and It wouldbe very easy I think working informally with Joe to look a bit more under thehood and identify/ map opportunities for alignment with the other initiatives.All the Best,MortenFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:45:43 +0000Greg Folkers (b)( 6) );Doepel, Laurie (NIH/NIAID) [ElPitt and INCAttachments: Commenc ement Remarks, generic 30-sec for UPitt and UNC SOM, - FINAL - for5-08-2020 (videos) .docxSee attachment with remarks for UPitt and UNC. I have left the tracked changesshowing so that you can see what I have done . Please accept these and thenproof it. It is now marked FINAL (tracking needs to be accepted) in the ODfolder . Thanks .Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail : (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:28:33 +0000Greg Folkers (b)(6) ;Doepel, Laurie (NIH/NIAID) [ElUSUHSCommencement Remark s, USUHS 2-min -FINAL- for 5-16-2020 (Vid eo).docxSee attachment with USU HS remarks . I have left the tracked changes showingso that you can see what I have done. Please accept these and then proof it. It isnow marked FINAL {tracking needs to be accepted) in the OD folder . Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent:To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 21:21:04 +0000Greg Folkers (b)(6) );Doepel, Laurie (NIH/NIAID) [ElAMACommencement Remarks, AMA 3-min - FINAL - fo r May 2020 (Video).docxSee attachment with AMA remarks. I have left the tracked changes showing sothat you can see what I have done . Please accept these and then proof it. It isnow marked FINAL (tracking needs to be accepted) in the OD folder. Thanks.Anthony S. Fauci , MODirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 20:58:32 +0000To: Doepel, Laurie (NIH/NIAID) [E);Greg Folkers ______(b)_( ...)_ .Subject: UCSFAttachments : Commencement Remark s, UCSF SOM - FINAL - for May 2020 (Video) .docxGreg/Laurie:I am attaching the UCSF 3 minute talk. I labeled it as "FINAL" and it is in the ODfolder. However, I have left in the tracked changes fo r you to see what I did.Please accept the changes and then go over it one last time . I like it the way it isand so please no trivial corrections.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent:To:Subject:Attachments :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 20:11:08 +0000Doepel, Laurie (NIH/ NIAID) [E);Greg Folkers (b)( )Holy CrossCommenc ement Remarks, Holy Cross - FINAL - for 05-22-2020 (video) .docxThe Holy Cross video script is in the OD File mar ked as "FINAL". I have left thetracked changes showin g so tha t you will know w hat I have done. Please acceptthe changes and take a final look. I am also attaching for your look.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 18:34:28 +0000To: Tromberg, Bruce (NIH/N IBIB) [E);'Sharpless, Ned-----------, (b=~=(6)) 'Cc:Subject:Thanks, Bruce.Anthony S. Fauci , MDDirectorConrad, Patricia (NIH/N IAID) [E)RE: 2 quick pointsNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: _ __,. ,_, (b)( 6)The information inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Tromberg, Bruce (NIH/NIBIB) [E) ---------- (b)( 6)>Sent: Sunday, May 3, 2020 2:28 PM- -------, a-s-r,= To: Fauci, Anthony (NIH/NIA ID) [E) (b)( ; 'Sharp less, Ned(b)( 6)Cc: Conrad, Patr icia (NIH/NIAID) [E] ______ (b) <_ >Subject: Re: 2 quick pointsHi Tony,Thanks! Hope you are doing well.This is basically exactly wha t we are working to facilitate with our RADx and digita l health (app) platforminitiatives ... greatly expanding test ing and creating a digita l backbone to provide people with ways toaccess tests and interpret results . For expanding test ing platforms, see https://www.nibib .nih.gov/news events/newsroorn/nih-mobil izes-national-innovation -initiative -covid-19-diagnostics We have > 700applicat ions that have been started in just a few days. For the digital health (e.g. app) platform we'veput a lot of thought into the design and are hoping a contractor wil l be able to launch a pilot study ofhealthcare workers soon. Ned and I plan on issuing additional calls in this area with multiple institute sas stakeholders in the coming weeks.Best,BruceBruce J. Tromberg, Ph.D.DirectorNational Institute of Biomedical Imaging and BioengineeringNational Institutes of HealthBuilding 31, Room 1C14Bethesda, MD 20892-2281(b)(6)301-480-0679 - FAX(b)(6)http://www.nibib.nih .govFrom: "Fauc i, Anthony (NIH/ NIAID) [E]" <- -------- (b)(6)Date : Sunday, May 3, 2020 at 1:55 PM --------------------------~~ To: "'Sharpless, Ned ~~~":""":"'.~========~;---------(-b)(-6)- 11 T ro m berg, Bruce (NIH/N IBIB) [E]" (b)(6)> ~-=========~ Cc: "Conrad , Patric ia (NIH/NIAID) [E]" ________ Cb _H_6JSubje ct : FW: 2 quick pointsNed/ Bruce:I t hought that I would pass this on to you in case you have int erest. Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)(6)>Sent: Saturday, May 2, 2020 8:23 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [El- ------- (b)( > Subject: 2 quick pointsDear Tony,l. I had planned to wr ite to thank you for giving an interview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it.was waiting for the chaos around you to subside before writing but... ..2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b) (6)As his email says, (b)(6) with Samsung's venture capital group, which hasan idea for a future , comprehensive surveillance system for COVID-19 (b)(4)It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-orien ted individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out Cb)<_ , and certainly nothing is more important these days than COVID-19 and the outstanding wor kyou are doing to manage it .All the very best,-EricFrom: Warren, John [mailto (b)(6)] ------------ Sent: Thursday, April 30, 2020 6:52 PMTo: (b)(6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up --------(b)(6)but I'm writing because it might yet bring at least the two of us together.------(b)(6)Samsung'sv enture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has ident ified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optimal ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MD 21201(b)(6)From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Sun, 3 May 2020 17:56:39 +0000NIAIDODAMSubject: RE: Dr. Antho ny Fauci & Avi Schiffm an/The Webby Awards????? Who is this person?Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Auchincloss , Hugh (NIH/NIAID) [El- ---------- (b)(6)> On Behalf Of Fauci, Anthony (NIH/NIAID) [ElSent : Sunday, May 3, 2020 1:55 PMTo: NIAID OD AM <NIAIDODAM@niaid .nih .gov>Subject: FW: Dr. Anthony Fauci & Avi Schiffman/T he Webby AwardsFrom: lesley lesleycahillroy.com <lesley@lesleycahillroy.com>Sent: Friday, May 1, 2020 12:13 PM -------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Subject: Re: Dr. Anthony Fauci & Avi Schiffman/The Webby AwardsHI Dr FauciI just wanted to follow up on below regarding Avi and The Webby Awards. Would be wo nderful if youcould be a part of this moment for him.Thanks so muchLesleyOn Apr 20, 2020, at 1:57 PM, lesley lesleycahillroy.com <lesley@lesleycahillroy .com>wrote :<6EDD370A-6106-4603-B557-7AAEE9A9EF79.png>Dear Dr. Fauci,I hope you and the family are all safe and healthy dur ing these challenging times. Hailedby The New York Times as "the Internet's highest honor," The Web by Awards has been t hepremiere award for on line excellence for over two decades, honor ing the companies andpeople who have crit ically shaped digital techno logy and culture.This year, due to the impact of the coronavirus The Webby Awards are moving theirrenowned award show to an online experience. On May 19th, 2020, the 24th AnnualWebby Awar ds wi ll bring together Webby Winners from around the world in an InternetCelebration which wi ll showcase the artists, organi zations, and creators using th eirplatforms to imagine a bette r tomorrow th rough informa t ion, educatio n, movement,comedy, all while inspiring audiences to take action to enact posit ive change.The 24th Annual Webby Awards are proud to honor Avi Schiffmann as the 2020 Personof the Year to recognize his creation of ncov2019.liv e to track the spread of COVID-19across the world. We would be honored if Dr. Fauci would "virtually" present Avi withhis award .As we collectively navigate the severe impact of COVID-19 on the world and late calls fornation-wide social distancing, the Internet has become the lifeblood for people lookingfor accurate information about the novel coronavirus. Since launching the site onDecember 29th , Avi Schiffmann's tracking site was a necessary tool that sounded thealarm on the novel coronavirus and its spread, notably calling attention to its severitylong before many global officials. By providing over 100 million visitors with real-timedata on the virus' spread, Schiffmann has helped people around the globe understandCOVID-19 and the necessity of upgrades to current health care systems and measures toflatten the curve.For having the fore sight to track the global spread of COVID-19 and for creating awebsite to provide real-time data about the virus to people everywhere, it is our greatprivilege to honor Avi Schiffmann as the 2020 Webby Person of the Year. Thecelebration will highlight the important work Avi and his fellow winners are doing, andwill mark his hallmark Webby 5-Word acceptance speech in Internet history. Dr. Fauci'spresenter speech could be recorded on his phone and we can send you through a scriptfor him to review, edit and details for format and deadline.This year's Webby Awards will also take action, t he impact of COVID-19 and govern mentresponses around the world, has brought the importance of vot ing into sharp focus. TheWebby Awards has partnered with Vote.or and aim to check the voter registration statusof 1 million voters in the United States, promoting the importance of voting to help ensurevote r turnout this November is the highest it has ever been. This partnership will integrateinto all elements of this year's on line celebration.Our thoughts are with all of you in this difficult time.BestLesley Cahill Roy(b)(6)From:Sent:To:(NIH/NIBIB) [ElCc:Subject:Attachments :Ned/ Bruce:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:55:14 +0000'Sharpless, Ned- ----------- (b)(6)';Tromberg, BruceConrad, Patricia (NIH/NIAID) [E)FW: 2 quick pointscovid contact tracing.pdfI thou ght that I wou ld pass thi s on to you in case you have int erest . Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)(6)Sent: Saturday, May 2, 2020 8:23 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] ______ Cb _H_ >Subject: 2 quick pointsDear Tony,1. I had planned to wr ite to thank you for giving an interview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. Iwas waiting for the chaos around you to subside before writing but .....2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b)(6)As his email says (b)(6) Samsung's venture capital group, which hasan idea for a future, comprehensive surveillance system for COVID-19 (b)( 4). It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-oriented individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) ~- and certainly nothing is more important these days than COVID-19 and the outstanding workyou are doing to manage it.All the very best,-EricFrom: Warren, John [mailto ----------- (b)(6)Sent: Thursday, April 30, 2020 6:52 PMTo: (b)(6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up (b)( ut I'm writing -------- because it might yet bring at least the two of us together.(b)(6)Samsung's ------ venture capital group and his team has what I th ink is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has identified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optima l ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MD 21201(b)(6)From:Sent :To:Subject:Eric:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:53:55 +0000Eric OttesenRE: 2 quick pointsThanks for your note . No problem . I will forward this to people here at NIHwho are pursuing such approaches. I hope that all is well with you.Best regards ,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Eric Ottesen (b)( >Sent: Saturday, May 2, 2020 8:23 AM -------~~ To: Fauci, Anthony {NIH/NIAID) [E] ---------(b)(6) Subject: 2 quick pointsDear Tony,1. I had planned to write to thank you for giving an inte rview (b)(6) for theWashington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it .was waiting for the chaos around you to subside before writing but .....2. Last evening I was asked to forward the message below to you. You might already know JackWarren, Professor of Medicine and Infectious Diseases at U. Maryland (b)(6)As his email says, (b)(6) Samsung's venture capital group, which hasan idea for a future, comprehensive surveillance system for COVID-19 (b)(4). It is interesting,but all I know is what I read in the power-point attached. I cannot imagine you would have timeto look at it yourself, but perhaps it could be shared with other systems-oriented individualsworking towards 'opening up' responsibly.Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out (b) ~_ , and certainly nothing is more important these days than COVID-19 and the outstanding workyou are doing to manage it.All the very best,-Ericl=rom: Warren , John [ma ilta (b)(6)] ----------- Sent : Thursday, April 30, 2020 6:52 PMTo: (b) (6)Subject: Jack WarrenEricA voice from the past. Covid-19 prevented us from meeting up (b)(6l b ut I' m wri.t.in gbecause it might yet bring at least the two of us together. ------------(b)(6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually open ing the economy up again. The idea is containedwithin the attachment.I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear toforwarding the attachment to him? The group has identified some appropriate test manufacturers butis at the point where they need to know the spectrum so as to focus on the optima l ones. The thoughtwas that Tony Fauci might be the best person to know what tests are in development stage.What are your thoughts?Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly aspossible.ThanksJack Warren MDProfessor of MedicineDivision of Infect ious DiseasesUniversity of Maryland School of MedicineBaltimore MO 21201(b)(6)From:Sent :Auch incloss, Hugh (NIH/NIAID) [E] on behalf of Fau.ci, Ant hony (NIH/ NIAID) [E]Sun, 3 May 2020 17:52:37 +0000To: NIAIDODAMSubject:Importance:FW: INVITE- American College of Cardiolog yHighFrom: Kim, Jonathan Ho-Youn (b)(6)Sent: Friday, May 1, 2020 3:09 PM ------ ..,.....,..-= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)Cc; Ryan Meye r (b)(6) Roby n Snyde ------- (b)(6) Subject: Re: INVITE- American College of CardiologyImportance: HighDr. Fauci- Of course, I appreciate how busy you are, so just reaching out again on behalfof the American College of Cardiology as noted below. We were hopeful we could stealjust an hour of your t ime in June for an important discussion on COVID-19 and exercisetraining. This is part of a virtual agenda for one of our national conferences (Care of theAthletic Heart) with outreach around the world given this is a part of the ACCeducational platform.We hope th is is something you have the bandwidth for, and simply appreciate yourconsideration. I hope to hear from you and thank you for all your service once again.My best, Jonathan KimJonathan H. Kim MD, MSc, FACCChief of Sports CardiologyDepartment of Medicine, Division of CardiologyDepartment of OrthopedicsEmory UniversityAdju nct Assistant ProfessorDivision of Applied PhysiologyGeorgia Inst itute of TechnologyTeam Cardiologist for Emory Athlet ics, Georgia Tech Athletics , Atlanta Falcons, Atlanta Hawks, AtlantaBraves, and Atlanta DreamOffice Phone: Cb) (6)Research Profile: http: // medicine .emorv .edu/cardiology/emory-first- facultydjrectory/profi le.htmi?f=JKIM10Email Cb) (6)From: Kim, Jonathan Ho-YounSent: Thursday, April 16, 2020 3:46 PMTo: (b)(6) Cc:- R-y-an-M =e=ye=r ===;--C--b)-( ·>; Robyn Snyder_ ____ C_>b_<_,>Subject: INVITE- American College of CardiologyDr. Fauci-On behalf of the American College of Cardiology (ACC), first I would like to thank you for yourtremendous service throughout your incredible career and certainly during these present andchallenging times. We are indebted to your service and thankful everyday we have you to helpguide public health measures through the COVID-19 pandemic .I am a member of the Sports and Exercise Council for the ACC and the Course Chair for ourannual ACC Care of the Athletic Heart Conference. Originally scheduled June 18-20, 2020 at ACCHeart House in Washington DC. I am also faculty at Emory University and direct our sportscardiology program in Atlanta.Of course, we have made the difficult decision to cancel our live meeting in June, but myselfalong with the staff at ACC are working very hard transitioning the course to a virtual courseand agenda. This course will be a much shorter version and the agenda will all be pre-recordedand distributed as a 'live simulated version' on June 20, 2020.With the impact of COVID-19 on all aspects of life and society, in our academic world of sportscardiology, we are dealing with how COVID has impacted exercise and athletes. As you canimagine, there are a multitude of different issues and questions that colleagues are raising.One new session for our virtual agenda that we think will generate a lot of interest and is ofhigh importance will be a panel discussion on sports, exercise, and COVID-19. We would like toget additional expertise on the panel from the ID/pub lic health and Sports Medic ine arenas, inaddition to sports cardiology. Of course, there is no one that carries the expertise you do fromthe ID and publ ic health perspective and we would be extremely honored if you could be a partof this one session and join our faculty for the course.Before getting into more details and a formal invite from the ACC, I wanted to first see if youhad the bandwidth for this. Understanding you are as busy, if not busier, than anyone in theworld right now. This session would be pre-recorded and we would certainly work to be flexiblewith anytime you had for this in early June to record.I hope this is something that could work- again we would be honored to host you virtually.Many thanks for considering, and hope to hear from you soon. Best, Jonathan KimJonathan H. Kim MD, MSc, FACCChief of Sports CardiologyDepartment of Medicine, Division of CardiologyDepartment of OrthopedicsEmory UniversityAdjunct Assistant ProfessorDivision of Applied PhysiologyGeorgia Institute of TechnologyTeam Cardiologist for Emory Athletics, Georgia Tech Athletics, Atlanta Falcons, Atlanta Hawks, AtlantaBraves, and Atlanta DreamOffice Phone: (b) (6)ResearchP rofile: http://medicine.emory.edu/cardiology/emory-first-faucltydirectory/profile. html?f=JKIM 1 OEmail (b) (6)This e-mail message (including any attachments) is 'or the sole use oflhe intended recipient(s) and may contain confidential and privilegedinformation. If the reader of this message is not the Intendedrecipient, you are hereby notified that any dissemination distributionor copying of this message (including any attachments) is strictlyprohibited.If you have received this message in error, please contactthe sender by reply e-mail message and destroy all copies of theoriginal message (including attachments).From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 17:50:45 +0000Jon LaPookSubject: RE: Today's segment on CBS Sunday MorningJon:Tenific piece on ":No time to abandon science"! Keep up this great work . We need to stay on course.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and lofectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Jnslirutes of HealthBethesda, MD 20892-2520Phone: (b)(6)f AX: (301) 496-4409E- mail: (b) (6)The informa1ion in this e-mail and any of its a1tachmen1sis confidential and may contain sensitive infom1ation. Itshould not be used by anyone who is not the original intended recip ient. If you have received this e-mail in errorplease inform the sender and delete it from your mailbox or any other storage devices. The National Institute ofAllergy and Infectiou s Disease s (NIAID) shall not accept liability for any statements made that are the sender's ownand not express ly made on behalf of the NlAID by one of its representatives.-----Original Message-----From: Jon LaPook.------ (=b)-..(=.6.,,),,(b) (6)>Sent: Sunday, May 3, 2020 I :31 PMTo: Fauci, Anthony (NIH/NlAfD) [E) ...,.._,.-,---,-----Subject: Today's segment on CBS Sunday MorningDear Tony,l hope (though would not bet my life that) you are getting at least a modicum of down time today.Here's a I ink to the segment l told you about. No commercial!htt:ps://www .youtube.com /watch?v-OjCohlBICgO[http://img.y outube.com /vi/OjCohlBICgO/O.jpg]<https: //www .yout ube.com/watch?v=OjCoh lBICgO>Dr. Jon LaPook: No time to abandon science - YouTube<https://www.youtube.com/watch?v=OjCohlBICgO>www .youtube.comAs we reach a point in the COVID-19 pandemic when some states are tempted to open sooner than health expertssay they should, Dr. Jon LaPook notes thatthis ...JonJonathan LaPook, M.D.Chief Medical Correspondent, CBS Even ing News Professor of Medici ne NYU Langone Health(bXS) - PCP.(bX5) -PCIFrom:Sent:To:Cc:Subject:Dr. Dama:Fauci, Anthony {NIH/N IAID) [E]Sun, 3 May 2020 17:23:12 +0000Paola DamaConrad , Patricia (NIH/N IAID) [E)RE: White House Coronav irus Task ForceThank you for your note. I am attaching a slide of the members of the USA TaskForce and as you can see, Dr. Antonio Giordano is not a member.Best regards,A.S. FauciWhite House Coronavirus Task Force -Announced Jan. 29, 2020Chair: VP Mike PenceResponse Coordinator: Deborah Birx■ Jerome Adams■ Alex Azar■ Stephen Biegun■ Robert Bla ir■ Ben Carson■ Ken Cuccinelli■ Kelvin Oroegeme ier■ Anthony Fauci■ Joe GroganAnthony S. Fauci, MDDirector■ Stephen Hahn■ Derek Kan■ Larry Kudlow■ Chris Liddell■ Steven Mnuch ln■ Robert O'Brien■ Matthew Pott inger■ Robert Redfield■ Joel SzabatNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MO 20892-2520Phone: (b) (6)FAX: (301 496-4409E-mail: (b)(6)■ Seema Verma■ Robert WllkleThe information in this e-mail and any of its attachments is confidentia l and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If you havereceived th is e-mail in error please inform the sender and delete it from your mailbox or any otherstorage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statements made that are the sender's own and not expressly made on behalf of theNIAID by one of its representatives.From: Paola Dama (b)(6)>Sent : Sunday, May 3, 2020 10:55 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: White House Coronavirus Task ForceDear Dr. Fauci,I hope to find you well with this ema il.I take the liberty to write you because I have some concern about the misinformationthat can discredit you r task and honors.On many occasions in tv and press, Antonio Giordano , Director of Sbarra Institute in Philadelphia,Keeps saying that he is a member of the USA Task Force.I'm wondering if it's true.I work in UK, but I'm originally from Naples (Italy).I held my PhD in Carlo Croce's lab at OSU and I specialized in immunotherapy at University of Chicago.Currently I'm a research fellow at University of Sussex.I apologize if you find this email inopportune, the time is unfortunate, I grant you .I don't like t he idea that some people might take advantage of this very unpleasant moment for all the world.So I wish that I made a mistake this time.I'm also wondering if you are willing to release a brief in te rview.I stand with you and USA that I miss very muchI really appreciate your timeThank youKind RegardsCiaoOPaola Dama, Ph DMolecular Oncology and PharmacologyUniversity of SussexSchool of Life SciencesJohn Maynard Smith (JMS) BuildingRoom 4B13Falmer, Brighton BNl 9QG-------- (b)(6) (USA)Email: (b)(6)Skype : -----(b)(6)website www .taskforcepandora .comFrom:Sent :Subject :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 15:44:23 +0000Great photo of Mommy and me in this article(b)( 6)https://ww w.usatoday.com/story/ne ws/nation/2020/05/03/coronavirus-white-house -expert -dranthony-fauci-americans-trust/3042991 001/Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (301) (b)( 6)FAX: (301) 4 6~09E-mail: .__....,.,___ (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please info rm the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: (b)(6)Sent: Sun, 3 May 2020 10:30:04 -0400To: Collins, Francis (NIH/OD) [E)Cc: Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID) [E);Wholley, David (FNIH)[Tl;Tabak, Lawrence (NIH/OD) [El;Denny, Joshua (NIH/OD) [E);Gebo, Kelly (NIH/OD) [Gl;lowy, Douglas(NIH/NCI) [El;Devaney, Stephanie (NIH/OD) [E];Adam, Stacey (FNIH) [T);Santos, Michael (FNIH)[T];Freire, Maria (FNIH) [T)Subject: Re: crazy ideaOn May 3, 2020, at 9:47 AM, Collins, Francis (NIH/OD) [E](b) (6) >wro te:Hi John, Cliff, and Tony,(b) (5)As we contemplate ways to stand up a master protocol that could enroll 50 - lOOKpart icipants in a multi-arm COVID-19 trial th is summer, I wondered if (b)(5)See below ---------------------- (b) <5 . What do you think?FrancisFrom: Denny, Joshua (NIH/OD) [El -------- (b)(6)>Sent : Saturday, May 2, 2020 11:22 PM -----~~ To: Collins, Francis (NIH/OD) [El (b)(6)Cc: Tabak, Lawrence (NIH/OD) [El --------- (b)(6)>Subject: Re: crazy ideaHi Francis,This is exciting to hear! Fabulous to hear we may be approaching such a trial.Best,JoshSent from my iPhoneOn May 2, 2020, at 8:34 PM, Collins, Francis (NIH/OD) [E]------- (b) (6J>wrote:Hi Josh,-(b)(5)(b) (5lFrancisFrom:Sent :To:Cc:Subject:Fauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 12:31:13 +0000Handley, Gray (NIH/NIAID) [ElConrad, Patricia (NIH/NIA ID) [ElRE: form Jorge Perez IPK CubaThanks.From: Handley, Gray {NIH/NIAID) [E] ________ Cb _H_Sent: Saturday, May 2, 2020 11:04 PMTo: Fauci, Anthony {NIH/NIAID) [El -------:a- (b.H,.=.6..J>Cc: Conrad, Patricia (NIH/NIAID) [El- -------- (b)(6)•> Subject: RE: form Jorge Perez IPK CubaWill send a reply tomorrow morn ing.I have spoken to State Department and have approved response . Someone will listen in.Will copy you.GrayFrom: Fauci, Anthony (NIH/NIAID) [E] -------- (b) (6Jr>Sent: Saturday, May 2, 2020 3:18 PMTo: Handley, Gray {NIH/NIAID) [El -------'='"'""'=Cc: Conrad, Patricia {NIH/NIAID) [El --------- Subject: FW: form Jorge Perez IPK CubaGray:Wou ld you please handle this .Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Perez Avila, Jorge (b)(6)Sent : Friday, May 1, 2020 12:13 PM To: Fauci, Anthony (NIH/NIAID) [E] -_-_-_-_- -~~ CbC>6)>Subject: form Jorge Perez IPK CubaDear Dr. FauciHello from Cuba.Have been a long time we haven't been in touch.Now the whole world is facing a new epidemic and in Cuba we are working in order to controling. Wewill like to re-new our contact regarding this disease Covid 19, we prepare a telephone conference inorder to exchange ideas to have a better understanding to control the epidemic. This conference will beheld from Cuba next tuerday 05/05/2020 at 4:30pm Cuban time. In douse I am sending the topics. Wewill like to have you and Dr. Handley in th is activity if it is possible to attend this conference. If you are inagreement we will like to know by answering this email and them we will you any other detail.If you have any other person to contact in order to participate will be helpful! for us.Waiting for your answer.Dr. Jorge PerezIPKCubaPreliminary programObjectives:Updating COVID-19 situation at global, regional and mainly in Cuba and USATo sharing data of how our two countries are facing this emergency including research studies , etcTopics for the discussion:• The main strategies that both countries are developing to face COVID-19 .• Diagnostic strategy• Clinical management in adults and children• Innovative Cuban biotechnology products incorporated into the treatment models used in thedifferent stages of treatment• Some other research studies• DiscussionEvents and courses at the following address :http://instituciones.sld.cu/ipk/From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [ElSat, 2 May 2020 20:17 :31 +0000Cassetti, Cristina (NIH/NIAID) [ElRE:ThanksAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Cassetti, Cristina (NIH/NIAID) [E] --------- Sent: Saturday, May 2, 2020 4:10 PM --------= ~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)> ~======:=:!~= Cc: Erbelding, Emily (NIH/NIAID) [E]- --------- (b)(6)>; Conrad, Patr icia (NIH/N IAID) [El (b)(6)Subject: RE:Hi,I already reached out to Dr. Bolognesi and some of us in Program have a call scheduled with him todiscuss th is propos al.I will let you know t he outcome.Kind regards,CristinaFrom: Fauci, Anthony (NIH/NIAID) [ElSe nt: Saturday, May 2, 2020 3:39 PM(b)(6))-------~~ To: Cassetti, Cristina {NIH/NIAID) [E] (b)(6)> ';========~ ~ Cc: Erbelding, Emily {NIH/NIAID) [El CbH6>C1o;n rad, Patricia (NIH/N IAID) [E] __________ ,(b)(6)Subj ect: RE:Import ance: HighCristina:It would be a good idea for you to show this to a couple of other NIAID peoplefor their opinion, and then out of courtesy to get back to Dr. Bolognesi one wayor another.Thanks,TonyAnthony S. Fauci, MDDirec torNational Institute of Alle rgy and Infectious DiseasesBuild ing 31, Room 7A -0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confiden t ial and may contain sens itiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Inst itute of Allergy and Infectious Diseases (NIA ID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its represen tatives.From: Cassetti, Cristina (NIH/NIAID) (E]Sent: Thursday , April 30, 2020 11:36 PMTo: Fauci, Anthony (NIH/NIAID) [E]------ (=b)""('=6)>(b)( >Cc: Erbelding, Emily (NIH/NIAID) [E) ---------(b)(6)> Subject: RE:Dear Dr. Fauci,I reviewed this proposal (b) (5)(b) (5). (b) (4)(b) (5), (b) (4l------------------------------- (b)(5) informative to discuss the project directly with them. Wou ld you like for me to put together a small group at NIAID(with reps from DMID and DAIDS) to talk with Dr. Bolognesi and his colleagues?Kind regards,CristinaFrom: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6) Sent : Thursday, April 30, 2020 7:58 PM --------=-=-= To: Cassetti, Cristina (NIH/NIAID) [E] ..!=======(~b)(6~) Cc: Erbelding, Emily (NIH/NIAID) [E] (b)(6)>Subject: FW:Importanc e: HighCristina :Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/ AIDSinvestigators from a few years back . He is a serious scientist. Let me know what you think.Thanks,TonyFrom : Eisinger, Robert (NIH/NIAID) [E] (b) (6)> On Behalf Of Fauci, Anthony(NIH/NIAID) [E]Sent : Monday, April 27, 2020 6:57 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Dani Bolognesi, Ph.D.- --------- (b)(6) Sent : Monday, April 27, 2020 6:09 PM ------~~ To: Fauci, Anthony (NIH/ NIAID) [E] _____ C_)b(6J>; Barasch, Kimberly (NIH/NIAID) [C](b)(6)Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together with you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4). (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opport unity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D ." ----------- (b)(6)Date: Monday, April 27, 2020 at 2:53 PM To : "Matthias Gromeier, M.D." ---------------------~- - (b)( > Subject : Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows:(b) (4). (b) (5)(b) (4), (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you. As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best,DaniBest,DaniSent from Dani BolognesiThe information in this electron ic mail is sensitive, pro tected inform ation int ended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmed iate ly by return electr onic mail, and to delete it without further reading or retention . The information is not to beforwarded to or shared un less in compliance with Duke Health policies on confidentiality and/or with the approva l of thesender.From:Sent :To:Fauci, Anthony (NIH/NIAID) [ElSat, 2 May 2020 19:08:58 +0000Lerner, Andrea (NIH/NIAID) [ElSubject:viral loadFW: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2Please take a look at this and respond if appropriate.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: ldonae Lovetrue (b)(6)>Sent: Friday, May 1, 2020 2:25 PM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Beigel, John (NIH) [E] CbH ; Booth, Mason (NIH/NIAID) [C]--------- (b)(6) Kim, Sonnie (NIH/NIAID) [E] (b)(6) Subject: Validated precise prediction of remdesivir's clinical efficacy on SARS-CoV-2v iral loadDear Dr . Fauc i,I'd like to share with you that the recent clinical trial results on remdesivir have validated ourprediction of the remdesivir-specific post -treatment viral rebound in human COVID -19 patients.More details can be found in our off icial announcement https ://b it. ly/RRemdesivir.This prediction of remdesivir's clinical efficacy on viral load made on Feb. 23 2020 (b) (4)(b)(4)We appreciate and respect all the efforts your have made towards the COVID-19 pandemic.Best regards,ldonaeldonae Lovetrue I CEO, Demiurge Technologies AG, Switzerlandwww.demiurge. technologyThis email and any attachments thereto may contain private, confidential. and privileged material for the sole use of theintended recipient. Any reV1ew, copying, or distribution of this email (or any attachments thereto) by others is strictly(b) (4)prohibited. If you are not the intended recipient, please contact the sender immediately and pe, manently delete the original andany copies of this email and any attachments thereto. This email is intended for information purposes only and is providedwithout any warranty of any kind, either expres1ed or implied. While some mformat1on used on this document may have beenobtained from various published and unpublished sources considered to be reliable, Demiurge Technologies AG neitherguarantees 1t5 ac..cur"cy 01 completene55 nor accepts liability for any direct or comequential lo5se5 arning from its use.ThankyouFrom:Sent:To:Subject:Ninio:Fauci, Anthony (NIH/NIAID) [E)Sat, 2 May 2020 19:00 :06 +0000Fetalvo, Ninio J. EOP/OVPRE: Back to CMSThanks for all your good work in the White House . Stay safe and well.Best regards,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (301) 496-4409E-mail : Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Fetalvo, Ninio J. EOP/OVP ----------- (b)( Sent: Friday, May 1, 2020 3:12 PMTo: (b)(6); Fetalvo, Ninio (CMS/OC} ----------- (b)(6)Subject: Back to CMSAll,Today is my last day on detail to the Office of the Vice President. I am heading back to CMS to cont inuesupporting the Trump Adm inistration's response to the coronavirus . It has been an incredible honorserving the Vice President and the Coronavirus Task Force, and a pleasure working alongside all of you . Ilook forward to our ongoing work together .Best,NinioNinio J.H. FetalvoPersonal: ------ (~b)-(6~) I Cb()6 )CMS: _______ C_~bC6)I __ C~b_C_6 )From: Fauci, Anthony (NIH/NIAID) [ElSent: Sat, 2 May 2020 18:27 :23 +0000To : Johnson, Martin S. (NIH/NIAID) [E];Auchincloss . Hugh (NIH/ NIAID) [E];NIAIDOCGR Leg;McGowan, John J. (NIH/NIAID) [E];Erbelding, Emily (NIH/NIA ID) {E];tane-, Cliff (NIH/N IAID)[E];Rotrosen, Daniel (NIH/N IAID) [E];Crum, Wayne (NIH/NIAID) [El ;Harper, Jill (NIH/NIAID) [ElCc: Eisinger, Robert (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia(NIH/NIAID) [El;Mar ston, Hilary (NI H/ NIAID) [El;Lerner, Andrea (NIH/N IAID) [E];Doepel, Laurie(NIH/NIAID) [El;Gilles, Sharon (NIH/NIAID ) [E];Routh, Jennifer (NIH/N IAID) [E];Stover, Kathy (NIH/NIAID)[E];Law, Kim (NIH/NIAID) [E];Lee, Kun-Lin (NIH/NIAID) [E];Bushar, Nicholas (NIH/NIAID) [E];Schneider,Johanna (NIH/NIAID) [ElSubject: RE: FY 2020 - COVID-19 - Actua l and Forecasted Spending - Weekly ReportEnding 4/24/ 20Thanks, Mart in.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail : (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The Nat ional Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:J ohnson, Martin S. (NIH/NIAID) [E] ________ C>bC_6 )Sent: Friday, May 1, 2020 7:40 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El --------- (b)( ; Auchincloss , Hugh (NIH/NIAID) [El ":'--.-~""."""'.~===(b=)(-6.)>.;.; _N-IA_I,D,, O:-C=G\R L eg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. (N_.IH:./..N..IA_I.D..). :[_El: ~==:e=,:;-----~--- (b)( >; Erbelding, Emily (NIH/NIAID} [El--:--"""".'"":"""'.":== (b=)=( 6=)-.>..;_:L_an .e.,._:c_1i"f f"~( =NIH / NIA ID) [El (b)( ·; Rotrosen, Daniel(NIH/NIAID) [El (b)( >; Crum, Wayne (NIH/NIAID) [El <wcrum@niaid .nih .gov>;Harper, Jill (NIH/NIAID) [El (b)( >Cc: Eisinger, Robert {NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6) >; Conrad, Patricia (NIH/NIAID) [El (b)(6); Marston, Hilary(NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/N IAID) IE] Cb)(Doepel, Laurie (NIH/NIAID) [El CbH6)>; Gilles, Sharon (NIH/N IAID) [ElCb)( >; Routh, Jennifer (NIH/NIAID ) [El CbH6)>; Stover, Kathy(NIH/NIAID) [El (b)(6}; Law, Kim (NIH/NIAID) [El (b)(6) >; Lee, Kun-Lin ======e:="':;----' (NIH/NIAID) [El (b)(6)>; Bushar, Nicholas {NIH/NIAID) [El (b)(6)v>;Schneider, Johanna (NIH/NIAID) [E] (b)(Subject: RE: FY 2020 - COVI0-19 -Actual and Forecasted Spending - Weekly Report Ending 4/24/20Tony,YTD spending is $110.8M, increasing $24.lM from last week.Spending driven by implementation of3 epidemiological studies, ramp up of resources necessary forvaccine candidate testing and vaccine candidate development.MartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, April 24, 2020 7:11 PM --------=-:~ To: Fauci, Anthony (NIH/NIAID) [El (b)( >; Auch incloss, Hugh (NIH/NIAID) [El--:-:-:--.:-:-:-:-:-::-:-(-b):(-6:)>:;" .N:.I:A:I:D:: O:~=C =G=RL =eg-. <;.N_IA--ID. OCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El--.--~~===:.:....._.(.b:)(.6.)_; _L.a;n_e_, C_l.if.f; ,(N IH/NIAID) [E] (b)( >; Rotrosen, Daniel(NIH/NIAID) [E] (bH6l>; Crum, Wayne (NIH/NIAID) [E] (b)(6);Harper, Jill (NIH/NIAID) [E] (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6); Marston,Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [El------~~==:!....:(.b,).( 6)>; _D oe_p;e_l,. .L.:a.u.r.i.e. ~(N IH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)> ;Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicho las (NIH/NIAID) [El---------- (b)(6J> ; Schneider, Johanna (NIH/NIAID) [E) (bH ,> Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 4/24/20Tony,YTD spending is $86.7M, an increase of $8.3M from last week.Spending driven by foundat ional research including the characterizat ion of factors associated withsevere disease, transmission dynamics, structural analysis of SARS-CoV-2 proteins . Small awards tosupport vaccine and therapeutic discovery.MartinFrom : Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, April 17, 2020 6:15 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)( ; Auch incloss, Hugh (NIH/NIAID) [E]"":"--.----:-:--.:.::::::=(b=)(6=); =N:I;A._ID- -O~-C, GRL eg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J. {NIH/NIAID) (El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El-------- (b)(6)> ; Lane, Cliff {NIH/NIAID) [E] (b)(6); Rotrosen, Daniel(NIH/NIAID) [El (bH6l>; Crum, Wayne (NIH/NIAID) [El (b)(6)>;Harper, Jill (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6); Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)>; Marston,Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [El(b)(6); Doepel, Laurie (NIH/NIAID) [E] (b)(6); Gilles, Sharon ":"--.--.-:-.:-::====:...-_;_~~(NIH/NIAID) [E] (b)(6)>; Routh, Jennifer (NIH/NIAID) [El (b)(6)Stover, Kathy (NIH/NIAID) [E] (b)(6); Law, Kim (NIH/NIAID) [E] (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicholas (NIH/NIAID) [E]---------- (b)(6)>; Schneider, Johanna (NIH/NIAID) [El (b)(6)> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/17 /20Tony,YTD spending is $78.4M, an increase of $10.9M from last week including costs to evaluate the rapeuticsin humans and NHPs, manufacture of a protype virus-like vaccine candidate developed byTaubenberger/Memoli, and spending to accelerate discovery of new therapeutics , vaccines anddiagnostics .Martin(b)(5)From: Johnson, Martin S. (NIH/NIAID) [ElSent : Friday, April 10, 2020 8:22 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)( >; Auchincloss, Hugh (NIH/NIAID) [El...-..- ---:-:-:-:-:;(b:):(6:)>=; =NI=AID= O=CG~R-L e-g~ <N~IA IDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6); Erbelding, Emily (NIH/NIAID) [ElCbH61>); Lane, Cliff (NIH/NIAID) [El Cb)( >; Rotrosen, Daniel":":""'-.-:-:-:----:-:-::--:;::::::="="".!_(NIH/NIAID) [El CbH6); Crum, Wayne (NIH/NIAID) [El CbH6);Harper, Jill (NIH/NIAID) [E) (b)(6)Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)(6)>; Marston,Hilary (NIH/NIAID) [E] (b)(6)::>; Lerner, Andrea (NIH/NIAID) [El(b)(6)>; Doepel, Laurie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)(6); Routh, Jennifer (NIH/NIAID) [El (b)(6)Stover, Kathy (NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [El----------(b)(6); Schneider, Johanna (NIH/NIAID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 4/10/20Tony,YTD spending is $67 .SM, unchanged* from last week . A summary is attached .I have also attached an updated budget plan reflecting our projected spending by research category byfiscal year. We are updating this weekly as we receive updates from the divisions on the timing ofclinical trials, observat ional studies, natural history studies and research resource needs.We will report mid-week on our YTD spending which will be in sync with the data the Dept. extracts.Martin• The reason that we have reported no weekly increase is to match our reported spending with thefinancial information that the Department is now extracting from our accounting system. We havealways included spending from our regular appropriat ion, as directed by the Department. Now theguidance from the Dept. has been updated to report only spending from the supplemental COVID-19 appropriations.From : Johnson, Martin S. (NIH/NIAID) (E]Sent: Friday, April 3, 2020 8:54 PMTo: Fauci, Anthony (NIH/NIAID) [E] ,r------- (=b)- c='>; Auchincloss, Hugh (NIH/NIAID) [E](b)(6J>; NIAID 0CGR Leg <NIAIDOCGRLeg@mail.nih.gov >; McGowan, John J.":":'"'."."."'.'"':"."".".""'."".":"":"7:":'--.:====::::....;.---::-,~(NIH/NIAID) [E] (b)( >; Erbelding, Emily (NIH/NIAID) [E]CbH6J;> Lane, Cliff (NIH/NIAID) [E] CbH6J>R; otrosen, Daniel(NIH/NIAID) [E] (b)(6l>; Crum, Wayne (NIH/NIAID) [E] (b)(6)Harper, Jill (NIH/NIAID) [E] (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El CbH >; Folkers, Greg (NIH/NIAID) [E](b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6J>; Marston,Hilary (NIH/NIAID) [E] CbH6l>; Lerner, Andrea (NIH/NIAID) [El(b)(6)>; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Gilles, Sharon"("N.""".l'".H.""-/"N:.'"."l'"A.""'~I.D"'.)""'[.:""E~'.]===..:....-:..,_ :(:b:.)-,(.=., >; Routh, Jennifer (NIH/NIAID) [E] (b)(6);Stover, Kathy (NIH/NIAID) [E] (b)(6)>; law, Kim (NIH/NIAID) [E] (b)(6);lee, Kun-Lin (NIH/NIAID) [E] (b)(6)>; Bushar, Nicho las (NIH/NIAID) [E]--------- CbH6;J Schneider, Johanna (NIH/NIAID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 4/3/20Tony,YTD spending is $67.SM, a weekly increase of $45.9M mostly for initial funding for set-up ofclinical tria ls for eva luat i.on ofremdesivir in patients with ear ly disea se stage and a placebocontrolledclinical trial of intravenous hyperimmune immunoglobu lin (IVIG) in patients withCOVID-1.9.I've provided a summary spending plan the team worked on and a table for the $ l .532B that wehave received in supplemental appropriations• $826M NIAID received 3/5/20 - the Coronavirus Preparedness and ResponseSupplemental Appropriation s Act• $706M NIAID received 3/25/20 - the Coronavirus Aid, Relief , and. Economic Security(CARES) ActIn the last document I've also included narrative summarizing activities funded by the $249MOther NIH Institutes received in the CARES ActMartinFrom: Johnson, Martin S. (NIH/NIAID) [E]Sent : Friday, March 27, 2020 7:39 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] CbH6l>A; uch incloss, Hugh (NIH/NIAID) [E]---:---~====:::(b:)!(6.):; N.-IA-ID~ 0~CG R l eg <NIAIDOCGRLeg@mail.nih .gov>; McGowan, John J. (NIH/NIAID) [E] (b)( >; Harper , Jill (NIH/NIAID) [E] (b)(6)>;Crum, Wayne (NIH/NIAID) [E] CbH6l>; Erbelding, Emily (NIH/NIAID) [El(b)(6); Lane, Cliff (NIH/NIAID) [E] (b)( >; Rotrosen, Daniel"(:N"-':l'"H."/-":N.-"' .I"A"'.l"'D":'".:)'"- -[~:E:]-====-_;__...;. ("b'")~'(6l>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [E]--------- (b)(6)· Conrad, Patricia (NIH/N IAID) [E] CbH6l>;M arston,Hilary (NIH/NIAID) [E] (b)(6)>; Lerner, Andrea (NIH/NIAID) [EJ(b)(6) 1 ; Doepel, Laurie (NIH/NIAID) [E] (b)(6)>; Gilles, Sharon(NIH/NIAID) [E] (b)(6); Routh, Jennifer {NIH/NIAID) [E] CbH6J> ;Stover, Kathy (NIH/NIAID) [El (b)( >; Law, Kim (NIH/NIAID) [El CbH6J> ;Lee, Kun-Lin {NIH/NIAID) [E] CbH6J>B; ushar, Nicholas (NIH/NIAID) [El--------- (b)(6J; Schneider, Johanna (NIH/NIA ID) [E) CbH ,> Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending- Weekly Report Ending 3/26/20Tony,YTD spending is $2 1.6M, a weekly increa se of $4.0M for clinica l trial site set-up fortherapeutics, further vaccine development, small animal development, and therapeuticdevelopment (mAhs) and basic research.Most of the $50M-$60M we listed last week we expect to be awarded before March 31. In manycases contractors have begun work without the award so as to not stall work.Early next week I' 11 prov ide a summary spending plan for the addi tional $706M that NIAIDrece ived in the suppl ementa l appropriation signed by the President today.MartinFrom: Johnson, Mart in S. (NIH/NIAID) [ElSent: Friday, March 20, 2020 4:54 PM -----~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6J>; Auchincloss, Hugh (NIH/NIAID) [El":"---:-----:-~=(b=)(6=)>;= NI=AID! .O-C:G.-Rl- e~g <=N IAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper, Jill (NIH/NIAID) [E] (b)(6J>; Crum,Wayne (NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [E]--------- (b)(6)>; Lane, Cliff(NIH/NIAID) [El (b)( > Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El---:-----===(:b!)(6.J:; .C,__on r_ad_, P_a_tric:ia~ (~NIH /NIAID) [El (b)(6J>; Marston, Hilary (NIH/NIAID) [El (b)( >; Lerner, Andrea (NIH/N IAID) (El (b)(6);Doepel, Laurie (NIH/NIAID) [El (b)(6) ; Gilles, Sharon (NIH/NIAID) [El(b)(6J>; Routh, Jennifer (NIH/NIAID) [El CbH >; Stover, Kathy(NIH/NIAID) [El (b)(6)>; Law, Kim (NIH/NIAID) [El (b)(6)>; Lee, Kun-Lin(NIH/NIAID) [El (b)(6)>; Bushar, Nicholas (NIH/NIAID) [E] (b)(6)Schneider, Johanna (NIH/NIAID) [E) CbH6J>Subject: RE: FY 2020 - COVID-19 -Ac tual and Forecasted Spending - Weekly Report Ending 3/19/20Tony ,YTD spending is $ l 7.6M, a weekly increase of $3.SM for clinica l trial site set-up, therapeuticdevelopment (mAbs ) and basic research.We greatly appreciate all your hard work.MartinFrom: Johnson, Martin S. (NIH/NIAID) [E]Sent : Friday, March 13, 2020 6:45 PMTo: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auchincloss, Hugh (NIH/NIAID) [E](b) (5)---:---~-==== (=b)=(6~)>..;._.N:.IAI_D_O~C~GR Leg <NIAIDOCGRLeg@mail.nih.gov>; McGowan, John J.(NIH/NIAID) [E] (b)(6)>; Harper, Jill (NIH/NIAID) [El (b)(6);""."":""::-'."."'"-:-=":--:-:"::.======-..;-~~Crum, Wayne (NIH/N IAID) [El (b)(6)>; Erbelding, Emily (NIH/NIAID) [El(b) (6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [El (b)( ; Marston,Hilary (NIH/NIAID) [El (bH6l>; Lerner, Andrea (NIH/NIAID) [E)~~~~~== (=b)=(6::):>.:.=;:_,,o_o_e;p_e_l,:.:L.-a,.=.u,rie (NIH/NIAID) [El (b)(6)>; Gilles, Sharon(NIH/NIAID) [El (b)( >; Routh, Jennifer (NIH/NIAID) [E) (b)(6)> ;Stover, Kathy (NIH/NIAID) [E] (b)(6)>; Law, Kim (NIH/NIAID) [E] (b)(6)>;Lee, Kun-Lin (NIH/NIAID) [E] (b)(6); Bushar, Nicholas (NIH/NIAID) [E]--------- (b)(6)>; Schneider, Johanna (NIH/NIAID) [E) (b)( > Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/12/20Tony,Since we our last report we have increased spending on the COVID-19 response by $1.SM for atotal YID spending of $14.lM.The $ I .SM increase is for the following:$ 1.0M awarded to set-up clinical sites at Emory and U. Washington Seattle for adaptableRCT of rerndesivir.$0.4M supported data analysis of rhesus animal model and grant to gain understanding of thehost pathways that regu late viral gene expression and viral subversion of the host immunesystem.$0. lM funded vaccine development at VRC and DIRMartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, March 6, 2020 5:31 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>; Auchincloss, Hugh (NIH/NIAID) [El---:----:-~===(=b)(6:)!>;. .N.I:A.I-D- O~CG~R l eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [E] (b)(6)>; Harper , Jill (NIH/NIAID) [El (b)( >;Crum, Wayne (NIH/NIAID) [El (b)(6)Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6J>; Conrad, Patricia (NIH/N IAID) [E] CbH ; Marston,Hilary (NIH/NIAID) [E] CbH6l>L;e rner, Andrea (NIH/NIAID) [ElCbH6JD;o epel, Laurie (NIH/NIAID) [E] (b)(6) Gilles, Sharon-(:N--::l-:H:-:/"-;N""..I'"A-':.1-"-D::--:)- :[:E':":]-.===::;.___;,~ (,b.).-.(.:6,-.=)>; Routh, Jennifer (NIH/NIAID) [El (b)(6);(b) (5)Stover, Kathy (NIH/NIAID) [El CbH6JL; aw, Kim (NIH/NIAID) [El CbH6J>;Lee, Kun-Lin (NIH/NIAID) [El (b)(6)Subject: RE: FY 2020 - COVID-19 -Actual and Forecasted Spending - Weekly Report Ending 3/5/20Tony,Since we our last report we have increased spending on the COVID-19 response by $0.2M for atotal YTD spending of $12.6M.The $0.2M increase is for vaccine candidate development at NIAID Intramural Labs includingRML. Costs are mostly for staffing and overhead and include a preclinical immunogen icitystudy designed to test the mRNA-1273 nCoV vaccine two-dose schedule in mice. The study willmeasure the immune response to this vaccine in an animal model in anticipat ion of clinical test inhumans.MartinFrom: Johnson, Martin S. (NIH/NIAID) [ElSent: Friday, February 28, 2020 11:57 AM To: Fauci, Anthony (NIH/NIAID) [E] -------------~-~ CbH6>>A;u chincloss, Hugh (NIH/NIAID) [E] ---:---~---::==(=b)(=6)>:;: N!IA..ID.. O..C:G.R-L -e~g <~NI AIDOCGRLeg@mail.nih.gov>; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper, Jill (NIH/NIAID) [E] (b)(6);Crum, Wayne (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)( >; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E (b)(6)>; Marston,Hilary (NIH/NIAID) [El (b)(6)>; Lerner, Andrea (NIH/NIAID) [E)(b)(6)>; Gilles, Sharon (NIH/NIAID) [E] (b)(6)1>; Routh, Jennifer(b) (5)(NIH/NIAID) [El CbH6>>S;to ver, Kathy (NIH/NIAID) [El CbH6>>L;a w,Kim (NIH/NIAID) [El CbH6>>L;e e, Kun-Lin (NIH/NIAID) [E] (b)(6)Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending - Weekly Report Ending 2/27 /20Tony,Since we our last report we have increased spending on the COVID- 19 response by $2.3M for atotal YTD spending of $12.4M.A recap of the $2.3 million spent in the last week is as follows:• $1.9M to set-up a Phase I trial (45 subjects) of the VRC/Modema mRNA platformcandidate at Kaiser Pennanente Washington Health Research Institute (One of theVTEUs )• $0.3M that supported University of Hong Kong research ers in the development of a RTPCRtest to detect SARSCo V2 from human samp les. The group has now shared the testsand relevant reage nts with over 30 labs globally to enable diagn osis of COVID- 19.• $0.lM vaccine candida te development at NIAID Intramura l LabsMart inFrom : Johnson, Martin S. (NIH/NIAID) [ElSent : Friday, February 14, 2020 3:56 PMTo: Fauci, Anthony (NIH/NIAID) [E]_ _____ "("b".~.,c=..6)>;A uch incloss, Hugh (NIH/NIAID) [El-----.~~===~.(.b:)(6_)>_; -N-IA~ID OCGRl eg <NIAIDOCGRleg@mail.nih.gov >; McGowan, John J. (NIH/NIAID) [El (b)(6)>; Harper , Jill (NIH/NIAID) [E] (b)(6)>;Crum, Wayne (NIH/NIAID) [El (b)(6)>Cc: Eisinger, Robert (NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El(b)(6)>; Conrad, Patricia (NIH/N IAID) [E] (b)(6)> ; Marston,Hilary (NIH/NIAID) (E] (b)(6)> ; Lerner, Andrea {NIH/NIAID) (E)-------- (b)(6)>; Gilles, Sharon (NIH/NIAID) [E] (b)(6) Subject: FY 2020 - COVID-19 - Actual and Forecasted Spending as of 2/13/20Dr. Fauci,Attached is a narrative we are updating weekly for NIAID's COVID-19 response.The accomp anying spreadsheet summar izes the figures and includes a summary of oursupplemental request.We' II provide an update by Thursday of next week.Martin(b)(5)Resource Planning and Mission Integration Branch (RPMIB) - NIAIDNIH Bldg. 31 Room 7A47Tel: (b)(6)From:Sent :To:Fauci, Anthony (NIH/N IAID) [ElSat, 2 May 2020 18:22 :37 +0000Fauci, Anthony (NIH/N IAID) [ElCc: (b)(6)Subject: RE: RE:Zeke:Thanks for your note. CbH6a) nd I would love to get together with you allfor dinner. Let us try to do so within a reasonab ly soon time frame.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Eisinger, Robert (NIH/NIAID) [E] ---------- (b)( > On Behalf Of Fauci, Anthony (NIH/NIAID) [E]Sent: Saturday, May 2, 2020 7:24 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: RE:Email from Zeke Emanue l.Robert W. Eisinger, Ph.D.Special Assistant for Scie ntific ProjectsImmediate Office of the DirectorNat iona l Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone : (b)(6)Email: (b)(From: Emanuel, Ezekiel J -------- (b)( >Sent: Friday, May 1, 2020 8:04 PMTo: Fauci, Anthony (NIH/NIAID) [E] ------ ~=Cc: ------------------- Subject: Re: RE:TonyYou are national--internationa l --treasure . And we are depending upon your sanity and smarts.We can have you and CbH6)over for dinner on the porch and order in fromsomething. Anytime you are ready.Ezekiel .J. Emanuel, M.D., Ph.D.Vice Provost of Global Initi ativesChair, Departmen t of Medical Ethics and Hea lth PolicyLevy University ProfessorCo-Director , Heal thcare Transformation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone: Cb(>6 )(b)(6) --------From: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Friday, May 1, 2020 6:55 PMTo: Emanuel , Ezekiel JCc:(b)(6)(b)(6) ------------------- Subject: RE: RE:Zeke:Cb()6 ) orThanks for the note. Indeed, we do agree.- I look forweard tochatting with you some time soon.Best,TonyFrom: Emanuel, Ezekiel J -------- (bH >Sent: Thursday, April 30, 2020 6:37 PM To : Fauci, Anthony (NIH/NIAID) [E] -------------- -(=b)(=6)>, Subject: Re: RE:(b)(6)Sorry for misreading what you said--1 think maybe I overin tepreted- -lots of f inance peoplecalled and seemed like I was a downer compared to you. But I think we agree.Are you and --(-b)(6) doing okay?Ezekie l J. Emanuel, M.D., Ph.D.Vice Provost of Global Initi ativesChair, Department of Medical Ethics and Health PolicyLevy University ProfessorCo-Director , Heal thcare Transform ation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone: (b)(6) -----------(b)(6) --------From: Fauci, Anthony (NIH/NIAID) [E] _____ (b)_C_6>)Sent: Thursday, April 30, 2020 5:33 PMTo: Emanuel, Ezekiel J (b) ~ >Subject: RE:Zeke:I did not "strongly " endorse it. I specifically said tha t it was not a knockout drugand was only a baby step in the direction of develop ing more and better drugs. Isaid that it was important because it proved in a well-powered, randomized ,placebo-contro lled clinical tria l tha t one can suppress the virus enough to see aclinical effect, as modest as the effect was. I do not think I forced anything.Happy to chat with you about it.Best,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301) 496-4409E-mail : -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Emanuel, Ezekiel J -------- (b)(6)>Sent: Thursday, Apr il 30, 2020 2:12 PM --------=-=~ To: Fauci, Anthony (NIH/NIAID) [E]_ _____ C>b<_>Subject:Tony ,I hope you and (b)(6) are doing well. You are doing an amazing job under difficultcircumstances. And just know we prefer the "real" Tony to the Brad Pitt version!!!I am a bit perplexed by your seeming strong endorsement of remdesivir . Was it just a bitforced?My reading was the data were weak and in normal times for norma l disease it is not enough toto approve. And very unlikely to really impact COVID-19 disease pattern --regardless of supplyissues.Stay safeEzek iel J. Emanuel , M.D., Ph.D .Vice Provost of Global InitiativesChair, Departm ent of Medical Ethics and Health Policy -------- Cb)< )Levy Unive rsity Profe ssorCo-Director, Healthcare Transformat ion InstitutePerelman School of Medicine and The Wharton SchoolUniversity of PennsylvaniaPhone : (b)(6)From :Sent :To :Subje ct:Thanks, Natalie !Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Sat, 2 May 2020 18:00 :31 +0000Hurst , Natalie R. EOP/OVPRE: Update - Whi te House Coronavir us Task Force Meet ingNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb) (6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .(bX5)-PCEFrom:Sent:To:Cc:Subject:Faud,Anthony (NIH/N IAID) [E)Sat, 2 May 2020 17:57 :11 +0000Conrad, Patricia (NIH/NIAID) [E)B~rasch, Kir,1bt?rly (NIH/NIAID) [C]FW: Greetings from IndiaLet us discuss.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Prof. Chirantan Chatterjee (b)(6)>Sent: Saturday, May 2, 2020 11:47 AM -------::-::-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)> ----====!---~~= Cc: Deepak Bhatt Manager - Communications (b)(6) _______.._. _Subject: Greetings from IndiaDear Dr Fauci,My greetings from India. I am a health econom ist and management professor at the Indian Institute ofManagement, Ahmedabad, India's premier management school. Also, i am a avid fan of your work evenfrom pre-covid19 days.I write to you requesting some time if possible to do a podcast of 45 minutes with you over zoom. Thescience and policy ecosystem in India i think would immensely benefit if you can offer your thoughts onwhat should be India's 12-month strategy going forward for COVID-19.We have done some recent podcasts relate dly and they are listed her(https://m .soundcloud.com/healthcastbycmhs/l.If you agree, and we are flexible all of May, my communication head Mr. Deepak marked in the emailwill arrange the zoom logistics and make it as seamless as possible for you.We will also go per your t ime zone conveniences and do this over webex/hangout/skype or phone call ifthat helps.It would be a delight Dr. Fauci if you can j oin us in the conversation, loo king forward to hearing fromyou. Our respectful namaste g from India for all the brave work you are doing.My best, Chirant anCh Iran tan Chatterjee (PhD, Carnegie Mellon ) 11 Associate Professor (Economics & Business Polley) & ICICI Bank Chair In Strategic Managemen t 11Chairperson, Center for Managemen t of Health Services at IIMA 11 2019-2020 Visiting Fellow, 2018-2019 Campbell & Edward Teller Nati onal Fellow,Hoover Inst itu tion, Stanford University 11 Office Address Wing lS F, Indian Institu te of Management 11 Ahmedabad, 380 015 Gujarat, India ! I Skvpe:--- ~"-"'~ 11 Email: ____ _. =--= ____ _,_!?}-® I I Hoover Inst it ution Website I IIMA Official WebsiteWhat is laid down, ordered, factual is never enough to erobroce the whole truth: life always spills over the rim of every cup. - Boris Pasternak in Bridges toInfi nity: The Human Side of Mathematics (1983) by Michael GuillenFrom: Fauci, Anthony (NIH/NIAID) [E)Sent : Sat, 2 May 2020 12:08 :00 +0000To: Conrad, Patricia (NIH/NIAID) [E)Cc: Billet, Courtney (NIH/NIA ID) [E);Haskins, Melinda (NIH/NIA ID) [E]; Barasch,Kimberly (NIH/NIAID) [CJSubject: FW: Congresswoman Sheila Jackson Lee invites your participation in a Virt ualTown Hall meeting hosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at7:00 PM CDTAttachments : Dr. Anthony Fauci - Town Hall lnvite.pdfPlease take a look at this . We obviously will have to get clearance through HHS and WhiteHouse Leg. This is for Th ursd.iy .ind so we would need to submit soon.From: Coney, Lillie ------------ (b)(6)>Sent: Friday, May 1, 2020 11:23 PM To: Fauci, Anthony .(,N;I,H_/N__IA ;I_D_)_ [;E,] ,-.-.-;;-_--:---=-=--=-=--=~==, ;:~;-:-----:-(:b):( -::---.:===-===-==---- Cc: Rushing, Glenn ----------- (b)( ; Coney, Lillie ---------- (b)(6) Subject: Congresswoman Sheila Jackson Lee invites your participation in a Virtual Town Hall meetinghosted by ABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PM CDTMay 1, 2020Dr. Anthony Fauci, M.D.Director of the National Institute of Allergy and Infectious DiseasesDepartment of Health and Human Services5601 Fishers LaneBethesda, MD 20892-9806Dear Dr. Fauci:Thank you for your tremendous steadfast leadership during this pandemic andhealth crisis. Our nation has not faced a crisis of this magnitude since the 1918Spanish Flu, but we will travel this journey together and defeat this virus . In the end, thenation will become stronger and more prepared.Your participation is requested in a Virtual Town Hall meeting hosted byABC affiliate Channel 13 in Houston, Texas on Thursday, May 7, 2020 at 7:00 PMCDT. This town hall meeting will focus on testing and guidelines for re-openingour nation. It is scheduled to last an hour with 2 or 3 guests including yourself. Houstonis the fourth largest city in the country and your knowledge and expertise would be mosthelpful in our fight to keep our infection and fatality rates low for this entire region andthe State of Texas .My office has been pushing testing and setting up testing sites since the firstnotification of the coronavirus . We currently have seven active testing sites andexpanding each week to get to the mass testing necessary to flatten the infection rate.Thank you for your consideration of this request and I look forward to participatingwith you in the Virtual Town Hall meeting. Again, thank you for your leadership. PleaseRSVP or if you have questions regarding this request with Glenn Rushing, my Chief ofStaff at .__ ____, CbH6) and Lillie Coney, my ChiefPolicy Advisor a CbH6)Regards,Lillie ConeyPolicy DirectorVery truly yours,JSheila Jackson LeeMember of CongressCongre sswoman Sheila J ackson Lee (TX-18)2079 Rayburn HOBWashingto n , DC 205 15(b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Sat, 2 May 2020 12:01 :04 +0000(b)(6)FW: RE:Let us try to do this next weekend.From: Eisinger, Robert (NIH/NIAID) [E]..._ ________ ~90n Behalf Of Fauci, Anthony(NIH/NIAID) [E]Sen t: Saturday, May 2, 2020 7:24 AMTo: Fauci, Anthony {NIH/NIAID) [E]------ -(-b=)(-=6)Subject: FW: RE:Email from Zeke Emanuel.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone : (b)(6)Email: (b)(From: Emanuel, Ezekiel J -------- (b) ( >Sen t: Friday, May 1, 2020 8:04 PM ------~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: ------------------- (b)( 6)> Subject: Re: RE:TonyYou are national--internationa l --treasure. And we are depending upon your sanity and sma rts.We can have you and CbH6)ovefro r dinner on the porch and order in fromsometh ing. Anytime you are ready.Ezekiel J. Emanuel , M.D., Ph.D .(b)(6) orVice Provost of Global InitiativesChair, Departm ent of Medical Ethics and Hea lth Policy ______ C_>b<'6j)Levy University ProfessorCo-Dir ector, Hea lthcare Transformation Institut ePerelman School of Medicine and The Wharton SchoolUniver sity of Penn sylvaniaPhone: (b)(6)From: Fauci, Anthony (NIH/NIAID) [E] (b) (6lv> _______ ,....Sent: Friday, May 1, 2020 6:55 PMTo: Emanuel , Ezekiel J (b)(6)>Cc:- ----------------- (b) ( > Subject : RE: RE:Zeke:Thanks for the note . Indeed, we do agree.- I look forweard tochatting with you some time soon.Best,TonyFrom: Emanuel, Ezekiel J -------- (b)( >Sent: Thursday, April 30, 2020 6:37 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: Re: RE:(b)(6)Sorry for misreading what you said--1 think maybe I overin t epreted-- lots of finance peoplecalled and seemed like I was a downer compared to you. But I think we agree.Are you and ---C-bH6Jdoingo kay?Ezekiel J. Emanuel, M.D., Ph.D.Vice Provost of Global InitiativesChair, Depa1tment of Medical Ethics and Health Policy ______ C_>b<)Levy University ProfessorCo-Director , Healthcar e Transform ation Institut ePerelman School of Medicine and The Wharto n Schoo lUniver sity of PennsylvaniaPhon e: (b)(6) -----------From: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Thursday, April 30, 2020 5:33 PMTo: Emanuel, Ezekiel J (b) ( >Subject: RE:Zeke:I did not "strongly" endorse it. I specifically said tha t it was not a knockout drugand was only a baby step in the direction of develop ing more and bette r drugs. Isaid that it was important because it proved in a well-powered, randomized ,placebo-controlled clinical tria l tha t one can suppress the virus enough to see aclinical effect, as modest as the effect was. I do not think I forced anything.Happy to chat with you about it.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Emanuel, Ezekiel J --------- (b)(6) Sent: Thursday, April 30, 2020 2:12 PM ------- == To: Fauci, Anthony (NIH/NIAID) [E] --------- (b)( 6) Subject:Tony,I hope you and ---(b)-(6) are doing well. You are doing an amazing job under difficult circumstances. And ju st know we prefer the "real" Tony to the Brad Pitt version!!!I am a bit perplexed by your seeming strong endorsement of remdesivir. Was it just a bitforced?My reading was the data were weak and in normal times for normal disease it is not enough toto approve. And very unlikely to really impact COVID-19 disease pattern--rega rdless of supplyissues.Stay safeEzekiel J. Emanu el, M.D., Ph.D.Vice Provost of Global InitiativesChair , Departm ent of Medical Ethics and Health Policy -------- Cb)< )Levy University ProfessorCo-Director, Healthcare Transformation InstitutePerelman School of Medicine and The Wharton SchoolUniversity of Penn sylv aniaPhone:- ---------....C1b(>6 )From: Fauci, Anthony (NIH/NIAID) [ElSent : Sat, 2 May 2020 02:04:00 +0000To: Selgrade, Sara (NIH/NIAID) [ElCc: NIAID OCGR Leg;Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/N IAID)[E];Conrad, Patricia (NIH/NIAID) [E]Subject:HearingAttachments :changes.docxRE: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELP2020 .05.12 NIAID Senate HELP testimony COVID 19 - with Fauci trackedI am attaching the document with minor tracked edits. Nice jo b! Thanks.From: Selgrade, Sara (NIH/NIA ID) [E) (b)(6)>Sent: Thursday, April 30, 2020 5:24 PMTo: Fauci, Anthony (NIH/ NIAID) [E] <f -----~ Cb-H=6J>Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; Billet, Courtney (NIH/NIAID) [ElCbH6J>F; olkers, Greg (NIH/ NIAID) [E (b)( >; Conrad, Patricia(NIH/ NIAID) [E] (b)(6)Subject: Requesting your assistance : Draft NIAID Statement for May 12 Senate HELP HearingDr. Fauci:In preparat ion for the upcoming May l ih COVID-19 hearing of the Senate Health,Educa tion , Labor, and Pens ions Committee (Chair: Sen. Lamar Alexander, R-TN),we have drafted the attached NIAID te stimon y, bu ilding on your prior te stimonyon COVID-19. Dr s. Giroi r, Hahn, and Redfield also have been invited to thehea ring.We expect that your te stimon y will be included as an insert to an HHS-widetestimony. At the request of NCH OD, we have incorporated into the draft COVID-19 activ ities across NIH .The testimon y has been reviewed by the Divi sions and Dr s. Lane , Harpe r,Marston, and Lerner , as well as Courtney Billet , Greg Folkers, Martin Johnson ,and Laurie Doepel.NIH OLPA has asked to receive your testimony for clearance by tomorrow, ifpossi ble .Thank you for your help.SaraSara Selgrade, Ph.D.Sect ion Chief for Legislative ActivitiesLegislative Affairs and Con-espondence Management BranchOffice of Communications and Government RelationsNIAJD/NIH/DHHSBldg. 31,Room 7Al7, MSC 2520Bethesda, MD 20892-2520Phone: (b) (6)(b)(6)Disclaimer:The i11for111atio11 in this e -111ail and a.11y of its altac/1111c11ts is co ,!fide:ntial and ,nay c:ontai n sensitive i11fon11,1tio11. it ,-,·l,ou/d not beused by anyone who is not the original intended recipienl. lf you have rr?ceived this e-mail i11 error please inform the sender anddelete it from y our mailbox or any other storaw; devices. National Institute ofA!lerf!)' and Infectious Dise,ases shall not acceptliabili(v,(ora ny slatements made !hat are sender's own and not e,xpresslym ade 011b ehalf of ,he NJAID by one o/ilsrepresentatives ,From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [ElFri, 1 May 2020 15:28:23 +0000Routh, Jennifer (NIH/NIAID) [ElRE: cl ipsThanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Routh, Jennifer (NIH/ NIAID) [E] (b)( >Se nt : Friday, May 1, 2020 8:56 AM --------, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)Cc: Billet, Courtn ey (NIH/NIA ID) [E] (b)(6); Conrad, Patricia (NIH/NIAID) [E]---------(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( > Subject: RE: clipsDr. Fauci-I have requested the full clips from our clipping service . I found the following on line in the meantime:Today Show:https://www .today .com/video/ d r-a ntho ny-fa uci-rem d esivir-is-a-very -i m port a nt -fi rst-step-in-fighti ngcoronavirus-82800 197863CNN Town Hall (clip discussing federal "reopening" guidel ines):https://twitter .com/CNN/status/1256023483638669313CNN Town Hall (clip discussing vaccines):htt ps:// twitter .com/CNN/ status / 1256044817093558272Thanks,JenJennifer Routh [E]News and Science Writing BranchOffice of Commu nications and Government RelationsNational Institute of Allergy and Infectious Diseases (NIAID)NIH/HHS31 Center Drive Room 7 A 17CBethesda, MD 20892Direct: (b) (6)(b)(6)Disclaimer : The information in this e-mail and any of its attachments is confidential and may contain sensit ive information. It should not beused by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for anystatements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.From: Fauci, Anthony (NIH/NIAID) [E] --------- (b)(6)Sent: Friday, May 1, 2020 7:44 AM To: Routh, Jennifer (NIH/NIAID) [E]-- --------------=---(-b)(: ->= Subject: clipsJen:Can we please make sure that I get the lips from yesterday from NBC TodayShow and CNN Town Hall with Sanjay and Anderson.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation_ It should not be used by anyone who is not the orig inal intended recipient_ If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices _ The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives_From:Sent :To:Subject:Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:26:55 +0000Fauci, Anthony (NIH/NIAID) [E)FW: (b)( 4)Another email from Andre Kalil.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone (b)(6)Email: (b)(From: Kalil, Andre C (b)(6)>Sent : Thursday, April 30, 2020 8:12 PMTo: Beigel, John (NIH) [El--:-:-::-:--:.=======.:.'"""'""-:-= (b)( ;Davey, Richard (NIH/NIAID) [El (b)( ; Lane, Cliff (NIH/NIAID) [El(b)(6)>; Proschan, Michael (NIH/NIAID) [E] (b)(6l>; Marston, Hilary(NIH/NIAID) [E] (b)( ·>; Fauci, Anthony (NIH/N IAID) [El (bH >Subject: RE: (b) (4)(b) (4)Thanks,AndreAndre Kalil, MD, MPH, FACP, FIDSA, FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transplant ID ProgramAssociate Editor. CMI. Official Journal of ESCMIDEditorial Board. CCM. Official Journal of SCCMl' UNMC.-,- t(JltUt.•University of Nebraska Medical Center985400 Nebraska Medical Center. Omaha. NE 68198-5400(b)(6) I fax 402.559-5581(b)(6)UNMC I Facebook I Twitter I You Tube I~"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditional probabilit ies. Giving due weight to the prior probabilities ... "Robert Ludlum - The Amb ler WarningFrom : Beige!, John (NIH) (E] -------- (b)( >Sent : Thursday, April 30, 2020 5:25 AM ------ --,;-,,= To: Dodd, Lori {NIH/NIAID) [E] (b)(6)>; Kalil, Andre C ~====~(b~)(6) >; Davey, Richard (NIH/NIAID) [E] (b)(6) ; Lane, Cliff (NIH/NIAID) [E] (b)( >; Proschan,Michael (NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [E](b)(6); Fauci, Anthony (NIH/NIA ID) [E] (b)( >Subje ct: Re: ------------- (b)( 4Non-UNMC email(b) (4)John Beige), M.D.Associate Direc tor for Clinical ResearchDivision of Microbiology and Infectious Disea~esNational Institute of Allergy and Infectious Diseases (NIAID)From: Lori Dodd CbH6)>Date : Thursday , Apr il 30, 2020 at 6:05 AMTo: John Seigel (b)(6)>, Andre Kalil (b)(6)>, Richard Davey(b)( >, Cliff Lane (b)(6), Michael Proschan =========~(b~)(6) >, Hilary Mars ton ---------- (b)(6)> , "Fauci, Anthony (NIH/ N IAI D) ,;I.E.-=]'-.'. ::====== (b)=C:6:) --=-:-.,.,,,,Subject: RE:- ------------- (b)(4)Andreilike what you wrote, and partic ularly like the first two sentences.From: Beigel, John (NIH) (E] (b)( >Sent: Thursday, April 30, 2020 5:53 AMTo: Kalil, Andre C (b)(6)> ; Davey, Richard {NIH/NIAID) [E] (b)(6)>; Lane,Cliff {NIH/NIAID) [El (b)( >; Dodd, Lori (NIH/NIAID) [El (b)(6)> ;Proschan, Michael (NIH/NIAID) [El (b)(6); Marston, Hilary (NIH/NIAID) [El(b)(6)>; Fauci, Anthony (NIH/NIA ID) [El (b)( >Subject: Re: (b) (4Andr e,We too are open for further editsJohnJohn Beige), M.D.Associate Director for Clinical ResearchDiv ision of Microbiology and Infectious DiseasesNational Institute of Allergy and Infectious Diseases (NIAID)Phone:email::=.=====:: ~=(b) (4)From: Andre Kalil (b)(6)>Date : Thu rsday, April 30, 2020 at 3:19 AMTo: John Seigel CbH6J>R, ichard Davey CbH >, Cliff Lane(b)(6), Lori Dodd CbH6)>M, ichael Proschan ~=======~~ (b)( >, Hilary Marston (b)(6)>, "Fauci, Anthony "':'---:--:-:--:--:-::.====:::;_;,--=.. ;...,; (NIH/NIA ID) [E)" CbH6)>Subject: -------------- (b) (4)Please let me know your t hough ts and suggestions.AndreAndre Kalil, MD, MPH, FACP, FIDSA, FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transp lant ID ProgramAssociate Edito r, CMI , Official Journal of ESCMIDEditorial Board, CCM, Official Journal of SCCM~ UNMc·~ f<)\U:,_.University of Nebraska Medical Center985400 Nebraska Medical Center , Omaha , NE 68198-5400___ (b_) (_6,) I fax 402.559-5581(b) (4)(b)(6)UNMC I Facebook [facebook.com) I Twitter (twitter.com) I You Tube [youtube.com) I Flickr [flickr.coml"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditiona l probabilit ies. Giving due weight to the prior probabil ities ... "Robert Ludlum - The Ambler WarningThe information in this e-mail may be privileged and confidential, intended only for the use of theaddressee(s) above. Any unauthorized use or disclosure of this information is prohibited. If you havereceived this e-mail by mistake, please delete it and immediately contact the se nder .The information in this e-mail may be privileged and confidential, intended only for the use of theaddressee(s) above. Any unauthorized use or disclosure of this informat ion is prohibit ed. If you havereceived this e-mail by mistake, please delete it and immediately contact the sender.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:25:50 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From : Dani Bolognesi, Ph.D.- ---------(b)(6) Se nt: Thursday, April 30, 2020 8:13 PM -------=-:-:= To: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6)> Subject: RE:TX Tony. Nice touch reminding fo lks of how AZT propelled the pharmas and great to see things movingwith this beast!Sei un campione !DaniFrom: Fauci, Anthony (NIH/NIAID) [E]Sent : Thursday, April 30, 2020 7:58 PM(b) ( >------~~ To: Cassetti, Cristina (NIH/NIAID) [E:] ,.=!:====== (=b)~(6;)',>.=Cc: Erbelding, Emily (NIH/NIAID) [E).__ _______ Cb _H_6JSubject: FW:Cristina:Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/ AIDSinvest igators from a few years back . He is a ser ious scientist. Let me know what you th ink.Thanks,TonyFrom: Eisinger, Robert (NIH/NIAID) [E) ----------- (b) (6J> On Behalf Of Fauci, Anthony (NIH/NIAID) [E]Sent : Monday, April 27, 2020 6:57 PMTo: Fauci, Anthony (NIH/NIAID) [E].__ _____ (b_H"""v"'>"'"Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7 A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Dani Bolognesi, Ph.D. ---------- (b)(6)>Sent : Monday, April 27, 2020 6:09 PM ------~= To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)>; Barasch, Kimberly (NIH/NIAID) [C] (b)(6)Subject: FW:Kimberly: Please see that t his reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getti ng together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows :(b) (4), (b) (5)(b) (4). (b) (5)We are prepared to discuss this with you and your team at any time that is convenien t for you . As youmay know, we are locked down here in the Research Triangle unt il May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opport unity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D."Date: Monday, April 27, 2020 at 2:53 PM(b)(6 )>To: "Matthias Gromeier, M.D." ------------------------=- -:(b-)(6=) , Subject : Please review th is draft email to Tony --TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows :(b) (4). (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you . As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best,DaniBest,DaniSent from Dani BolognesiThe information in this electronic mail is sensiti •,e, protec ted information intended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmed iately by return electronic mail, and to delete it without further reading or retent ion . The informat ion is not to beforwarded to or shared unless in compliance with Duke Health policies on confidentiality and/o r with the approva l of thesender.From:Sent :To:Subject:Importance:Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElFri, 1 May 2020 12:10:09 +0000Fauci, Anthony (NIH/NIAID) [E)FW: ACTT pub licationHighAnother email from Andre Kalil.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email (b)(From: Kalil, Andre C (b)(6)>Sent : Friday, May 1, 2020 2:59 AM ------~~ To: Seigel, John (NIH) [El (b)( >; Davey, Richard (NIH/NIAID) [E]======~~(b) (6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6l; Dodd, Lori (NIH/NIAID) [E] (b)(6)>; Proschan, Mic hael {NIH/NIAID) [E) (b)(6) Marston , Hilary(NIH/NIAID) [E] (b)( ; Fauci, Anthony (NIH/N IAID) [El (b)(6)Subject: FW: ACTT publicationImport ance: HighNot my first choice, but I want to share the invitation email below with you.AndreAndre Kalil, MD, MPH, FACP, FIDSA , FCCMProfessorDepartment of Internal MedicineDivision of Infectious DiseasesDirector, Transp lant ID ProgramAssociate Edito r, CMI , Official Journa l of ESCMIDEditoria l Board , CCM , Official Journal of SCCM If UNMC--.ut1BIUGHl !'MIA.·Uni vers ity of Nebr aska Medi ca l Center985400 Nebraska Medical Center , Omaha , NE 68198-5400(b)(6) I fax402.559-5581===~ (b:).(.6=:c)UNMC I Facebook I Twitter I YouTube I Flickr"Lucky? Obviously you haven't heard anything I've said . It was a matter of applying Bayes' Theorem toestimate the conditional probabilit ies . Giving due weight to the prior probab ilities ... "Robert Ludlum - The Amb ler WarningFrom: (b) (4) ------------------ Sent : Thursday, April 30, 2020 1:03 PMTo: Kalil, Andre C (b)(6)Subject: ACTT publicationImportance: HighNon-UNMC emailDear Dr. Kalil,(b) (4)From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Fri, 1 May 2020 11:38:53 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: FW: int erview request by Greek newspaper EthnosFYIAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone (b) (6)FAX: (301)4 96~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representative s.From: ru.:.,pyo<h; a¢u5ac; <gskafidas@ethnos.gr>Sent: Friday, May 1, 2020 6:07 AM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Subject: inte rview request by Greek newspaper EthnosDear Dr. Fauci,my name is George Skafidas and I'm a journal ist working for the Greek nationa l weekly ETHNOS(www.ethnos.g r).We would be very much interested in doing an interv iew with you, to be published in theSunday edition of the paper, regarding the developments surrounding the COVID-19pandemic.Best regardsEG>NOEGeorge SkafidasSenior editor, World Affairstel: +30 210 6510550mob: (b)(6)o, n>-ripocpopiE<;n ou nEp1txovT01 aE OUTOT O μ~vuμo 11>-E><Tpov1KTooux uopoμEiou (e-mail) KoOw~ KOi aE Tuxov ouv11μμtvoEiVOIE μmOTEUTIKEK<O; i npoopi~OVTOyI 10 XPrt<Jro noKAEIOTIKCoIn e>T O OUVKEKplμEVnOo poArimr, (-E<;). o, nAr,pocpopiE<O; UTE<;μnopEi VO KOAUnTOVTOonI 6 EnlXEIPrJOIOKrOi 6 >>.oo n6pprJTOr i oAAouc;v 6μouc; KOi OEVE nlTpEOETOVIO OVOKOIVW9ou<vJ Eono1ovo,;noTE TpiTo. !E nEpimwori nou OEV EiOTE o nopoAr'lnTric; Tou μrivuμoroc; ri ro npoawno nou Eivo1 opμ6o10 y,o TrJVnopooooii TOU OTOVn opo>-r'lnTfJ, anoyopt:U€TOI VO TO OVOKOIVWO"E:TOtV, TIYPOljJE:"ToE,o:,v ciμE:"TEr:i OIOTrJPriOE:TEE:V: 6 Awv ri EVUEPEI.From:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Fri, 1 May 2020 11:38:08 +0000(b)(6)Subject: RE: Coronavir us: Covid 19Ato:Thank you for you note . We will know soon whether hydroxychloroquine hasany beneficial effec ts as the results of randomized, controlled trials becomeavailable. The pathogenesis of COVID-19 is sti ll an open question . You are correctin that ther e is a more recent tendency to use ventilators only as a very last resortsince oxygenation rathe r than ventilation appears to be key to recovery.Best regards,TonyAnthony S. Fauci, MDDirec torNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Inst itutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: gabriel stephens ---------- (b)( Sent: Friday, May 1, 2020 4:53 AM ------~= To: Fauci, Anthony {NIH/ NIAID) [E] (b)(6)> _______ _.Subject: Coronavir us: Covid 19Hi Dr Fauci,Please find an audio attached of a doctor descr ibing the experience with regards to covid 19 in thehospital. She seems to suggest covid 19 is a virus tha t rather attacks the blood cell, leading to respi ratoryand other organ comp lications, hence they need to loom at tre atme nt in a differ ent light. In the UKsome hospitals have moved away from using ventilators due to the high death rate of those onventilators, and are rather using ventilators for sleep apnea, as they are less invasive, and the results aremuch much better compared to invasive ventilatorsThere are some anecdotal observations I have also made. The infection rate in most African countriesseem to be comparatively low, which could possibly due to the rate of testing being conducted.However t he death rates are also comparative ly very low. From in itial informat ion with regards tohydroxychloroquine and some antimalaria drugs usage, it was suggested that those who were allegedto have had some benefits had mild symptoms of covid 19. I know some clinical trials have shownhydroxychloroquine not to be effect ive in the treatment of covid 19 in very ill patients. However, myhypothesis is, are the low death rates in Africa linked to the fact that malaria is very prevelant in Africa,and lots of Africans take antimalarial drugs, making them less susceptible to covid 19, hence the lowdeath rate. Is there a similar trend in other countries where malaria is prevalent? Is there an unintendedbenefit of taking antimalarial drug (or other medication) before covid infection, or at the onset, makingpeople less susceptible to covid19 .As I said, this is based on anecdota l observations.Yours sincerelyAto StephensFrom:Sent :To:Cc:Bee:Subject:Fauci, Anthony (NIH/N IAID) [ElThu, 30 Apr 2020 23:58 :07 +0000Cassetti, Cristina (NIH/NIAID) [ElErbelding, Emily (NIH/NIAID) [ElDani Bolognesi, Ph.D.FW:Attachment s: Brown et al submitted .pdf, NIH Presentation final.pptx,prepr ints202002.0147.v2 (1).pdf, Mosaheb et al 2020.pdfCristina :Please take a good look at th is. It is from Dani Bolognesi, one of our top HIV/A IDSinvestigators from a few years back. He is a serious scientist. Let me know what you think.Thanks,TonyFrom: Eisinger, Robert (NIH/NIAID) (El (b)(6)> On Behalf Of Fauci, Anthony(NIH/NIAID) [ElSe nt: Monday, April 27, 2020 6:57 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)>Subject: FW:Email from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room ?A-03Bethesda MD 20892Telephone (b)(6)9Email (b)(From : Dani Bolognesi, Ph.D._ _______ C_>b_<_6>)Sent : Monday, April 27, 2020 6:09 PM ------~= To: Fauci, Anthony (NIH/NIAID) [El ______ CbC>_6>); Barasch, Kimberly (NIH/NIAID) [C](b)(6)>Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4), (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15 . If it makes sense, we couldarrange a WebEx as an initial step .Many thanks for the opportunity to share th is with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D." (bH6J>Date : Monday, April 27, 2020 a-t 2-:5-3- P-M- ------,; ~ To: "Matthias Gromeier, M.D." (bH >Subject: Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows :(b) (4), (b) (5)We are prepare c!Tciaiscuss this wit h you and your tea at any time tnaf 1s convenient for you. As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step.All the best ,DaniBest,DaniSent from Dani BolognesiThe information in this electronic mail is sensitive, protected information intended only for the addressee(s). Any other person,including anyone who believes he/she might have received it due to an addressing error, is requested to notify the senderimmediate ly by return electronic mail, and to delete it without further reading or retention. The information is not to beforwarded to or shared unless in compliance with Duke Health polic ies on confidentiality and/or with the approva l of thesender.From:Sent:To:Cc:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:35 :34 +0000Jeremy Farrar ;Dzau, Victor J.;George GAORichard(b)(6);Hannon, Emma;Conrad,......". ""'.""":--:'~~:--"'""":""':'".':""'."~-"'."-:".~----------===~~"'.:"""""---:"'-.--Patricia (NIH/NIAID ) [E];Teresa Miller de Vega;- ---(b-)( 6);Rebeka Yasmin - CEPl;ben.t inker@cnn .com;Amanda.Sealy@cnn .com;Neel.Khairzada@turner.com;T ia.Miller@turner .com------- (b)(6)McGinnis, J. Michae l;Balatbat, Celynn e;Mun , Jenny; CbH ;Redfield, Robert R. (CDC/OD)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regard ing yourSaturday April 25 part icipat ionJeremy:Many thanks for the update. Please continue to keep me informed.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:J ere my Farrar _________ C_>b_<6 )Sent: Tuesday, April 28, 2020 10:39 Arvl -------, ~= To: Fauci, Anthony (NIH/NIAID) [E]- -------- (b)( ; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b)(6) >Cc: Richard Hatchett (b)(6)(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia"':'-""."'."":-'.'"-:-'.'-:-:"::.:=======:;....,.= (NIH/N IAID) [E] (b)(6); Teresa Miller de Vega (b)(___ C_b>_<_6); Rebeka Yasmin - CEPI (b)(6) ; ben .tinker@cnn .com; ----- ~= Amanda .Sealy@cnn.com ; Neel.Khairzada@turner .com; Tia.M iller@turner. com; (b)( 6)McGinnis, J. Michael (b)(6)>; (b)( >; Mun, Jenny<JMun@nas.edu> (b)( ; Redfie ld, Robert R. (CDC/OD) (b)( 6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25participationQuick updateUpdate in confidenceEuropean network from this morning:16 Paris, 2 Geneva, few Madrid last 10 days - nothing like this usually seen even with seasonalKD or TSSBarcelona have slightly different experience of 6 'Kawasaki' in last 2 weeks - couple now whohave large coronary aneurysms, as have one child South London and one in Bristol.Most UK PICU have 1-2 of these type of casesPhenotype seems Diarrhoea and abdominal pain, refractory shock then various degrees ofheart invo lvement and inflammation ++ - several have had their normal appendix whipped outMost negative respiratory and stool PCR for anything, some positive resp PCR COVID - GOSHearly case has seroconverted, but had immunog lobu linWe are establishing database UK and Europe and trying to define what the clinician features areand agree investigat ions.Notably , none in US reported (just 0/W Boston childrens who have been running sharedinternational COVID experience web calls) and none in Rome, unsure about rest of Italy yetDoes seem BAME preponderance-?? immune related or social phenomenon, in terms ofdeprivation prevalence and ability to isolateFrom: "Fauci, Anthony (NIH/NIAID) (E]" CbH6)Date: Monday , 27 April 2020 at 12:36To: Jeremy Farrar (b)(6) , Victor Dzau <VDzau@nas.edu> , George Gao(b)(6) >Cc: Richard Hatchett Cb()6 )Patricia (NIH/NIAID) [E]""Hann on, Emma " <EHannon@nas.edu> , "Conrad ,CbH6)T, eresa de VegaCb) (6) Rebeka Yasmin - CEPI---------- Cb)( 6) , "ben. tinker@cnn.com" <ben. tinker@cnn.com>, "Amanda.Se al y@c nn. com" <Amanda.Sealy@cnn.com >, "Neel.Kbairzada(a),turner.com"<Neel.Khairzada@turner.com> , "Tia.Miller@turner.com " <Tia.Miller @turner.com> ,Cb)(6) "McGinnis, J.Mic hael" <MMcGinnis@nas.edu> ,CbH>6,) ''Mun, Jenny" <JMun@nas.edu >,---------- CbH6l, "Redfield , Robert R. (CDC/OD)" (b)( >Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 participationJeremy:Thanks for the heads up. Is there any more detail ed description of the preciseclinical manifestations? They describe a "mult isystem infl ammatory state 11• It isvasculitis or anything more specific? Could be an infectiou s agent that hasnothing to do with SARS-CoV-2in fection even though some children arecircum stanti ally infected with SARS-CoV-2or it could be a post-SARS-CoV-2inflammatory syndrome, perhaps a Kawasaki syndrome- like disease. Please keepme inform ed if you hear any further inform ation .Best regards,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone· (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender 's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jeremy Farrar --------- (b) (6)>Sent: Monday, April 27, 2020 7:13 AM To: Fauci, Anthony (NIH/NIAID) [El-- ----------=---=---=(b=)(6 )>; Dzau, Victor J. <VDzau@nas.edu>; George GAO (b)(6)>(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia(b)(6) >; Teresa Mil ler de Vega(b)(6)· Rebeka Yasmin - CEPI (b)( t>; ben.ti nker@cnn.com ; ____ _,,(b)(6);Amanda.Sealy@cnn.com; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b) (6)McGinnis, J.Michael< MMcGinnis@nas.edu>; (b)(6)>; Mun, Jenny<JMun@nas.edu> (b)(6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25participationTo be aware of- news over night so a huge amount of uncertainty - important for COVID19 now, and apotentia l concern for how we view immunity, prot ection, post-infectiou s immunopathology.https://www.hsj.eo.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-beemerging-in-children/7027496 .articlehttps://t .co/Bj6YH U8ziFrom: "Fauci, Anthony (NIH/NIAID) [E]" CbH6>)Date : Sunday , 26 Ap1i l 2020 at 19:52To: Victor Dzau <VDzau@nas.edu >, George Gao CbH L---------~ =Cc: Jeremy Farrar CbH , Rich ard Hatchett CbH6)(b)(6) -----------"Hannon,Emma" <EHannon@nas.edu >, "Conrad , Patricia (NIH/NTAJD) [E]" Cb)( >,Teresa de Vega CbH>6), RebekaYasmin - CEPI (b)(6) "ben.tinker@cnn.com " <ben.tinker@cnn .com>,"Amanda.Sealy@cnn .com" <Amanda.Sealy@cnn.com> , "Neel.Khairzada@turner.com "<Neel.Kh airzada@tumer.com >, "Tia.Miller@tumer.com " <Tia.Miller@tumer.com> ,(b)(6) "McGinnis, J.Mic hael" <MMcGinn is@nas.edu >,(b)(6) "Mun, Jenny" <JMun@nas.edu >,(b)(6)Subject: RE: NAS Annual Meeti ng Sess ion on COVID- 19 -- Information regarding yourSaturday Ap ril 25 participationIt was a real pleasure to join all of you on this impor ta nt session. Many tha nks forinviting me.Anthony S. Fauci, MDDirectorNational Institute of Alle rgy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipie nt. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J. <VDzau@nas.edu>Sent: Saturday, Apr il 25, 2020 3:59 PMHannon,Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIA ID) [El ----------------- (b) ( ; rebeka.yasmin-@-ce-pi.-ne-t; -be-n.-tink-er-@cnn.com ; Amanda.Se a I y@ c n n. com ; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)McGinnis, J.Michael< MMcGinnis@nas.edu >; (b)(6)>; Mun, Jenny------ (b)(6)>; haja.bally@cepi.net Subject: Re: NAS Annual Meeting Session on COVID-19 -- Informat ion regarding your Saturday April 25part icipationDear Jeremy, Tony, Sanjay, George, Susan and Richard,Thank you so much for your superh contri hutions. Tt was a spectacu lar session- a trnly inspi ringone. I am grateful to all of you.Hope to see you soon.Warm est regards,VictorOn Apr 25, 2020 , at 1: 22 PM, George GAO- ------ CbH6)w rote:I am waiting for being connected and will use s lides which were sent to your officeGeorge'&.§ it IYi:Pl honet£ 2020~4 ~ 24 B . 0 I :49, Dzau, Victor J. <VDzau@nas.edu>'.ij'.~ :Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really looking forward to this panel on COVID-19 at the NAS AnnualMeeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendousexcitement and enthusiasm, and registrat ion is through the roof.I am sending this note to do a last minute check to see if there is anyt hing youneed from me. I also want to check whether you are planning to use slides.Wi ll you be sending your slides to us to project or use the share screenfeature to advance your own slides? Regardless, it would be helpful to me ifyou could send me your slides for my preparation.I would greatly appreciate it if you wou ld respond to this email.Best,VictorPS,- -----(b)(6) ,· m y special assistant, will be sending you additional information about the session logistics shortly.From: Dzau, Victor J. <VDzau@nas.edu>Sent : Thursday, Apr il 9, 2020 11:01 AM ------~~ To: Mun, Jenny <JMun@nas.edu >, (b)(6); 'ben.tinker@cnn .com' <ben.tinker@cnn.com >;'Amanda.Sealy@cnn .com' <Amanda.Sealy@cnn.com >;(b)(6)'Neel . Khai rzada@turner.com' <Neel .Khai rzada@tumer.com >;'Tia.Mi ller@turner.com' <Tia. M iller@turner.com >; _____..._.Subject: RE: NAS Annual Meeting Session on COVID-19 -- Informationregarding your Saturday April 25 participationDear all,Thank you for agreeing to participate in a special late breaking sessionon the COVID-19 pandemic at the NAS annual meeting. Knowing howbusy you are, l am sending this email in lieu of a call to prepare for thesession.As you know , this is a 90 minute session which aims to provide ouraudience with deeper insights into the latest developments in theCOVID-19 response. I plan to hold an engaging discussion that coversthe whole experience on dealing with this pandemic - from US tointernational, to preparedness and response, the biology of the vims, thestate of diagnostic , treatment and vaccine development, and theimportance of commun ication.I will begin the session by providing brief ( ~3 min) opening remarksdescribing the circumstances of the pandemic . Then, I will introduce thepanelists and you will each have 7 minutes to provide remarks. Youmay use a limited number of slides for illustration. I hope that eachpanelist will provide their own perspective and speak to the issuesproposed below.• Jeremy Farrar will discuss the global response to the pandemic,drawing from his experience as a globa l leader, the chair of theScientific Advisory Group for the WHO's R&D Blueprint and asa member of the Global Preparedness Monitoring Board.• Tony Fauci will discuss the US pandemic and provide hisperspective as a member of the White House Corona virus TaskForce addressing the 2019-20 coronavirus pandemic.• George Gao will discuss China's response to the pandem ic andlessons learned for the rest of the globe .• Susan Weiss will discuss the viral characteristics of SARSCOV2 , insights into its pathobiology, immunity anddevelopment of a pan-Co V antiviral.• Richard Hatchett will discuss the development of new vaccinesand treatments against COV ID-19 .• San jay Gupta will comment on the health system response to thepandemic and challenges related to communication and publicengagement in responding to COVID-19.Following remarks from each panelist, we will have a moderateddiscussion amongst ourselves - I will ask you a set of questions ( 15mins) and then we will take questions from the web (25 mins). Toprepare me to be your moderator, please send me any questions youwould like me to ask you. For those of you who would like to have aprep call, please let me know and I will set it up.Best,VictorFrom: Mun, JennySent: Wednesday, April 8, 2020 10:56 AMben .tinker@cnn .com'; 'Amanda.Sealy @cnn.com'; 'Nee l.Khairzada@turner .com'; 'Tia.Miller@turner.com'Subject: NAS An nual Meeting Session on COVID-19 -- Information regardingyour Saturday April 25 participationDear Speakers:I am the logistical contact for the COVID-19 session that will be held as part ofthe Annual Meeting (online) program on Saturday, April 25 at 2:00 pm EDT.Thank you for agreeing to participate in this session. To help you with yourplanning, I have provided additional details below.Please note that the session will be live webcast and the general public willalso be able to watch the session. Video from the session will also beuploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting . We willneed to obtain signed speaker release forms for your participation in thissession. I have attached the speaker release form for your review andsubmission. Please return the signed speaker release form by Monday, April13.Session speakers are asked to connect 30 minutes prior to the session starttime (by Saturday, April 25 at 1:30 pm EDT) to allow the technical staff tocheck connections and prepare for the session. Details on how to connect willbe sent before the meeting .We will list you in our promotional materials as noted below . If this isincorrect, please let me know .Anthony S. Fauci, Director, National Institute of Allergy and InfectiousDiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control &PreventionSanjay Gupta, Chief Medica l Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microbiology, Perelman School of Medicine,University of PennsylvaniaSince many of us have moved to remote work environments, you mayalready be proficient with Zoom and other online meeting/collaborationapplications. I am attaching a 'speaker guidelines' file in case you have anyquestions on how best to prepare for and stage your remote talk . We havetechnical staff available to help you become familiar with Zoom and itssettings - such as "sharing your screen" (if you have slide presentations thatneed to be shown during your talk) . We can arrange for a training session thisweek or next week. If you would like to schedule a session, please let meknow as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If youhave any other questions, please let me know.Regards, JennyJenny MunMembership DirectorNational Academy of Sciences(b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:19 :19 +0000Alexander PattersonRE: (b)(6) made a Video Game of Yo: "Fauci's Revenge"Thanks, Alex! Much apprecia t ed.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Alexander Patterson <alex.patterson@beatthebomb .com>Se nt: Thursday, April 30, 2020 11:26 AMTo: Fauci, Anthony (NIH/NIAID) [E) (b)(6)>Cc: Daniel La hart <dlahar t@r egis.org>Subject: (b)( made a Video Game of Yo: "Fauci 's Revenge"Dear Dr. Fauci -My name is Alex Patte rson and I'm (b)(6) I made a v ideo game about you called Fauci 'sRevenge. Link to play: https://beatthebomb .com/beatthevirusWe are stream ing the Finals of a tournament live tonight at 8 PM EST on Twitch , FB, and YouTube.Twitch Stream Link (free to watch): https://www .tw itch.tv/beatthebomb1000Also available on:Facebook : https://www.facebook .com/ BeatTheBomb/YouTube: https ://www.youtube .com/channel/UCOyh7vo1knuKuaaCKUssAzAPlease watch the Twitch Stream if you can! Otherw ise I will follow up tomorrow w ith a video!Media coverage of the Fauci's Revenge in the News:• NBC New YorkSpectrum NY1 NewsTimeout New YorkNews 12 New YorkBushwick DailyFox 5 Good Day New YorkTo date we've raised over $6,150 for New York City's Public Health System (NYC Heal th +Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We'vedonated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields toMaimonides Medical Center. Men for others!Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!Best,Alex Patterson~Alex PattersonCEO BEAT THE BOMBwww.beatthebomb.comFollow us on instagram: @beatthebomb247 Water Street, Suite 106, Brooklyn, 11201work : 718-643-0200 I I cell: (b)(6)From:Sent:Attachment s:Yikes!Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 22:18 :45 +0000(b)( 6) Grad made a Video Game of Vo: "Fauci's Revenge"Fauci's Revenge Game Logo.pngNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409(b)( 6)E-mail: .___,. __., (b)( 6)The information in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Alexander Patterson <alex.patte rson@beatthebomb .com>Sent : Thursday, April 30, 2020 11:26 AlvlTo: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid .nih.gov>Cc: Daniel La hart <dlahar t @regis.org>Subject: (b)(6) made a Video Game of Yo: "Fauci's Revenge"Dear Dr. Fauci -My name is Alex Patterson and I'm (b)(6) I made a video game about you called Fauci'sRevenge . Link to play : https:/Jbeatthebomb.com/beatthevirusWe are streaming the Finals of a tournamen t live tonight at 8 PM EST on Twit ch, FB, and YouTube.Twitch Stream Link (free to watch): httos://w ww.twitch.t v/beatthebom b1000Also available on:Facebook: https://www.facebook.com/BeatTheBomb/YouTube: https:// www.yout ube.com/channel/UCOyh7vo1knu KuaaCKUssAzAPlease watch the Twitch Stream if you can! Otherwise I will follow up tomorrow w ith a video!Med ia coverage of the Fauci's Revenge in the News:• NBC New YorkSpectrum NY1 NewsTimeout New YorkNews 12 New YorkBushwick DailyFox 5 Good Day New YorkTo date we've raised over $6,150 for New York City's Public Health System (NYC Health +Hospita ls). We've created limited edition t-shirts (including a Fauci's Revenge one). We'vedonated 6,150 Protective Suits and 4,500 Gloves to the NYC Mayor's Office and face shields toMaimonides Medical Center. Men for others!Looking forward to being back in the halls soon at a Jug Night or Career Day. Enjoy the game!Best,Alex Patterson Cb) (6)Alex PattersonCEO BEAT THE BOMBwww.beatthebomb.comFollow us on instagram : @beatthebomb247 Water Street, Suite 106, Brooklyn, 11201work: 718-643-0200 I I cell: (b)(6)
From: Fauci, Anthony (NIH/NIAID) [E)Sent: Thu, 30 Apr 2020 22:14 :57 +0000To: (b)( 6)Cc: Tromberg , Bruce (NIH/NIBIB) [E];Sharpless, Norman (NIH/NCI) [E];Birx, DeborahL. EOP/NSC;Redfi eld, Robert R. (CDC/OD);Collins, Francis {NIH/OD) [E) ( CbH6>1C1)o;nrad,Patricia {NIH/NIAID ) [E]Subject: FW: Stanford National Daily Health Survey for COVID - "Open Up AmericaAgain"Attachments: 4.28.20 NDHS Overview Slides-Rusty -Fauci_ 1.pptxRod:Great to hear from you. Thanks very much for sending this . Very impressive! Iwill forward this to Bruce Tromberg and Ned Sharple ss who have been working onCOVID-related apts. In addition, I have cc'd Deb Birx {Coordinator of the WhiteHouse COVID-19 Task Force) as well as CDC Director Bob Redfield and FrancisCollins. I hope that all is well with you. Stay well and safe.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Pett igrew, Roderic ISent: Thursday, Apr il 30, 2020 4:20 AM ---------- ~= To: Anthony S. Fauci {NIH/NIAID) (b)(6)Subject: Stanford Nat ional Daily Health Survey for COVID - "Open Up America Again"Hi Tony ,Greetings from Houston, wher e the numb er of cases peak ed ~2 w eeks ago, dropped 35 -40%and seemed to have plateaued since. Grea t to see you on TV and see t he nat ion (includi ng BradPitt©) get to know the rigorously informed, keenly rationale and consistent ly clear Tony yourcolleagues have long known.(b) (4), (b) (5)Thank you , Tony . Very proud to know you. Kind regards ta ---(b-)( -.RodRoderic I Pettigrew , PhD, MDCEO EnHealth I Health Science Center and College of EngineeringRobert A Welch Professor and Executive Dean EnMed I Colleges of Medicine, Engineering and Houston MethodistHospitalTexas A&M University ALKEK Building I Suite 11032121 W Holcombe Blvd I Houston , TX 770?/Jwww.enmed.tamu.eduPh:_ __ .C..>b_ < .-~1- ____ C...>b_ < ..~..MAKING WHAT IF POS SIBLE I whatif.tamu.eduFrom: Hofmann, Lawrence, M .D. (b)(6)Sent: Tuesday, April 28, 2020 11:19 AtvlTo: Pettigrew, Roderic I (b)(6)Cc: Pelc, Norbert J (b) (6)Subject: [EXTERNAL]National Daily Health Survey for COVID - "Open Up America Again"Best,RLawrence "Rusty" Hofmann , MDProfessor and Chief, lntervent ional RadiologyMedical Director, Digital Health IntegrationMedical Director, Cardiac and lnte rventional Services@rustyhofmannMD(ml CbH6lAssistant:(b)(6)(b)(6)(b) (4), (b) (5)From:Sent :To:Cc:Fauci, Anthony (NIH/N IAID) [ElThu, 30 Apr 2020 22:05 :19 +0000Barillas, Carolina (NIH/NIAID) [ElAuchi ncloss, Hugh (NIH/NIAID) [E]RE: (b) (5) --------------------------Carolina:Thanks for se nding thisBest regards,TonyAnthony S. Fauci, MDDirector(b) (5) ------National Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone Cb()6 )FAX: (301 496-4409E-mail: (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Baril las, Carolina (NIH/NIAID) [E] ---------(b)(6)Sent : Thursday , April 30, 2020 11:25 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)> ~-=======---~= Cc: Auchinclo ss, Hugh {NIH/ NIAID) [E] (b)(6)Subject: (b) (5)Dear Tony,(b) (5)All the best,Carolina(b)(S)(b)(5From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 21:47 :05 +0000(b)(6)Subject: FW: Autopsy data suppor t ing Remdesivir trialTake a look at the Figures in the manuscript.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)(6)FAX: (301 496-4409(b) (5)(b) (4)E-mail,___,,. __ _, (b)(6)The in ormation in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Timothy Schacker (b)(6)Se nt: Thursday, April 30, 2020 1:10 PM -------~ = To: Fauci, Anthony (NIH/NIAID) [E] ---------- (b)(6l!> Subject: Autopsy data supporting Remdesivir trialTony., __________________________________ ~=(b) (4)Stay well (please) and thank you for all you are doing!TimTimothy Schacker , M.D.Vice Dean for Research , Medical SchoolDirector, Program in HIV MedicineUniversity of MinnesotaMail:MMC250420 Delaware Street SEMinneapolis, MN 55455FedEx/UPS:Mayo C688420 Delaware Street SEMinneapolis, MN 55455Phone: Cb()6 )Fax: 612-626-5599email: (b)(6) -------(bX5) -PCI(bXS)- PCPFrom:Sent:To:Cc:Fauci, Anthony (NIH/NIAID) [ElThu, 30 Apr 2020 14:17:43 +0000Conrad, Patricia (NIH/NIAID) [E)Billet, Court ney (NIH/N IAID) [ElSubject: FW: May the Official Nobel documentary program at Swedish Television get aninterv iew with you Dr Fauci about Covid-19 before May 7th please?Please get clearance and set it up if possible.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: .___,. ,. , (b)(6)The information in t ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Johan Bergendorff <johan.bergendorff@svt.se>Sent: Thursday, April 30, 2020 9:56 AM ------ ::;..,..-,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>; Barasch, Kimberly (NIH/NIAID) ICJ________ C_>b_C_6>) ; Stover, Kathy (NIH/NIAID) [El (b)(6)Subject: May the Officia l Nobel documentary program at Swedish Television get an interview with youDr Fauci about Covid-19 before May 7th please?Dear Dr . Fauci,I had the honor to interview you in april 2016 about the zika ep idem ic at your off ice for aprogram for national Swedish radio as their global health cor respondent. I hope I may have theho nor again now Sir?I am now working as science corresponden t for the nat ional Swedish Te levis ion (noncommercial public service, half the populat ion as daily viewe rs) in our official Nobel prizelaureau te documentary program "Vetenskapens Va rid" (the World of Science) and wonder ifyou have any chance to give us a 10 minute interview by web video before May 7th please?I would like to ask you two questions: What is most crucial now to suceed with an covid-19pandemic exit in the US? How do you find the Swedish strategy against Covid-19 so far (Dr.Mike Ryan praised it yeasterday at the WHO press conference as a model for an exit strategy,what is your view)?In this one hour program aired on May 11th we will have other prominent scientists as welltalking about exit strategies, among others Nobel prize winner prof. Paul Krugman, prof. BengtHolmstrom MIT, prof. Angus Deaton Princeton, as well as Prof Gabriel Leung Dean UniversityHongkong etc.Here you can see the reports I did from my earlier interview with you about the zika epidemicin 2016 (in Swedish). News report: https://sverigesrad io.se/artikel/642089120 mindocu men ta ry: https ://sverigesrad io.se/ avsn itt/712016One option is that I send you a link for a web video Conference call. Another option is that I callyou on the phone and your media department may have the oportunity to record a video ofyour anseers with HD quality that is better to air.Please let me know if you are available and when.Best regards,Johan BergendorffScience correspondent, Swedish Television(b)(6)From:Sent :To:Cc:Subject:resultsJuli e:Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 13:31 :50 +0000Julie.Steen huysen@thomsonreuters .comGreg Folkers Cb) (6)FW: Fauci says leak concerns fueled his White House revelation of Gilead drugYou did a good job in reporting our conversati on last night . Thanks.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) [E] (b)(6J>Se nt: Thursday, April 30, 2020 8:59 AMTo: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAIDOD AM <NIAIDODAM@niaid.nih .gov>Subject : Fauci says leak concerns fueled his White House revelation of Gilead drug resultsHealth NewsApril 30, 2020 / 1:07 AM/ Updated 4 hours agoFauci says leak concerns fueled his WhiteHouse revelation of Gilead drug resultsJulie Steenhuysen5 Min ReadCHICAGO (Reute rs) - Concerns over leaks compelled the top U.S. infectious disease of fi cial to reveal dataon Gilead Sciences Inc's experimental drug remdesiv ir, the first in a scientifically rigorous clinical tr ial toshow benefit in t reating COVID-19.National Institute of Allergy and Infectious Diseases Director Dr. Ant hony Fauci attends a coronavirusresponse meet ing between U.S. President Donald Trump and Louisiana Governor John Bel Edwards inthe Oval Office at the White House in Washington , U.S., April 29, 2020. REUTERS/Carlos BarriaThe dramatic announcement by Dr Anthony Fauci in the Oval Office on Wednesday prompted concernsamong scientists that the Trump administration was raising hopes about a coronav irus treatment beforesharing the full data with researchers.As a cautionary example of inflating the potential value of a therapy, some pointed to President DonaldTrump's repeated endorsements of malaria drug hydroxychloroquine as a treatment , with no evidencethat it works .Newer data suggests the malaria treatments may carry significant risks for some sufferers of therespiratory disease caused by the virus.Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), which is running thetrial, said he took the first opportunity to get the word out that patients taking a dummy treatment orplacebo should be switched to remdesivir in hopes of benefiting from it .He expressed concern that leaks of partial information would lead to confusion . Since the White Housewas not planning a daily virus briefing, Fauci said he was invited to release the news at a newsconference with Louisiana Gov. John Bel Edwards(D). "It was purely driven by ethical concerns," Faucitold Reuters in a telephone interview."I would love to wait to present it at a scientific meeting, but it's just not in the cards when you have asituation where the ethical concern about getting the drug to people on placebo dominates theconver sation ."An independent data safety and monitoring board, which had looked at the preliminary results of theNIAID trial, determined it had met its primary goal of reducing hospital stays.On Tuesday evening, that information was conveyed in a conference call to scientists studying the drugglobally."There are literally dozens and dozens of investigators around the world/' Fauci said. "People werestarting to leak it." But he did not give details of where the unreported data was being shared.Several scientists interviewed by Reuters felt the White House sett ing seemed inappropriate for therelease of highly anticipated government-funded trial data on the Gilead therapy .They had expected it to be presented simultaneously in a detailed news release, a briefing at a medicalmeet ing or in a scientific journal, allowing researchers to review the data.Informat ion from various trials of remdesivir has been leaked to media in recent weeks. In a statementon Wednesday, Gilead said the NIAi D's much anticipated trial had met its primary goal, but gave nodetails .Data in a separate NIAID statement after Fauci spoke detailed preliminary results showing that patientswho got the drug had a 31 percent faster t ime to recovery than those who got a placebo, cuttinghospital stays by four days.The trial also came close to showing the drug helped people survive the disease, but the data fell justshort of statistical significance."I want to see the full data. I want to understand the statistics. I want to understand the benefit and risk.I want to understand the structure of the study, and all of it," said Dr. Steven Nissen, the chief academicofficer at the Cleveland Clinic."Am I encouraged from what I've heard? Yes, I'm encouraged . But I want to get a full understanding ofwhat happened here, and not get it via a photo opportunity from the Oval Office ."Data Gilead released on its own trial of remdesivir drew less attention, as it did not compare outcomesbetween those receiving therapy and those who did not .Results from a third study in China suggesting remdesivir failed to help COVID-19 patients were releasedin the British medical journal the Lancet after review by a peer group of scientists ."That's the only thing I'll hang my hat on, and that was negative ," said Dr. Eric Topol, directo r andfounder of the Scripps Research Translational Institute in La Jolla, California.He was unimpressed by remdesivir's modest benefit ."It was expected to be a whopping effect," Topol added . "It clearly does not have that ."At the Oval Office news conference, Fauci compared the study findings to AZT, the fi rst drug to show anybenefit against HIV, decades ago."We know that was an imperfect drug. It was the first step," Fauci said in the interview."Similar to AZT, it's (remdesivir) the first baby step towards what hopefully will be a number of betterdrugs that will come in and be able to treat people with COVID-19.11(This story has been refiled to correct spelling of "clinical 11 in paragraph one)Reporting by Julie Steenhuysen; Editing by Michele Gershberg and Clarence FernandezOur Standards :The Thomson Reuters Trust Principles.Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those of NIAlD , NIB, HHS, or the U.S. government.From:Sent:To:Cc:Subject :Bill:Fauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 10:20:32 +0000STEWART SIMONSO Cb)(Masur, Henry (NIH/CC/CCMD) [E);STEWART SIMONSONRE: COVID-19 and Haiti(b)(6) Work --------------------------------- with him. As per our prior conversation and as you know better than anyone, Haiti is strugglingand I know that Stewart wi ll do whatever he can to assist you.Warm regards,'TonyFrom: STEWART SIMONSON (b)(6) ------------ Sent: Thursday, April 30, 2020 5:44 AMTo : (b)(6)Cc: Fauci, Anthony (NIH/NIAID) [E. ,,_~~~-===(b)=(6) =M-a-su~r~, H enry (NIH/CC/CCMD) [E] ------- (b)(6)>; STEWARTS IMONSON (b)(6) Subject : COVID-19 and Hait iDear Dr. Pape:I lead the World Health Organization (WHO) delegation to the United Nations and know of you throughTony Fauci and Henry Masur, (b)(6). For nearly 5 years immediatelypreceding my appointment at WHO,, I was an technical advisor at Hop ital Sacre-Cawr in Milot andremain in close contact with institution. Because of this, PAHO leadership asked me to join their COVID-19 planning discussions related to Haiti. I understand from Henry that you have been appointed byMSPP to coordinate COVID-19 preparedness and response activities. If you have some time available onFriday, it would be good to talk via Zoom or Webex. I can arrange th is and would plan to have thePAHO deputy director as well as other PAHO officials on the line. Would you be available Fridayafternoon for such a discussion? If not Friday, anytime over the weekend would also likely work on ourend.Thanks so much for considering t his.With best regards,Stewart SimonsonSTEWART SIMONSONWashington, DC/ New YorkCb) (6) or(b)(6)Cb) (6)1S)IS)------ (Switzerland)From:Sent :To:Subject:Please respond.Fauci, Anthony (NIH/NIAID) [ElThu, 30 Apr 2020 01:24:46 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Has anyone tried palivizumab (Synagis)From: Rich May (b)(6)Se nt: Wednesday, April 29, 2020 10:21 AM To: Fauci, Anthony {NIH/NIAID) [E] ----------~-=- -- (b)(6) Subject: Has anyone tried palivizumab (Synagis)Good morning Dr. Fauci,Has anyone tried palivizumab (Synagis) on any new COVID-19 patients?Thank you for your time,Richard May, MD, PhD, D.H.Sc- -(-b)(6)From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElWed, 29 Apr 2020 22:42:24 +0000Lerner, Andrea (NIH/N IAID) [ElFW: NAO repl etion for Covid-19Please t ake a look and respond if approp riateAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Mel Cohen (b)(6)Se nt: Wednesday, April 29, 2020 1:52 PM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: NAD repletion for Covid-19Import ance: HighDear Dr. Fauci,Recent research has shown that SARS-CoV-2 plays havoc with NAO function wit hin cells.Coronavirus Infect ion and PARP Expression Dysregulate the NAO Metabolome: A Potentially ActionableComponent of Innate Immunity:http s://www .bio rxiv.org/content/10 .1101/2020.04.17.047480v3The Molecular Story of COVID-19; NAD+ Depletion Add resses All Questions in th is Infection :https://www.preprints.org/manuscript/202003.0346/vlOther research has shown that NAD+ levels decline from aging and obesity, both significant factors inCovid-19 severity. But it has also been demonstrated that NAD levels can be replenished through oraladministration of nicotin amide ribo side (NR) and nicotinamide mononucleotide (NMN). NR in particularhas had several human studies demonstrating its safety and efficacy, and roughly 50 human studieslisted on clinicaltrials.gov fo r all manner of disorders.There is at least one anecdotal repo rt of dramatic improvement in a Covid-19 patient afteradministration of NMN.NMN shows great promise in case studies of humans with COVID-19:https://alivebynature.com/nmn-shows-promise-for-treatment-of-covid-19-in-casestudies/?utm campaign=NMN%20for%20covid%20%28TqFTyz%29&utm medium=email&utm source=Main%20List& ke=eyJrbF91bWFpbCl61CJtZWx/l2.GlzdHJpYnVOZWwuY2EiLCAia2xfY29tcGFueV9pZCl61CJSbWROWFoifQ%3D%3DThat article begins with the disclaimer, "There are no human trials that prove effectiveness of any NAO+boost ing suppfements for preventing or curing COV/0-19."That is a problem . When I see the resources that have been wasted pursuing hydroxychloroquine, I amsaddened to learn that there are no clinical trials of nicotinamide riboside as part of a treatmentregimen for Covid-19. Can you do anything about getting such a study done?Regards,Mel Cohen(b)(6)From:Sent:Fauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 22:01:22 +0000To: Folkers, Greg (NIH/NIAID) [E);NIAID OD AMSubject: RE: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEWIN ODNow FINAL in the OD fo lder. Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) [E] (b)(6)>Sent: Wednesday, April 29, 2020 5:03 PMTo: NIAID OD AM <NIAIDODAM@niaid .nih.gov>Subject: ASF----- slides for Business Roundtable, Friday 5-1-2020, 12-1 / FOR REVIEW IN OD• This is a zoom call.• I think you will be able to use slides.• I have put in OD a draft "curtain-raiser" set that you could show to kick things off - oruse them as TPs if you prefer.• I will update any epi or other numbers tomorrow night• The "ask" is belowFrom: Silverberg , Kristen <K5ilverberg@brt .org>Sent: Tuesday, April 14, 2020 4:11 PM ------~ = To: Fauci, Anthony (NIH/NIAID) [E] (b)( >Subject: invitation from BRTDr. Fauci,First, thank you for everyth ing you are doing . I have always been grat eful for yo ur public service, butfeel part icular ly indebted to you these days.To add to the debt ... Josh and I wanted to see if you would be willing to join a call with BusinessRoundtable CEOs. We have been doing COVID-19 calls with them every Friday at 1:30pm . Typically,about 100-125 CEOS of large, U.S.-based firms will join. They are all managing and planning for difficultissues around employee and customer safety . They would love to hear from you directly and to ask afew questions . It might also be a good place to deliver any messages you want them to hear.We completely understand if it isn't doable, of course. If you are able, we would love to host yousometime between 1:30pm -2:30pm this Friday (or any Friday on which your schedule wou ld allow it).Best,KristenFrom:Sent:To:Subject:Attachments :Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 15:09:44 +0000Antho ny FauciFW: Potential slides fo r Remdesivir presentationRemdesivir bullet slides - FAUCI - FINAL.pptxNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Fauci, Anthony (NIH/NIAID) [E]Sent : Wednesday, April 29, 2020 11:02 AM --------~~ _T_o_ : Short.,.; _M __a_r_c T. EOP-/-O(bV')"P(~'6" )'>_ ________ (b)(6_)_, ; 'Mi ller, Katie R. EOP/OVP'Subject: Potential slides for Remdesiv ir presentationMarc/Katie:Here are 3 slides that I might use in the press briefing. If necessary, I couldmake the presentat ion without them, but it might be clearer to have them just incase.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892 -2520Phone Cb) (6)FAX: (301 496-4409E-mail: --------- (b)( 6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [E)Wed, 29 Apr 2020 14:18:44 +0000Billet, Courtney (NIH/N IAID) [E]RE: two thingsThanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496~ 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Billet, Courtney (NIH/NIAID) [E (b)(6)Sent: Wednesday, April 29, 2020 9:16 AM ------ --=-= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Folkers, Greg (NIH/NIAID) [El (b)(6);; Conrad, Patricia (NIH/NIAID) [El(b)(6) >; Stover, Kathy (NIH/NIAID) [El CbH ; Routh, Jennifer"'.".---:------:-~~==~_;_-- ~~(NIH/NIAID) [E] (b)( >; Marston, Hilary (NIH/NIAID) [El CbH >Subject: ASF: two thingsTalked to FDA. They have written (and cleared with Gilead) a new sentence in place of what we had inthere about an EUA. Our release has been updated (attached) with the sentence highlighted below .ALSO: Bill Hall called me to ask if you had alerted the Secretary to th is (so the press release clearanceprocess isn't the way he first learns of it). I told him I wasn't sure. If you haven't done so, perhaps youwish to now?As part of the U.S. Food and Drug Administration's commitment to expediting the developmentand availability of potential COVID-19 treatments, the agency has been engaged in sustained andongoing discussions with Gilead Sciences regarding making remdesivir available to patients asquick ly as possible , as a_p_propriate.From: Fauci, Anthony (NIH/NIAID) [ElSent: Wed, 29 Apr 2020 10:45:24 +0000To: Billet, Courtney (NIH/NIAID) [ElCc: Folkers, Greg (NIH/NIAID) [El;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary(NIH/NIAID) [El;Routh, Jennifer (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [El;Lane, Cliff (NIH/NIAID)[El;Erbelding, Emily (NIH/NIAID) [ElSubject: RE: please read, Gilead statementLooks fine. Thanks.From: Billet, Courtney (NIH/NIAID) [E] <billetc@niaid.nih.gov>Sent: Wednesday, April 29, 2020 6:43 AMTo: Fauci, Anthony (NIH/NIAID) [E] <afauci@niaid.nih.gov>Cc: Folkers, Greg (NIH/NIAID) [El <gfolkers@niaid.nih .gov>; Conrad, Patricia (NIH/NIAID) [El<conradpa@niaid .nih.gov>; Marston, Hilary (NIH/NIAID) [El <hilary .marston@nih.gov>; Routh, Jennifer(NIH/NIAID) [El <jennifer.routh@nih.gov>; Stover, Kathy (NIH/NIAID) [El <kathy .stover@nih .gov>; Lane,Cliff (NIH/NIAID) [El <clane@niaid.nih.gov>; Erbelding, Emily (NIH/NIAID) [El <emily .erbelding@nih.gov>Subject: ASF: please read, Gilead statementFYI - this will go out before markets open this morning:GILEAD SCIENCES STATEMENT ON POSITIVE DATA EMERGINGFROM NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUSDISEASES' STUDY OF REMDESIVIRFoster City, Calif., April 29, 2020 - Gilead Sciences. Inc. (Nasdaq: GILD) is awareof the positive data emerging from the National Institute of Allergy and InfectiousDiseases' (NIAID) study of remdesivir. We understand that the trial has met itsprimary endpoint and that NIAID will provide detailed information at an upcomingbriefing.In addition to the NIAID trial, Gilead expects to share additiona l remdesivir datafrom the company's open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-dayduration of therapy may have similar efficacy and safety as the 10-day treatmentcourse evaluated in the NIAID trial and other ongoing tria ls. Gilead expects data atthe end of May from the second SIMPLE study evaluating the 5- and 10-day dosingdurations of remdesivir in patients with moderate COVID-19 disease.Gilead will continue to discuss with regulatory authorities the growing data setregarding remdesivir as a potential treatment for COVID-19.From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Wed, 29 Apr 2020 03:09:03 +0000Berkowitz, Avrahm J. EOP/WHORE: Jared Kushner Defends Dr. Fauci After Fox News Host Criticises TopCoronav irus Task Force ExpertThanks , A vi.-----Original Message-----From: Be rkowitz , Avrahm J. EOPfWHO (b)(6)Scot : Tuesday , April 28, 2020 I 0:00 P-M- ----. ;;-s-r;o= To: Fauci , Anthony (N1H/NIAlD) [E] CbH >Subject: Jar ed Kushn er Defends Dr . Fauc i After Fox News Host Criticises T op Coronavirus Task Force ExpertJust wanted to share an article- all the best!Avihtt:ps: //www .newsweek. conv'j ared-kushner-defends-dr-fauc i-fox -news-host-Ii ttle-tough-I 5003 3 9Sent from my iPhoneFrom: Fauci, Anthony (NIH/N IAID) [E)Sent: Wed, 29 Apr 2020 03:08:36 +0000To: Billet, Courtney (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E);Routh, Jennifer(NIH/NIAID) [El;Erbelding, Emily (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID) [El;Marston, Hilary (NIH/NIAID)[ElCc: Conrad, Patricia (NIH/NIA ID) [E)Subject: RE: DRAFT NIAID statement on remdesivir , ACTT 2Attachments: SHORTENED NIAID statement NEW NEW -with Fauci edits .docxSee my minor edits. (b)(5)From: Billet, Courtney (NIH/NIAID) [El (b)(6)>Sent: Tuesday, April 28, 2020 10:40 PM ------~ = To: Folkers, Greg {NIH/NIAID) [E) (b)( •>; Fauci, Anthony {NIH/NIAID) [E)CbH6>>R; outh, Jennifer (NIH/NIA ID) [E] CbH6)E; rbelding, Emily(NIH/NIAID ) [E) CbH6l>; Lane, Cliff (NIH/NIAID ) [E) (b)(6)>; Marston,Hilary (NIH/NIAID) [El (b)( >Cc: Conrad, Patricia (NIH/NIAID) [El (b)(6)Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2From: Billet, Courtney (NIH/NIAID) [ElSent: Tuesday, April 28, 2020 10:02 PM ------- -== To: Folkers, Greg {NIH/NIAID) [El (b)(6); Fauci, Anthony (NIH/NIAID) [El(b)(6)v>; Routh, Jennifer (NIH/NIAID) [El (b)(6)>; Erbeldlng, Emily(NIH/NIAID) [E) CbH6)>L;a ne, Cliff (NIH/NIAID) [E] CbH6>; >Marston , Hilary (NIH/NIAID) [E] Cb)( >Cc: Conrad, Patricia (NIH/NIAID) [E) Cb)( v>Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2(not sure what happened with spacing). Cliff- I got your suggestion too . I'll blend yours, mine, andGregs and send a clean new one shortly.From: Billet, Courtney (NIH/NIAID) [E]Sent: Tuesday, April 28, 2020 10:01 PM -------~ = To: Folkers, Greg (NIH/NIAID) [El (b)( >; Fauci, Anthony (NIH/NIAID) [E](b)(6b ; Routh, Jennifer (NIH/NIAID) [El< CbH6)>E; rbelding, Emily(NIH/NIAID) [El (b)(6)>; Lane, Cliff (NIH/NIAID ) [El (b)(6);Marston , Hi la ry_(NI H./.,N-IA-1D. ..) . .[.-E )-::::::===:::!...:~___.:.~ (~b)~( >Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2I took a crack at a revision as well. We can blend these.From: Folkers, Greg (NIH/NIAID) [El (b)(6)Sent: Tuesday, April 28, 2020 9:57 PMTo: Fauci, Anthony (NIH/NIAID) [El .e-f----~ (b~)( =6J; Routh, Jennifer (NIH/NIAID) [E](b)(6)>; Billet, Courtney (NIH/NIA ID) [El (b)(6); Erbelding, Emily(NIH/NIAID) [El (b)(6)>; Lane, Cliff (NIH/NIAID) [E] (b)(6); Marston,Hilary (NIH/NIAID) [E] (b)(6):,.Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>Subject: RE: DRAFT NIAID statement on remdesivir, ACTT 2Here is my suggested edit to the short version.From: Fauci, Anthony (NIH/NIAID) [E] ------- Sent: Tuesday, April 28, 2020 9:21 PM ------~~ To: Routh, Jennifer (NIH/NIAID) [El (b)(6); Billet, Courtney (NIH/NIAID) [El(b)(6)>; Folkers, Greg (NIH/NIAID) [E] (b)( >; Erbelding, Emily(NIH/NIAID ) [El (b)(6)>; Lane, Cliff (NIH/NIAID) [E] ------- (b)(6); Marston , Hilary (NIH/NIAID) [El (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [El (b)( >Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThanks for all your work.this.From: Billet, Courtney (NIH/NIAID) [El -------- (b)(6)Sent: Tuesday, April 28, 2020 7:29 PM -------= = To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Cc: Routh , Jennifer {NIH/NIAID) [El (b)(6)>; Stover, Kathy (NIH/NIA ID) [Elange(b)(6)>; Conrad , Patricia (NIH/NIAID) [El (bH >; Folkers, Greg(NIH/NIAID) [El (b)( >; Erbelding, Emily (NIH/NIAID) [El (b)(6)>;'.":"":":"::-'.'::"":-:-:::":--:::====--~~Lane, Cliff (NIH/NIA ID) [E] (b)(6)>; Marston, Hilary (NIH/NIAID) [El(b)(6)Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElWed, 29 Apr 2020 01:53:28 +0000Lane, Cliff (NIH/NIAID) [ElRE: BulletsRendesivir bullet slides - FAUCl.pptxI added another bullet.From: Lane, Cliff (NIH/NIAID) [El _______ Cb _H_6)Sent: Tuesday, April 28, 2020 9:51 PMTo: Fauci, Anthony {NIH/NIAID) [El_ _____ "("b"")"(="6")Subject: Re: BulletsGraph inserted.From: Anthony Fauci (b)(6)>Date: Tuesday, April 28, 2020 at 9:47 PM -------=-:~ To: "Lane, Cliff (NIH/NIAID) [E]" -------- (b)(6) ,> Subject: RE: BulletsI made some minor changesFrom: Lane, Cliff (NIH/NIAID) [El -------- (b)(6)Sent: Tuesday, April 28, 2020 9:27 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El- -------- (b)(6J>Subject: BulletsFor commentFrom:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/N IAID) [ElWed, 29 Apr 2020 01:50:16 +0000Lane, Cliff (NIH/NIAID) [ElRE: DRAFT NIAID statement on remdesivir, ACTT 2ACTT 2 NIAID statement CB KS EE HM HCLl - with minor edits.docx(b) (5) I made some minor edits.From: Lane, Cliff (NIH/NIAID) [E] ______ (_b)_(_ >Sent: Tuesday, April 28, 2020 9:44 PMTo: Fauci, Anthony {NIH/NIAID) [E] ------ -(-b==)-(=6)Subject: Re: DRAFT NIAID statement on remdesivir, ACTT 2Attached for consideration.From: Anthony Fauci (b)(6)>Date: Tuesday , April 28, 2020 at 9:21 PM ------- -== To: "Routh, Jennifer (NIH/NIAID) [E]" (b)(6)>, "Billet, Courtney (NIH/NIAID)[E]" (b)(6)>, "Folke rs, Greg (NIH/NIAID) [El" (b)(6)"Erbelding, Emily (NIH/NIA ID) IE]" (b)(6), " Lane, Cliff (NIH/NIAID) [E]"(b)(6)>, Hila ry Marston --------- --========:e:=~ Cc: "Conrad, Patricia (NIH/NIAID) [E]" (b)(6)>Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Thanks fo r all your work. (b) (5)(b) (5)-------------------------- (b)( 5) Please change t his.From: Billet, Courtn ey (NIH/NIAID) [El ------- (b)(6)>Sent: Tuesday, April 28, 2020 7:29 PM ------= = To : Fauci, Anthony {NIH/NIAID) [El (b)(6)>Cc: Routh, Jennifer (NIH/NIAID) [E] (b)(6) ,; Stover, Kathy (NIH/NIAID) [E](b)(6)>; Conrad, Patricia (NIH/NIAID) [El (b)(6); Folkers, Greg(NIH/NIAID) [El~---:~-=== (=b)=(6::)!>....;:.E. ~rb_el~ding, Emily (NIH/NIAID) IE] (b)(6);Lane, Cliff (NIH/NIAID) [E) (b)(6); Marston, Hilary (NIH/NIAID) [El(b)(6)Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From: Fauci, Anthony (NIH/N IAID) [E)Sent: Wed, 29 Apr 2020 01:21:27 +0000To: Routh, Jennifer (NIH/NIAID) [E);Billet, Courtney (NIH/NIAID) [E];Greg Folkers(GFOLKERS@niaid.nih.gov);Erbelding, Emily (NIH/NIAID) [El; Lane, Cliff (NIH/NIAID) [El;Marston , Hilary(NIH/NIAID) [ElCc: Conrad, Patricia (NIH/NIA ID) [E)Subject: FW: DRAFT NIAID statement on remdesivir, ACTT 2Attachments: ACTT 2 NIAID statement CB KS EE HM.docx, SHORTENED NIAID statement .docxThanks for all our work. HoweverCb) (5). Please change --------------------------- this.From: Billet , Courtney (NIH/NIAID) [El --------- (b)(6) Sent: Tuesday, April 28, 2020 7:29 PM -------=-:-= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Routh, Jennifer (NIH/NIAID) [E) (b)(6h; Stover , Kathy (NIH/NIA ID) [E)(b)(6)>; Conrad, Patricia {NIH/NIAID) [E) (b)(6); Folkers, Greg":'----:-------:--:--:-.:==~(NIH/NIAID) [E)~-~-==== (b=)(=6l->:; ..E~..r.be~lding, Emily {NIH/NIAID) [E) (b)(6)>;Lane, Cliff (NIH/NIAID) [E] Cb)( >; Marston, Hilary (NIH/NIAID) [E)(b)(6)>Subject: ASF: DRAFT NIAID statement on remdesivir, ACTT 2Importance: HighThere are two versions for your consideration here, as discussed.From:Sent :To:Subject:Attachme nts:Fauci, Anthony (NIH/NIAID) [ElWed, 29 Apr 2020 00:56:02 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Coronavirus info about a program that can help.BCA_id_Vl (wecompress.com) .pdfPlease take a look and respond if appropria te-----Original Message-----From: Alex Holbus .:-------- (b~)~(=6)Scot: Tuesday , April 28, 2020 6:59 PM- ----- --,;;..,....,-= To: Fauci , Anthony (N1H/NIAlD) [E] CbH >Subj ec t: Cor onavirn s info about a pr ogram that can he lp.Dear Dr Faucilt's a pleasure to send you this email my name is Alex Holbus I am from the UK I currently live in Serbia or exYugoslavia.l am a Economist and Humanitarian. I can talk about my Biography but. at this time the subject I want to share withyou I much more important.ln January 2016 1 sent a letter to Mr Trump (b) (6) telling him that 1 was happy that hewill bring change to America and the world and that ifhe needed my expertise that I wou ld help your count ry andthe world. As 1 have not got any responses from him nor his people I can see that he might not be interes ted. But as Ihave been following you over the media and be read ing about your carrier as a Doctor I believe you know what yourdoing and would like to take this opportuni ty to help you and your country at this time when it's the worst then everbefore in the modem world. I have a program that can help with the coronavirus in the way of identifying peopleand following there movement that can help you collect data faster and more suffic ient. The progr am is based on anapp so every one can use it. Countries in Europe are starting to use it by the end of May the Europe Union has madeit mandatory that all member state, need to use it and the future members like Serbia. So you will see attached apresentation about the program and if you or your country is interes ted please let me know and I will put you incontact with the company making this program. I did not send this email to you so we make money on people it's tohelp I ju st wanted to help. I will be contacting my contacts in the USA from Thursday morning but first 1 wanted totalk with you and give you the opportunity to see if Mr Trump would interested in this program for your country. Tfnothing comes back from you anyway my friend and contact in the USA will talk with the white house but l wantedto do it the proper way by talking to you as you are the main medical person in the USA for the coronavirus .Anyway wish you and your country all the best and that the world will become a better place after this epidemic isover.Jt's one life one world one human we arc all one on this planet no one is bigger or better the all of us as human ity asone.Kind regardsAlex HolbusDirector at Real Five Compan y.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Tue, 28 Apr 202017 :41:52 +0000(b)(6)Subject: RE: worrisomeYes. Please call to th eir att ention.a nasa l swab___________ C_b>_<6> It is merelyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From : (b)(6) ------------------- Sent : Tuesday, April 28, 2020 10:32 AMTo: Fauci, Anthony (NIH/NIAID) [E] -------= (b=)(=6)Subject: worrisomeFrom today's Medscape.https://www.medscape.com/viewarticle/929407?nlid=135287 5653&src=wnl newsalrt daily 200427MSCPEDIT&uac=71367AK&impl0=2361940&faf=1Older adults with COVID-19, the illness caused by the coronavirus , have several "atypical " symptoms,complicating efforts to ensure they get time ly and appropriate treatment, according to physicians.COVID-19 is typically signaled by three symptoms: a fever, an insistent cough and shortnes s of breath.But older adults - the age group most at risk of severe complications or death from t his cond ition -may have none of these characte ristics.Instead, seniors may seem "off" - not acting like themselves - early on afte r being infected by thecoronavirus . They may sleep more than usual or stop eating. They may seem unusually apathetic orconfused, losing orientation to their surroundings. They may become dizzy and fall. Sometimes, seniorsstop speaking or simply collapse.(b)(6)From:Sent :Fauci, Anthony (NIH/NIAID) [ElTue, 28 Apr 2020 17:39:34 +0000To:Subject:Janet Tobias;Conrad, Patricia (NIH/NIAID) [ElRE: Riding along tomorrow amOKAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Janet Tobias <jane t @ikanamedi a.com>Sent: Tuesday, April 28, 2020 12:46 PMTo: Fauci, Anthony (NIH/NIAID) [El -------------- (=b)(6)•1>; Conrad , Patr icia (NIH/NIAID) [El (b)(6)Subject: Riding along tomorrow amHi Tony and Patty:Would it be ok to do the 6:45 am ride to NIH tomorrow? We would also get thereearly to do one more paper throw. And last night was great!JanetFrom: "Fauc,i Anthony (NIH/NIAID) [E]" <_ _____ Cb<>6>)Date: Sunday, April 26, 2020 at 4:30 PMTo: Janet Tob ias <janet@ ikanamedia.com >Subject: RE: Quick questionMy work with the Coronavirus Task Force and the large volume of incomingemails precludes me or my staff from answering each individual message. I wouldencourage you to visit www.coronavirus.gov for the latest information andguidance related to COVID-19.Thank you, and best regards.Anthony S. Fauci, M.D.From:Sent :To:Subject:Attachme nts:I don't think so.From: Elizabeth HaenleAuchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]Tue, 28 Apr 2020 15:50:24 +0000NIAIDODAMFW: Invitation from the Investment CommunityLetter of invitation_Dr. Anthony Fauci from UBS Investment Bank (1).pdf--------- Sent: Tuesday, April 28, 2020 11:36 AM To: Fauci, Anthony (NIH/NIAID) [El -------------- -(b=H6~J> Subject: Invitation from the Investment CommunityDear Dr. Fauci,I am the co-founder of SAGE Wor ldwide, a global speaker and consulting company. I am reaching out onbehalf of one of my partners, Robert Karofsky, Co-President of UBS Investment Bank, with an invitationto join the UBS Global response to Covid-19 in a live streaming moderated discussion on May 18.Alternatively your conversation could be pre-recorded to accommodate your busy schedule. At thiscritically important time in our nation's history, the investment community wants to help our nationfight Covid-19 and use our country's economic engine to find a cure and solutions for Covid-19. Theyalso are thinking through how to help our nation's businesses going forward. Your expertise isimportant to this conversation .By way of background, I served in the White House for eight years in the Bush Administration as theSocial Secretary to Vice President Cheney. In that capacity, I had the privilege of curating a range ofdiscussions with global thinkers and thought leaders on the world's most pressing topics. At SAGE, webring that level of excellence to our business partners as we help curate discussions that have an impacton public awareness and investor sentiment, which is part icular ly impor tant as the U.S. responds toCovid-19.Participants at the UBS Global Healthcare Conference provide critical funding to pharmaceuticals andhealthcare research and are the businesses on the frontline of the Covid-19 healthcare response.Attached please find an invitat ion from UBS with further details of the event. I welcome the opportunityto hear from you at your earliest convenience, and thank you for your important work and dedication toour country's well being over the course of your distinguished career and service at NIAID.Warmest regards,Elizabeth HaenleCo-Founder, SAGE WorldwidePhone: (b)(6)Attachment 1Elizabeth Haenle CmH!l.Co-founder and PresjdeotM: -------(b)(6)E:- -------- (b)(6)W: SAGEworldwide.comcotmThis email and any files transmitted with it are confidential and intended solely for the use of theindividual or entity to whom they are addressed. If you have received this email in error please notifythe system manager. This message contains confidential information and is intended only for theindividual named. If you are not the named addressee you should not disseminate, distribute or copythis e-mail. Please notify the sender immediately by e-mail if you have received this e-ma il by mistakeand delete this e-mail from your system. If you are not the intended recipient you are notified thatdisclosing, copying, distributing or taking any action in reliance on the contents of this information isstrictly prohibited.From:Sent :To:Subject:For discussionAuchincloss, Hugh (NIH/ NIAID) [E] on behalf of Fauci, Ant hony (NIH/NIAID) [ElTue, 28 Apr 2020 14:46:56 +0000NIAID ODAMFW: HIGH SCHOOL MUN CONFERENCEFrom: Dane Cohn (b)(6)>Sent: Tuesday, April 28, 2020 10:44 AM -----~= To: Fauci, Anthony (NIH/ NIAID) [El (b)( >; Barasch, Kimberly (NIH/ NIAID) [C](b)(6); Conrad, --:---:----:----:--:--:-;::::::::::c.:..._ _ Patricia (NIH/NIAID ) [El (b)(6) ; Fauci, ___,:__~=Ant hony (NIH/ NIAID) [E] (b)( 6)Subject: HIGH SCHOOL M UN CONFERENCEDear Dr. Anthony Fauci,My name is Dane Cohn, and I am an (b)( 6). I have oftenlistened to your inspiring words on the news and followed your assiduous work to helpus through this pandemic. Our school participates in Model UN, an event in which highschool studen ts represent various countries in debates on international issues from thepast and present. Colorado's final Model UN conference was canceled , so our school----------- (bH6) ) decided to host an online conference for the whole state of Colorado and beyond . Our team would like to formally invite you to give a shortaddress (be it pre-recorded or live online) to the students during our openingceremony .We hope that our conference will inspire the youth of our nation and the world to standup and fight for our futu re rather than resign their aspirations to lockdown . We host thisconference because we see the importance of keeping our academ ic passions goingwhile staying safe within the confines of our homes. We host this conference becausewe want to contribute to the fight against COVID-19 - money raised from ourconference will go towards buying masks, food, and other resources for those who needit most.This is why we ask you , a hero during this troubling time, to speak to the students of ourconference, who not only include the youth of Colora do , but also the youth of ourcountry and world. Any type of address would be greatly and wholeheartedlyappreciated. If your address is pre-recorded , we would appreciate it if we could receiveit by May 1st, as our conference is the morning of May 2nd . We believe you can bringtrue inspiration into our hearts and minds . We know you are very busy, but if it were atall possib le to share with us even a short 2-3 minute pre-recor ded greeting andmessage to the students participating in this Model UN conference , it would be trulyinspirational. Thank you so much for your time , we hope to hear from you soon .Most Respectfully,Dane Cohn and the entire --------- (b)( 6) Model UN TeamFrom:Sent :To:Cc:Fauci, Anthony (NIH/N IAID) [ElTue, 28 Apr 202011 :25:09 +0000Haskins, Meli nda (NIH/NIAID) [ElConrad, Patricia (NIH/NIA ID) [ElSubject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 68:30 AM would be good. Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Haskins, Mel inda (NIH/NIA ID) [El ---------- (b) ( '> Sent: Tuesday, April 28, 2020 7:08 AM ------~= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6):>Subject: RE: Please advise LHHS Hearing w/ Dr. Fauci -- Wed nesday, May 6Let me know when you 'd like me to call please.From: Fauci, Anthony (NIH/NIAID) [E] CbH >Sent : Tuesday, April 28, 2020 7:04 AM ------- -,a-s-r= To: Haskins, Melinda (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Subject: Re: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6Let us chat by phone t his morningOn Apr 28, 2020, at 5:51 AM, Haskins, Melinda (NIH/NIAID) [E]wrote:(b) ( >We do not know if the Dela uro hearing would be remote. The Senate HELP one would bein person with some form of social distanc ing.Sent from my iPhoneOn Apr 27, 2020, at 10:36 PM, Fauci, Anthony (NIH/NIA ID) [E)-------- (b) (6) wro te :E should make sure that we schedule it at a time of day that does notconflict with the COS visit.From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)>Se nt: Monday, April 27, 2020 8:20 PM ------ --=-<= To : Fauci, Anthony (NIH/NIAID) [E] (b)(6)Subject: Fwd: Please advise LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6This is the day of the VIP visit-whoever it is. VP or COS. Pis advise. And notsure if these are I person or not. I suspect remote right??Sent from my iPhoneBegin forwarded message:From: "Haskins, Melinda (NIH/N IAID) [E]"(b)(6)Date: Apri l 27, 2020 at 8:10:52 PM EDTTo: "Conrad, Patricia (NIH/NIAID) [E]"(b) ~ >Cc: NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>, " Billet ,Courtney (NIH/NIAID) [E)" (b)( , "Harper, Jill(NIH/NIAID) [E]" (b)(6)Subject: Please advise LHHS Hearing w/ Dr. Fauci -Wednesday,May 6Patty,See below . Another hearing.Thank you,MelindaSent from my iPhoneBegin forwarded message:From: " Hallett, Adrienne (NIH/OD) [E]"(b)(6)Date: April 27, 2020 at 7:57:36 PM EDTTo: "Haskins, Melinda (NIH/NIAID) [E]"(NIH/NIAID) [E)" (b)(6)>,"LaMontagne, Karen (NIH/OD) [E]"(b)(6)>, "Higgins, Lauren-( N- I-H-/:0--D"').-"[:"E--]: ,-': -:=:===~ (b~) ~( > -------- Subject : Fwd: LHHS Hearing w/ Dr. Fauci -Wednesday,May 6Guess they really are coming back.Begin forwarded message:From: "Steigleder, Stephen"(b)(6)>Date: April 27, 2020 at 7:41:56 PMEDTTo: "Hallett, Adrienne (NIH/OD) [E]"(b) ( >Subject : LHHS Hearing w/ Dr. Fauci -- Wednesday, May 6Hi Adrienne,I hope you're doing well.I'm reaching out because ChairDelauro would like to invite Dr. Faucito a hearing next Wednesday, May 6,with the House LHHS appropriationssubcommittee . The focus of thehearing, not surprisingly, would beCOVID-19. Members of thesubcommittee wo uld very much liketo hear from Dr. Fauci on anythingrelated to COVID-19, but I think themain topics would be:• Mitigation and Testing; and• Progress on vaccines,therapeutics, anddiagnostics, as well asnecessary preparations tomanufacture anddisseminate a vaccine once itis ready.Chair Delaura is flexible about astarting time for the hearing onWednesday , so she would be happyto accommodate a t ime that worksfor Dr. Fauci's schedule.Please let me know as soon aspossible, so we can plan accordingly.Thanks so much,StephenStephen SteiglederHouse Appropriations CommitteeLabor/HHS/Education SubcommitteeFrom:Sent :To:Subject:Attachments :Fauci, Anthony (NIH/NIAID) [E)Tue, 28 Apr 2020 00:22:50 +0000(b)(6)FW: Remdesivir--good news20-0006 _DSMB _primary _analysis_report_for _OMI D.pd fFrom: Erbelding, Emily {NIH/NIAID) IE] _______ C>b<_>Sent: Monday, April 27, 2020 8:05 PMTo: Fauci, Anthony {NIH/NIAID) [E] _____ ("b"~""(6=) >Subject: Remdesivir--good newsTon'l,,_ ______________________________ --~(b) (5)EmilyEmily Erbelding, M.D., M.P.H.Director, Division of Microb iology and Infectious DiseasesNIAID/N IH5601 Fishers LaneRockville, MD 20852Tel: (b)(6)From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 22:56:59 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW:Attachme nts: Brown et al submitted .pdf, NIH Presentation final.pp tx,prepr ints202002.0147.v2 (1) .pdf, Mosaheb et al 2020.pdfEmail from Dani Bolognesi.Robert W. Eisinger, Ph.D.Special Assistant for Scientific Project sImmediate Office of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From : Dani Bolognesi , Ph.D. ---------- (b)(6)>Sent : Monday, April 27, 2020 6:09 PM To: Fauci, Anthony (NIH/NIAID) [E] ---------------= C=bH6 l;B arasch, Kimberly (NIH/NIAID) [C] (b )( 6)Subject: FW:Kimberly: Please see that this reaches Tony as per our call today.TX in advance.DaniHi Tony:In advance of getting together wi th you and your team, I am forwarding a short presentation for youguys to look at. The key elements are follows:(b) (4). (b) (5)(b) (4), (b) (5)We are prepared to discuss this with you and your team at any time that is convenient for you. As youmay know, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEx as an initial step.Many thanks for the opportun ity to share this with you !All the very best,Dani(b)(6)Best,DaniSent from Dani BolognesiFrom: "Dani Bolognesi, Ph.D." (b)(6)>Date: Monday, April 27, 2020 at 2:53 PM -----------~~ To: "Matthias Gromeie r, M.D." (b)(6)Subject: Please review this draft email to Tony--TXMatthias: Please review and edit the proposed email to Tony.DaniHi Tony: In advance of getting together with you and your team, I am forwarding a short presentationfor you guys to look at. The key elements are follows:(b) (4). (b) (5)We are prepared to discuss this with you and your tea at any time that is convenient for you . As you mayknow, we are locked down here in the Research Triangle until May 15. If it makes sense, we couldarrange a WebEX as an initial step .All the best,DaniBest,DaniSent from Dani BolognesiThe infor matio n in this electronic mail is sensitive, protected information inte nded only for the addressee(s). Any othe r person,including anyone who believes he/she might have received it due to an address ing error, is requeste d to notify the senderimmediate ly by return electronic mail, and to delete it without further reading or retention . The information is not to beforwarded to or shared unless in compli ance with Duke Health policies on confidentiality and/o r with the approva l of thesender.From:Sent :Fauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 22:17:19 +0000To:Subject:Folkers, Greg (NIH/NIAID) [E);NIAID OD AMRE: COVID/Transportation ImpactsOk. Let us discuss forwarding to CDC>Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 3 I, Room 7 A-0331 Center Dri ve, MSC 2520Nationa l Ins titutes of HealthBet hesda , MD 20892-2520Phone: (b) (6)FA X: (301) 496-4409E-mail (b) (6)The informati on in this e-ma il and any of its attachme nts is confidential and may contai n sensitive infom1ation. Itshould not be used by anyone who is not the original intended recipie nt. lf you have received this e-mail in erro rplease inform the sender and delete it from your mai lbox or any other storage devices. The Nationa l Inst itute ofAllergy and Infectio us Diseases (NlAI D) shall not accept liability for any stateme nts made that are the send er's ownand not expressly made on behalf of the NlAID by one of its representatives.-----Original Message-----From: Folkers, Greg (NlH/NlAID) (E] ---------(b)( Sent: Monday , April 27, 2020 6:15 PM --------= To: Fauci, Anthon y (NTH/NlAID) [E] ---------(b)( ; NJAID OD AM <NIAJD0DAM @niaid.nih.gov > Subject: RE : COYID/fransportation Impactsthis seems like CDC issueThey address some of the issues here:What Ridesbare, Tax i, Limo, and other Passenger Driv ers -for-Hire Need to Know about COVJD - 19https://www.cdc.gov / coronavi ms/20 I 9-ncov /community / orga nizati ons/ ridesbare-drivers -for-h ire.htm ICommunication Too lkit for Transpo1tat ion Parto el'S to Inform Road Travelers Monday, April 27, 2020https: //www .cdc.gov / coronav irus/2019 -ncov / travelers /transportat ion-toolkit.htm lCleaning and Disinfect ion for Non-eme rge ncy Transpo rt Vehicles Tuesday, April 14, 2020https: //www .cdc .gov/ coronav i ru s/? 019-ncov / community /organizations / d isi n fectinQ.-transport-vch icles. h tm I-----Original Mcssage-----F[Ero]m : Conrad, Patricia (NIH/NIAID) [E] ....__ ____ (b_)(_6_) , On Beha l f OfF auci, Anthony (NIH/NIA ID)Sent: Monday, Apri l 27, 2020 6:05 PMTo: NIAID OD AM <NIAID0DAM @niaid.nih.gov >Subject: FW: COVID/Transportation Impacts-----Original Message-----From: Anthony Foxx (b)(6) >Sent: Monday, April 27, 2020 4:39 PM- ------~~ To: Fauci , Anthony (NIH/NIATD) [E] --------- (b)( Subject: COVID/Transportation ImpactsDr. Fauci:This is Anthony Foxx, immediate former US Transportation Secretary, and T great ly enjoyed our interactions (briefthoughts they were) during my time in the last Admi nistrat ion.I write to request your help in advising the transportation community about how to manage through the presentcrisis, particularly as some areas are easing restrictions. I would welcome an opportunity to join you in a Q/ A, whichcould be valuable for rideshare companies (b) (6l), transit agencies, airlines etc. I wouldthink that a I 0-15 minute chat would do wonders. That said, I know you are terribly busy and have so many thingsto do but would appreciate any opportunity to help you get important infonnation out.This could be pulled together rapidly and done within the next week or so,Thanks for your attention to this matter. All my best,Anthony.Sent from my iPhoneFrom :Sent :To :Subject :FYIAnthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 22:00:13 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Update - White House Coronavirus Task Force Mee t ing - 4.28.20National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From:Sent :To:Fauci, Anthony (NIH/N IAID) [ElMon, 27 Apr 2020 21:57:57 +0000Lusso, Paolo (NIH/N IAID) [ElSubject: RE: Covid t hrombiThanks, Paolo.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Lusso, Paolo (NIH/NIAID) [E] ---------(b)(6)Sent: Monday, Apri l 27, 2020 12:34- P-M- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] (b)(6) -~"."':=======~~ Cc: Kovacs, Joseph (NIH/CC/CCMD) (E] (b)(6) Masur, Henry (NIH/CC/CCMD) [E](b)( ; Lane, Cliff (NIH/':N':"".I"A':."l'"D:'".:)'-[":"E':.:]'. ====::- .(.b,.,)...(..,6.:,);>;, -------- Subject: Re: Covid thrombiDear Tony,I talked with Dr. Viecca this morning who shared additional info rmation about his protocol. They startedfrom the pathologica l observation that all patients dying of Covid-19 pneumo nia had diffuse pulmonarymicrothrombosis . Since th ey detect ed almost exclusively white th rombi, they reasoned that they had toblock platelet activation/aggregation, whi le heparin would be ineffective at that stage. Thus, theyt reated a first group of five critica l pati ents with potent anti-aggregant therapy (Tirofiban/ Aggrastat) andapparen t ly in all of them the p02 started to rise within less than 2 hours, they got off the vent ilators andwent on to full recovery. Viecca is an intervent ional cardiologis t (b)( 4)I sent copy of his protocol and contact information to Joe.Let me know if I can be of any further help. All the best,PaoloPaolo Lusso, M.D., Ph.D.Chief, Section of Viral PathogenesisLaboratory of lmmuno regulationBldg. 10, Rm. 6AllNIAID, NIHBethesda, MD 20892Phone: (b)(6) (personal)(b)(6) (lab)Fax: (301) 480-5291E-mail: (b)(6) --------The information in this e-mail and any of its attachments is confident ial and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If you havereceived this e-ma il in error please inform the sender and delete it from your mailbox or any otherstorage devices. The Natio nal Institute of Allergy and Infect ious Diseases (NIAID) shall not acceptliability for any statement made tha t are the sender's own and not expressly made on behalf of theNIAID by one of its representatives.******************************~From:Sent:To:Cc:Subje ct:Attachment s:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 21:57:23 +0000 -----~~ Collins, Francis (NIH/OD) [El- ------ (b)(6) Mascola, John (NIH/VRC) [E)FW: Revised SlidesVaccine Development Slides Revised Draft 042720.pptxPleas respond for both of us. I already cc'd you on an email that I sent to Johnwith a minor comm ent about slide #2.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone (b) (6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Marks, Peter- --------- (b)(6) Sent: Monday, April 27, 2020 1:14 -P-M- ---~~ To: Fauci, Anthony (NIH/NIAID) [El- ------- (b)( >; Collins, Francis (NIH/OD) [El (b )( 6)Cc: Mascola, John (NIH/VRC) [E] -------- (b)( >Subje ct : Revised SlidesDear Francis and Tony,Apologize that t he prior slides were too busy. John conveyed that message. Please see these versionsthat may be more along the lines that you are looking for . (b) (5)Best Regards,PeterFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 21:54:37 +0000Schwetz, Tara (NIH/OD) [ElSubject: RE: Flagging NIH Media Product for Release TomorrowYou could play the role in the movie of my medical school girl friend, which wou ldgive you the possibility of working with Brad Pitt QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail : (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Schwetz, Tara (NIH/OD) [E] (b)(6)Sent: Monday , Apri l 27, 2020 5:49 PM ------~~ To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Subject: Re: Flagging NIH Media Product for Release TomorrowNow, you also have the answer to who would play you in a mov ie! ©Tara A. Schwetz, PhDActing Director, NINRAssociate Deputy Director, NIHA: Building 1, Room 138 P: (b)(6) I M: ---------(b-)(,6;) -,-=From: "Fauci , Anthony (NIH/NIAID) [E]" CbH6)Date : Monday, April 27, 2020 at 5:46 PMTo: Tara Schwetz (b)(Subject: RE: Flagging NIH Media Product for Release TomorrowThanks, Tara. Pitt was amazing. One reviewer of the SNL show said that Pittlooked "exact ly like me". That stateme nt made my year. (Q)Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveInformation. It should not be used by anyone who Is not the orig inal Intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Schwetz, Tara (NIH/OD) [El (b)( >Sent : Monday, April 27, 2020 5:11 -PM-- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [El (b)(6)Cc: Marston , Hilary (NIH/NIAID) [E] (b)(6) ; Conrad, Patricia (NIH/NIAID ) [E](b)(6)>; Barasch, Kimberly (NIH/NIAID) [CJ (b)(6) Myles,Renate (NIH/OD) [El (b)( ; Walsh, Elizabeth (NIH/OD) [El (b)(6)Subject: Flagging NIH Media Product for Release TomorrowTony,Please see below and attached a ti me-sensit ive COVID-19 item for your awareness and sharing wit h t herema inder of the Task Force, as appropriate. The plan is to release this tomorrow.Item 1: Title : Rapid Acceleration of Diagnostics (RADx) InitiativeActivity Type : Funding of new research programSummary: With a (b)(5) investment from fede ral st imulus fund ing, RADx initiat ive will infusefund ing into early innovation techno logies to speed deve lopment of rapid and widely accessibleCOVID-19 tes ting. At the same time, NIH will seek opportunit ies to move more advanceddiagnost ic technolog ies swiftly through the development pipeline towa rd commercialization andbroad availabil ity. As part of the init iat ive, NIH is urging scientists and inventors with a rapidtest ing technology to compete in a nat ional COVID-19 test ing challenge for a share of up to $500million over all phases for further developmen t. The goal is to add tens of millions per month ofaccurate and easy-to-use tests to all Americ ans by Fall 2020.Impact on COVID-19 Pandemic Response: RADx will accelerate the development, validation, andcommercializ ati on of innovative new testing methods that can be deployed in point-of-care andhome settings. These technologies are urgently needed to guide and inform safe return to work,schoo l, and life activities.Office : National Institute of Biomedical Imaging and BioengineeringAction Date: Solicitation announcement April 28, 2020Type of Action: Research Program AwardPotential for Press Coverage: Mainstream PressPress Release in Development? : YesDo let me know if you have any questions.(Also, Brad Pitt?! Wow, that was a real ly nice shout out/thank you.)Best,Tara A. Schwetz, PhDActing Director, NINRAssociate Deputy Director, NIHA: Building 1, Room 138 ---~~ P: (b)(6) I M: (b)(6)From :Sent:To:Cc:Subject :Att achment s:Deb:Fauci, Anthony (NIH/N IAID) [E)Mo n, 27 Apr 2020 21:48:46 +0000Birx, Deborah L. EOP/NSCRedd, Stephen (CDC/DDPHSIS/OD);Hahn, StephenFlagging NIH l'vledia Product fo r Release Tom orrow2020-04-27 COVID-19Week lyReport _ NIBIB OD_tas.docxAs an FYI. This is an initia tive from NBIB/N IH on development of POCdiagnost ics for SARS-CoV-2.Best,TonyAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 21:39:57 +0000Stover, Kathy (NIH/NIAID) [E)Cc:(NIH/N IAID) [ElSubject:Billet, Courtney (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, PatriciaRE: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in childrenLooks fine. Thanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)(6)FAX: (301 496-4409E-mail,___,,. __ _, (b)(6)The in ormation inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Stover, Kathy (NIH/NIAID) [El (b)(6)>Sent: Monday, Apri l 27, 2020 4:57 PM ------= = To: Fauci, Anthony (NIH/NIAID) [El (b)(6)>Cc: Billet, Courtney {NIH/NIAID) [El (b)(6)>; Folkers, Greg (NIH/NIAID) [El_______ Cb>C_6,); Conrad, Patricia (NIH/NIAID) [E) (b)(6)>Subject: FOR ASF REVIEW: Draft PR re: SARS-CoV-2 incidence in childrenHi Dr. Fauci,Please find attached fo r your review a draft release about the launch of t he HumanEpidemiology and Response to SARS-CoV-2 (HEROS) study, which is intended to help determinethe percentage of children infected with SARS-CoV-2 and the percentage of infected childrenwho develop COVID. In addition , the study will examine whether rates of SARS-CoV-2 infectiondiffer between children who have asthma or other allergic conditions and children who do not.Your draft quote is as follows :110ne interesting feature of this novel coronavirus pandemic is that very few childrenhave become sick with COVID-19 compared to adults," said NIAID Director Anthony S. Fauci,M.O. "Is this because children are resistant to infection with SARS-CoV-2, or because they areinfected but do not develop symptoms? The HE ROS study will help us begin to answer theseand other key questions."Thanks much,KathyKathy StoverBranch ChiefNews and Science Writing BranchNational Institute of Allergy and Infectious Diseases (NIAID)Office of Communications and Government RelationsNational Institutes of Health/HHS31 Center Drive, Room 7Al 7EBethesda, MD 20892Phone: (b)(6)E-mail (b) (6)NIAID Media Line: (301) 402-1663From :Sent:Fauci, Anthony (NIH/N IAID) [E)Mon, 27 Apr 2020 21:04:24 +0000To: ---------~~ Auch incloss, Hugh (NIH/N IAID) [C) ----------- (b)( 6) Cc: Conrad, Patricia NIH/NIA ID [E);Jean W PapeSubject :Attachment s:Hugh:Than ks,To nyAnthony S. Fauci , MDDirec torPlease t ake care of it.National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)(b) (4)(b) (6), (b) (4)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From : (b)(6) ---------------- Sent: Monday , April 27, 2020 3:01 PM To: Fauci, Anthony (NIH/NIAID) [E] ---------------=---=-(b)-(6-) :-= Subject : (b) (4)To ny,(b) (4), (b) (6)Best,BillJEAN WILLIAM PAPE, MDHoward and Carol Holtzmann Professor of Clinical Medicine,Center for Global Health, Division of Infectious Diseases, Department of Medicine,Weill Cornell Medical College, New York, New York, USA402 East 67th Street, New York, NY 10065Tel (Office) (b)(6)Director,Les Centres GHESKIO,33, Blvd. Harry Truman, Port-au-Prince, Ha'iti.Tel (Office): (b)(Voip: (b)(6)From:Sent:To:Conrad, Patricia (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 16:09:04 +0000NIAIDODAMSubject: FW: The National Organization of Ital ian Americans in Film & Television(NOIAFT) - Int erview RequestPatricia L. ConradPublic Health Ana lyst andSpecial Assistant to the Direc torNational Inst itut e of Allergy and Infectious DiseasesThe National Institutes of Heal th31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The informat ion in this e-mail and any of its attachments is confidentia l and may conta in sensi tive information. It should not be usedby anyone who is not the original intended recipient. If you have rece ived this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID ) shall not acceptliab ility for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.From: Taylor Taglianetti <taylor@noiaft.org>Sent: Monday, April 27, 2020 12:03 PM -------~~ To: Fauci, Anthony (NIH/NIAID) [El .:=========~~ Cc: Fauci, Anthony (NIH/NIAID) [El ________ ...Subject: The National Organization of Italian Americans in Film & Television (NOIAFT) - InterviewRequestDear Dr. Fauci,I hope this email finds you wel l. My name is Taylor Taglianetti and I am the founder of the Nationa lOrganization of Italian Americans in Film & Television (NOIAFT).Our organization is so very proud of the work you are doing for our country and sends tremendousthanks for the hope and reassurance you have instilled during these trying times.It would be an honor to conduct a short inte rview with you. Our organization includes many youngItalian Americans breaking into the entertainment industry and with the coronavirus dramaticallyimpact ing our field, I'd love to ask you a few questions about what the future of theentertainmen t business looks like. We'd be happy to send the questions in advance for your approval. Ifyou don't have time for a phone call, the questions can be answered via email at your leisure .Thank you for your time and consideration.Sincerely,Taylor TaglianettiFounder, The National Organization of Italian Americans in Film & Television (NO/AFT)(347) 686-4968www.noiaft.orgtaylor@noiaft.org
(bX5)-PCl1(bX5) -PCP.(bXS) - PCP.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 14:19:38 +0000Conrad, Patricia (NIH/NIAID) [E)Subject: RE: Media query: CNN, re: ASF's NAS web briefing on SaturdayI was referring only to animal (macaque) models. I never said that it looked goodin humans. Human clinical trials are ongoing to answer t hat question . Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E] (b)(6)Sent: Monday, April 27, 2020 9:30 AMTo: Fauci,A nthony (NIH/NIAID) [E]------= (b")"(=6J>Subject: Fwd: Media query: CNN, re: ASF's NAS web briefing on SaturdayPis adviseSent from my iPhoneBegin forwarded message:From: "Leifman, Laura (NIH/NIAID) [E]" --------- (b) (6),>Date: April 27, 2020 at 9:27:13 AM EDT -------~~ To: "Conrad, Patricia (NIH/NIAIO} [E]" ----------- CbH6J>N, IAID FOG <fog@ niaid .nih.gov>Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquir ies<mediainquiries@niaid.nih.gov>Subject: Media query: CNN, re: ASF's NAS web briefing on SaturdayElizabeth CohenCNNElizabeth.Cohen@turner.comTopic: Statement by ASF during Saturday NAS web briefingDeadline: urgentHi Patty,Elizabeth would like to clarify something that Dr. Fauci apparently said about remdesiv irduring his NAS web briefing on Saturday. The transcribed segment of the talk that she isfocused on says:"Remdesivir is the one that's gotten the most publicity. It is interesting that if you look at itin a prophylactic therapeutic model in MERS coronavirus infection, it looked pretty good.There was clinical benefits just reported a couple of weeks ago of SARS coronavirus 2 inrhesus macaques."She wants to clarify what Dr. Fauci meant by looking at remdesivir " in a prophylactictherapeutic model in MERS"-whether this means in an animal model or something else. Itsounds like that phrase is referring to the RML study in which remdesivir successfullyprevented disease in MERS-infected rhesus macaques, as reported in the Feb. 13 NIAIDmedia availability pasted below . Is that correct?Best,LauraRemdesivir Prevents MERS Coronavirus Disease in MonkeysResults Support Testing Antiviral Against 2019 Novel CoronavirusFebruary 13, 2020The exper imental antiviral remdesivir successfully prevented disease in rhesus macaquesinfected with Middle East respiratory syndrome coronavirus (MERS-CoV), according to anew study from National Institutes of Health scientists. Remdesivir prevented diseasewhen administered before infection and improved the condition of macaques when givenafter the animals already were infected.The new report from NI H's National Institute of Allergy and Infectious Diseases (NIAID)appears in the Proceedings of the National Academy of Sciences.MERS-CoV is closely related to the 2019 novel coronavirus (SARS-CoV-2, previously knownas 2019-nCoV) that has grown to be a global public health emergency since cases were firstdetected in Wuhan, China, in December.Remdesivir has previously protected animals against a variety of viruses in labexperiments . The drug has been shown experimentally to effectively treat monkeysinfected with Ebola and Nipah viruses. Remdesivir also has been invest igated as atreatment for Ebola virus disease in people.The current study was conducted at NIAID's Rocky Mountain Laboratories in Hamilton,Montana. The work involved three groups of animals: those treated with remdesivir 24hours before infection with MERS-CoV; those treated 12 hours after infection (close to thepeak time for MERS-CoV replication in these animals); and untreated control animals.The scientists observed the animals for six days. All control animals showed signs ofrespiratory disease. Animals treated before infection fared well: no signs of respiratorydisease, significantly lower levels of virus replication in the lungs compared to controlanimals, and no lung damage. Animals treated after infection fared significantly betterthan the control animals: disease was less severe than in control animals, their lungs hadlower levels of virus than the control animals, and the damage to the lungs was lesssevere.The scientists indicate that the promising study results support additional clinical trials ofremdesivir for MERS-CoV and COVID-19, the disease that SARS-CoV-2 causes. Severalclinical trials of remdesivir for COVID-19 are under way in China, and other patients withCOVID-19 have received the drug under a compassionate use protocol.The Biomedical Advanced Research and Development Aut hority (BARDA), part of the U.S.Department of Health and Human Services, also provided support for this study . GileadSciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in theresearch.MERS-CoV emerged in Saudi Arabia in 2012. Through December 2019, the World HealthOrganization had confirmed 2,499 MERS-CoV cases and 861 deaths (or about 1 in 3).Because about one-third of MERS-CoV cases spread from infected people being t reated inhealthcare settings, the scientists suggest that remdesivir could effectively prevent diseasein other patients , contacts of patients , and healthca re workers . They also note the drugmight help patients who are diagnosed with MERS or COVID-19 if given soon aftersymptoms start.ARTICLE:Ede Wit et al. Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesusmacaque model of MERS-CoV infection. PNAS DOI: 10.1073/pnas .1922083117 .WHO:NIAID Director Anthony S. Fauci, M.D., and Emmie de Wit, Ph.D., a principal investigator inNIAi D's Laboratory of Virology, are available to comment on this study.From:Sent :To:Subject:Fauci, Anthony (NIH/NIAID) [ElMon, 27 Apr 2020 14:11:59 +0000Lerner, Andrea (NIH/N IAID) [ElFW: Coronavirus Antigen Mi croarrayPlease t ake a look and handle.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Anderson, Cassandra (NIH/NIDDK) [E] ------------(b) (6)•> Sent: Monday, Apri l 27, 2020 8:17 AM ------ --=~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: Coronavirus Antigen MicroarrayGood morning Dr. Fauci,I work in NIDDK in bldg. 50 in the Laboratory Endocrinology and Receptor Biology.Thank you for all the information you have provided to our nation . I also want to say you are doing aterr ific job in handl ing the COVID-19 virus, without you and your staff I don't know wher e our countrywould be.I received the email below this morning from Jiang Yufei from Sino Biological. Not sure why I was sentthis email, but I tho ught of you and your staff . Please see the email below .Thank you again for all that you are doing to help keep us safe!Stay safe!Cassandra AndersonAdmin istrative ProfessionalBldg. SO Room 4133301-402-7845From: Yufei Jiang <yufei.jiang@sinobio logical.info>(b)( >Sent : Monday, April 27, 2020 8:04 AMTo: Anderson, Cassandra (NIH/NIDDK) [E) ------------- Subject: Coronavirus Antigen MicroarrayHi Cassandra,Happy Day! I am excited to let you know that Sino Biological just released Coronavirus antigenMicroarray (CoVAM) which belongs to our Sinommune™ Mu ltiplex Antigen Microarray product line. Youmay get more details from the following link:https ://www. sinobio logica I .com/ research/virus/ coronavi rus-arrayCurrently the standard pre-printed CoVAM array is sold in the unit of slide, 16 arrays/slide. In each arraythere are 65 antigens related to the viruses that can cause upper respiratory tract infections includingthe most recent SARS-CoV-2T. he list price is $3,200/slide . Please contact me for how to place the orderif you are interested or need more information.So far, this array has mainly been used for two purposes: 1) Sero-surveillance studies of COVID-19infect ion, and 2) Evaluating antibody reactiv ity in animals (monkeys and mice) after vaccination . Pleasebe advised that our array is for research use only (RUO), not for the diagnostic purpose which needs theFDA approval.After you run the samples on the slide, you may read the slide on the following compatible machines:https://www.innopsys .com/en /lifesciences-products/m icroarrays/innoscanhttps://www.moleculardev ices.com/produc ts/additional -products/genepix-microarray-systemsscanners#grefhttps://www.agilent .com/en /produ ct/cgh -cgh-snp-microarray-platform/cgh- cgh-snp-microarrayscanners-equipment/surescan-m icroarray-scanne r-228493Thanks.-YufeiYufei Jiang, PhDManager, NY, MD, DC, VASales & Business DevelopmentSino Biological US Inc.1400 Liberty Ridge Dr., Suite 101Wayne, PA 19087Celli (b) (6)Email: yufei jiang@sinobiological.comwww.sinobiological.comFrom:Sent :To:Subject:Let us discuss.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 14:11:06 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Otto e Mezzo - Ita lian ShowNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representative s.From: Torchia Patrizia <Patrizia.Torchia@la7.it>Sent: Monday, Apri l 27, 2020 8:05 -AM-- -----, .....,....,= To: Fauci, Anthony (NIH/NIAID) [E] --------- (b)(6) Subject: Otto e Mezzo - Italian ShowDear Mr. Fauci,I'm Patrizia Torchia, I'm a journalist and I am a member of the team on the Italian show Otto e Mezzo,hosted daily by journa list Lilli Gruber on La7 channel.I'm reaching out to invite you in our show. Mrs. Gruber would be honored to have you, Dr. Fauci explorein more depth the challenges Coronavirus has forced the world to face. Can make this happen?Below is Lilli Grube r's bio and a brief descript ion of the show.WHO :Lilli Gruber is the editor-in-chief and host of Italy's most influential political daily talk show, "Otto emezzo", airing on prime-t ime on La7 TV. She's received Italy's most prestigio us journalism awards forher work and was the first woman to ever conduct the prime-time News broadc ast in Italy (RAI TV,1987). As a foreign correspondent she covered most of last 30 years' major world events, from the fall ofthe Berlin wall to 9/11 to the Iraq war. Beside her te levision work, Ms. Gruber wrote eleven bestsellerbooks including "Eredita", which was top seller for 20 weeks and ran 14 reprints. In 2004, Ms. Gruberwon a head-to-head campaign against Silvio Berlusconi by a large margin of votes and was elected to theEuropean Parliament. There, among other appointments, she was the Head of the EU Delegation to theGulf States and Yemen and a member of the EU Delegation to Iran."Otto e mezzo"Italy's most influential political daily ta lk show shown on prime-time on La7 TV. Through interviews withelected political figures and candidates for office, commentators, and journal ists, the show focuses oninternational political news and economy wi th a special focus on Italy and Europe. Beginning in2008 "Otto e Mezzo" became Lilli Gruber's way to keep her commitment to holding those in poweraccountable by asking questions and touching on topics citizens are curious about. Otto eMezzo airs Monday to Saturday from 8:35pm to 9:10pm. Within this time-frame Paolo Pagliaro's newscolumn "II Punto" stands out for accuracy and thoughtfulness by pulling the thread on the highest ratedissues in an agenda. During the current season Otto e Mezzo has become Italy's most watched politicaltalk show reaching an average of 7.3% of share wi th 2.5 million viewers per day.Production location( s): La7 studios, via Umberto Navaro 32, Rome, ItalyPresented by: Lilli GruberOriginal network: La 7Executiv e produ cers: Stefania BucciarelliDirected by: Lorenzo Fontanawww.live.la7.itwww.ottoemezzo.la 7 .itTwitter: @OttoemezzoTW)Facebook : Ottoemezzola7)Thank you in advance for the considering. Looking forward to hearing from you.Patty TorchiaOtto e Mezzo(b)(6)From:Sent :To:Subject:Not really.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Mon, 27 Apr 2020 14:08:24 +0000Conrad, Patricia (NIH/NIAID) [E)RE: Fauci and PayPalNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Conrad , Patricia (NIH/NIAID) [E] ----------(b)(6) Sent: Monday, Apri l 27, 2020 9:54 AMTo: NIAID OD AM <NIAIDODAM@niaid .nih.gov>Subject: FW: Fauci and PayPalPatricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496 -4409 faxDisclaimer:The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID ) shall not acceptliab ility for any statement made that are sender's own and not expressly made on behalf of the NIAi D by one of its representatives.From: Fetalvo, Ninio J. EOP/OVP (b)(6) _________... __Sent : Monday, April 27, 2020 9:51 AM -------- == To: Conrad, Patricia (NIH/NIAID) [E] ---------- (b)(6) Subject: FW: Fauci and PayPalFYI-Defer to you on this.From: Miller , Amanda <amanmiller@paypal.com >Sent : Monday, April 27, 2020 9:18 AMTo: Fetalvo, Ninio J. EOP/OVP_ _________ ("b"~'"'(=6)Cc: Walters, Lindsay <Lindsay.Walte rs@edelman.com >Subject: [EXTERNAL] Re: Fauci and PayPalHi Ninio,We are wondering if Dr. Fauci would like to have a taped Skype conversation with PayPal CEO andPresident Dan Schulman to talk about safety measures, health and science tied to COVID-19. We wou ldair the conversation during a global employee all hands to our 23,000 employees and then we couldsyndicate parts of it externally on our social channels.Thanks for any help in reaching Fauci's team .Thanks,AmandaAmanda Christine Mill erSenior Director, Corporate Communications408.219.0563@PayPalNews• PayPalFrom:Sent:To:Fauci, Anthony {NIH/NIAID) [E]Mon, 27 Apr 2020 14:07:40 +0000Lerner, Andrea {NIH/NIAID) [E]Subject : RE: ------------------------ (b) (4)Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: {301 496-4409E-mail: (b)(The info rmation in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intend ed recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Lerner, Andrea {NIH/NIAID) [E) --------- (b)( >Sent: Monday, April 27, 2020 10:05 AMTo: Fauci, Anthony {NIH/NIAID) [E) ------ -(=b-)s(-=r6)Subject: Re: ------------------------ (b)(4I will make sure they get a response!From: "Fauci, Anthony (NIH/NIAID) (E]" ---------(b)(6) >Date: Sunday, April 26, 2020 at 8:43 PM To: "Lerner, Andr ea (NIH/NIAID) [E]" ----------=-:C-b):(6-) =Subject: FW: Update: -------------------------- (b)(4Please respond to this person. Thanks.From: Kircheis Dr. Ralf <RKircheis@syntacoll.de>Se nt: Wednesday, Apr il 22, 2020 9:41 AM --------~~ To: Coomes, Stephanie {NIH/NIAID) [E) _________ CbH_6)>; Fauci, Anthony {NIH/NIAID) [E)(b)(6)Cc: '-:-""'."""".~-:----::== (b=)=(6:)::;: :K.:..:i:.r.:c:.:..h::~e. .i:s..:.D::.r;...: .:R..::a..l;.f: .<...R:=K=i=rc=h=ei=s:@=::s::y:::n:::t=:a=c:o::1::1:::d.::::e::>_. ___ ,.._,,._,Subje ct: Update: (b)( 4) ------------------------ 1 mp o rt an c e: HighDear Dr. Fauci,dear Dr. Coomes,thank you for your reply from 13. April with the notice that the information has been shared with NIAID'sCOVID-19 research team.Has the project already been initially evaluate d by the team?Are there any questions or need for additional information?Looking forward to hearing from you.Kind regards,RalfMit freundlichen Gru~en / Kind regardsDr. Ralf KircheisDirector R&DResearch & DevelopmentMail: RKircheis@syntacoll.dePhone: +49 9441 686048s~ntacollSyntacoll GmbH, Donaustrasse 24, 0·93342 Saal a. cl. DcnauTel: +499441 / 68 60 0, Fax: +49 9441/6860 30Handelsregister : Amtsgericht Regensburg - HRS 1612USt- JdNr. DE 128580796Gesch3ftsfuhrerin: Dr. Alexandra Dietr ichUnsere Hinweise zum Datenschutz, insbesondere zu den Jhnen zustehenden Rechten, finden Sie unterwwws votacond.eJdatenschutz(b) (4)Von: Coomes, Stephanie (NIH/NIAID) [El -------------- (b)(6) Ge send et : Montag, 13. Apri l 2020 02:37An: Kircheis Dr. Ralf <RKircheis@syntacoll.de>Betr eff: RE: ___________________ Cb _H_4) _,CbH_5)Dear Dr. Kircheis,Thank you for your recent email to Dr. Anthony Fauci. Your message was forwarded to the Division ofMicrobiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Diseases(NIAID). As a member of DMID's Office of Scientific Coordination and Program Operations, I am pleasedto respond .I want to thank you for reaching out to share this informat ion and let you know that your mes:;age ha:;been shared with NIAi D's COVID-19 research team .Sincerely,StephanieStephanie M. Coomes, Ph.D.Health Scientist AdministratorOffice of Scientific Coordinat ion and Program OperationsDivision of Microbiology and Infectious DiseasesNational Institute of Allergy and Infect ious DiseasesNational Institutes of Health5601 Fishers Lane, Room 7G68Rockville, MD 20892(b)(6)(b)(6)Disclaime r: The informat ion in this email and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inally intended recipient. If you have received th isemail in erro r, please inform the sender and delete it from your mailbox or any ot her storage devices. The Nationa lInstitu te of Allergy and Infectious Diseases shal l not accept liability for any statements made that are the sender 'sown and not express ly made on behalf of NIAID by one of its represe ntatives .From: Kircheis Dr. Ralf ') (b)( ~ >Sent: Wednesday, Apr il 8, 2020 2:49 AMTo: Fauci, Anthony (NIH/NIAID) [El ..------ --,.(b.)._c=- >; Billet, Courtney (NIH/NIAID) [El-------- (b)(6)>; NIAID Ocpostoffice (NIH/NIAID) <OCPOSTOFFICE@niaid.nih.gov> Cc: Fischer, Elizabeth (NIH/NIA ID) [El (b)(6>i>; Foster, Erin (NIH/NIAID) [El(b)(6) Foster, Sarah {NIH/NIAID) [El CbH >; Vasilenko, Olga{NIH/NIAID) [El (b)( >; Vasquez, Aurelio (NIH/NIAID) [El---------- CbH >; Vostal, Alexander (NIH/VRC) [Fl (b)(6J>;V azquez- Maldonado , Nancy (NIH/NIAID) [El (b)( >; Austin, James (NIH/NIAID) [ElCbH '>; Agulto, Liane (NIH/NIAID) [E] CbH6JD; eckhut, Alison(NIH/NIA ID) [El (b)(6) Kircheis Dr. Ralf <RKircheis@syntacoll.de>Subject: WG: ------------------------ (b) (4), (b) (5) 1 mp o rt an c e: HighDear Dr. Fauci,dear Madams/Sirs,(b) (4), (b) (5)I want to bring to your attension some pote nt ially impo rtant experimenta l data and a new proposa l fortreatment of COVID-19 patients with acute respiratory distress syndrome and organ failure. Sorry forthe broad distribution but I wanted to make sure tha t my message reaches you.(b) (4), (b) (5)Please forward this mail to the colleages you consider relevant for evaluation, discussion andconsideration for your clinical strategy for COVID-19.Please let me know if additional informations are necessary.(b) (4). (b) (5)To my person: I have MD PhD degree and have many years experience in phar maceutical development{Boehringer lngelheim ), Biotech {lgeneon , Aphton , Virolog ik GmbH) {for reference see also PubMedKircheis r) currently leading R&D activities at Syntacoll {part of lnnocoll). I am providing this informationpersonally in order to help to find a treatment for COVID-19 patients .Looking forward to getting feedback from you,With kind regards,Ralf Kircheis {MD PhD)(b)(6)rkircheis@svn ta coll .de(b) (4), (b) (5)Mit freundlichen Grur..en / Kind regardsDr. Ralf KircheisDirector R&DResearch & DevelopmentMail: RKircheis@syntacoll.dePhone: +49 9441 686048s~ntacollSyntacoll CmbH, Donoustrasse 24, D 93342 Saa l a. d. DcnauTel: +49 9441 / 68 60 O, Fax: +49 9441 / 68 60 30Handelsregister: Amtsgericht Regensburg - HRB 1612USt-ldNr DE 128580796Gescha~sfuhrenn: Dr . Alexandra Dietr ichUnsere Hinweise zum Datenschutz, insbesondere zu den Ihnen zustehenden Rechten, finden Sie unterwww.syntacoll .de/da tenschutz(b) (4). (b) (5)
(bX5) -PCP.
From:Sent :Fauci, Anthony (NIH/NIAID) [E)Mon, 27 Apr 2020 12:33:44 +0000To: Jeremy FarrarSubject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 part icipati onThanks, Jeremy. I saw the report in the Post from Saturday. These children hadmostly respiratory disease and diarrhea . I wi ll check with the docs at DCChildren's Hospital about the presence of " mult isystem inf lammatory state". Thiscould just be the advanced stage of their disease compatible with advancedSARS-COV-2Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892 -2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and dele te it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Jeremy Farrar _______._... _ (b)(6)Sent : Monday, Apri l 27, 2020 7:38 AMTo: Fauci, Anthony (NIH/NIAID) [E] _____ --,a(b.~,.c=..6)>; Dzau, Victor J.<VDzau@nas.edu>; GeorgeGAO (b)(6)>(b)(6); Hannon, Emma <EHannon@nas.edu>; Conrad, Patricia ========-=-~ (b)( >; Teresa Miller de Vega (b)( >;(b)(6); Rebeka Yasmin - CEPI (b)(6); ben.tinker@cnn.com; ---- -----~= Amanda.Sealy@cnn.com; Neel.Khairzada@turner .com; Tia.Miller@turner.com; (b) (6)McGinnis, J. Michael <MMcGinnis@nas.edu>; (b)(6) Mun, Jenny<JMun@nas.edu>; (b)( Redfield, Robert R. (CDC/OD) (b)( '>Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25participationThanks Tony- have asked for that and wi ll share as soon as I can.I believe the re have been reports in the Washington Post.https://www .washingtonpost .com/local/new-dc-hospital-numbers-suggest-kids-do -face-some-riskof-coronavi rus-hospitalization/2020/04/25/Se 78c268 -86fe-11ea-878a-86477 a 724bdb story.htmlFrom: "Fauci, Anthony (NIH/NIAID) [E]" <f CbH>6 )Date: Monday, 27 April 2020 at 12:36To: Jeremy Farrar (b)(6) , Victor Dzau <VDzau@nas.edu >, Geo rge Gao(b)(Cc: Ric hard Hatchett (b)(6)" ann n, Emma" <EHannon@nas.edu>, "Conrad,Patricia (NIH/NIA ID) [E]" Cb)< >, Teresa de Vega------------- Cb>< , Rebeka Yasmin - CEPI ---------- (b) (6 ) "ben.tinker@cnn.com" <ben.tinker@cnn.com>, "Amanda. Sealy@cnn .com" <Amanda.Sealy@cnn.com >, "Neel. Khairzada@turne r.com"<Neel.Khairzada@turner.com >, "Tia.Miller@turner.com " <Tia .Miller@turner.com >,(b)(6) "McGinnis, J.Mic hael" <MMcGinn is@nas.edu >,(b)(6) "Mun, Jenny" <JMun@nas.edu>,CbH6") Redfield , Rob ert R. (CDC/OD)"(b)(6)r------------Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding yourSaturday April 25 participationJeremy:Thanks for the heads up. Is there any more detailed description of the preciseclinical manif estation s? They describe a "mul tisystem inflammatory state 11• It isvasculitis or anything more specific? Could be an infectious agent that hasnothing to do with SARS-CoV-2 infection even though some children arecircumstantially infected with SARS-CoV-2or it could be a post-SARS-CoV-2inflammatory syndrome , perhaps a Kawasaki syndrome-like disease. Please keepme informed if you hear any further information.Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: Cb()6 )FAX: (301) 496-4409E-mail --------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jeremy Farrar ________ (b _)_(6)>Sent: Monday, April 27, 2020 7:13 AM ------- ~= To: Fauci, Anthony (NIH/NIAID) [E] _______ (b_H_6); Dzau, Victor J.<VDzau@nas.edu>; GeorgeGAO (b)(6) >Cc: Richard Hatchett (b)(6) --=====~--~--~--~:----:--~ "':""""-:---"".'"":"-:.:======H=a-n~no~n , Emma <EHannon@nas.edu>; Conrad, Patricia (NIH/NIAID) [E] (b)(6) Teresa Miller de Vega (b)(6) ;(b)(6)· Rebeka Yasmin - CEPI (b)( >; ben.tinker@cnn.com; ____ _,,Amanda.Sealy@cnn.com: Neel.Khairzada@turner.com; Tia.Miller@turner.com; (b) (6);McGinnis, J.Michael< MMcGinnis@nas.edu>; (b)(6)> ; Mun, Jenny<JMun@nas.edu>; (b)(6)Subject: Re: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25pa rtici pat ionTo be aware of - news over night so a huge amount of uncertainty - important for COVID19n ow, and apotenti al concern for how we view immunity, protection, post-infect ious immunopathology.https://www .hsj.co.uk/acute-care/exclusive-national-alert-as-coronavirus-related-condition-may-beemerging-in-children/7027496.articlehttps://t.co/Bj6YH U8ziFrom: "Fauci, Antho ny (NIH/NIAID) [E]" (b)(6)Date: Sunday, 26 April 2020 at 19:52To: VictorD zau <VDzau@nas.edu >, George Gao ______ ...- -------~ =Cc: Jeremy Farrar (b)( 6} , Rich ard Hat chett _________ (b><6 )"Hanno n,Emma" <EHannon@ nas.edu >, "Conrad , Patricia (NIH /NIA ID) [E]" (b) (6)>,Teresa de Vega (b) (6)>, RebekaYasmin - CEPI (b)( , "ben. tinker@cnn.com " <ben. tinker@cnn.com >,"Amanda.Sealy@cnn.com " <Amanda.Sealy@cnn.com >, "Neel.Khairzada@turner.com "<Nee l.Khairzada@turner .com>, "Tia.Miller@turner.com" <Tia .Miller@turner.com >,---------------- (b)( 6) "McGinni s, J.Mi chael" <MMcG innis@nas.edu >,CbH>6,) "Mun, Jenny" <JMun@nas.edu>,(b)( 6)Subject: RE: NAS Annual Meeting Sess ion on COVID-19 -- Information regarding yourSaturday April 25 participationIt was a real pleasure to join all of you on this important session. Many thanks forinviting me.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb()6 )FAX: (301) 496-4409E-mail -------- (b)(6) The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and dele te it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J.< VDzau@nas.edu>Sent: Saturday, April 25, 2020 3:59 PMTo: George GAO (b)(6)Cc: Fauci, Anthony (NIH/NIA ID) [E] ----------------~~Emma <EHannon@nas.edu >; Conrad, Patricia (NIH/NIA ID) [El; Hannon,------------------------- (b) (6) ben.tinker@cnn .com; Amanda.Se a I y@ c n n. com; Neel.Khairzada@turner.com ; Tia.Miller@turner.com ; (b)(6)McGinnis, J.Michael< MMcGinnis@nas.edu >; (b)(6J>; Mun, Jenny------ (b)(6); haja.bally@cepi.net Subject: Re: NAS Annual Meet ing Session on COVID-19 -- Informat ion regarding your Saturday April 25participationDear Jeremy, Tony, Sanjay, George, Susan and Richard,Thank you so much for your superb contributions. It was a spectacular session- a tmly inspiringone. I am grateful to all of you.Hope to see you soon .Warm est regards,VictorOn Apr 25, 2020 , at 1: 22 PM, George GAO -------CbH6>) wrote:I am waiting for being connected and will use slides which were sent to your officeGeorge~ § ilt 1¥-JiPhone1± 2020~4 Fl 24 B . 0 l :49, Dzau , Victor J. <VDzau @nas.edu>~Ji:Dear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really looking forward to this panel on COVID-19 at the NAS AnnualMeeting on Saturday, April 25th at 2:00-3:30 pm ET. There is tremendousexcitement and enthusiasm, and registrat ion is through the roof.I am sending this note to do a last minute check to see if there is anything youneed from me. I also want to check whether you are planning to use slides.Will you be sending your slides to us to project or use the share screenfeature to advance your own slides? Regardless, it would be helpful to me ifyou could send me your slides for my preparation.I would greatly appreciate it if you wou ld respond to this email.Best,VictorPS, (b)(6) my special assistant, will be sending you additionalinformation about the session logistics short ly.From: Dzau, Victor J.< VDzau@nas.edu>Sent: Thursday, Apr il 9, 2020 11:01 AM---------- (b)(6); 'ben .tinker@cnn.com ' <ben.tinker@cnn.com >; 'Amanda.Sealy@cnn.com ' <Amanda .Sealy@cnn.com >;'Neel. Khai rzada@turner .com' <Neel.Khairzada@turner.com >;'Tia.Miller@turner .com' <Tia.Miller@turner .com>; 'hujr@chinacdc.cn'(b)(6)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Informationregarding your Saturday April 25 part icipa t ionDear all,Thank you for agreeing to participate in a special late breaking sessionon the COVID-19 pandemic at the NAS annual meeting. Knowing howbusy you are , I am sending this email in lieu of a call to prepare for thesession.As you know, this is a 90 minute session which aims to provide ouraudience with deeper insights into the latest developments in theCOVlD-19 response. I plan to hold an engaging discussion that coversthe whole experience on dealing with this pandemic - from US tointernational, to preparedness and response, the biology of the virus, thestate of diagnostic , treatment and vaccine development , and theimportance of commun ication.I will begin the session by providing brief ( ~ 3 min) opening remarksdescribing the circumstances of the pandem ic. Then , I will introduce thepanelists and you will each have 7 minutes to provide remarks. Youmay use a limited number of slides for illustration . I hope that eachpanelist will provide their own perspective and speak to the issuesproposed below.• Jeremy Farrar will discuss the global response to the pandemic,drawing from his experience as a global leader, the chair of theScientific Advisory Group for the VvHO's R&D Blueprint and asa member of the Global Preparedness Monitoring Board .• Tony Fauci will discuss the US pandemic and provide hisperspective as a member of the White House Coronavirus TaskForce addressing the 2019- 20 coronavirus pandemic.• George Gao will discuss China 's response to the pandemic andlessons learned for the rest of the globe.• Susan Weiss will discuss the viral characteristics of SARSCOV2, insights into its pathobiology, immunity anddevelopment ofa pan-CoV antiviral.• Richard Hatchett will discuss the development of new vaccinesand treatments against COVID-19.• Sanjay Gupta wtll comment on the health system response to thepandemic and challenges related to communication and publicengagement in responding to COVID-19.Following remarks from each panelist, we will have a moderateddiscussion amongst ounelves - I will ask you a set of questions ( 15mins) and then we will take questions from the web (25 mins). Toprepare me to be your moderator , please send me any questions youwould like me to ask you. For those of you who would like to have aprep call, please let me know and I will set it up.Best,VictorFrom: Mun, Jennysent: Wednesday, April 8, 2020 10:56 AMTo:(b)(6)'ben .tinker@cnn .com' ; 'Amanda .Sealy@cnn.com'; 'Neel.Khairzada@turner.com'; 'Tia.Miller@turner .com'Subject: NAS Annual Meeting Session on COVID-19 -- Information regardingyour Saturday April 25 participationDear Speakers:I am the logist ical contact for the COVID-19 session that will be held as part ofthe Ann ual Meet ing (online) program on Saturday, Apri l 25 at 2:00 pm EDTThank you for agreeing to participate in this session. To help you with yourplanning, I have provided additional details below .Please note that the session wi ll be live webcast and the general publ ic willalso be able to watch the session. Video from the session will also beuploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting. We willneed to obtain signed speaker release forms for your participation in thissession. I have attached the speaker release form for your review andsubmission. Please return the signed speaker release form by Monday , April13.Session speakers are asked to connect 30 minutes prior to the session starttime (by Saturday , April 25 at 1:30 pm EDT) to allow the technical staff tocheck connect ions and prepare for the session. Details on how to connect willbe sent before t he meeting .We will list you in our promotional materials as noted below . If this isincorrect , please let me know.Anthony S. Fauci, Directo r, National Institute of Allergy and InfectiousDiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control &PreventionSanjay Gupta, Chief Medical Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microbiology , Perelman School of Medicine,University of PennsylvaniaSince many of us have moved to remote work environments, you mayalready be proficient with Zoom and other on line meeting/collaborationapplications . I am attaching a 'speaker guidelines' file in case you have anyquestions on how best to prepare for and stage your remote talk. We havetechnical staff available to help you become familiar with Zoom and itssettings - such as "sharing your screen" (if you have slide presentations thatneed to be shown during your talk). We can arrange for a training session thisweek or next week. If you wou ld like to schedule a session, please let meknow as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If youhave any othe r questions , please let me know.Regards, Jenny********************~***********Jenny MunMembership DirectorNational Academy of Sciencesjmun@nas.edu(b)(6)From:Sent:Subject:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 18:45:27 +0000SNL revi ew(b)(6)OKAY, so here is something even better than having Brad Pitt portray me onSNL. It is a recent review of Pitt 's performance in which the TV reviewer said :" Kicking things off, the Oscar winner dropped jaws during the cold open withhis monologue about President Donald Trump's recent (and concerning)comments about COVID-19."Good evening, I'm Dr. Anthony Fauci," Pitt began his monologue and lookednearly identical to the director of the Nationa l Institute of Allergy and InfectiousDiseases."Someone said Pitt looked "nearly identical" to me. Yikes!! QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: Cb()6 )FAX: (301 496-4409E-mail: (b)( 6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 18:37:57 +0000Barnes, FreddieSubject: RE: Appr eciationFreddie:Many thanks fo r your kind note . It is much appreciated .Best regar ds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301) 496-4409E-mail : Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barnes, Freddie <freddie.barnes@ncdps.gov>Sent: Sunday, April 26, 2020 10:48 AM ------~~ To: Fauci, Anthony {NIH/NIAID) [E] (b)(6)>Subject: AppreciationDr. Fauci I just wanted to express my profo und appreciat ion to you for your work during this COVID-19pandemic. I especially appreciate how you have spent considerable time and capital reaching out to theBlack and brown communities. I saw exerts of your snapchat with Will Smith and saw nearly all of yourinterview on the Breakfast Club. I regret I have to send an email to you re this matter. But t his is theday we live in. Minority communities continue to be over-looked in crises and the impact of such criseson their respective communities. For you to be int entional about keeping the minor ity communities inthe loop is commendable, especially since these communities will be absorbing the disproport ionateshare of the sicknesses and deaths coming from COVID-19.Thanks for all of what your are doing in keeping the nation informed. Thanks for informing based on thefacts, data, and truth.Take care and "Cover your six."Email correspondence to and from this address may be subject to the North Carolina Public Records Law and may be disclosed to thirdparties by an authorized state official.From:Sent :Fauci, Anthony (NIH/NIAID) [E)Sun, 3 May 2020 13:29:53 +0000To:(HHS/OASH)Cc:Adams, Jerome (HHS/OASH)-- ---------------~-~ CbH61G) iroir, Brett(b)(6)Subject : RE: High touch points(b) (5)From: Adams, Jerome (HHS/OASH) ---------(b) ( ">Sent : Sunday, May 3, 2020 7:37 AM ------ ~= To: Fauci, Anthony (NIH/NIAID) (E] (b)(6J>; ----------(b)( ; Giroir, Brett (HHS/OAS H) (b)(6)>Cc: CbH6JSubject: Fwd: High touch pointsPlease see short thread below. Senator Young reached out to me about this and I forwarded to CDC. AsJeromeVADM Jerome Adams20th US Surgeon GeneralBegin forwarded message:From: "Adams, Jerome (HHS/OASH)" --------- (b)( > 0 ate: May 3, 2020 at 7:32:46 AM EDTTo: "Jernigan, Daniel B. (CDC/DDID/NCIRD/1D)" __ .;._.:...::~~---Cc: "Schuchat, Anne MD (CDC/OD)" (b)(6)(b) (6)>Subject: Re: High touch pointsThank ou.(b)(5(b) (5)(b) (5)Please keep me posted . And should I refer the senator to you or someone at CDC to closethe loop?Thanks!JVADM Jerome Adams20th US Surgeon GeneralOn May 2, 2020, at 7:08 PM, Jernigan, Daniel B. {CDC/DDID/NCIRD/ID)------(b)(6)> wrote :ADM Adams:Thanks for sending this. There has been a lot of guidance on disinfection andcleaning, notably some very recent collaborative work we have done withEPA (https://www .cdc.gov/coronavirus/2019-n cov/communi ty/ reopenguidance.html) . Attached are two documents focused on re-opening Americawith emphasis on cleaning and disinfection, including high-to uch surfaces.Also below are a number of websites that address cleaning and disinfectionwhich point out the importance of disinfecting high-touch locations likedoorknobs. They give guidance how to clean them, but they don't addressmethods for using a paper towel or Kleenex to first turn the knob and thendiscard the towel. (b)(5)ThanksDan.Daniel B. Jernigan, MD MPHDirector, Influenza Division; HHS CDC Lead, FEMA-HHS COVID-19 ResponseCaptain, USPHS (RET)National Center for Immunization and Respiratory DiseasesCenters for Disease Control and Prevention1600 Clifton Rd NE, Atlan ta, GA 30329Phone (b) (6) , Cell (b) (6)------- (b) (6) www.cdc.gov/fluhttps://www.cdc.gov/coronavirus/2019-ncov/community/disinfectingbuildi ng-facil ity. htmlhttps://www.cdc.gov/coronavirus/2019-ncov/prevent-gettingsick/disinfecting-your-home.htmlhttps://www.cdc.gov/ coronavirus /2019-ncov / community/disinfectingbui ldi ng-facil ity-H.pdfFrom: Adams, Jerome (HHS/OASH) --------- (b) (6)>Sent : Friday, May 1, 2020 5:35 PMTo: Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) __.:. ._~~~---Cc: Schuchat, Anne MD {CDC/OD) (b)( >Subject: High touch pointsDr. Jernigan,I got a message from a Senator asking why we didn't have specific reopeningrecommendations for "high touch" points like door knobs/ handles/ elevatorbuttons . The Senator stated that (b) (5)JeromeVADM Jerome Adams, M D, MPH20th U.S. Surgeon General<Reopening_America_Guidance.pdf><ReOpening_America_Cleaning_Disinfection_Decision_Tool.pdf>From:Sent :Fauci, Anthony (NIH/N IAID) [E)Thu, 30 Apr 2020 22:37 :05 +0000To :Subject:Hahn, Stephe n;Debi Birx;Redfie ld, Robert R. (CDC/OD);Verma, Seema (CMS/OA)RE: Serology Studies in GermanyThanks, St eve !Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"44 09E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Hahn, Stephen (b)( •>Sent: Thursday, April 30, 2020 6:34 PMTo: Debi Birx (b)(6l>; Redfi eld, Robert R. (CDC/OD) ---------(b)( , Seem a (CMS/OA ) (b)( >; Fauci, Anthony (NIH/NIAID) [E)(b)(6)Subject: Fwd : Serology Studies in GermanyInteresting information from GermanyFrom: Shuren, Jeff ---------(b) (6)>Date : Apr il 30, 2020 at 5:46 :27 PM EDT_To_: H_a hn.,. .S.te:p,h_en_ :...,__..!(:b):(6:J=>, ~Sh~ah~, A--n-a-.n.d. .....!=====~(~b)(-6J->-, Lenihan , Keagan (b )( >, Guram, Jeet (b)( >, Rom, Colin======== (b~)(~6)~>--Subject: Serology Studies in GermanyFYSA regarding serology studies being conducted in Germany, including status of tests to be used forthose studies. This is the follow up to what I sent you last week . (b)( 5From: Hoshi, Ryan (b)(6)Sent: Thursday, April 30, 2020 3:17 PMTo: Shuren, Jeff (b)(6)Cc: Nalubola, Ritu (b)(6); louati, Claudia (FSN)* .:=:::::========~~ .;.....!:::========~;;-" O'Leary, Brendan (b) < >; Torres, Melissa A ----------- Stenz e I, Timothy (b) ( >Subject: FW: PLEASE REVIEW» Meeting Notes - Call with (b)(5(b)(5)(b)(S )Thank you,RyanRyan A. Hoshi , Ph.D.Internat ional Po licy Analyst I Center for Devices and Radiological Health I ______ .C.,.b).,.(.6,.)., I phon e(b) (6)1 mobil e Cb) (6) .,__ ____U.S. FOOD & DRUGADM IHISTUTIONExcellent customer service ,s ,mporta~t to usPlease take a moment to provl:fe feedback regarding the customer service you have receivedclick here for survey(b) (5)From: Fauci, Anthony (NIH/NIAID) [E)Sent : Mon, 27 Apr 2020 14:14:36 +0000To: Halkovich, Townshend ConnieSubject: RE: Appr eciation to my hero --Dr. Fauci--our country 's voice of reason in th eseunsett ling, uncertain t imes--We NEED YOU!!!! Please don' t leave us now wh en we need you most!!!Connie:Many t hanks fo r you r kind note . Mu ch appreciated .Best regards,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Halkovi ch, Townshend Connie (b)(6)Sent : Monday , April 27, 2020 9:04 AMTo: Fauci, Anthony (NIH/NIAID) [E] _____ ("b"~'""('6=)>Cc: Halkovich , Tow nshend Connie (FDA/OC) (b)(6)Subject: RE: Appreciat ion to my hero--Dr. Fauci--our country 's voice of reason in these unsett ling,uncertain t imes--We NEED YOU!!!! Please don 't leave us now when we need you most!!!Where is Dr. Fauci?I know where Dr. Fauci is-I saw him on SNL- remarkably he looked like Brad Pitt - except [to many ofus] Dr. Fauci is better looking . Smile, wink Why? We look with our heartsI remember someone asked Dr. Fauci [in jest ] who would he like to represent him in a movie ... Dr. F. saidBrad Pitt. Well - Dr. F. Your dream suggestion came t rue. But, in many of our hearts- NO ONE can takethe place of our beloved, we ll respected, honored Dr. Anthony Fauci !!! !God Bless Amer ica, God Bless Dr. Fauci ! ! !From: Halkovich, Townshend ConnieSe nt: Friday, March 13, 2020 11:06 AM(b) (6)>To: 'anthony .fauci@nih.gov ' (b)(6)Cc: Halkovich , Townshend Connie <Constance.Halkovich@fda.hhs.gov>Subject: AppreciationDear Dr. Fauci:1st & foremost - please keep you rself healthy .... get more rest than 3 hrs/nigh t.© Why? We need you!THANK YOU for all your very informat ive updates . YOU are voice of reason ... in t ime of coronavirusfear ... you give us hope ... saying that action is what is needed ... not fear!You are someone we can be proud of ... you provide service we can count on!!!!God bless You & Your Family!! !Warmest Regards from:Connie Leigh Townshend Halkovich, Management Analyst, 410-867 -0878,#FDA OIMT D10 Proud: Peo le & Service ou can count on!©(b)(6)My Wish 4 U: Peace, Love. Laugher -blessed Z work with U ALL! Abe Lincoln: "folks are as happy as they choose 2be" -Bhappy all circumstances -H ope all well with you, yours--ifnot, pretend it is.FDA M ission: Responsible for protecting public hea lth by ensuring safety, efficacy/security of human & vet. drugs, biol. products, med.devices, aur nation 's food supply, cosmetics, & products that emit radiation.D10 Mission: -Provide excellent implementation, aperatian , maintenance of IT {equipment, services} to promote FDA's PublicHealth Mission.D/0 Vision: Provide state -of-the -art IT services-inclusive of surrounding policy, planning, customer service, in tegration, &oversight necessary to make the mission successful & sustainable.From: Fauci, Anthony {NIH/NIAID) [E)Sent : Tue, 5 May 2020 22:26:27 +0000To: Foikers, Greg (NIH/NIAID) [E);Billet, Courtney (NIH/ NIAID) [E];Stover, Kathy(NIH/NIAID) [E);Routh , Jennifer (NIH/N IAID) [E];Awwad , David (NIH/NIAID) [C]Cc: NIAID OD AMSubject:Attachment s:0RE: ASF RE: Dr. Fauci video reque st: Public Service Recognit ion WeekASF pub lic service recognition - w ith tracked edits -05-0 5-2020 .docxSee minor tr acked changes.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (301) 496-4409E-mail Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/ NIAID) [E] CbH >Sent: Tuesday, May 5, 2020 6:16 PMTo : Billet, Courtney (NIH/NIAID) [E] -----~ Cb ~H=6)>; Stover, Kathy (NIH/NIA ID) [E]CbH6J;> Routh, Jennifer {NIH/ NIAID) [E] CbH6>1A; wwad,David (NIH/NIA ID) [C] CbH6J>Cc: NIAID OD AM <NIAIDODAM@niaid.n ih.gov>Subject: ASF RE: Dr. Fauci v ideo request: Pub lic Service Recognition Wee kASFHereis a short script for Public Serv ice Recognition Week. We agreed to do a short videoASF - can u tweak as needed?David, could u record in some format that is easy? Cell phone or other I just learned they want by COBtomorrow<< File: ASF public service recogn ition.docx >>From: Seigfreid , Kim (NIH/OD) [E] CbH6J>Sent: Monday, Apri l 27, 2020 4:30 PM --------=-~ To: Billet, Courtney (NIH/NIAID) [E] (b)(6J>; Stover, Kathy (NIH/NIA ID) [E]--------- (b)(6)>; Routh, Jennifer (NIH/NIAID) [E] (b)(6)> Cc: Fine, Amanda (NIH/OD) [E] Cb)( >; Polimeni, Lydia (NIH/OD) [E](b)(6)Subject: Dr. Fauci video requ est: Public Service Recognition WeekHi there,Please see below. HHS is taking over the Partnership for Public Service IG accoun t next week for PublicService Recogn ition Week . They asked if Dr. Fauci would be willing to do a short 30-second or less prerecordedvideo thanki ng public servants for their work . It would be featured during the takeover , and alsoon NIH's other sm handles next week . It can be taken on a cell phone as sm does not require higherresolution . Let me know if you would like to accept or decline the request.Many thanks ,KimKim SeigfreidSocial Media LeadNIH Office of Communications and Public Liaisonph: (b)(6)(b)(6)From: Muhammad, Janell (HHS/ ASPA) (b)(6),Sent : Monday, Apri l 27, 2020 4:10 PM ---------~~ To: Seigfre id, Kim (NIH/OD) [E] CbH6J>; Channer, Amber (OS/OASH)---------- CbH6J>;F oster, Timothy (OS/ ASPA) CbH6)> Cc: Palczewski, And rew (HHS/ASPA) CbH6J>; Pratt, Michael (OS/ASPA)--------- (b)(6J>; Sherman, Jennifer (HHS/OASH) (b)(6) Wi lker, Michael (HHS/ASPA) (b)(6); Dine, Brooke (HHS/ASPA)(b)( 6)Subject: Public Service Recognition WeekHello All,Hope eve ryone is holding up well !OHR is taking over the Partnersh ip for Public Service (PPS) lnstag ram account during PublicService Recognit ion Week (May 3-9, 2020). The OHR team has reached out about want ing todevelop a senio r leade r "mashup " video -perhaps including the DepSec. TThey asked about the feasibility of this request. They also inquired about perhaps Dr. Fauci andthe SG doing a pre-recorded video thank ing public servants for their work.I wanted to gather the troops so we can identify what all is being planned for this week ofrecognition and provide a POC for OHR if the request is feasible.Happy to set up a call, if tha t is needed to discuss further .Thanks,JanellJanell MuhammadASPA Digital Engagement (Team Lead)U.S. Department of Health and Human ServicesEmail: (b) (6)Office: (b) (6)iPhone: Cb()6 )HHS on Facebook I HHS on Twitter I HHSLatinoFrom:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [E)Tue, 5 May 2020 21:58:55 +0000Adams, Jerome (HHS/OASH)RE: Update on Sara AlertWhat do you mean by ------------------------ (b) (5)Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sende r's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Adams, Jerome (HHS/OASH)- --------(b)( > Sent : Tuesday, May 5, 2020 2:49 PMTo: Birx, Deborah L. EOP/NSC -------- "C"'.bH.,.".6."J"'; Fauci, Anthony (NIH/NIAID) [E)(b)(6)>Subject: FW: Update on Sara AlertImportance: HighJeromeVADM Jerome Adams, MD, MPH20th U.S. Surgeon GeneralFrom: Jarris, Paul (b)(6J>Sent: Friday, May 1, 2020 7:29 P-M- -----~~ To: Adams, Jerome (HHS/OASH) CbH6)> ...;..::=======-~:a;-Cc: Wright, Janet (HHS/OASH)- --------- CbH6)(b) (5)Subject: Update on Sara AlertImportance: HighDear Jerome,I hope you are well. Thank you for all you are doing to represent public health and our nation. It is verycomforting knowing you are informing the nations COVID-19 response.I wanted to give you an update on called Sara Alert, the software program I am leading at MITRE. SaraAlert is being provided free of any costs and deployed in state, tribal, and local health departments tosupport public health in contact tracing and active monitoring of individuals in isolation and quarantine.We are engaged with ASTHO, NACCHO, CSTE, and the application is hosted live on APHL's AIMSplatform. Sara Alert officially launched on April 3 and is currently supporting multiple jurisdictionsincluding Commonwealth of the Northern Mariana Islands, Danbury, CT, and the State of Arkansas. It isalso being rolled out in Washington, Arizona, Pennsylvania, Virginia, Maine and Vermont. We are gettingready to launch in additional jurisdictions over the next couple of weeks.We have recently responded to questions we were told came from the White House so I wanted tomake sure you have background materials. I imagine you are the person that the President and VicePresident would turn to for information. I am happy to arrange any briefing mater ials or demo thatwould be helpful for you to respond.As I mentioned previously, Sara Alert is a standards-based, open source tool that automates the processof monitoring individuals exposed to or infected with COVID-19 (or any disease, it's configurable) - andwi ll serve as an enduring national resource to contain disease. Sara Alert is free for use by public healthorganizations.Best wishes to you. Stay healthy for all of us.PaulABOUT SARA ALERTIn response to the COVID-19 pandemic, the MITRE Corporat ion, a not-for-profit that works in the publicinterest, developed Sara Alert, a standards-based, open source tool in partnership with national publichealth organizations. Sara Alert automates the process of monitoring individuals exposed to or infectedwith COVID-19 (or any disease, it's configurable) - and will serve as an enduring national resource tocontain disease. Sara Alert is free for use by public health organizations .• Sara Alert allows public health officials to import and enroll individuals (or households) at risk ofdeveloping or infected with COVID-19.• Individuals enter their symptoms daily via web, text, email or phone, allowing public healthofficials to focus on high risk and non-reporting individuals .• The web-based tool enables increased efficiency in tracking cases, leading to earliercontainment of the virus and reduction of burden on public health resources.• Sara Alert is a national system and allows transferal of monitorees across jurisdictions for tighte rcontact tracing.Sara Alert launched on April 3 and is now supporting multiple jurisdictions .Sara Alert YouTube Video : https://youtu.be/lQxAuNsg-RAPaul E. Jarris, MD, MBAChief Medical AdvisorHealth Transformation CenterMITRE Corporation(b) (bJj-=-=-=-=-;:((bb:))( ~(66))] ] OMfofbicieleFrom:Sent :To:Cc:Subject:Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [ElSun, 3 May 2020 17:45:26 +0000Lane, Cliff (NIH/NIAID) [El;Collins, Francis (NIH/OD) [ElLowy, Douglas (NIH/NCI) [E);Mascola, John (NIH/VRC) [ElRE: Gallo and OPV(b) (5)National Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Lane, Cliff (NIH/NIAID) [El -------- (b) ( >Se nt: Sunday, May 3, 2020 1:22 PM -----~~ To: Collins, Francis (NIH/OD) [El (b)( >Cc: Lowy, Douglas (NIH/NCI) [El (b)(6) ; Fauci, Anthony (NIH/NIAID) [El-------- (b)(6) >; Mascola, John {NIH/VRC) [El (b)(6)> Subject: Re: Gallo and OPVFrancis,(b)( 5)CliffOn May 3, 2020, at 12:55 PM, Collins, Francis (NIH/OD) [El _______ Cb _H_6) wrot e:Hi all,I'm a bit at a loss to know how to respond to Bob Gallo.FrancisFrom: Gallo, Robert- --------- (b)( > Sent: Sunday , May 3, 2020 12:07 PM ------~~ To: Collins, Francis (NIH/OD) (E] ..._ _____ Cb_) _(6)Subject: RE: Your query to Dr. KadlecDear Francis,It was a pleasure to hear from you, and yes, it has been a long time since we met oreven spoke. Moons ago I was set to write to you after reading your wonderfulbook, but I ended up instead speaking with others about it. I should add at thispoint that I did not quickly respond to your email of a few days ago because Isimply missed it.It is true that I strongly suggest that OPV be quickly (already it is not quickly)brought forward for induction of a strong innate immune response to prevent ormarkedly reduce SARS-CoV-2in fection and/or severity until the field obtains aproven safe and efficacious vaccine producing a long lasting, adaptive immunity .OPV is very safe (notably for OPV 1 and 3 as bOPV which we will use andcompletely safe in a vaccinated population), simple, cheap, rather obvious, yetunique among the massive number of vaccines many (maybe most) of which arethe same or at least if not exactly the same aiming at the same mechanism(targeting the spike and searching for the putative correlate of neutralizing Abs.).OPV should work for a few months and possibly longer. Also it should be workingmultip le times so I think could cover more than a few months, giving us time for aproven vaccine of adaptive immunity, which might be very long lasting as is hoped.In the main the WHO comments are correct. Of course we sought and have lettersof support from them as well as from many others . Though they are againsupportive in their notes to you, there is one item that surprises me. They addthat there was no clinical efficacy results as yet. They know or certainly shouldknow that there is plenty of clinical data for this concept with BCG, OPV, and liveMeasles vaccine. Needless to say this is what turned me on during our regularGlobal Virus Network (GVN)conference calls. (Incidentally GVN is an organization Ihave thought of bring ing to your attention. I th ink you would find it impressive anduseful). I would be happy to share with you the clinical observations with OPV ifyou wish.I would like to take a small diversion, but I suspect you are aware of these things.My colleagues and I respect the WHO because of its representation and becausewe have colleagues/friends there as well. However, sometimes bureaucracy of amassive degree leads to inaction or even much worse-- political expediency. I won'tbother you with details of these unless you ask, but I had such experiences withHTLV-1 which we discovered in 1980 as the 1st human retrovirus and which causenot only the highest incidence of cancer(% of infections) of any virus and otherfatal diseases as well but mainly in less developed countries (plus Japan) and againwith HIV in 1984. Behavior was not beneficial. Perhaps it will be of relevance in thefuture because a few at WHO took a position to remove OPV (Sabin) in favor of IPV(Salk) in their polio eradication scheme. It was a huge failure. As my FDAcollaborator, Konstantin Chumakov, says "Blessed be Bill Gates" because he savedOPV and saved the day and in so doing has produced a still better OPV.There is indeed data also for BCG as well as live Measles though I know less of thelatter. BCG is less available, requires injection, harder to make, not as safe, and wethink unlikely to be as effective as OPV. Nonetheless, we favor its use too. Themechanisms will be similar.You asked whether monkey trials are planned. For several reasons definitely not -thoughwe are planning some monkey experiments, but not large enough for"clinical" conclusions. The main reasons are: 1) cost; 2) that billions not thousandsor millions have received OPV safely and in our collective view (and we know thestudies pretty well) protection has been clinically shown; 3) In a pandemic wewished to move quickly (so far we must say that has not been achieved). A typicalmonkey vaccine study will take time, but 4) in this case it would be a huge amountof lost time as monkeys require great doses of polio for infection and monkeyshave to be trained to drink their orange juice. It would be hard to imagine that suchstudies would even give us useful information.On a final digression Francis I have had 36 years of on/off experiences withglycosylated spike proteins-their analyses immunologically and especiallyregarding use in vaccines and developing neutralizing Abs. I believe it will be amistake to put most eggs in that basket. The risks: shortened antibody half life; 2)protection NOT correlating with neutralizing Abs; 3) sometimes hazards from them.Admittedly, they might work, but I trust and hope that not everything is going inthis bag. If you wish to discuss this again I will be available.Finally, I hd no idea you were into vaccines or SARS-2 nor any part of CoVID-19disease, but I am very happy to learn this.Thanks.Bob GalloFrom: Collins, Francis (NIH/OD) [E] (b)( >Sent: Thursday, April 30, 2020 5:00 PMTo: Gallo, Robert Cb) (6J>Cc: Disbrow, Gary (OS/A SPR/BARDA) CbH6J>K; adlec, Robert(OS/ASPR/I0) Cb)( >; Tabak, Lawrence (NIH/OD) [E)CbH6J>S;h uy, Bryan (OS/ASPR/I0) Cb)( >; Johnson,Robert (OS/ASPR/BARDA) Cb)( >; Mascola, John (NIH/VRC) [E)--------- (b)(6b ; Lane,C liff (NIH/NIAID) (E] (b)(6J>Subject: Your query to Dr. KadlecCAUT ION; Tbis message 01iginnted from II oon UMB, UMSOM, FPI , or UMMS cmnil sys tem . Wheth er thesender is known or not known, hover over any links before c]jcking and use caution opening attachments.Dear Bob,It's been quite a while since we've chatted. Bob Kadlec asked me to respond toyour query about the possible use of OPV to activate innate immunity and provideCOVID-19 protection. Has this been tested in a non-human primate model? I notethe recommendation below that says a clinical trial is planned - can you tell memore about that?As you can imag ine, we are all flat out on the vaccine development pathway!Franc isThe use of oral polio vaccine( OPV) to prevent SARS-CoV2(P olio EradicationCampaign)There is no evidence that ora l poliovirus vaccine (OPV) protects people againstinfection with COVID-19 virus.A clinical trial address ing this question is planned in the USA, and WHO willevaluate the evidence when it is available.In the absence of evidence , WHO does not recommend OPV vaccination for theprevention of COVID-19. WHO continues to recommend OPV as part of essentia limmunization services to prevent poliomyeli tis and as part of global polioeradication efforts.There are experimental signals from various studies over the years that OPV hasnon-spec ific effects on the immune system. These effects have not been wellcharact erized and the ir clinical relevance is unknown. Such non-specific effects maynot be limited to OPV, as other live vaccines have also been associated with nonspecificprotective effects (such as BCG vaccine against tuberculosis). Non livevaccines in contrast do not seem to have the same effects.The exact mechanism of non-specific protection induced by live vaccines needs tobe elucidated f urther. Clinical studies could begin immed iately because thevaccines in question are licensed and have an excellent safety record. Clinical tria lsinvolving off-label use of various drugs licensed for other indications are currentlyunderway. The existing scientific rationale suggests that the same should be donefor OPV and other live vaccines. A study is currently being discussed with variouspartners and vaccine manufacturers, including the US FDA, the outcomes of whichwill be carefully assessed to determine potential use in the context of the spread ofSARS-CoV2 until the time when specific vaccines and antiviral therapies are ready.From: Kadlec, Robert (OS/ASPR/10) (b)(6)Sent : Thursday, April 30, 2020 10:28 AMTo: Gallo, Robert CbH6l; Collins, Francis (NIH/OD) IE](b)(6); Tabak, Lawrence (NIH/OD) [E] (b)( >; Shuy,Bryan {OS/ASPR/10) (b)( >Subject: Re: ResponeDr Gallo thank you for your note and I appreciate you reaching out to me. I have copied DrCollins and Dr Tabak to consider the ACTIV forum they have created to br ing industryacademia and government to consider scientific base approaches That you havedescribed. Dr Collins has organ ized a vaccine group and I assess could be the best andfastest place to discuss your concept. I am sure they will connect with you soonestBestBob Kadlec.Sent from my iPhoneOn Apr 30, 2020, at 10:02 AM, Gallo, Robert ---------- (b)(6)>wrote:Dear Dr. Kaldec ,I have not heard from you in over a week. You mentioned getting backto me in a day or two. l ime is passing. I am asking you to look at OPV 1plus 3 serotypes as a bivalent, completely safe vaccine with powerfulstimulation of innate immunity lasting several weeks, which can begiven a second or third time, and with a historical track record ofpreventing other infections from entirely different RNA viruses (such asprotecting against influenza). Therefore, it should be really helpful forsome months, and I think get us past a second wave of SARS-CoV-2,and help people return to work safely. I don't understand delays orapparent lack of interest . Who can possibly be against this? If you hearof hypothetical prob lems we can show you that these are false. Justask the questions, and we can give you the evidence.However, no answer from you suggests no interest and must quicklymake alternative pathways. I am though quite surprised and fear youare receiving "fake news" if you will pardon the expression . Some havebeen against th is who defend their old and fai led position on polioeradication with their promotion of the use of the inactivated poliovirus vaccine. Please note that in the US between 1962 and 1985 wereceived (safely) the oral polio (OPV). Moreover, if vaccinated alreadythere has not been a single case of a complication and BILLIONS havereceived it . No it will not last long as innate immunity is short lived, butwe strongly believe that we can break the back of the SARS-CoVID-2spread. Also note that this is what Bill Gates is doing now in India andmuch of the Eastern hemisphere .There are countries outside the US wanting to move fast on th is. Weare waiting for your reply .Robert GalloDirector, Institute of Human Virology,Professor of Medicine and Professor of Microbio logy,UMB, School of Medicine , Baltimore,AndCo-founder and International Science Advisor of the Global VirusNetwork (GVN)From:Sent:Fauci, Anthony (NIH/NIAID) [E)Thu, 30 Apr 2020 15:17:01 +0000To :[ElCollins, Francis (NIH/OD) [E);Mascola, John (NIH/VRC) [E);Lane, Cliff (NIH/NIAID)Cc: Tabak, Lawrence (NIH/OD) [ElSubje ct: RE: ResponeFrancis:Thanks for the not e. I will let Cliff speak for himself, (b) (5 '(b) (5)--------- Cb>5>< but I will let him speak for himself . We can discuss further if you wish.Best,TonyAnthony S. Fauci, MODirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MO 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in er ror please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Collins, Francis (NIH/OD) [El ------- (b)(6)>Sent : Thursday, April 30, 2020 10:58 AM ------~~ To: Mascola, John (NIH/VRC) [El (b)( >; Lane, Cliff (NIH/NIAID} [El--------- (bH ; Fauci, Anthony (NIH/NIAID) [El (b)(6)•> Cc: Tabak, Lawrence (NIH/OD) [El (b)( >Subject: FW: ResponeHi John, Cliff, and Tony,Ignore the silly part of the message below, where -:-~===========(b)=( 5) ~ . But let me ask you guys whetherFrancisFrom: Collins, Francis (NIH/OD) [E]Sent : Thursday, April 30, 2020 10:55 AM -------..,,.,..., = To: Kadlec, Robert (OS/ ASPR/10) ~======~~ Cc: Tabak, Lawrence (NIH/OD) [El >; Shuy, Bryan (OS/ASPR/10)(b)(6); Disbrow, Gary (OS/ASPR/BARDA) (b)( >; Johnson, Alfred(NIH/OD) [El (b)(6)Subject: RE: ResponeBob,I I I I . : .. • • • • I I • I I I • I I• (b) (5). . • • IFrancisFrom : Kadlec, Robert (OS/ASPR/10) (b)(6)Sent: Thursday, April 30, 2020 10 :28 AMTo: Gallo, Robert (b)(6)>; Collins, Francis (NIH/OD) [El -------- (bH6J; Tabak, Lawrence (NIH/OD) [El (b)(6)> ; Shuy, Bryan (OS/ ASPR/10)(b)(6)Subject: Re: ResponeDr Gallo thank you for your note and I appreciate you reaching out to me. I have copied Dr Collins andDr Tabak to consider the ACTIV forum they have created to bring industry academia and government toconsider scientific base approaches That you have described. Dr Collins has organized a vaccine groupand I assess could be the best and fastest place to discuss your concept. I am sure they will connectwith you soonestBestBob Kadlec.Sent from my iPhoneOn Apr 30, 2020, at 10:02 AM, Gallo, Robert- --------- (b) (6)> wrote:Dear Dr. Kaldec,I have not heard from you in over a week. You ment ioned getting back to me in aday or two. Time is passing. I am asking you to look at OPV 1 plus 3 serotypes as abivalent, completely safe vaccine with powerful stimulation of innate immunitylasting several weeks, which can be given a second or thi rd time , and with ahistorical track record of preventing other infections from entirely differen t RNAviruses (such as protecting against influenza). Therefore, it should be really helpfulfor some months, and I think get us past a second wave of SARS-CoV-2, and helppeople return to work safely . I don't understand delays or apparent lack of inte rest.Who can possibly be against this? If you hear of hypothetical problems we canshow you that these are fa lse. Just ask the questions, and we can give you theevidence .However , no answer from you suggests no interest and must quickly makealternative pathways. I am though quite surprised and fear you are receiving "fakenews" if you will pardon the expression. Some have been against this who defendtheir old and failed position on polio eradication wit h their promotion of the use ofthe inactivated polio virus vaccine. Please note that in the US between 1962 and1985 we received (safely) the oral polio (OPV). Moreover, if vaccinated alreadythere has not been a single case of a comp lication and BILLIONS have received it.No it will not last long as innate immunity is short lived, but we strongly believethat we can break the back of the SARS-CoVID-2 spread. Also note that this is whatBill Gates is doing now in India and much of the Eastern hemisphere.There are countr ies outside the US wanting to move fast on this. We are wait ing foryour reply.Robert GalloDirector, Institute of Human Virology,Professor of Medicine and Professor of Microbiology,UMB, School of Medicine, Baltimore,AndCo-founder and International Science Advisor of the Global Virus Network (GVN)From:Sent :To:(b)(6)Wed, 29 Apr 2020 13:39:44 -0400Billet, Courtney (NIH/NIAID) [E]Subject: Fwd: ASF: For review ASAP: draft Sec. Azar Remdesivir statementAttachments : 4 29 20 remedesivir.docx, ATTOOOOl.htmCann ot do right now. Go without meBegin forwarded message:From: "Billet, Courtney (NIH/NIAID) [E]" (b)(6)Date: April 29, 2020 at 1: 11: 19 PM EDTTo: "Fauci, Anthony (NIH/NlAID) [E]" --------=-::-:-=Cc: "Routh , Jennifer (NIH/NIAID) [E]" (b)(6) , "Stover, Kathy(NIH/NIAID) [E]" (b)(6) "Lane, Cliff (NIH/NIAID) [E]"(bH6) >, "Marston, Hil ary (NIH/NIAID) [E]"(bH6) >, "Conrad, Patricia (NIH/NIAID) [E]"(b)( >, "Folkers , Greg (NIH/NIA.ID) [E]"(b)(6) >Subject: ASF: For review ASAP: draft Sec. Azar Remdesivir statementFrom: Fritz, Craig (NIH/OD ) [E] (b)(Sent : Wednesday, April 29, 2020 10:38 AMTo: Billet, Courtney (NIH/NIAID) [El -------= (b")"(""6=>"r>; Stover, Kat hy (NIH/N IAID) [El-------- (b)(6) Routh, Jennifer (NIH/N IAID) [El (b)( > Cc: Burklow, John (NIH/OD) [El (b)( ; Myles, Renate (NIH/OD) [El(b)(6) ; Fine, Amanda (NIH/OD) [El (b)(6)>; Wojtowicz,Emma (NIH/OD) [El (b)(6)>; NIH News Clearance (NIH/OD)<NIHNewsClearance@mail.nih.gov>Subject: FW: For review ASAP: draft Sec. Azar Remdesivir statementImportance: HighHi all - please let us know if you have any comments to the attached.Thanks !CraigFrom: Brennan, Patrick ( OS/ ASPA) (b)(6)>Sent: Wednesday, April 29, 2020 10:33 AMTo : Fritz, Craig (NIH/OD) [El CbH6J>; Burklow, John (NIH/OD) [El(b)(6)>; Myles, Renate (NIH/OD) [El (b)(6); Fine,Amanda (NIH/OD) [El CbH >; Wojtowicz, Emma (NIH/OD) [El(b)(6)>; Charrow, Robert (HHS/OGC) (b)(6)Cc: Pence, Laura (HHS/ASL) (b)(6J>; Hall, Bill (HHS/ASPA)(b)(6);,; Pratt, Michael (OS/ ASPA) (b)(6);,; Blakeman,Scott (05/ASPA ) (b)(6)>Subject: For review ASAP: draft Sec. Azar Remdesivir statementNIH and Mr . Charrow,Below and in the attached is a draft statement from the Secretary regarding theRemdesivir trial - please let me know as soon as you can if this looks OK. (I pulled thefrontmatter from the NIH press release.) Thank you!- PatrickPatrick BrennanDirector of SpeechwritingDepartment of Health and Human ServicesOffice: Cb) (6) I Cell Cb) (6)(b) (5)Frmn:Sent:To:Fauci, Anthony {NIH/NIAID) [E)Wed, 29 Apr 2020 01:56:42 +0000(b)(6)vEi ubject:Attachments:FW: DRAFT document for WH Briefing TomorrowDevelopment-Medical-Countermeasures-WH-B riefing 29 Apr il.pptxHere it is.From: Collins, Francis (NIH/OD) [E] Cb)( '>Sent: Tuesday, April 28, 2020 8:08 PM To: Fauci, Anthony {NIH/NIAID) [E) ------ =(bH= >Subject: FW: DRAFT document for WH Briefing Tomo rrowHi Tony,FrancisFrom: Mango, Paul (HHS/1OS) CbH6)>Sent: Tuesday, April 28, 2020 7:2-6- -PM-- --::-,--:=, To: Collins, Francis (NIH/OD) [E] CbH6)>; Kadlec, Robert (OS/ASPR/1O)CbH6)>; Fauci, Anthony (NIH/NIAID) [E] Cb)( >; Marks,Peter {FDA/CBER) CbH6);W oodcock, Janet (FDA/CDER) --------~~ ----------- CbH >; Tromberg, Bruce (NIH/NI BIB) [E] CbH6) Subject: DRAFT document for WH Briefing TomorrowThank you all for your timely responses for contributions to this today. Please give this a lookand let us know if there is anything glaringly out of place. We will have time to address editsdu ring and after our 930am check in tomorrow. The Secretary may or may not use page 1du ring his introdu ctory remarks.From: Fauci, Anthony (NIH/NIAID) [E)Sent: Sun, 26 Apr 2020 18:14:04 +0000To: Gibbo ns, Gary(NIH/NHLB I) [E]Cc: Koroshetz, Walt er (NIH/NINOS) [E); (b)(6) ;Auch incloss, Hugh(NIH/N IAID) [CJ (b)(6) ;Coll ins, Francis (NIH/OD) [E) (b)(6) ;Tabak,Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/N IAID) [E);Barasch, Kimberly (NIH/NIAID) [C]Subject: Thrombotic phenomena in COVID-19Gary:In follow -up of our recent conversation regarding the growing evidence that theextremely catastrophic course of many patients with COVID-19 seems to mepathogenically associated with the find ings of microthrombi in the lungs andoften a multisystem process resembling DIC. In addition, there have beengrowing numbers of cases of indiv iduals (some young and otherwise healthy)who have had unexplained strokes, only to find out that they actually haveCOVID-19. I (bH 5~I- ----- (bH 5l Thanks. Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phon e: (b) (6)FAX: (301 496-4409E-mail: (b)(6)(b)( 5)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:Subject:I wou ldn't think so.Auchincloss, Hugh (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [ElSun, 26 Apr 202017 :42:12 +0000NIAIDODAMFW: Invitation to Webinar as keynote speaker.From: Secretary ARP (b)(6)>Sent: Saturday, Apr il 25, 2020 2:07 PM ------- ~= To: Fauci, Anthony (NIH/NIAID) [El- -------- (b)(6) Subject: Invitation to Webinar as keynote speaker.To,Anthony S. Fauci,Office of the Director,Nationa l Institute of Allergy and Infect ious Diseases,National Institutes of Health, 9000 Rockville Pike, Bldg 31, Room 7A03,Bethesda MD 20892Subject: Invitat ion to Webinar as keynote speaker.Dear Sir,On behalf of ASSOCIATIONO F REGISTEREDP HARMACIST( An association working for PharmacyProfession and having more than 2000 membe rs) in collaboration with Divine Internationa l, Gwalior (APioneer Pharmacy Institute) I am pleased to invite you to our Web inar having THEME "CHALLENGESA NDOPPORTUNITIESF OR PHARMACISTI N THE PRESENTE PIDEMIC COVID-19" that will be held from 2ndMay 2020 to 3rd May 2020. This Web inar is the get together of Pharma professionals through the web.The vision of this Webinar is to Aware, Prepare and strengthen our Pharmacy professionals in ourcountry to th is epidemic COVID-19 for present and future aspect and exports more real istic ideas andpresent scenario of this epidemic COVID-19.You are one of the legends of Pharma Expert of our country, it is a great pr ivilege for us to see if youshare your experience with us, we really expect and want that you join our Web inar and share with usthe great exper ience of your life, we want to learn something from you so that we can create a greatideas, opportunity, and roll of Pharma professional for our country in th e present scenario.We wou ld be pleased to have you present at th is point at this web inar to listen to what the role andimportance in the Pharmacist advancement and thei r impact on our society and daily life we would alsolove to hear your thoughts and opinion about the Pharma professional that is a dream of our pharmacyfraternity .Therefore you are requested to send your recorded Lecture/ presentation of 30-40 minSincerely,ThanksRajesh Singh JadonSecretary (National)Association of Registered PharmacistsGwalior MPMob: (b)(6)From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Sun, 26 Apr 2020 15:43:25 +0000(b)(6)Subject: REAttachments :From: ------------------- (b) ( > Sent: Sunday, April 26, 2020 11:32 AMTo: Fauci, Anthony {NIH/NIAID) [E] _____ "("b"")"("=6")Subject: FW: ---------------(b)(6), (b)(4)To work on at homeFrom: Ulrich, Connie M (b)(6)Sent: Saturday, Apr il 25, 2020 2:35 PMTo: Cynda Rushton (b)(6)>;Subject (b) (6), (b) (4)Hi Christine and Cynda,(b) (6), (b) (4)(b) (6), (b) (4)(b)(6)I finished my section and unfortunately have to keep changing the COVID numbers! I will add somethoughts to the last section . Not sure how much we can add there but maybe some reflections wouldbe helpful. Enjoy the sunshine today! IBest.ConnieFrom:Sent :To:Cc:Bee:Subject:Francis:Fauci, Anthony (NIH/N IAID) [ElSun, 26 Apr 2020 02:57:3 1 +0000Collins, Francis (NIH/OD) [ElTabak, Lawrence (NIH/OD) [E] -----~~ Mascola, John (NIH/VRC) [El- ------ (b)(6) RE: agenda for Kadlec et al., Sun noon meetingSorry that I took so long to respond . (b) (5)1,,.,(b) (5)(b)(5) [ et us connectby phone first th ing in the AM>Thanks,TonyFrom : Collins, Francis (NIH/OD) [ElSe nt: Saturday, Apr il 25, 2020 2:55 PM(b) (6)·>-----~~ To: Fauci, Anthony (NIH/NIAID) (El '°.._ _____ C_Hb_~ ; Tabak, Lawrence (NIH/OD) (E](b)(6)>Subject: RE: agenda for Kadlec et al., Sun noon meet ingFrom: Collins, Francis (NIH/OD) (ElSent : Saturday, Apr il 25, 2020 2:49 PM ------~~ To: Fauci, Anthony (NIH/NIAID) (El- ------- (b)(6)>; Tabak, Lawrence {NIH/OD) [E) (b )( 6)Subject: agenda for Kadlec et al., Sun noon meetingHi Tony and Larry,(b) (5)For the meeting tomorrow at noon (currently invitees are Kadlec, Disbrow, Johnson, Woodcock, Marks,and us three), I would propose the following framework :(b) (5)(b)( 5)Thoughts? Tony , should --------------------- (b) (5)FrancisFrom:Sent :To:Cc:Subject:Fauci, Anthony (NIH/N IAID) [E)Sun, 26 Apr 2020 01:22:2 1 +0000Corey MD, LarryConrad, Patricia (NIH/NIAID) [ElRE: (b)( --------------Let us talk tomorrow (Sunday). I am sorry that I did not get back to you today.From: Corey MD, Larry _______ Cb_) _(6)Sent: Saturday, Apr il 25, 2020 5:36 PMTo: Mascola, John {NIH/VRC) [E] ______ --,;(b"H"'="' >Cc: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)!; Collins, Francis (NIH/OD) (E] (b)(Subject: Re: --------------- (b)(6)Agree. ______________ Cb><_6lSent from my iPhoneOn Apr 25, 2020, at 1:59 PM, Mascola, John (NIH/VRC) [E)wrote:------ (b)(6) seem reasonableSent from my iPhone(b)(6)>On Apr 25, 2020, at 15:54, Corey MD, Larry --------- (b)(6) wrote:A do have to say I am surprised . but okFrom: Fauci, Anthony (NIH/NIAID) [E] (b)( >Sent: Saturday, April 25, 2020 12:53 PMTo: Corey MD, Larry (b)(6l; Mascola, John (NIH/VRC) [E)(b)(6)>Cc: Collins, Francis {NIH/OD) [E] (b)(6)Subject: Fwd: New England Journal of Medicine 20-13479Let us discuss next stepsBegin forwarded message:(b)(6)From:Sent :To:Cc:(b)(6)Sat, 25 Apr 2020 13:05 :04 -0400Collins, Francis (NIH/OD) [E)Tabak, Lawrence (NIH/OD) [E]Subject: Re: White House Task Force Briefing Monday(b) (5)On Apr 25, 2020, at 11 :42 AM, Collins, Franc is (NIH/OD) [E](b) (6):FCFrom: Collins, Francis (NIH/OD) [E)Se nt: Saturday, April 25, 2020 10:36 AMTo: (b)( (OS/IOS) (b)(Cc: Tabak, Lawrence---(-N:"-':.l":H".'"./""07':..:"D:"-.):-:[~E:].====--------=- (b-):(--6:-)=; Fauci, Anthony (NIH/NIAID)[E] (b)(6)>; Pence, Laura (HHS/ASL) (b)( ; Harrison,Brian (HHS/10S) (b)(6J>; Wood, Gretc hen (NIH/OD) (E]-------- (b)(6) McManus, Ayanna (NIH/OD) [E] (b)(6J Subject : FW: White House Task Force Briefing MondayHi Mr. Secretary,Francis(b)(5)-PrnGlad to speak with you about how best to handle, if(b)(6)(b)(5)-PCE
(bX5)-PCI
From:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 14:25:16 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Italy Covid-19La Stam pa is one of the two most important newspapers in Ita ly.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recip ient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not express ly made onbehalf of the NIAID by one of its representatives .From: Mastro lilli Paolo <Paolo .MASTROLILLl@lastampa.it>Sent: Friday, April 24, 2020 10:08 AM -------- To: Fauci, Anthony (NIH/NIAID) [EJ(Subject: Italy Covid-19 1--,------Dear Doctor Fauci,My name is Paolo Mastro lilli, I am the US Bureau Chief for the Italian daily La Stampa.I am writing because we would appreciate very much the opportunity to have a phone orwr itten Q&As interview with you to discuss the Covid 19 pandemic. Considering the difficultsituation Italy is experiencing, the help President Trump is sending to Italy, and the plan to openAmerica again, it would be very helpful for Italy to hear from your experience and competenceto address the Covid 19. We think that your advices would be very helpfu l to help our countryand our citizens in dealing with the pandemic .We understand that you are very busy and this request has no deadline.La Stampa is a leading Italian daily, it is owned by the Agnelli Elkann family, owner of FiatChrysler as well.I am also a contributor for the Vatican Radio and the official news portal of the Holy See, Iwould share the interview with them as well, if you like.My cellphone number ief CbH6YPlease let me know if you need any further information.Best regardsPaolo MastrolilliII presente messagglo (inclusi gli allegati) contiene informazloni riservate esclusivamente al destinatario/ai destlnatari lndicato/i nel messaggio, ed eprotetto dalla legge. La diffusione, distribuzlone e/o la copia del contenuto del presente messaggio da parte di qualsias i soggetto diverso daldestinatario e severamente vletata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei datl personali . Se non siete idestinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediala comunicazione inviando un messaggio di ritorno all'indirizzoe-mail del mittente.This message (including any attachments) contains confidential information intended only for the reclpient(s) named above, and is protected by law.Any disclosu re, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art616 c.p, and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately aboutthe deletion by sending a message lo the sender's e-mail address.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 10:33:49 +0000Holland, Steven (NIH/NIA ID) [E]Cc:Subject:Marston, Hilary (NIH/NIAID) [E];Lerner, Andrea (NIH/NIAID) [E]RE: Successful Submission of a Manuscript to Science (abc4208)Thanks, Steve.-----Original Message-----From: Holland , Steven (NIWNIAID) [E] --------- (b)( Scn t: Thur sday, April 23 , 2020 11: 48 P-M- ---- --:a-,-= To: Fauci, Anthony (N1H/NIAlD) [E] ':======= (=b~-~(6~)Cc: Marston , Hilary (NIH/NJ AID) [E] (b)( ; Lerner , Andr ea (NIH/NT AID) [E](b)(6)Subject: FW: Successful Submission of a Manuscript to Science (abc4208)This is the acalabrutinib paper today submitted to Science. NEJM was interested but wanted a month delay to besure about the results but some of the authors (Not the NI AID one) balked and have gone elsewhere. Just keepingyou in the loop.SteveDirector, Divisi on of Intramural Research Nat ional Institu te of Allergy and Infectious Diseases National Institute s ofHea lthBldg. IO/ l IN248 MSC 1960Bethesda, MD 20892-1960(b) ( voice.3,..0.,-l.-..4.,"8.'"0,.-..4...."5,".0,'.7., .fax(b)(6)Assistant lab: Eva Portillo(b)(6)(b)( voice ____ _,,Assistant to SD: Beth Schmidt(b)(6)(b) (6) voice ____ _,,On 4/23/20, 1: 59 PM, "Lionakis, Michail (Nll-1/NIAID) [E]" ________ (b)_(6_J> wrote:Attached the submitted paper, which will be deposited to MedRx iv.org today I think.Mihali sOn 4/23/20, I :34 PM, "science_editors@aaas.org"< science:..e_ditors@aaas.org> wrote:Manuscript Title: Inhibition of Bruton Tyrosine Kinase in Patients with Severe Covid-19Author: LionakisManuscript Number: abc4208Dear Dr. Lionakis:You are listed as a coauthor on the above manuscript, which has recently been submitted to Science.According to Science policy, all authors must have seen and approved the submission of their manuscript. If youhave seen the manuscript and approved its submission, no action is necessary.Tfyou have not read this paper or do not approve its submission to Science, please let us know as soon aspossible. Please refer to the manuscript number listed above in any correspondence (you can just reply to thismessage) .You can see the status of your manuscript at any time by logging into your account at the Science JournalsSubmission and lnfonnation Portal at https://cts.sciencemag.org.If you do not yet have an account, please go to https://cts.sciencemag.org/scc /#/ forgot-password and use theemail at which you received this correspondence because that is linked to your manuscript. Then, follow the promptsto set your password and login. After login, you can access your manuscript and monitor its status.Once you are registered, we encourage you to link your account to your ORCID ID, an identifier that facilitatesthe correct attribution of your publications to you. To learn more about ORCID or to obtain an ORCID ID, visit theirsite at: http ://orcid.org.Your manuscript is now undergoing an initial screening to detennine whether it will be sent for in-depthreview. If the manuscript is sent to review, its status will change to "To Review".Sincerely ,The EditorsScienceFrom:Sent :Fauci, Anthony (NIH/N IAID) [E)Fri, 24 Apr 2020 01:58:36 +0000To: Greg Folkers (b)(6)Subject: FW: HIVR4P postponed to 17-21 January 2021FYI. See yellow highlighted request.From: HIVR4P- Secretariat <secretariat@hivr4p.org>Se nt: Thursday, April 23, 2020 11:23 AM -------~= To: Fauci, Anthony {NIH/NIAID) [E]Cc: Conrad, Patricia (NIH/NIAID) [E~) =======~ =; Dieffenbach, Carl (NIH/NIAID) [E](b) (6) >Subject: HIVR4P postponed to 17-21 January 2021Dear Dr. Fauci,HIV RESEARCHFOR PREVENTIONCb.PET OWN SOUTHA FRICA·1 7-21J ANUA'.-l2V0 21As the research community responds to the global challenges of the COVID-19 pandemic, HIV preventionscience matters as much as ever. Our priority as organizers of the HIV Research for Prevention (HIVR4P)conference remains the safety and wellbeing of all participants .After careful consideration, we have decided to postpone the HIVR4P conference to 17-21 Janua ry2021 . Updated details for the session(s) are listed below:Session title: HIV prevention 2020 - Where are we now and where are wegoing?Session type: Opening plenarySuggested presen tation Much accompl ished; Much to do -An overview on HIVtitle/topi c: prevention researchSession descr ipt ion: Today's plenary sets the stage for the conference week ahead,outlining the big-picture chal lenges we face in research, productdevelopment and access to prevention. Speakers will providediverse perspectives on the state of the field today, theopportunities and obstacles ahead and priorities for actionmoving forward .Session date and time: Monday, 18 January 2021 -16:00-18:00Meet the Experts lunchesWe invite you to host an informal table discussion at a Meet the Experts lunch on 20 January 2021 ,12:00-13:00. Daily meet the experts lunches provide early-ca reer investigators and community advocateswith valuab le opportunities for informal, in-depth exchange with experts represen ting a cross-section ofresearch issues, implementation challenges and HIV-affected communities.Please reply to this email by Wednesday, 6 May if you are still available to deliver this importantpresentation and, if so, please also include a photo and a brief biography.We are acutely aware many researchers and research organizations with critica l studies and submissionsto HIVR4P are now also heavily engaged in the COVID-19 response. Our hope is that postponing theconference , rather than presenting it virtually in October, will allow for the broadest participation to fosterknowledge-exchange, debate and direction-setting in the field of HIV prevention research that HIVR4P isknown for.Thank you for your consideration.Sincerely,HIVR4P - SecretariatHIV Research for PreventionW: -------(b)(6) Avenue de France 23 I CH-1202 Geneva I SwitzerlandHIVR4P Conferenc e 117-21 January 2021 I Cape Town , SouthAfri caHIVR4P.org 0 @HIVR4PxFrom : HIVR4P- SecretariatSen t: 21 February 2020 16:57To: (b) (6)0 /HIVR4PCc: Bargavi Thyagarajan ---------------------- (b)(6) Subject: HIVR4P 2020 - Invitation to presentDear Dr. Fauci,HIV RESEARCHFOR PREVENTIONUF>i OWN. ~JTH Af~ICA · 11-·& OCTOB~ 2020We are writing with great pleasure to invite you to present at the 4th HIV Research for PreventionConference (HIVR4P 2020 ) in Cape Town, South Africa, from 11-15 October 2020. HIV Research forPrevention is the only global scientific conference focused exclusively on the challenging and fastgrowingfield of HIV prevention research. HIVR4P fosters interdisciplinary knowledge-exchange onHIV vaccines, microbicides, PrEP, treatment as prevention and biomedical interventions as well astheir related social and behavioura l implicat ions.Details for the session(s) are listed below:Session title:Session type:Suggested presentationtitle/topic:Session description:Session date and time:Meet the Experts lunchesHIV prevention 2020 - Where are we now and where are we going?Opening plenaryMuch accomplished ; Much to do - An overview on HIV preventionresearchToday 's plenary sets the stage for the conference week ahead,outlining the big-picture challenges we face in research, productdevelopment and access to prevention. Speakers will provide diverseperspectives on the state of the field today, the opportunities andobstacles ahead and priorities for action moving forward.Monday , 12 October 2020 - 16:00-18:00We invite you to host an informal table discussion at a Meet the Experts lunch on 14 October 2020,12:00-13:00 . Daily meet the experts lunches provide early-career investigators and communityadvocates with valuable opportunities for informal, in-depth exchange with experts representing across-section of research issues, implementation challenges and HIV-affected commun ities.As an invited-speaker , you would be eligible to receive:• Complimentary conference registration ;• Roundtrip economy airfare arranged through the HIVR4P travel agency; and• Accommodation at one of the hotels pre-blocked by the conference secretar iat.To accept this invitation, please reply to this email by Thursday, 27 February and include a photoand a brief biography . Please find also attached for your record the official invitation signed by theHIVR4P 2020 Co-Chairs.We ask that you please send any questions to the HIVR4P Secretariat at secretariat@hivr4p.org .Thank you for your consideration. We look forward to you joining us in Cape Town!Sincerely ,From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Fri, 24 Apr 2020 01:30:49 +0000blonda quir icoSubject: RE: estimation of dynam ics of COVID-19 in USA new simulations at 23 Apri l 2020Thanks.From: blonda qu irico (b)(6bSe nt: Thursd ay, Apr il 23, 2020 5:02 PM ------ To : Fauci, Ant hony {NIH/NIAID) [E] -------- (~b)(=6)> ; COPPIETERS'TW ALLANT Yves (b) (6)>Subject: est imat ion of dy namics of COVID-19 in USA new simulations at 23 Apri l 2020Tony,We send you our simu lations.Best regards.QuiricoLe mercred i 22 avril 2020 a 00:09:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E)ecrit:Thanks.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)(b)(6) > aThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: blonda quirico Cb) (6)Sent: Tuesday , April 21, 2020 11 :18_A_M__ __ ~~To : Fauci, Antho ny (NIH/N IAID) [E] Cb)( ; COPPIETERS'T WALLANT Yves(b) (6)>Subject: Re: estimation of dynamics of COVID-19 in USA new simulations at 21 April 2020Tony,Professor COPPIETERS and I, we send you our new simulations :In summary, the USA COVID-19epidemic model says :- the final size of epidemic= more than 85061 0 people infected and detected;- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day duringthis peak - about +/- 35520;- end of epidemic=+/- 19-28 June 2020 (we use two methods) ;- mortality at the end of epidemic :** if death rate 5% = +/- 42.530 deceased people (for the moment the death rate= 5%)** if death rate 10% = +/- 85.060 deceased peopleYou reached 91, 1 % of the theorical logist ic curve .Best regards .Quirico00 32 475 48 68 42Le dimanche 19 avril 2020 a 15:57:50 UTC+2, Fauci, Anthony (NIH/NIAID) [E]ecrit:Quirico :Cb)( > aThanks again! Please keep this information coming to me.Best regards,TonyFrom: blonda quirico Sent: Sunday . April 1-9, 2-02-0 5-:04- A--M- ----- -=-<'"= To: Fauci, Anthony (NIH/NIAID) [E] CbH >; COPPIETERS'T WALLANT Yves(b)(6) -------Subject: Re: estimation of dynamics of COVI D-19 in USA new simulations at 18 April 2020Tony,We send you our new simulations.In summary, the USA COVID-19 epidemic model says:- the final size of epidemic = more than 779000 people infected and detected;- date of epidemic peak=+/- 7 April 2020 with theorical new cases - in one day duringthis peak - about +/- 35063;- end of epidemic=+/- 4-13 June 2020 (we use two methods);- mortality at the end of epidemic :** if dead rate 5% = +/- 40000 deceased people** if dead rate 10% = +/- 80.000 deceased peopleYou reached 8 7 .5 % of the theorica I logistic curve.Best regards.Quirico00 32 475 48 68 42Le lundi 6 avril 2020 a 03:32:35 UTC+2, Fauci , Anthony (NIH/NIAID) [E]_ _____ C>bC_6>) a ecrit:Dr. Bionda:Thank you for sending me this information. I appreciate it.Best regards,TonyFrom: blonda quirico (b)( .....,,.,=-e-..,,....,,-,,--,:,-,-,---- ....Sent: Sunday , April 5, 2020 9:23 PM-- ---~~ To : Fauci, Anthon NIH/NIAID) [E] (b)( >; COPPIETERS'T WALLANT Yves(b)(6)> -------Subject: estimat ion of dynamics of COVID-19 in USAProfessor Anthony F AUCY,Sorry to disturb during the COVID-19 in USA.But I would you inform about the COVID-19 in USA.I'm medical doctor in Belgium.With my teacher Professor Yves COPPIETERS ( Ecole de sante publique - ULB -Brussels) , we make simulations about the COVID-19 for many countries.In summary, the USA COVID-19 epidemic model says:- the final size of epidemic=+/- 462760 people infected and detected;- date of epidemic peak = +/- 1- 2 April 2020 with theorical new cases - in one dayduring this peak - about +/- 28390;- end of epidemic = +/- 15 May 2020;- mortality :** if dead rate 5% = +/- 23140 deceased people** if dead rate 10% = +/- 46275 deceased peopleIf you are interrested by our simulations, you can contact us.Best regards.Dr Quirico BLONDA(b)(6)From:Sent :Fauci, Anthony (NIH/NIAID) [E)Fri, 24 Apr 2020 00:50:12 +0000(b)(6)Subject: FW: The Tablet I find myself thinking back to his father, Stephen Fauci, whosedrugstore our family relied on back in the 1950s.You have got to read this!!!From: Folkers, Greg {NIH/NIAID) [E] ---------(b)(6)>Sent: Thursday, April 23, 2020 7:21 PMTo: NIAID COGCORE <COGCDRE@mail.nih.gov> ; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>; NIAIDOD AM <NIAIDODAM@niaid.nih .gov>Subject: The Tablet I find myself thinking back to his fathe r, Stephen Fauci, whose drugstore our familyrelied on back in the 1950s.https://thetablet.org/only-in-print-dr-faucis-roots-in-dyker-heights/~ I 0,A™F uz, I jiQ!ftACi vsTHE~LETNt:WS O.PINIO.N PJUUSHa SCHOOLS SPORl'S AIIOUNI> THC OIOCES£CCIIIONAVUtU.SOnly in Print; Dr. Fauci's Roots in Dyker Heights:.,,,, a 2Q'20D CJSCJDI A/IIIIOllyF auci mlH!l$ •!II Rf9,$ H,O,, Stl'>OONI udelltS a1t11,,ucll00P/fl~ FJU>er~ Ill U ~an$ J ,,t 20•l l 4uc• ,_.,,_ t;,m ty OWNld• ,,..g1,bomood pl,.rmKf ,n Oy/(fl' i-.gt,ta/ IS a 19$4 f}<8<1,;atecltl>t Jew.I WtOOI (Phelo COIIIWf of FIM:I t;Jm#f)CATHOLIC NEWS SERVICERiMQIOUStO Ucallon COfflinUtsi n dlffnntfOffllalOu!lnQ Pllldem.tC81$hop" ,~ ~ IJ•Qt Peru to QU4td tnaigenou$Plil<l3 du!ln g pano.m1cFrom the Neighborhoodby Frank DerosaFrank DeRosa retired as Associate Publisher of TheTablet and director of the Diocesan PublicInformation Office in 2008When I see Dr. Anthony Fauci on the TV screenexplaining expertlyeverything we need to know about thecoronavirus pandemic, I find myself thinkingback to his father, Stephen Fauci, whosedrugstore our family relied on back in the 1950s.Steve Fauci was the neighborhood pharmacist.The Fauci Pharmacy stood on the southwestcorner of 13th Ave. and 83 rd St., in the DykerHeights section of Brooklyn, diagonally acrossfrom the Shrine Church of St. Bernadette. Welived two blocks away on 85 th .Long ago parishioners like me remember whatthe store looked like, thesoda fountain that ran along the right wall, thetelephone booths at the left close to theentrance and the counter straight ahead downthe center.Whenever my mother sent me there, Mr. Fauciwould be behind thecounter, but it was a family enterprise. Theylived in an apartment above the store, and if thepatriarch wasn't serving you, his wife, Eugenia,or daughter, Denise, was there. Young Anthony,I've since learned, pitched in too, his fathersending him out on his bike to deliver items tocustomers.I've never met the man who has become themost important medical voice in the country. Norhave former parishioners that I've spoken toabout him in recent days, like boyhood palsAnthony LoFrisco, from80th St., now in Connecticut, and Bob Orlando,who lived on 84th, now a New Jersey resident,as well as Bishop Gerald Barbarito of the PalmBeach Diocese, from 11th Ave. But eachremembers the pharmacy as a Dyker Heightsinstitution.While we don't know him personally, in a sensehe's become everyone'sfriend. With his steady television presence, he'simparted his vast knowledge andstraightforward advice in a trademark,sometimes gravelly or raspy, Brooklyn accentthat has endeared him to people far and wide.You can't be anything but proud of someone ofhis prominence who came from the parish.Anthony became known as Tony, as he tells it,when Father Flanagan,principal of Regis High School, decided to callhim that on his first day as a freshman. Thename stuck.Tony took buses and trains to the Jesuit schoolin Manhattan, including the old Sea BeachExpress. He traveled 70 minutes each way, didthree hours of homework, captained thebasketball team and excelled in the classroom.I remember hearing that when Tony was a highschooler, he had a parttimejob working in St. Bernadette's rectory,answering the phone and doing whatever elseparishioners wanted him to do to put them intouch with one of the parish priests. In thosedays, the rectory had a priestly bonanza. Therewere four of them.Because St. Bernadette's School had not yetbeen established, Tony went to Our Lady ofGuadalupe School, where he was taught byDominican Sisters. It was, and is, St.Bernadette's neighboring parish.Like most kids, he loved sports. He played CYObaseball and basketball. At Dyker Park on 86thSt., he and his friends developed skills inimitation of their heroes. A Yankee followerliving in the midst of Brooklyn Dodgers fans whoadored The Boys of Summer, he's said hisfavorite players were Joe DiMaggio and MickeyMantle.Tony's father and mother married at 18, afterthey graduated from NewUtrecht High School. Steve went on to Columbiato study pharmacy.Sometime after he opened his pharmacy, hebecame friends with Father Al Varriale, one of St.Bernadette's beloved parish priests. At onepoint, Steve, as a parent, and the priest knownas Father V, who directed the parish's robustCYO sports program for youths, shared aconcern. It was the easy availability of indecentand immoral publications that they knew was athreat to the moral development of youngpeople.So, with the approval and support of the Dioceseof Brooklyn, together they formed a diocesancommission against pornography. Both men arenow long gone, and so is the commission, but itwas a good idea, though it did not survive them.Remarkably, just a few houses up the block fromwhere Steve established his pharmacy, lived thePellegrinos, another family of St. Bernadette'sparishioners that produced a renowned medicalprofessional. The eldest son, Edmund, became abioethicist, a "preeminent" one, as onenewspaper described him after he died. But hewas more. He helped develop medical programsat Kentucky, Stony Brook and TennesseeUniversities. Later, he took on the presidency ofThe Catholic University of America. Then, aftercompleting his tenure there, he became, asphysician and philosopher, the director of theKennedy Institute of Ethics at GeorgetownUniversity.Though years apart in age, both Dr. Fauci andDr. Pellegrino becameHippocratic stars, nurtured on the same block.Only in Brooklyn, I say, not without bias.Steve Fauci was known by members of hisextended family and friends for his personality,kindness, sense of humor and wit, and for tellinggood stories. So they said in comments after hedied in 2008.Tony appears to have inherited Steve's gene forlightheartedness. Hisdaughter once told the Washington Post that herdad could be a "goofball ... he works hard anddoes his thing, but he comes home and he'ssinging opera in the kitchen and dancingaround."That kind of calm can help a man maintain hisbalance as he deals with the pressure of talkingto millions of people every day about thecomplexity of a global pandemic.As one newsman said, "When Fauci appears onthe screen, you turn up the volume."He once said the Jesuits at Regis and HolyCross College taught him theimportance of "precision of thought andeconomy of expression."That's what he delivers every day: accurateinformation given concisely.That's Tony Fauci, now a national treasure. Andto think, he came from the neighborhood.Dr. Anthony FauciTOSLOWEADHe graduated from RegisHigh School and theCollege of Holy Cross.He graduated numberone in his class atCornell Medical Schoolin 1966.He completed hismedical residency atNew York HospitalIn 1984, he becamedirector of NationalInstitute of Allergy andInfectious Diseases, aposition he holds today.Front row, kneelingU.it1lc Cr~ l\ or r-,,,.,,St~\, was on<c known as th< chmp ut ysprmta nov. he u .tl' ls H lhc cla:.; K"~t J, . 1.-rA r.?guhr fellow w11h ., re3dy <n,tl~ ,1td fullot ~pun You could ilJ"ns count on St~\C bt:-1n,: p:.•stnt .it cv~r\· cli-,5 .tnd sdmol affairDisclaimer: Any third-part y material in this email has been shared for internal use under fair use provi sionsof U.S. copyright law, without further verification of its accuracy/veracity. lt does not necessa rily repr esentmy views nor those ofNIAlD, NTH, HHS, or the U.S. government.From:Sent:To:Subject:Fauci, Anthony (NIH/NIAID) [ElFri, 24 Apr 2020 00:35:33 +0000Lerner, Andrea (NIH/NIAID) [ElFW: Another PossibleT ool in The Fight Against SARS-CoV-2?Pleas take a look and figure out where to send it.From: Gary Radin <GRadin@dhs.lacounty.gov >Sent: Thursday, April 23, 2020 8:31 PM ------ ~= To: Fauci, Anthony {NIH/NIAID) [E] -------- (b)(6)> Subject: Another Possible Tool in The Fight Against SARS-CoV-2 ?Dr. Fauci---Forgive the crude and unsolicited manner in which I am attempting to reach out toyou but I don't really KNOW any other way!I am not a medical doctor nor am I a principle investigator. I am just a Cytologist employed inthe Anatomic Pathology department at LA County-USC Medical Center here in SouthernCalifornia.But I have been reading a lot- -- and in my own exploration I have come across several articleswhich suggest the possibility of using a class of agents calledSPHINGOSINE-1-PHOSPHATER ECEPTORA GONISTSi n combination with antivirals likeoseltamivir (or perhaps Remdesivir?) to treat both the viral pathogen responsibl e for thecurrent pandemic as well as the runaway immune response of the host leading to the oft fatalcytokine storms.Apparently these compounds have been approved for flare-ups of multiple sclerosis, and haveeven been tried on Alzheimer's patients. The commonly known drug is FINGOLIMOD. But thesepapers that I have cited for you below seem to indicate that structural analogs of thiscompound could be important in damping down the dysregulated pro -inflammatory cascadeswhich seem to be leading to DIC, alveolar exudates and diffuse alveolar damage, capillary leaksyndrome and ultimately the multiple organ failure that is killing an unacceptably high numberof people.The fly in the ointment Dr. Fauci here is that these 5-1-PR agonists have only beendemonstrated to be effective in non-human primates and other mammals. And much of thesestudies on these compounds has been done not on coronaviruses but on influenza viruses .So it would be a gamble. But is that not how we have learned much about human health anddisease is by the gracious sacrifice of our anim al cousins? And might it not be a general effectthat these sphingosine derivat ives have on viral sepsis so that maybe what works for influenzamight work for the coronavirus?In the dire situation that many of the most critically ill COVID 19 patien ts find themselves, itseems they are on the precipice of a rapid demise once they begin to show certain keylaboratory resu lts---(sp ikes in 0-DIMER, C-Reactive Protein, Serum Ferritin, prolongation ofprothrombin and APTT, increased card iac troponin 1, surges in IL-6, IL-7, monocytic andmacrophage chemo-attractant cytokines etc) .With pat ients isolated by these aberrant lab values, the window may be narrow but it may be atime where application of antiviral compounds in combination with these inflamma torymod ulat ors could have a striking impact on mort ality? Indeed maybe even TWO differentantivirals with diff ering mechanisms of action in combination with these S1-PR Agonists wouldeven be better. And the possibilit ies of other combinat ions of course would be there forfurther exploration .Fully cognizant of the Hippocratic Oath to 'first do no harm' I still believe that at least themedical rat ionale is sound for the inclusion of these agents into the possible arsena l oftherapeutics for the more severe COVID 19 patients.Please refer below to the st udies I found particularly helpful or promis ing. Perhaps you can puttogether some 'teams ' to further explore investigate these opt ions??We all appreciate everyt hing you have done, and continue to do !Gary Radinhttps://www .sciencedirect.com/science/article/pii/S0140673620303056https ://www.pnas.org/ conte nt/108/29 /12 018https://www .clinical key .com/# !/con tent/p layContent/1-s2. 0-S0042682214000063 ?return url=http s:%2 F%2Fli nkinghu b.elsevier .com%2 Fretrieve%2Fpii%2FS0042682214000063%3Fshowall%3Dtrue&referrer=Suppression of cytok ine storm with asphingosine analog prov ides protectionagainst pathogenic influenza virus IPNASHuman pandemic H1N1 2009 influenza virus rapidlyinfected millions worldwide and was associated withsignificant mortality. Antiviral drugs that inhibit influenzavirus replication are the primary therapy used to diminishdisease; however, there are two significant limitations totheir effective use: ( i) antiviral drugs exert selectivepressure on the virus, resulting in the generation of ...www.pnas.orghttps://www.thelancet.com / journals/lancet/article/PIISO l 40-6736(20)30566-3 /fu lltextClinical course and risk factors for mortality of adult inpatientswith COVI D-19 in Wuhan, China: a retrospective cohort study1 - The LancetThe potential risk factors of older age, high SOFA score, and d-dimer greater than 1μg/ml could help clinicians to identify patients with poor prognosis at an early stage.Prolonged viral shedding provides the rationale for a strategy of isolation of infectedpatients and optimal antiviral interventions in the future.www.thelancet.comhttps:/ /www.ncbi.nlm.nih.gov /pmc/articles/PMC317 6439 /Endothelial cells are centralorchestrators of cytoki neamplification duringinfluenza virus infection -PubMed Central (PMC)Cytokine storm during viral infection isa prospective predictor of morbidityand mortality, yet the cellular sourcesremain undefined. Here, using geneticand chemical tools to probe functionsof the S 1 P 1 receptor, we elucidatecellular and signaling mechanismsimportant in initiating cytokine storm.While S1 P 1 receptor is expressed onendothelial cells and lymphocyteswithin lung tissue ...www.ncbi.nlm.nih.govFrom: Fauci, Anthony (NIH/NIAID) [E)Sent: Thu, 23 Apr 2020 22:47 :07 +0000To: Billet, Courtney (NIH/N IAID) [E];Greg Folkers ---------- (b)(6} ;Conrad, Patricia (NIH/NIAID) [E];Routh, Jennifer (NIH/NIAID) [ElCc: Barasch, Kimber ly (NIH/NIAID) [C]Subject:Attachments:FW: Sammies recognition th is year - congratulationsAFauci, NIH.pdfPlease take a look at this and let us discuss. Thanks.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Max Stier <msti er@ourpubl icservice.org>Sent: Thursday, Apr il 23, 2020 2:57 P-M- ------,;- = To: Fauci, Anthony (NIH/NIAID) [E) (b)( 6)>Cc: Barasch, Kimberly (NIH/NIAID) [C] _________ Cb _H_ ; Sammies<Sammies@ourpublicserv ice.org>Subject: Sammies recognition this year- congratulat ionsDr. Fauci:I hope you are healthy and well. The Partnership for Public Service is honored to inform you that wehave selected you as a fi nalist for the 2020 Samuel J. Heyman Service to America Medals, otherwiseknown as the Oscars of government service.You were nominated by Francis Collins for your outstanding career at NIAID and th e wor k you arecurrently doing on behalf of the American people to prepare, inform and protec t lives in our country andaround the wor ld during th is uncertain time . Your work truly embod ies the best of governm ent tha t westrive to recognize through the Sammies program.Attached, I've included the profi le we have drafted to summarize your work and accomplishments -both for recognizing you as a fina list and for having the selection committee vote for the awardrecipients . Should you have any edits or wish to add a personal quote, please send those to us at yourconvenience. We will be releasing your profile publicly with the rest of the final ists on Sunday, May 3.Again, thank you for the work you do on behalf of the NIH and our country.Best,Max StierPresident and CEOPartnersh ip for Public ServiceFrom: Fauci, Anthony (NIH/N IAID) [ElSent : Thu, 23 Apr 2020 22:37 :35 +0000To: Greg Folkers CbH6);Conrad, Patricia (NIH/NIAID) [ElSubject: FW: NAS Annual Meet ing Session on COVID-19 -- Information regarding yourSaturday April 25 part icipationFYIAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Dzau, Victor J. <VDzau@nas.edu>Se nt: Thursday, Apr il 23, 2020 1:49 PMTo: Fauci, Anthony (NIH/NIAID) [E] ----------------~~Cc: Hannon, Emma <EHannon@nas.edu>; Conrad , Patr icia {NIH/NIAID) [El (b) (6);(b)(6)'ben.t inker@cnn .com' <ben.t inker@cnn .com>;'Amanda.Sealy@cnn.com' <Amanda.Sealy@cnn.com> ; 'Neel.Khairzada@t urner .com-'- ----; ~,s, <Neel.Khairzada@turner .com>; 'Tia.Mille r@turner.co m' <Tia.Mi ller@turner .com>; (b) (>; McGinnis, J. Mic hael <MMcG innis@nas.edu>; (b)( =======~ -------- (b)(6) ; Mu n, Jenny <JMun@nas .edu>; (b)(6) Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regard ing you r Saturday April 25part icipationDear Jeremy, Tony, Sanjay, George, Susan, and Richard,I'm really look ing for ward to th is panel on COVID-19 at the NAS Annual Meeting on Saturday, April 25that 2:00 -3:30 pm ET. There is tremendous excitement and enthusiasm, and registr ati on is thr ough theroof .I am sending this note to do a last minute check to see if there is anything you need from me. I also wantto check whether you are planning to use slides. Will you be sending your slides to us to project or usethe share screen feature to advance your own slides? Regardless, it would be helpful to me if you couldsend me your slides for my preparation.I wou ld greatly appreciate it if you would respond to th is email.Best,VictorPS,- ----- Cb)~ , my special assistant, will be sending you additional information about the session logistics shortly.From: Dzau, Victor J. <VDzau@nas.edu>Sent: Thursday, April 9, 2020 11:01 AM ---------------~ ~---:---:-:--:-:--:-:---:-=(=b)(=6)>=; =Ha=nn:o.n.., ;E_m-m-a= <~EH annon@nas.edu>; 'conradpa@niaid.nih.gov ' (b)(6)>; 'T.MillerdeVega@wellcome.ac .uk'(b)(6)>; 'jsi@cepi.net ' (b)(6) 'rebeka.yasmin@cepi .net' =========.~;;;--:-:-- (b )( 6) >; 'ben.tinke r@cnn.com' <ben.tinker@cnn.com >; 'Amanda.Sealy@cnn.com' _____._. ___<Amanda.Sealy@cnn.com >; 'Neel.Khairzada@turner .com' <Neel.Khairzada@t urne r.com>;'Tia.Miller@turner .com' <Tia.Miller@turner.com >; (b)(6)Subject: RE: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday April 25participationDear all,Thank you for agreeing to participate in a spec ial late breaking session on the COVID-19pandemic at the NAS annual meeting . Knowing how busy you are, I am sending this ema il inlieu of a call to prepare for the session.As you know, this is a 90 minute session which aims to provide our audience with deeperinsights into the latest developments in the COVID-19 response . I plan to hold an engagingdiscussion that covers the whole experience on dealing with this pandemic - from US tointernat ional, to preparedness and response , the biology of the virus, the state of diagnostic ,treatmen t and vaccine development, and the importance of communication.I will begin the session by providing brief ( ~ 3 min) opening remarks describing thecircumstances of the pandemic. Then, I will introduce the panelists and you will each have 7minutes to provide remarks. You may use a limited number of slides for ilJustration. I hope thateach panelist will provide their own perspective and speak to the issues proposed below.• Jeremy Farrar will discuss the global response to the pandemic, drawing from hisexperience as a global leader, the chair of the Scientific Advisory Group for the WHO'sR&D Blueprint and as a member of the Global Preparedness Monitoring Board .• Tony Fauci will discuss tbe US pandemic and provide his perspective as a member of theWhite House Coronavirus Task Force addressing the 2019 - 20 coronavirus pandemic.• George Gao will discuss China's response to the pandemic and lessons learned for therest of the globe.• Susan Weiss will discuss the viral characteristics of SARS COV2 , insights into itspathobiology , immunity and developmen t of a pan-CoV antiviral.• Richard Hatchett will discuss the deve lopment of new vaccines and treatments againstCOVID-19.• Sanjay Gupta will comment on the health system response to the pandemic andchallenges related to communication and public engagement in responding to COVID-19.Following remarks from each panelist, we will have a moderated discussion amongst ourselves -I will ask you a set of questions (15 mins) and then we will take questions from the web (25mins) . To prepare me to be your moderator, please send me any questions you would like me toask you. For those of you who would like to have a prep call, please let me know and I will set itup.Best,VictorFrom: Mun , JennySent: Wednesday, Apri l 8, 2020 10:56 AM(b) (6) ;--------------------------- (b)(6) 'ben.tinker@cnn.com'; 1 Amanda.Se a I y@ c n n. com'; 'Neel.Khai rzada@turne r.com' ; 'Tia.Miller@turn er.com'Subject: NAS Annual Meeting Session on COVID-19 -- Information regarding your Saturday Apri l 25participa t ionDear Speakers:I am the logistical contact for the COVID-19 session that will be held as part of the Annual Meeting(online) program on Saturday, April 25 at 2:00 pm EDT. Thank you for agreeing to participate in thissession. To help you with your planning, I have provided additional details below.Please note that the session will be live webcast and the general public will also be able to watch thesession. Video from the session will also be uploaded on the NAS YouTube channel(https://www.youtube.com/user/theNASciences ) after the meeting . We will need to obtain signedspeaker release forms for your participation in this session. I have attached the speaker release form foryour review and submission. Please return the signed speaker release form by Monday , April 13.Session speakers are asked to connect 30 minutes prior to the session start time (by Saturday, April 25at 1:30 pm EDT) to allow the technical staff to check connections and prepare for the session. Details onhow to connect will be sent before the meeting.We will list you in our promotional materials as noted below . If this is incorrect, please let me know .Anthony S. Fauci, Director, National Institute of Allergy and Infectious DiseasesJeremy Farrar, Director, Wellcome TrustGeorge F. Gao, Director-General, Chinese Center for Disease Control & PreventionSanjay Gupta, Chief Medical Correspondent, CNNRichard J. Hatchett, CEO, Coalition for Epidemic Preparedness InnovationsSusan R. Weiss, Professor of Microb iology, Perelman School of Medicine, University of PennsylvaniaSince many of us have moved to remote work environments, you may already be proficient with Zoomand other online meeting/collaboration applications. I am attaching a 'speaker guidelines' f ile in caseyou have any questions on how best to prepare for and stage your remote talk . We have technical staffavailable to help you become familiar with Zoom and its settings -such as "sharing your screen" (if youhave slide presentations that need to be shown during your talk). We can arrange for a t raining sessionthis week or next week. If you would like to schedule a session, please let me know as soon as possible.Dr. Dzau's office will be in touch regarding the agenda for this session. If you have any othe r questions,please let me know .Regards, Jenny******************* *************Jenny MunMembership DirectorNational Academy of Sciencesjmun@nas.edu(b)(6)From: Fauci, Anthony (NIH/NIAID) [E)Sent : Thu, 23 Apr 2020 22:36:33 +0000To: ----- -=-a=Ca, ssetti, Cristina (NIH/N IAID) [E);Lerner, Andre a (NIH/NIA ID) [El (b)(6) ;Conrad, Patricia (NIH/NIAID) [El;Marston, Hilary (NIH/N IAID) [ElSubject: FW: New sheetAttachment s: COVID.docxAnthony S. Fauci , MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7 A-O331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail=--__,. __., (b)(6)The information inlh ,s e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Dani Bolognesi, Ph.D. (b)( 6)Sent : Thursday, April 23, 2020 1:01 PM ------- == To: Fauci, Anthony (NIH/ NIAID) [El ~=======-~ = Cc: Conrad, Patr icia (NIH/NIAID) [E]Subject: FW: New sheetHi Tony :I hesitate to bother you with th is as I am sure that you are inundat ed with requests of this sort over andabove everyth ing else you are doing which is tr uly magnific ent. I beli eve th at th ere is something ofpotentia l importance in what is commun icated below but you are in the best position to tell me whethe rit could fit in the toolb ox you are assembling for COVID 19 in both the short and longer term . I have toacknowledge our fr iend Bob Gallo for triggering this(b) (4)Reaching out to you to see if you think this approach has merit. Since your time is so precious, I do notexpect you to review this but perhaps you can forward to one of your trusted colleagues.PPS. loved the interview with Coach K!Con un forte abbraccio IDani(b) (4)From:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 22:25 :14 +0000(b)( 6)Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before TrumpMin imized Coro navirus I MSNBC http s://bit. ly/2yynEPfI may have already sent this to you, but I do not think so. It is short (6 minutes)but it has a segment that shows me 37 years ago. Yikes!!! You will get achuckle.Anthony S. Fauci , MODirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone (b) (6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barasch, Kimber ly (NIH/NIAID) [CJ- --------- (b)(6) Sent: Thursday, April 23, 2020 9:04 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6) Subject: FW: MSNBC: See Dr. Fauci's Stunni ng Pandemic Warn ing - Long Before Trump Mi nimizedCoronavirus I MSNBC https ://b it.ly/2yyn EPfKim Barasch [ClOffice of the DirectorNational Institute of Allergy & Infectious Diseases(b)(6)(b)(6)From: Folkers, Greg {NIH/NIAID) [E)- ------- (b) (6)> Sent: Tuesday, April 21, 2020 11:06 PMSubject: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing- Long Before Trump Minim izedCoronavirus I MSNBC https :ljbit.ly /2yynEPfDisclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily representmy views nor those ofNTAID, NIB , HHS, or the U.S. government.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 22:14 :31 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject:Attachme nts:FW: A proposal to stop COVID-19 and reopen our schools and businessesScientists_to_Stop_COVID19_2020_04_23_FINAL.pdfEmail below from David Liu.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone (b)(6)Email: (b)(From: David Liu (b)(Se nt: Thursday, April 23, 2020 6:-0-1- P-M- -=-::-:-= To: Collins, Francis {NIH/OD) [E] (b)( >; Fauci, Anthony {NIH/NIAID) [E](b)(6); Lane, Cliff (NIH/NIAID) [El (b)( >; Austin, Christopher(NIH/NCATS) [E] (b)(6 )'>; Whalley, David (FNI_H_) [T:.] ...:......:..!::::====~~ (FNIH) [T] (b)(6); Tabak, Lawrence (NIH/OD) [El '.=========~-= = Cc: Michael Rosbash (b)(6)>; Ramnik Xavier (b)(6)>;EDWARD SCOLNICK (b)(6); Stuart Schreiber (b)(6)>; Michael Z Lin -----~=--- ":"'""~----(:b~ )( 6-) ->-; B-e:n.= Cr=av:a:tt. ...;.-=-:~ (b)(6J>; Thomas Cahil l (b)(6) R. Scott Kemp (b)(6)Subject: Re: A proposal to stop COVID-19 and reopen our schools and businessesDear Francis, Anthony , Cliff, Christopher, David, Maria , and Lawrence,I hope you are all well. Attached is the updated set of four proposals on:1) Rapid repurposing of antiviral drugs to treat COVID-19;2) Expedited development of neutralizing monoclonal antibodies to t reat COVID-19;3) Rapid COVID-19 vaccine development;4) Risk-reduced ways to reopen schools and businesses, and the healthcare system changes that areneeded to enable them.We hope you find these updated proposals useful , and would be happy to engage in any way that couldbe helpful.Sincerely yours,Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT), Michael Lin(Stanford), David Liu (Harvard/Broad), Michael Rosbash (Brandeis), Stuart Schreiber (Harvard/Broad), EdScolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier (MGH/Broad)David R. LiuRichard Merkin Professor and Director of the Merkin InstituteofTransformative Technolog ies in HealthcareDirector of the Chemical Biology and Therapeutic Sciences ProgramCore Institute Member and Vice-Chair of the Faculty, Broad InstituteInvestigator, Howard Hughes Medical InstituteThomas Dudley Cabot Professor of th e Natu ral Sciencesand Professor of Chemistry & Chemical Biology, Harvard Unive rsity75 Ames StreetCambridge, MA 02142On Apr 19, 2020, at 8:48 PM, Collins, Francis (NIH/OD) [E] -------- (b)(6)> wrote:Dear David et al.,Thanks for forwarding this very thoughtful document, which presents a series ofimportant recommendations - most of which I agree with. I don't know if you sawFriday's announcement (attached) of the new public private partnership calledACTIV (for Accelerating COVID-19 Therapeutic Interve ntions and Vaccines), but ithas taken on most of the points you raise in sections 1- 3 of your letter. I shareyour hopes that remdesivir will show benefit, and the current large NIH-sponsoredRCT has completed enrollment and shou ld reveal results in about a month. But ofcourse we want to test multiple other interventions - both small molecules andantibody-based therapies, so we need our tria l system to be optimized like neverbefore. I will share your letter with the leaders of ACTIV, who are working withunprecedented speed to prioritize the next set of therapeutic candidates as well aspushing vaccine development programs to adopt exceptionally creative trialdesigns to test safety and efficacy (with full engagement by FDA).Best regards , FrancisFrom: David Liu Cb()6 )Sent : Sunday, April 19, 2020 5:20 PMTo: OD Labc (NIH/OD) (b)( •>; Collins, Francis (NIH/OD) [E](b)(6)--------...!::===~~----___(b,).( 6)>;R amnik X-a-v-i-e-r - ~=":'"":'~~---:::====== (=b):;(:~- ;~EDWARDS COLN_ICK--=====~~Schreiber (b)(6)>; Michael Z Lin CbH ; Ben Cravatt-----=== ('ab~:'s:(;6~)----Cc: Michael RosbashSubject: A proposal to stop COVID-19 and reopen our schools and businessesDear Francis,I hope you are well.I write on behalf of a group of citizen -scientists, most or all of whom you know. Motivatedsolely by our desire to help defeat the serious threat our nation and the world now faces,we wrote a set of four actionable, non-partisan proposa Is (attached) to produce safe andeffective COVID-19 therapeut ics and vaccines in the shortest possible timeframe, and toreopen our society in a manner that reduces the risk of future COVID-19 outbreaks .We hope you find these ideas interesting, and might be willing to share this set ofproposa ls with Dr. Tony Fauci, along with our willingness to discuss any part of theproposals with him if we can be helpful. We understand from our efforts to contact Dr.Fauci through emai l routes that his standard inbox may be too overwhelmed for ourproposa l to reach him.The four proposals attached describe: (1) How to rapid ly repurpose an ant iviral drug totreat COVID-19 patients; (2) How to expedite the development of human antibody drugs totreat patients and to provide short-term protect ion for healthy individuals; (3) How todevelop COVID-19 vaccines on an expedited t ime scale; and (4) How to reopen ourbusinesses and schools in a manner that reduces the risk of future outbreaks and deaths.Thank you for any help or thoughts you might be able to provide.Sincerely yours,Ben Cravatt (Scripps), Lynn Goldman (GWU), Akiko Iwasaki (Yale), Scott Kemp (MIT),Michael Lin (Stanford), David Liu (Harvard/Broad), Michae l Rosbash (Brandeis), StuartSchreiber (Harvard/Broad), Ed Scolnick (Broad), Jonathan Simons (PCF), and Ramnik Xavier(MGH/Broad)David R. LiuRichard Merkin Professor and Director of the Mer kin Instituteof Transformative Technolog ies in HealthcareDirector of the Chemical Biology and Thera peut ic Sciences ProgramCore Institut e Member and Vice-Chair of the Faculty, Broad InstituteInvestigator, Howard Hughes Medical Instit uteThomas Dudley Cabot Professor of the Natural Sciencesand Professor of Chemistry & Chemical Biology, Harvard University75 Ames StreetCambridge, MA 02142<NIH_ACTIV _Release_041720.docx>From:Sent:To:Cc:Subject :FYIAnthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 21:47 :13 +0000Conrad, Patricia (NIH/NIAID) [E)Barasch, Kimberly (NIH/NIAID) [C]FW: Whit e House Coronavir us Task Force Meet ing - 4.24.20National Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent:To:Cc:Subject :Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 21:40 :33 +0000Conrad, Patricia (NIH/NIAID) [E)Barasch, Kimberly (NIH/NIAID) [C]FW: Update: White House Coronaviru s Task Force Meet ingHeads-up! Change in schedule for tomorrow.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.(bX5) -l'UFrom:Sent :To:Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 21:29 :50 +0000Fauci, Anthony (NIH/NIAID) [ElSubject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - long Before TrumpMin imized Coro navirus I MSNBC http s://bit. ly/2yynEPfhttps://bit. ly/2yyn EPfAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (3 96':44li9E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces. The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Barasch, Kimberly (NIH/NIAID) [C]- --------- (b)(6) Se nt: Thursday, April 23, 2020 9:04 AM ------~~ To: Fauci, Anthony (NIH/NIAID) [E] -------- (b)(6)> Subject: FW: MSNBC: See Dr. Fauci's Stunning Pandemic Warn ing - Long Before Trump MinimizedCoronavirus I MSNBC https ://b it .ly/2yyn EPfKim Barasch [CJOffice of the DirectorNational Institute of Allergy & Infectious Diseases(b)( 6)(b)(6)From: Folkers, Greg (NIH/NIAID) [E] ---------(b)( 6)> Sent : Tuesday, April 21, 2020 11:06 PMSubject: MSNBC: See Dr. Fauci's Stunning Pandemic Warning- Long Before Trump Minim izedCoronavirus I MSNBC https://bit .ly/2yynEPfDisclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. Tt does not necessarily representmy views nor those ofNTAID, NIB , HHS, or the U.S. government.From: (b)(6)Sent :To:Subject:Thu, 23 Apr 2020 14:34:36 -0400Conrad, Patricia (NIH/NIAID) [E)Fwd: Thank you, and ...Attachments : image002.png, ATT0000l.htm, PasstheMic Expert Outreach.pdf, ATT00002.htmLet us discussBegin forwarded message:From: Gay le Smith <gayle.smith@one .org>Date : April 23, 2020 at 1 :49 :04 PM EDT To: "Fauci, Anthony (NIH/NlAID ) [E]" ----------=:--:-(b-)(:6)- =- _____._. ___Cc: Tom Hart <tom.hart@one.org>Subject: Thank you, and ...Dear Tony,I have always felt reassured when the good Dr. Fauci speaks, and now more than ever. Asan American, a former colleague, a long-time admirer and student of your wisdom - thankyou. We are all safer because of you, and the world will be a better place because ofyou. Again.As you know, I am now leading the ONE Campaign. We've been quite active wi th theONEWorld Campaign, dedicated to the fight against this newest virus, and focused onAfrica . We've made some progress on debt, and next up is a focus on ensuring that avaccine, when it comes, is available to everyone.One of the things we want to do is educate people, in all of the places we work. It won'tsurp rise you that of particular urgency amongst our partners in Africa is that facts andinformation get to people across the continent, but we also know that more facts areneeded everywhere . So next month we are going to launch #PassTheMic, where every dayfor 19 days we will ask a celebrity to turn his or her social media channels over to an experton COVID-19 for one day. So Julia Roberts might turn her Twitter account to you to ta lkabout the critical elements needed to flatten the curve and slow the spread. Or Idris Elbacould give up his lnstagram to the head of the African CDC so that he can illustrate theimpact COVID-19 will have across Africa and what that means for the rest of the world .We know artists want to be helpful right now, but that it is hard to know what to do. Andwe know there are experts like you out there who have the answers. We've thought aboutthis a lot at ONE and wanted to do something we felt would truly have an impact . As welook ahead we know COVID-19 does not know borders and until it is beaten everywherewe are not in the clear. We need a global response plan and we need it now. By turn ingover their platforms for the day, celebrity influencers will be donating one of their biggestassets - their followers - to YOU, giving you the platform you need (and we all need) to tellthe world why a global response is critical. Because none of us are safe until all of us aresafe.We wi ll work with each expert/celebrity pair to personalize the content to our and ourcelebrity partners' audiences - in North America, Europe and Africa, and help createcontent that both part ies are happy with . We are now confirming our talent partners, andso far are getting a terrific response.We know you're a busy man, so we've planned it so that the amount of time on your endwould be minimal. But the impact wou ld be maximal.I'm attaching more information about the campaign. Please let me know what you thinkand if you have questions. Ideally we would like to get this off the ground in early May, soare hoping to confirm folks by April 28th at the latest. Our team will be in touch with youroffice to follow up.Thanks as always for everything you do. All my best to you, Gayle
Gayle Smith I President & Chief Executive Officer I ------- (b)(6)ONE.ORG I Twitter I Facebook I lnstagramONE is a global movement campaigning to end extreme poverty and preventable disease by2030 so that everyone, everywhere can lead a life of dignity and opportunity .From: Fauci, Anthony (NIH/N IAID) [E)Sent:To:Subject:Thu, 23 Apr 2020 18:25 :56 +0000Simmons-Butler, Kirk (NIH/NIA ID) [C]Re: Thank you Dr. Fauci!Attachments : image001.png, image002.gifKirk:Thank you for yom· kind note. Much appreciated.Best regards ,TonyOn Apr 23, 2020, at 2:16 PM, Simmons -Butler , Kirk (NIH/NIAID) [C]Cb)( wrote:Greetings Dr. Fauci,I just wanted to take a moment to personally thank you for all of your support andleadership during these unprecedented times. I am proud to be a part of the NIAD familyand you represent us and the country well ! God continue to bless and keep you and yourfamily! Thank you again sir!Regards,KirkKirk D. Simmons-Butler, M.S.Assistant Facility Manager 14DNR. Charles River Laboratories Inc.NIH/NIA--I D-- ~~ (Office) (b)(6)(fax) (301) 761-6013Charles River website - www.criver.com<image00 1. png><image002. gif>The information in this e-mail and any of its attachments is confidential and may containsensitive information. It should not be used by anyone who is not the original intendedrecipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. The National Institute of Allergy andInfectious Disease (NIAID) shall not accept liability for any statement made that are thesender'so wn and not expresslym ade on behalf of the NIAID by one of itsrepresentatives.From: Fauci, Anthony (NIH/N IAID) [E] (b)( >Sent: Friday, March 27, 2020 11:55 AMTo: NIAID Announcements <NIAID-announce@niaid .nih.gov>Subject: Platelet Donations Down are Down Amid Coronavirus Outbreak -- Please DonateDear Colleagues:The NIH Platelet Donor Center has an urgent need for healthy individuals to give lifesavingplatelets to patients. The need for platelet donations is especially acute now with thecoronavirus pandemic. While social distancing and increased telework are necessary tocontain and slow the spread of coronavirus, we have seen a marked decline in platelet andblood donations for our patients.To alleviate this shortage, NIAID and the Department of Transfusion Medicine (DTM) areco-sponsoring a two-week Platelet Drive from March 30 -April 10. Platelet collections, aswell as whole blood and Double Red Cell donations, can only be made at the NIH BloodBank on campus in Building 10, Room 1(713 Monday through Friday from 8:00 am to 5:00pm. The Platelet Center at Fishers lane is temporarily closed and plate let collections arenow on the main campus through at least the next 30 days. This move helps to ensure thatblood donors are protected by visitor screening, minimizing possible exposure toindividuals at risk.What is a double red cell donation? A double red cell donation enables donors to donatetwo units of red blood cells in one visit. During a procedure called apheresis, whole blood isseparated through a cell separator and red blood cells are collected. The remainder of theblood components are returned to the donor along with saline to replace the lost volume.I encourage participation of all employees who are eligib le to provide a donation to benefitour NIH patients. I understand employees may be hesitant to participate under the currentconditions, but I would like to reassure you that blood donation is a safe process.Additiona l precautions have been put in place at our Blood Bank to help prevent thespread of infection and protect the health of donors and staff .Thank you to all who support our quarterly platelet drives. Your efforts provide a lifelinefor our patients . Those who participated in the last drive are now eligible to help onceagain. In appreciation of your dedication to helping others, NIAID grants administrativeleave to any NIAID federal employee who donates platelets at the NIH Blood Bank.Specifically, you will be granted 4 hours of administrative leave to be used immediatelyfollowing your platelet donation appointment. As always with such activities, please notifyyour supervisor for approval prior to donating at the NIH Platelet Center .. Contractoremployees should speak directly to their contract companies to determine what leaveoptions are available . Please contact the Donor Center at 301-496-4321 to schedule yourappointment. let the Donor Center staff know you are with t he NIAID Platelet/Double RedCell Drive. They will answer eligibility questions and provide information about thedonation process.Thank you for consider ing donat ing during t his stressful t ime. Best regards.Sincerely,A.S. FauciAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892 -2520Phone (b)(6)FAX: (301) 496-4409E-mail: (b)(6) --------The information in this e-ma il and any of its attachments is confidential and maycontain sensitive informat ion. It should not be used by anyone who is not theoriginal intended recipient. If you have received this e-mail in error please informthe sender and delete it from your mailbox or any other storage devices. TheNational Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statements made that are the sender's own and not expresslymade on behalf of the NIAID by one of its representatives.~CHARLERSI VERlABOAATORIES
From:Sent :Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 17:39 :48 +0000To: Auchincloss, Hugh (NIH/NIAID) [C)-- -------------~-~-- (b)(6) Subject: F W: Wellness Initiat ive ProposalAttachme nts: Wellness ln iti ative_POC_Sundar .zip, Wellness Initiative Proposal_Sundar .pdf,Managing Anxiety Around COVID-19 March 27 {007) .pdfPlease take a look at th is and handle.From: Sundar, Sachin {NIH/NIAAA) [F] --------- (b)( > Sent : Thursday, April 23, 2020 1:05 PM To: Fauci, Anthony (NIH/NIAID) (E]-- -------- ---- (~b)=(6) > Subject: Wellness Initiative ProposalDear Dr. Fauci,I have an idea regarding science commun icat ion and wellness . Here's a rough proposal and proof ofconcept . At fu ll effect , I think it could have noteworthy potential. (b) (5)Thank you for your time .Respectfully,Sachin SundarFrom:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 13:25 :22 +0000Stephen L. HoffmanSubject: RE: Follow Up ThanksThanks, Steve. I appreciate your note.Best rega rds,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Stephen L.Hoffman<slhoffman@sanaria.com>Sent : Wednesday, April 22, 2020 9:56 PM -------::-::-:-= To: Fauci, Anthony (NIH/NIAID) [E] (b)( >Subject: Follow Up ThanksDear Tony,I hear continuously from people from all walks of life how grate ful they are for your presence on theCOVID-19 team . You are perform ing an incredible service to our country and the world.Thanks again,SteveStephen L. Hoffman, M.D.Chief Executive and Scientific OfficerSanaria Inc.9800 Medical Center Dr. ste 209aRockville MD 20850tel: (b)(6) (work)tel : (bH (mobile)fax: 301-770-5554E-Mail: slhoffman@sanaria.comwww .sanaria.comFrom:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 13:00 :55 +0000Redfield , Robert R. (CDC/OD)Cc:Subject:Attachments :All ison Arwady ;David Barr;Conrad, Patricia (NIH/N IAID) [E)FW: Dr. Fauci asked me to send Chicago questionWorkforce _Proposal_ Chicago April2020. pdfBob:Please take a look at this . This question evolved from a te leconference that Ihad 2 nights ago with people " in the t renches" including Alison Arwady(Chicago ). The question is what w ill be the relationsh ip between the publichealth workforces at the federal and local levels. Youi had spoken of the CDCpeople that will be assigned locally and that will help build up a local workforce.How will COD interact and relate to the locals. Is there any possibility of Federalfunding of their proposal (see attachment). If not, do you have any suggestionsfor them? I can discuss this with you today at the Task Force meet ing. Thanks.Best,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone Cb) (6)FAX: (301 496 -4409E-mail: Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The Nat ional Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E)Sent: Wed nesday, April 22, 2020 3:53 PM To: Fauci, Anthony (NIH/NIAID) [E)-- ------------- .(b.)(,6.) ....,...= Subject: FW: Dr. Fauci asked me to send Chicago questionPis advise.(b)(6)From: Allison Arwady (b)(6)Sent: Wednesday, April 22, 2020 3:42 PM To: Conrad, Patricia (NIH/NIAID) [E] -_-_-_-_--_- -~ C_>b_<=.,.>Subject: Dr. Fauci asked me to send Chicago questionDear Patty,Last night on his call with public health leaders from cities across the country , Dr. Fauci asked me tosend him/you my follow -up question from Chicago:How will the necessary public health workforce expansion (e.g. for wide-scale case investigation,contact tracing, linkage to care, community testing, and vaccination) be supported at the federallevel?Our understanding is that state or local ju risdictions will be able to develop their own workfor ces ratherthan supporting a single workforce at the federal level, and we agree with this approach , but it would bevery helpfu l to understand next steps and potential timelines, particularly as the reopening drumbeatgets louder.For example, Chicago has developed a local plan/proposal (attached) that would meet our local needs,help address some of our underlying race and economic equity concerns, and build on our existingcommunity and clinical partnerships. We have shared it with some partners, but it is not at all clearhow/whether/when/how much funding might be available. Given the need to quickly expand ourworkforce and plan ahead, it would be very helpful to get a sense of:a. How much funding/support might be available, and how that will be determinedb. Whether funding might come through HHS/CDC (our preferred mechanism), FEMA, or anothermechanismc. Will support be available in weeks or months ... and for how long-we are strongly advocatingfor 5 years, similar to what was done for Ebolad. Any other information about how our local or state plans need to be adapted to fit into federalthinking on this approachThank you so much; I deeply apprec iate Dr. Fauci taking the time to meet with us directly and hear ourconcerns.AllisonAllison Arwady, MD, MPHCommissionerChicago Department of Public Health(b)(6)HEALTHYC H IC A GOFrom: David Barr (b)(6) ------------ Sent: Wednesday, April 22, 2020 8:47 AMTo: Al lison Arwady --:-:-:--:=====~~~(b)(-6)-; Percak, Jeffrey M ------- (b)(6)>; Fauci, Anthony (NIH/NIAID) [El (b)(6)>; Conrad, Patricia (NIH/NIAID) [El======~~-(b)(6)>; Demetre Daskalakis (b )( 6) >; Barasch, Kimberly (NIH/NIAID) [C](b)(6)>; Mushatt, David M(b) (6)>; Iyengar,Preetha (DO.H.). .:..=========~~----------------- (b)(6) Duch in, Jeff (b)(6)Subject: Notes from call with Dr. FauciHello - Thank s for all for a very informa tive and sobering discussion last night. I've providedbullets below to capture the main points. Please add or change as needed. I've kept this relativelyshort but can supply a full recording of the call if you want it.We will have another call next Tuesday.DavidPPE supplies:- whi le hospitals are in better shape than a few weeks ago, significant shortages remain at longtermcare facilitates , skilled nursing facilitates , outpatient settings like doctors' offices and urgentcare clinics, shelters, prisons. Gowns are the biggest problem, but gloves, masks and shields arealso short. Doctors offices are closing for lack of PPE.- each city is trying to solve these shortages in a short-term , piecemeal way. They need a longe rtermsolution to stab ilize availability. Outpatient settings are looking to health departments toprovide supplies , something HDs are not set up to do.- testing in most places still requires PPE use (e.g. no avai lability of anterior nasal swabs) and thePPE shortages are severely limiting testing scale up.- even at hospitals , supply limitations make re-opening elective surgeries and other proceduresimpossible at this stage.- If considering re-opening businesses, this will drastically increase PPE needs to a whole newsecto r.TESTING challenges:- Each city reported that, despite improvements, a very limited number of tests are beingperfom1ed compared to need.- Supply shortages are the biggest challenge: swabs, PPE, sample kits, reagents arethe biggest obstacles. Not clear where this is going to come from or who is responsiblefor addressing problems.- Private labs limit number of sample kits distributed each week. In places where publiclabs are available, there is a push to get providers to use the public labs. But manyplaces don't have public labs.- There is no clear guidance on how to prioritize who gets tested first. So, in some places, thatmeans that people at lower-risk are being testing but people at greater risk (due to symptoms ,exposure , high-risk living/work environment, etc) are not being testing. Guidelines are neededto help prioritize where testing resources are used first.- Public testing produces skewed results . Testing becomes available only to those whocan make an appointment and who can drive to the site. This means many lowerprioritypeople get tested but high-priority people do not. This skews understanding ofpositivity rates.- Some labs are underutilized - but the reason is that there are breakdowns in the supply chainthat make it difficult to test people and get tests to the labs. (e.g .) (b) <4)- Reimbursement is an obstacle. CMS offering to cover test costs ($100 per test) would help getlabs to do more testing. It would not solve the problem , but it would help.- Proliferation of unvalidated antibody tests is causing confusion. High rates of false results,misinterpretation of what results mean ( e .g. telling people who test antibody positive that theymust quarantine for two weeks). Chicago spends a lot time shutting down these testing sites asthey make things harder and use up supplies.- there is increasing pressure to reach a target nwnber of tests performed each day in order to getto 're-opening'. But the number needed is contextual based on the environment, population -there isn't one 'right' number for everywhere.- Need better public messaging on difference between virology and serologic tests.- Current testing capacity is no where near what is needed to make informed decisions about reoperung.TESTING: reporting challenges- CwTent PoC tests have no link to provide results to health departments . Many outpatientfacili ties and SNFs have no system for reporting test results to HDs. Need electronic link forreporting PoC test results.- While aggregate positive tests may be reported, negative result'> are not.- Impossible to really understand population levels of infection because ( 1) number of testsperfom1ed is too low and (2) not testing the 'right' people- Every one is pushing for rapid scale up of antibody tests, but we still don't know what theresults of these tests mean and bow to apply them to policy development.- CDC and NIH will each coordinate sere-surveys. No details on CDC approach yet. NIH studyis up. Still not clear how to use the results of these studies , but useful to collect data now andapply it as knowledg e grows. Locally-coordinate aero-surveys can be helpful but only if tests arehighly validated .The Future:- How many tests should we being doing? How much PPB/testings /beds/staff will be needed inthe coming year? Next winter, we will face dual flu and COVID outbreaks, without stable testingcapacity, how will we differentiate between the two?- What are the plans for contact tracing? Who will recruit and train? Is there a federal plan orguidelines for this? How will it be paid for? What do we do to effectively isolate those infected?This e-mail , and any attachments thereto , is intended only for use by the addressee(s) namedherein and may contain legally privileged and/or confidential information . If you are not theintended recipient of this e-mail ( or the person responsible for delivering this document to theintended recipient ), you are hereby notified that any dissemination, distribution, printing orcopying of this e-mail, and any attachment thereto, is strictly prohibited. If you have receivedthis e-mail in error, please respond to the individual sending the message, and permanently deletethe original and any copy of any e-mail and printout thereof.From:Sent :To:Fauci, Anthony (NIH/NIAID) [E)Thu, 23 Apr 2020 12:53:24 +0000Stover, Kathy (NIH/NIAID) [E)Cc:(NIH/N IAID) [ElSubject:Billet, Courtney (NIH/NIAID) [El;Folkers, Greg (NIH/NIAID) [El;Conrad, PatriciaRE: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine /azithromycinstudyLooks fine.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Stover, Kathy (NIH/NIAID) [El (b)(6)Sent: Wednesday, April 22, 2020 3:56 PMTo: Fauci, Anthony (NIH/NIAID) [E) ------ --=-=·'======~~ Cc: Billet, Courtney (NIH/NIAID) [E) (b)( ·; Folkers, Greg (NIH/NIAID) [E)-------- (b)(6)>; Conrad, Patricia {NIH/NIAID) [E) (b)(6) Subject: FOR ASF REVIEW: Draft PR re: launch of hydroxychloroquine/azithromycin studyHi Dr. Fauci,Please find attached for your review a draft press release describing the launc h of the ACTGhydroxychloroqu ine/azithromycin study for COVID-19. NIAID will issue the release after the firstparticipant(s) has enrolled, which is currently anticipated around May 1.The following is the quote we have drafted for you:"We urgently need a safe and effective treat ment for COVID-19. Repurposing existing drugs isan attractive option because these medications have undergone extensive testing, allow ingthem to move quickly into cli nical trials and accelerating thei r potential approval for COVID-19t reatment ," said NIAID Director Anthony S. Fauci, M .D. "Although there is anecdota l evidencethat hydroxychloroquine and azithromycin may bene f it peop le with COVID-19, we need soliddata from a large random ized, control led clinical trial to determ ine whether this experimentaltreatment is safe and can improve clinical outcomes. "Thanks much,KathyKathy StoverBranch ChiefNews and Science Writing BranchNational Institute of Allergy and Infectious Diseases (NIAID)Office of Communications and Government Relat ionsNational Institutes of Health/HHS31 Center Drive, Room 7A17EBethesda, MD 20892Phone: (b)(6)E-mai Cb) (6)NIAID Media Line: (301) 402-1663From:Sent:To:Cc:Subject:Attachments:Larry /John:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 11:54 :41 +0000Corey MD, Larry (b)( ;Masco la, John (NIH/VRC) [E]Conrad, Patricia (NIH/NIA ID) [E);Fauci, Antho ny (NIH/NIA ID) [E]NEJM manuscriptCOVID vaccine editoria l_ prefinal April2 1_7pm fsc - with minor Fauci edits. docxI have gone over the changes that Francis has inserted and I have edited someof them. Please accept his changes and my edits of them (or any additional editsthat you have) and then it is OK to send in . Please let me know if you have anyquestions.Thanks,TonyAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :Eisinger, Robert (NIH/NIAID) [El on behalf of Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 11:13 :29 +0000To: Fauci, Anthony (NIH/NIAID) [E)Subject: FW: seeking your advice on a COVID-19 questionEmail from Pardis Sabeti.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Office of the DirectorNational Institute of Allergy and Infectiou s DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email: (b)(From: Pardis Sabeti (b)(6) ---------- Se nt: Wednesday, April 22, 2020 9:47 PMTo: Fauci, Anthony (NIH/NIAID) [E)--------=- (b:)-(-=6: )>Cc: Collins, Francis (NIH/OD) [E] ------- (b)(6) Subject: Re: seeking your advice on a COVID-19 questionAwe, thank you, here for you two any time, and grateful for the enormous positive impact you have onthe world, PardisOn Wed, Apr 22, 2020 at 9:43 PM Fauci, Anthony (NIH/NIAID) [E] ------- (b)(6)> wrote:Thanks, Pardis. It was great to spend time with you and your colleagues. We learned a lot.Warm regards,TonyFrom: Collins, Francis (NIH/OD) [E] ______ CbC>6)>Sent : Wednesday, April 22, 2020 8:44 PMTo: Pardis Sabeti (b)(6)>Cc: Fauci, Anthony (NIH/NIAID) [El -------- (b)( > Subject : RE: seeking your advice on a COVID-19 questionHey there Pardis,You are much too kind - but we are grateful for YOU and your team!It was fun to talk science for a litt le whi le. QBest, FrancisFrom : Pardis Sabeti (b)(6)>Sent : Wednesday, April 22, 2020 8:38 PM ------ == To: Collins, Francis (NIH/OD) [El (b)( >Cc; Fauci, Antho ny (NIH/NIAID) [El (b)(6)>Subject : Re: seeking your advice on a COVID-19 questio nDear Francis and Tony,Thank you for a great conversation. Jacob, Bronwyn, and I stayed on a moment after you left andtalked about how inspired we are by each of you and by the camaraderie between you two . Jacobadded those two are national treasure s, and Bronwyn and I whol eheartedly agreed.Grateful for you both,PardisOn Wed, Apr 22, 2020 at 8:21 AM Collins, Francis (NIH/OD) [E] -------- (b)(6):> wrote:Hi Pardis,See attached paper that argues there may be a significant difference in virulence of the COVI0-19clade that predominates on the west coast compared to the east coast. Tony Fauci and I would liketo kno (b) (5)Also attached is a MedRxiv preprint that describes major differences in pathogenicity of differentviral st rains. I just got this (b)(5)Can I talk with you later today after you have a chance to review this?Thanks, FrancisPardis Sabeti, MD, DPhilProfessor, Harvard University & Harvard T.H. Chan School of Public HealthBroad Institute of MIT and HarvardHoward Hughes Medical InstituteAssistant: (b)(6)Phone:_.!===~ (b~H~-----------Website: www .sabeti lab.orgPardis Sabeti, MD, DPhilProfessor, Harvard University & Harvard T.H. Chan School of Public HealthBroad Institute of MIT and HarvardHoward Hughes Medical InstituteAssistan,t. ..!:==~~:;:;;------------ Phone: (b)(6)CbH >------ Website : www.sabetilab.orgFrom:Sent:To:(b)(6)Thu, 23 Apr 2020 07:09 :44 -0400Conrad, Patricia (NIH/NIAID) [E)Subject: Fwd: invitation to New Zealand conversationSent from my iPhoneBegin forwarded message:From: Pat Brittenden <info@blindfi sh.medi a>Date: April 23, 2020 at 12:02: 13 AM EDT,------- --;;-~To: "Fauci , Anthony (NIH/NIAID ) [E]" -------- (b)( Subject: invitation to New Zealand conversationGood afternoon Dr Fauci,We are intere sted in seeing if you would be ava ilable for a chat via Zoom to NewZealand abou t COVID- 19The US is an essential part of the NZ economy contr ibuting between $1.5 and $2billion dollars annually from tourism alone and we would love to have aconversation about where the US is at, how COVID-19 is being dealt with, and thefuture of things that could lead up to opening our borde rs again.We're happy to have you for any length of time, but if you have 10-20 minutes thatwould be amazing.Thank you for what you are doing in this global event, I hope we can connectsometime soonSincer ely,Pat Brittendenwww. theDOC.nzwww .patbrittenden.com /abou t(b)(6)From:Sent :To:(b)(6)Thu, 23 Apr 2020 07:08:26 -0400Barasch, Kimberly (NIH/NIAID) [CJSubject: Fwd: Global Health Leaders Call, Thursday, 23 April, 14:30 CETSent from my iPhoneBegin forwa rded message:From: "KABIR, Sophia" (b)( >Date: April 23, 2020 at 6:54:46 AM EDTTo: SHOC <shoc@who.int >, Office of the Director-Genera l <DGOffice @who.int>,"Redfie ld, Robert R. (CDC /OD)" (b) (6)(b)( , "Felicity Harvey, "Chris.Elias"(b)(6)"Fauci, Anthony (NIH/NIAID) [E]''(b)(6)(b)(6). ,------ (b)(6)., "COX, Paul Michael""GREIN , Thomas"(b)("SCHWARTLANDER, Bernha rd F."Raman" ----------. "Conrad, Patricia (NIH/NIAID) [E]" --------. Jaouad" (b)( , "FALL, Ibrahima Soce", "MINHAS,(b)(6)(bH6) >, "MAHJOUR ,(b) (6), "Thomas(b)(6),--------(b)(6) , Preside nt I Resolve to Save LivesSHORBAn, Farah""DRURY, Patric k Anthony"(b) (6), "Amadou.SAL L"(b)(6) "AL(b)(6)1--c,~ Robynn Leidig (b) (6),(bH · , "Dr VAN KER.KHO VE, Maria"(b)(6)----------------- "GRAAFF , Peter Jan"CbH6), "POOLE, Marcia" Cb()6 ) , Tarik MohammedCb()6 ) CarlosNavarro Colorado, Ryan Morhard ------ ~ (b)(6)~"BRIAND, Sylvie" CbH6, )"MORGAN, Oliver' -------- (b)(6) "Ha JT i es, Jenny" CbH , "Awwad, David (NIH/NIAID)[C]" CbH6>), "SIMONSON, Stewart" CbH6)"SINGER , Peter Alexander" CbH , "Jayatunga , Wikum"(b)(6)"Julie.HA LL"RIOUX, "SHIN, Young-Soo""SMITH, Ian Michael"Raymond Bruce J."Cc: SHOC <shoc@who.int >, Office of the Director-General <DG0ffice @who.int> ,"SCHWARTLANDER, BernhardF." ....__ __ _,, CbH6") MAHJOUR,Jaouad" CbH , "FALL, Ibrahima Soce" CbH , "GREIN,Thoma s" CbH6>J, "MINHAS , Raman" CbH6, )"COX, PaulMichael" ____ CbH6J , "AL-SHORBAJI, Farah" CbH >,"POOLE , Marcia" CbH6l , "DRURY, Patrick Anthony"------ CbH · , "GRAAFF, Peter Jan" CbH6J, "Dr VAN KERKHOVE , Maria" Cb<>6 ,J "FARES, Christine Youssef'(b)(6)Subject: RE: Global Health Leaders Call, Thursday, 23 April, 14:30 CETDear colleagues,Apologies for the mistake in the below subject line.The meeting starts at 14.30 CET, as mentioned in the email.Kind regards,SophiaFrom: KABIR, SophiaSent : Thursday, April 23, 2020 10:51 AMTo: SHOC <shoc@who .int>; Office of the Director -General <DG0ffice@who.int>;(b)(6)(b)(6), ,TLANDER, Be rd F. (b)(6); MINHAS,"'.'--~==::!.....::..__ _____ .:_ ___ ..!::::======~ (b:):(-~=6);-MAHJOUR, Jaouad (b)(6); FALL, lbrahima Soce :..--.....:=======::;..,:-:-= ; 'Thomas R. Frieden' (b)( ; 'Elhadj SY' ======"=~ -------- (b)(6); 'Lynn Banks' (b)( ·; 'President I (b )( 6)ALnLeidig' (b)( ·; DRURY, ~-:-::-:-:::--:-:---:--;::::=====:::-,-;,.;.-.-s-= r VAN KERKHOVE, Maria (b)( 6)(b)(6) SMITH, Ian Michael (b)(Cc: SHOC <shoc@who.int>; Office of the Director-Gen eral <DGOffice@who .int>;SCHWARTLANDER, Bernhard F. (b)(6) ; MAHJOUR, Jaouad====~~(b)-(6)-r>; FALL, lbrahima- S-o-c-e -===~(b~)(6)~; G REIN,T homas ::::::==(=b)(=6J'=c; >M~IN-H=AS , Raman (b)(6); COX, Paul Michael (b)(6); Al -SHOR BAJ I, Farah (b)( ; POOLE, Marcia ====~~ ::::::===(b=)(6)= >;~ D~RU RY,P atrick Anthony (b)(6)·> ; GRAAFF,P eter Jan _____ (bJ~(6~);_Dr VAN KERKHOVEM, aria _______ (_b~_<_.·>; FARES,Christine Youssef (b)(6)Subject: Global Health leaders Call, Thursday, 23 April, 14:00 CETDear colleagues,Ahead of the Global Health leaders Call at 14.30 CET today, please find an epidemiologicalupdate and analysis attached , in addition to the "Consideration s in adjusting public healthand social measures in the context of COVID-19" inte rim guidance document, which waspubl ished on the WHO website on 16 April.Please find below, t he key questions for your consideration and input.1. What is your view on the latest epidemiology, virus transmission and severity inaffected countries?2. What are the emerging issues/challenges that you see as impo rtant?3. What should be the priorit ies for the 1-2 weeks?4. Any other issues you see as important?You will be able to connect via t he Webex connection below. If you experience anytechnical difficulties, please contact the WHO HQ EOC operator at: +41 22 79 15 533 or viaemail: shoc@who.int.Best,SophiaMeeting number (access code): ------ (b) (6), (b) (4)Meeting password ------- (b) (6), (b) (4)Thursday , April 23, 20202:00 pm I (UTC+02:00) Brussels , Copenhagen, Madrid, ParisJoin meetingJoin by phoneTap to call in from a mobile device (attendees only)(bH6JTZERLANDTo llSTollGlobal call-in numbersFrom:Se nt:To:Subject:Attachment s:2020.04.14 .. pdfAlice:Fauci, Anthony (NIH/NIAID) [E]Thu, 23 Apr 2020 02:16:12 +0000Alice ParkFW: Time follow upMedRxiv_ Mutat ions impact pathogenicity SARS-CoV-2_ Lanjuan Li et al.Here is another manuscript.TonyFrom:Sent:To:Subject:Lou:Fauci, Anthony (NIH/N IAID) [E)Thu, 23 Apr 2020 02:11:27 +0000Lou lgnarroRE: Greeti ngs- NOT urgentThank you for your kind note. It is much appreciated. I hope that you are well.Best regards,TonyFrom: Lou lgnarro (b)(sent: Tuesday, April 21, 2020 5:38 PMTo: Fauci, Anthony (NIH/NIAID) [E] -------= (b,.),(.=.6)Subject: Greet ings- NOT urgentHi Tony,This is Lou lgnarro from UCLA. You and I shared the stage in the "Shoe" at the OhioState University a few years ago, where you gave the Graduation Address to theundergraduate seniors . I was on stage with you, to receive an award for my basicbiomedical research which resulted in my being awarded the Nobel Prize in Medicinein 1998. I recall the nice conversations we were enjoying with Sanjay Gupta whilerobing for the event.Thanks for the tru ly spectacular job you are doing, regarding the coronaviruspandemic. We Nobel Laureates especially regard your work as the most importantduring our lifetime. Thank you and God bless.My best wishes,Lou lgnarroFrom:Sent :To:Cc:Subject:Attachments:Fauci, Anthony (NIH/NIAID) [E]Thu, 23 Apr 2020 01:50:03 +0000Conrad, Patricia (NIH/NIAID) [E]Barasch, Kimberly (NIH/NIAID) [C]FW: letter from the Governor of Puerto RicoDr. Anthony S. Fauci, MD[2].pdfHeads up for a call from the Puerto Rican Health Minister.From: Pablo L. Pena Antonmarch i <ppena@fortaleza.pr.gov>Sent: Wednesday, April 22, 2020 5:24 PMTo: Fauci, Anthony (NIH/NIAID) [E]------ (=b)""('=6)>Cc: Conrad, Patricia (NIH/NIAID) [E] (b)(6):>; Barasch, Kimberly (NIH/NIAID) [CJ---------- (b)(6J>; Jennifer M. Storipan <jstoripan@prfaa.pr .gov>; Juan L. Negron < j neg r on@ p rf a a.pr .gov>; Maria del C Reyes Crespo <mreyes@fortaleza.pr.gov>; Antonio L. PabonBatlle <apabon@forta leza.pr.gov>Subject : letter from the Governor of Puerto RicoImportance: HighDear Dr. Anthony Fauci:I am sending you for your attention a letter from the Governor of Puerto Rico Hon. WandaVazquez Garced.Cordially,Pablo L. Pena Antonmar chiExecutive AssistantLedo . Antonio Pabon BatlleChief of Staff OfficeLa Fortaleza. * ., LA PORTALEZANOTA DE CONFIDENCIALIDADE: sta transmisi6n electr6nica cont iene informaci6n perteneciente ala Oficina del Gobernado r, que es confidencial, privilegiada y/o privada bajo las leyes aplicables.Solamente podra ser util izada par la persona o entidad a la cual se dirige. Si usted no es eldestinatario intencional, se le notifica que se prohibe cualquier uso, disem inaci6n o copia de estacomunicaci6n. Si usted recibe esta comunicaci6n por erro r, favor de notificar al remit ente yeliminar este correo electr6nico de su sistema.CONFIDENTIALITYN OTE: This electronic transmission contains information belonging to theGovernor's Office, which is confidential , privileged and exempt from disclosure under theapplicable law. It is intended solely for the use of the individual or entity to which it is addressed. Ifyou are not the intended recipient, you are hereby notified that any use, dissemination, or copyingof the communication is strictly prohibited. If you have received this communication by error,please notify the sender and delete this e-mail from your system.From:Sent :To:Subject:Attachments :Alice:Fauci, Anthony (NIH/NIAID) [ElThu, 23 Apr 2020 01:40:52 +0000Alice Park;Conrad, Patricia {NIH/NIAID) [ElRE: Time follow upViral Clades Brufsky 42020 Accepted Final.pdfIt was great working w ith you today. Here is the reference. I believe that it will be in theJourna l of Medical Virology . It has been accepted, but is no yet in print.Best regards,To nyFrom: Alice Park <alice.park@time.com>Sent: Wednesday, April 22, 2020 6:30 PMTo: Fauci, Anthony (NIH/NIAID) [El <AFAUCl@niaid.nih.gov>; Conrad, Patricia {NIH/NIAID) [El<conradpa@niaid.nih.gov>Subject: Time follow upDear Dr. Fauci -- many thanks for your time today; we are thrilled to have you as part of theTIME 100 Talks, which will go live tomorrow.In the meantime, I wanted to double check the reference to the study you mentioned about theeast and west coast strains and their potentia l difference in virulence. Realize it's preliminary,so just wanted to confirm any references we make to it. I checked the biorxiv and medrx iv butdidn't find the citation. Would appreciate the journal if it was pub lished . Many thanks! AlicePLEASE NOTE NEW PHONE NUMBERAlice ParkTIME(b)(6)a lice. park@time.com@aliceparknyFrom:Sent :To:Cc:Subject:Attachment s:Francis:Fauci, Anthony (NIH/N IAID) [ElWed, 22 Apr 2020 16:29:19 +0000 -----~~ Collins, Francis (NIH/OD) [El (b)(6)Corey MD, Larry CbH6lMascola, John (NIH/VRC) [ElFW: "final draft"COVID vaccine editorial _ prefinal April21_7pm.docxHere is the paper th at I mention ed to you and t hat we are plannin g to submit tothe NEJM. I have put you r name on it as the senior author. If you arecomfort able with th at, we will go wit h it. Please tak e a look at th e manu scriptand make any comment s or edits t hat you see fit.Thanks,TonyFrom:Sent:To:Fauci, Anthony (NIH/N IAID) [E)Wed, 22 Apr 2020 14:41:09 +0000Billet, Courtney (NIH/N IAID) [E]Cc: Greg Folkers (b)( 6) ;Conrad, Patricia (NIH/NIAID) [ElSubject: RE: Request for Dr. Fauci+ Ryan Zimm erman Pros For Heroes I COVID-19 ReliefFundI was t hinking the very same t hing.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone (b) (6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Billet, Courtn ey (NIH/NIAID) [E) -------- (b)(6) >Sent: Tuesday, April 21, 2020 8:43 PM ------ ::;..,..-,= To: Fauci, Anthony (NIH/NIA ID) [El (b)(6)> ~======~ = Cc: Conrad, Patr icia (NIH/NIAID) [E] ---------- (b)( >; Folkers, Greg (NIH/NIAID) [E] (b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundPs - what do you want to bet you get invited to throw a first pitch next year?From: Billet, Courtney (NIH/NIAID) [E]Sent: Tuesday, April 21, 2020 8:38 PMTo: Fauci, Anthony (NIH/NIAID) [E)_ _____ "("b"..~',.c=.6)>Cc: Conrad, Patricia (NIH/NIAID) [E) (b)(6) •> ; Folkers, Greg (NIH/NIAID) [E)(b)(6)>Subject: FW: Request for Dr. Fauci+ Ryan Zimmerm an Pros For Heroes I COVID-19 R@lief FundWe're a "go" on this . I'll circle back with his rep tomorrow.On Apr 21, 2020, at 6:50 PM, Billet, Courtney (NIH/NIAID) [E] -------- (b) (6) >wrote :Hi guys - as a huge Nats fan, Dr. Fauci very much wants to do this chat with RyanZimmerman. Can I get a green light to work on this with them? I'll get the q's but it will bethe same general theme as with Steph Curry, YES Network, etc.From: Judee Ann Williams <judeeann.williams@caa.com>Se nt: Tuesday, April 21, 2020 5:54 PM --------=-s-= To: Billet, Courtney (NIH/NIAID) [E] (b)(6)Cc: Christine Lancman <christine .lancman@caa.com> ; Routh, Jennifer (NIH/NIAID) [E](b)(6)Subject: Re: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 ReliefFundAbsolute ly! We would 100% be able to work around that and avoid any association offund raising.We wou ld set this up however he will be most comfo rtab le, seed questions in advance, etc.and shed a light on what is most helpfu l.Will wait to hear and if you need anything else ju st let us know. Thank you so much!From: "Billet, Courtney (NIH/NIAID) [E]" --------- (b)(6) Date : Tuesday, Apr il 21, 2020 at 4:41 PMTo: Judee Williams <judeeann .will iams@caa.com>Cc: Christine Lancman <christine.lancman@caa.com>, "Routh, Jennifer (NIH/NIA ID)[E]" (b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19Relief FundI *Exte rnal Sender*Hi - thanks for your message - we will check and someone will get back to you in the nextfew days. One caveat is that as a Federal official, Dr. Fauci cannot be associated withfundraising in any way . Please confirm that is someth ing you would be able to workaround?From: Judee Ann Williams <judeeann.williams@caa.com>Sent : Monday, Apri l 20, 2020 5:21 PMTo: Routh, Jennifer {NIH/ NIAID) [E] (b)(6)>; Billet, Courtney (NIH/N IAID)[E] (b)( >Cc: Christine Lancman <christ ine.lancman@caa.com >Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundJennifer & Courtney -Hello! Our fr iends fr om Steph Curry's team passed along your contact informat ion to usand we work at CAA where we represent Wor ld Series Champion, Ryan Zimmerman.Ryan wanted to express his grat itude first & fo remost to Dr. Fauci, the ent ire team and allthose behind the scenes working around the clock.Ryan recently launched the Pros for Heroes Covid-19 Fund last week, with more than 30professional athle tes suppo rting and over $300,000 raised across 1,400 separate donat ions.(>www .prosforhe roes.org<). Since its launch last Tuesday, contribut ions from the Pros ForHeroes Fund have gone directly :awards PPE needs throug hout the I nova hospita l netw orkt hroughout the mid-Atlantic and have helped provide meals to those cr it ical care fron t -lineworkers - keeping these front -line heroes covered at work and comfortable at home .If Dr. Fauci was up to it, Ryan would love to host eithe r a short 15 minute Q&A on hisFacebook to continue raising awareness for how we need to be responding to the ongoingcrisis. Or even simply thank Dr. Fauci for the tire less work he is doing and shine a light onhow fo lks can support these critical fron t line workers.We are also open to what you th ink would work best ! Wou ld there any openings thatwould work best?We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we canever be support ive or help navigate anything in the world of pop cultur e, please do nothesitate to ask.Warmest wishes,Judee AnnJudee Ann Williams I Co-Head, CAA Social ImpactT: 212-277 -5294 I M: (b)(6) I Washington, DCNEW YORK - LONDON -NASHVILLE-MUNICH - LOS ANGELES -BEIJING - SHANGHAI>https://www .caa.com/<Pros For Heroes"Teamwork is the ability to come t ogether tow ards a common goal. We are looking forwardto at tracting as many supporters to help join this cause and give back as much as we can totho se who have given us so much," said Washington Nationa l All-Star, Ryan Zimmerman,the fu nd's fo under.Social Links:>https://www.instagram.com / prosforheroes/<>http s://twitter.com/prosforheroes<Today Show:>https://www.today.com/video/ryan-zimmerman-talks-pros-for -heroes-fund -for -feedinghealth-care-wor ke rs-82 2026935 77 <Washington Post Launch Article:>https://www.washingtonpost .com/sports/2020 / 04/ 14/nationals-ryan-zimmerman-startsfund-hea Ith-care-workers -with- lO0k-gift/ <This e-mail and any files transmitted with it are intended solely for the use of the individualor entity to whom they are addressed. If the reader of this e-mail is not the intendedrecipient or the employee or agent responsible for delivering the message to the intendedrecip ient, you are hereby notified that any use dissemination, forwarding, printing orcopying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients arefree to do their best work without experiencing harassment and want to ensure they havethe relevant resources they need. Clients can go to >https://www .caa.com/legal/sexual harassment-guidelines-caa-clients< to learn more about their rights, and how to reportviolations.This e-mail and any files transmitted with it are intended solely for the use of the individualor entity to whom they are addressed. If the reader of this e-mail is not the intendedrecipient or the employee or agent responsible for delivering the message to the intendedrecipient, you are hereby notified that any use dissemination, forwarding, printing orcopying of this e-mail is strictly prohibited. CAA is committed to ensuring that clients arefree to do their best work without experiencing harassment and want to ensure they havethe relevant resources they need. Clients can go to >https://www .caa.com/legal/sexualharassment-guidelines-caa-clients< to learn more about their rights, and how to reportviolations.From:Sent :Fauci, Anthony (NIH/NIAID) [ElWed, 22 Apr 2020 00:29:33 +0000To: -----~~ Collins, Francis (NIH/OD) [El- ------ (b)(6) Subject: FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, andmutations affect dead liness of strains, Chinese study findsMore on mutationsFrom: Fauci, Anthony (NIH/NIAID) [E]Sen t: Tuesday, April 21, 2020 1:58 PMTo: Graham, Barney (NIH/VRC) [E)------- =(b=H=6)Subject: FW: SCMP: Coronavirus's ability to mutate has been vast ly underestimated, and mutat ionsaffect deadliness of strains, Chinese study findsNot peer reviewed, but what do you t hink?Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892 -2520Phone : (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender 's own and not expressly made onbehalf of the NIAID by one of its representatives .From : Folkers, Greg {NIH/NIAID) [E] (b)( >Sent: Monday , Apri l 20, 2020 1:53 PMSubject: SCMP: Coronavirus's ability to mutate has been vast ly underestimated, and mutations affectdeadl iness of strains, Chinese study findsChina/ ScienceCoronavirus's ability to mutate has been vastlyunderestimated, and mutations affectdeadliness of strains, Chinese study finds• The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as theleast potent type• New York may have a deadlier strain imported from Europe, compared to less deadly viruseselsewhere in the United StatesStephen Chen in BeijingPublished: 10:41pm, 20 Apr, 2020Updated: 1:33am, 21 Apr, 2020A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possibleimplications for the pandemic . Photo: EPA-EFEA new study by one of China's top scientists has found the ability of the new coronavirus to mutate hasbeen vastly underestimated and different strains may account for different impacts of the disease invarious parts of the wor ld.Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patientsmany mutations not previously reported. These muta tions included changes so rare that scientists hadnever considered they might occur.They also confirmed for the first time with laboratory evidence that certain mutations could createstrains deadlier than others."Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity, " Li and hercollaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.Li's study provided the first hard evidence that mutation could affect how severely the virus causeddisease or damage in its host.Li took an unusual approach to investigate the virus mutation. She analysed the viral strains isolatedfrom 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, andthen tested how efficiently they could infect and kill cells.The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,while the milder strains were the predominant varieties found in parts of the United States, such asWashington state, according to their paper.A separate study had found that New York strains had been imported from Europe. The death rate inNew York was similar to that in many European countries, if not worse.But the weaker mutation did not mean a lower risk for everybody, according to Li's study. In Zhejiang,two pat ients in their 30s and 50s who contracted the weaker strain became severely ill. Although bothsurvived in the end, the elder patient needed treatment in an intensive care unit.This finding could shed light on differences in regiona l mortality. The pandemic's infection and deathrates vary from one country to another, and many explanations have been proposed.Genetic scientists had noticed that the dominant strains in different geographic regions were inherentlydifferent. Some researchers suspected the varying mortality rates could, in part, be caused by mutationsbut they had no direct proof .The issue was further complicated because survival rates depended on many factors, such as age,underlying health conditions or even blood type.In hospitals, Covid-19 has been treated as one disease and patients have received the same treatmentregardless of the strain they have. Li and her colleagues suggested that defining mutations in a regionmight determine actions to fight the virus."Drug and vaccine development , while urgent, need to take the impact of these accumulating mutations... into account to avoid potential pitfalls," they said.Li was the first scientist to propose the Wuhan lockdown ,according to state media reports. Thegovernment followed her advice and in late January, the city of more than 11 million residents was shutdown overnight.The sample size in this most recent study was remarkably small. Other studies tracking the virusmutation usually involved hundreds, or even thousands, of strains.Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - werenew.They found some of these mutations could lead to functional changes in the virus' spike protein, aunique structure over the viral envelope enabling the coronavir us to bind with human cells. Computersimulation pred icted that these mutations would increase its infectivity.To verify the theory, Li and colleagues infected cells with strains carrying different mutat ions. The mostaggressive strains could generate 270 times as much viral load as the weakest type. These strains alsokil led the cells the fastest.It was an unexpected result from fewer than a dozen patients, " indicating that the true diversity of theviral strains is still largely underapprecia ted," Li wrote in the paper.--Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: XinhuaThe mutat ions were genes different from the earliest strain isolated in Wuhan, where the virus was firstdetected in late December last year.The coronavirus changes at an average speed of about one mutation per month . By Monday, more than10,000 strains had been sequenced by scientists around the globe, containing more than 4,300mutations, according to the China National Centre for Bioinformation.Most of these samples, though, were sequenced by a standard approach t hat could generate a resultquickly . The genes were read just once, for instance, and there was room for mistakes.Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of thevirus genome was read more than 100 times, allowing the researchers to see changes that could havebeen over looked by the conventional approach.The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-year-old patient , which was a rare event. Usually the genes mutated at one site at a time. This patientspent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeceswere infectious with living viral strains."Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li andcolleagues said in the paper .Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for Informat ionScience and Technology at Tsinghua University, said ultra-deep sequencing could be an effectivestrategy to track the virus' mutation."It can produce some useful information," he said.But this approach could be much more time consuming and costly. It was unlikely to be applied to allsamples."Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the viruscame from, why it could kill some healthy young people while generating no detectable symptoms inmany others still left scientists scratching their heads."If there is a discovery that overturns the prevailing perception, don't be surprised."Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those ofNIAID, NIH, HHS, or the U.S. government.From:Sent :Fauci, Anthony (NIH/NIAID) [ElWed, 22 Apr 2020 00:16:44 +0000 To: Collins, Francis (NIH/OD) [El -----~~ (b)(6) ------- Subject: FW: For your attent ionAttachments : COVAX2020- A GLOBAL EFFORTfo r the ACCELERATEDD EVELOPMENT,PRODUCTIONa nd EQUITABLEA CCESSto COVID-19 VACCINES_16Apr2020_0RAFT.docxSee attachment that Hilary sent me.From: Marston, Hilary (NIH/NIAID) [El (b)(6) ________ _,Sent: Tuesday, April 21, 2020 7:44 PMTo: Fauci, Anthony (NIH/NIAID) [E]Subject: Re: For your attent ionFrom: Anthony Fauc i Cb)< >Date: Tue sday, April 21, 2020 at 7:30 PMTo: Hila ry Marston (b)( v>Subject: FW: For your attention(b)(6)(b) (5)Have you heard of this on any of the calls where you represent me??From: Collins, Francis (NIH/OD) (El (b)(6)Sent : Tuesday, April 21, 2020 7:28 PMTo: Fauci, Anthony (NIH/ NIAID) (El--------=- (b")"("= ; Lane, Cliff (NIH/N IAID) (El(b) (5)-------- (b)( ·; Tabak, Lawrence (NIH/OD) (El (b)(6)>; Freire, Maria (FNIH) (Tl <mfreire@fni h.org>; Wholley, David (FNIH) (T) <dwholley@fnih.org>Subject: FW: For your attentionHi all,See note below from Victor Dzau about a globa l effort on COVID-19. I can't tell if this is morethan a fund-raising effort. I know we have Gates reps on our ACTIV working groups- has any ofthis plan come up, David ?FrancisFrom: Dzau, Victor J. <VDzau@nas.edu>Sent : Tuesday, April 21, 2020 4:10 PMTo: Collins, Francis (NIH/OD) [El ------=- (b')"("=6' -)Cc: Kanarek, Morgan <MKanarek@nas.edu>Subject: For your attenti onDear Francis,Congratulat ions on your launch of Public Private Partnership to speed COVID 19 vaccine and treatmentoptions. This is very timely and much needed. Kudos to your leadership .I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics andtherapeutics. I have been part of the conversation and planning along with Jeremy Farrar, RichardHatchett , Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and EuropeanCommission have been leading the planning. This has advanced rapidly and is in the final stages indevelopment that wil l be soon announced. It has involved European Commission, Germany, Japan, UK,Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, GlobalFund, CEPI, GPMB and private sector industry . The initiative will begin with a Pledge conference for $8Bas a starting point. This will be led by President van der Leyen and is co-chaired by the above countryleaders. This will occur on May 4 . In addition by the end of this week or early next week there will be anannouncement on the global coordinating structure with will involve Gates, WHO etc.I am writing to be sure that you and the White House are aware of these upcoming events . Can youshare this information with the White House? Besides you, who else should I share this informationwith? I will be happy to send you background documents if you wish.Please call me anytime.Best,VictorFrom:Sent :To:Subject:Infect ionEisinger, Robert (NIH/ NIAID) [El on behalf of Fauci, Ant hony (NIH/NIAID) [ElTue, 21 Apr 2020 23:10:36 +0000Fauci, Anthony (NIH/NIAID) [E)FW: Consideration of IM COVID Immune Globul in for Prevent ion of COVID-19Attachment s: Prophylact ic Intramuscular COVID-IG - Oxman.pdf, FURTHER ARGUM ENTS INFAVOR OF INTRAMUSCULAR COVID-IG Version 4 - Oxman.pdfEmail from Gary Noble, advisor to Bob Windom in the 1980s.Robert W. Eisinger, Ph.D.Special Assistant for Scientific ProjectsImmediate Off ice of the DirectorNational Institute of Allergy and Infectious DiseasesNational Institutes of Health31 Center Drive, Room 7A-03Bethesda MD 20892Telephone: (b)(6)Email : (b)(From : Gary Noble (b)(6)Sent : Tuesday, Apr il 21, 2020 4:56 PM -----~= To: Fauci, Ant hony (NIH/ NIAID) [E] (b)(6)>Cc: McGowan, John J. (NIH/ NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E]-------- (b)(6J·; Oxman, Michael (b)( · Subject: Consideration of IM COVID Immune Globulin for Prevention of COVID-19 InfectionDear Tony,I will always remember our amazing collaboration during the HIV/AIDS days inthe 1980s, when I served as AIDS Advisor to Bob Windom , the DHHSAssistant Secretary for Health during President Reagan's administration. Andnow, I am delighted and amazed to watch you so adroitly maneuver theCOVID-19 scientific policies and keep them front and center in the currentWhite House!!---------------- Cb><6M>\i,c hael Oxman, has worked with John Zaia at City of Hope, and a Mayo/Hopkins /Michigan Stateconsortium for a tria l of IM COVID-IG as a prefe rred method for treatmentand prevent ion of COVID-19.This week , Mike expects to complete the protocol for a placebo (normalIG)-controlled trial of IM COVID-IG prophylaxis in at-risk healthcare workerswho are engaged in direct patient care at UCSD, but they need a modicumof support. Mike asked if I would reach out to see if NIAID might provide ofsupport for this effort, using IM, as opposed to IV, COVID-IG.I've copied Mike, who has provided the attached background information.Tony , with all my respect and admiration for what you are doing for the U.S.and for all of us.GaryGary R. Noble, MD, MPH, MA (Oxon)From:Sent :To:Subject:Let us discuss.Anthony S. Fauci , MDDirectorFauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 22:14:24 +0000NIAIDODAMFW: Invitation to Speak at UC Berkeley COVID-19 HackathonNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (30 496"'4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformat ion. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Saahil Chadha <saahil@calhacks.io>Sent: Tuesday, April 21, 2020 11:00- -A-M-- -~~ To: Fauci, Anthony (NIH/NIAID) [E]_ ______C bH6)> _,Subject: Invitation to Speak at UC Berkeley COVID-19 HackathonDear Dr Fauci,My name is Saahil , and I'm a director at Cal Hacks, a student organization at theUniversity of California, Berkeley. This upcoming weekend, we will be hostinghack:now ,a 36-hour global online hackathon to foster innovative and technical solutions to tacklethe challenges faced around the current COVI D-19 pandemic. We're projected to have1,500 participants from around the world. I'm reaching out to invite you to be ouropening ceremony speaker.Specifically , this Friday night, April 24, from 7-8pm Pacific Daylight Time, we're going tobe hosting the opening ceremony of our event. At this time, we want to inspire ourhackers to help solve global challenges related to health and community. We would beabsolutely honored if you would join us to speak at our opening ceremony forjust a few minutes to share your experiences with and response to the COVID-19pandemic. Your unique perspective and expanse of knowledge makes you the mostqualified person, and we would be humbled to include you as our opening ceremonyspeaker. Please let us know if you are able to accept this invitation.Stay safe,Saahil Chadha(b)(6)Calhacks .ioFrom:Sent :Fauci, Anthony (NIH/N IAID) [ElTue, 21 Apr 2020 22:06:57 +0000To:Subject:Folkers, Greg (NIH/NIAID) [E);Conrad, Patricia (NIH/NIAID) [ElRE: Message for Dr Anthony FAUCIOK. Please take care of this. Thanks.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Folkers, Greg (NIH/NIAID) [El --------- (b)(6) Sent: Tuesday, April 21, 2020 11:31 AMTo : Conrad, Patricia (NIH/NIAID) [El --------,;- (b")('"=6'"):'>; Fauci, Anthony (NIH/NIAID ) [El(b)(6)Subject: RE: Message for Dr Anthony FAUCII wou ld be extreme ly grateful to you if you can provide me with the most recent and pertinen t scientificand population data concerning covid-19. I know how extremely busy you are but maybe a collaboratorof yours whether he can send me the data via e-mail (b)(6)_Not exactly sure what he wants but I can send him some links that will get him the latest CoVinfo from pubmed, prepr ints, CDC etcFrom: Conrad , Patricia (NIH/NIAID) [ElSent: Tuesday, April 21, 2020 11:16 AtvlTo: Fauci, Anthony (NIH/NIAID) [E]-------= (b")"(=6' )>Cc: Folkers, Greg {NIH/NIAID) [El _______ CbCJ_6 )Subject: FW: Message for Dr Antho ny FAUCICan we direct her somewhere? Gray?(b) (6)>Patricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7 A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The information in this e-ma il and any of its attachments is confidentia l and may contain sensi tive information . It should not be usedby anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete itfrom your mailbox or any other storage devices. Nationa l Institute of Allergy and Infectious Diseases (NIAID) shall not acceptliability for any statement made that are sender's own and not expressly made on behalf of the NIAIO by one of its representatives .From: Jean-Louis Touraine ------------------(b)( > Sent: Tuesday, April 21, 2020 11:06 AMTo: Conrad, Patricia (NIH/NIAID) [E] _______ ("b")'"("=6' )Subject: Potential SPAM :Message for Dr Anthony FAUCII wou ld be very grateful to you if you can forward the following mail to Dr Anthony FAUCI.Many thanks.Sincerely yours,Pr Jean-Louis TOURAINE, Lyon and Paris, France.Dear Tony,You may remember, that we have met repeatedly and worked in parallel and in association, during theearly years of the HIV epidemic .You and I have been trained in immunoly. Both of us are much sollicitated to help facing and f ighting thecovid-19 epidemic .During the past years, as well as recently, I have followed with great interest and respect youraccomplishments and your advices in the fights against epidemics. I would be extremely grateful to youif you can provide me with the most recent and pertinent scientific and population data concerningcovid-19. I know how extremely busy you are but maybe a collaborator of yours whether he can sendme the data via e-mail (b) (6) This will allow me to give moredocumented informations to the French President and Government. Cooperation between countries willbe crucial against covid-19 as it has been against HIV and other agents.I look forward to seeing you again in quieter times.Many thanks and very best personal regards.Jean-Louis TOURAINE, M.D., Ph. D., M.P.Ce message, ainsi que les pieces jointes, sont etablis, sous laseule responsabilite de l'expediteur, a !'intention exclusivede ses destinataires ; ils peuvent contenir des informationsconfidentielles . Toute publication, utilisation ou diffusiondoit etre autorisee prealablement.Ce message a fait l'objet d'un traitement anti-virus.11 est rappele que tout message electronique est susceptibled'alteration au cours de son acheminement sm Internet.Yous pouvez consulter le site de l'Assemblee nationale al'adresse suivante : http://www.assemblee-nationale.frFrom: Fauci, Anthony (NIH/N IAID) [ElSent: Tue, 21 Apr 2020 21:39:30 +0000 -----~~ To: Collins, Francis (NIH/OD) [El (b)(6)Cc: Myles, Renate (NIH/OD) [E);Burk low, John (NIH/ OD) [E);Billet, Courtney(NIH/N IAID) [E);Conrad, Patricia (NIH/NIAID) [E]Subject: FW: STAT: Director of U.S. agency key to helming vaccine developme nt leavesrole suddenly amid coro navirus pandemic https://bi t. ly/ 2XRZqKaAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)( 6)FAX: (301 496-4409E-mail (b) (6)(b) (5)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/N IAID) [E)- ------- (b) (6) > Sent: Tuesday, April 21, 2020 3:01 PMSubject: STAT: Director of U.S. agency key to helming vaccine development leaves role sudde nly amidcoronaviru s pandemic ht t ps:// bit .ly/2XRZqKaDirector of U.S. agency key to helming vaccinedevelopment leaves role suddenly amidcoronavirus pandemicBy Nicholas Florko @NicholasFlorkoApril 21, 2020Rick Bright HHSWASHINGTON - Rick Bright, one of the nation's leading vaccine development experts and the directorof the Biomedical Advanced Research and Development Authori ty, is no longer leading the organization,officials to ld STAT.The shakeup at the agency, known as BARDA, couldn't come at a more inopportune time for the office,which invests in drugs, devices, and other technologies that help address infectious disease out breaksand which has been at the center of the government's coronaviru s pandemic response.Bright, whose departure was confirmed by th ree industry sources and two current Trump admin istrationsources, will instead move into a narrower role at the National Institutes of Health overseeing a similarbut lim ited public-pr ivate part nership aimed at vaccine development. Gary Disbrow, Bright's formerdeputy at BARDA, wi ll serve as the acting director of the office, an HHS spokesperson confirmed toSTAT.BARDA was expected to play an even larger role in the coming months; Congress more than tripledBARDA's budget in the most recent coronavirus stimulus package. Already, the office has a role in someof the splashiest Covid-19 projects, including partnerships with Johnson & Johnson and ModernaTherapeut ics, both of which are developing potent ial Covid-19 treatments .Related:This tiny federal agency was built to respond to a crisis likecoronavirus. Now that it's here, is BARDA ready?BARDA has been plagued with management issues virtually since its creation in 2006, with much of thecriticism aimed at a contracting department that some say is unresponsive to industry partners. Theoffice has only had two permanent directo rs since its creation in 2006. Bright has led the organizationsince 2016.None of the sources articu lated the reason for Bright's departure, though several mentioned recentchafing between Bright and Bob Kadlec, the HHS Assistant Secretary for Preparedness and Response,which has oversight over BARDA.An HHS spokesperson confirmed that Bright will work on a recently announced NIH public-privatepartnership with 16 drug makers aimed at develop ing vaccines and treatments for Covid-19."Dr. Rick Bright will transfer the skills he has applied as Director of the [BARDA) to the [NIH) .... Dr. Brightbrings extensive experience and expertise in facilitating powerful public-private partnerships tha tadvance the health and well -being of the American people," the spokesperson said.Bright did not immed iately respond to requests for comment.Bright's career has largely centered around vaccine and drug development . His work at the Centers forDisease Control and Prevention focused on influenza viruses, antiviral drugs and tests . He has alsoworked in the biotechnology industry and served as an advisor to the World Health Organization. Beforebecoming BARDA director, he led the agency's Influenza and Emerging Infectious Diseases Division.Lev Facher contributed reporting.Disclaimer: Any third-party material in this email bas been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy /veracity. It does not necessarily representmy views nor those of NlAID , NlH, HHS, or the U.S. government.From: Fauci, Anthony (NIH/N IAID) [E)Sent: Tue, 21 Apr 2020 21 :18:24 +0000To: Crawford , Chase (NIH/NIAID) [E);Auchincloss, Hugh (NIH/NIAID) [E);McGowan ,John 1. (NIH/NIAID) [E];Ha rper, Jill (NIH/NIAID) [E];Gilles, Sharon (NIH/NIAID) [E);Lane, Cliff (NIH/NIAID)[E];John son, Martin S. (NIH/NIAID) [E);Marston, Hilary (NIH/NIA ID) [E];Billet, Courtney (NIH/NIAID) [E]Cc: Haskins, Melinda (N IH/NIAID) [E];Selgrade , Sara (NIH/NIAID) [E)Subject: RE: Atte ntion: COVID-19 legislative package bill text releasedThanks.Anthony S. Fauci, MDDirec;torNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Crawfo rd, Chase (NIH/NIAID) [E] --------- (b)(6)> Sent: Tuesday, April 21, 2020 3:27 -PM- -----,;; = To: Fauci, Anthony (NIH/NIAID) [E) CbH >; Auchi ncloss, Hugh (NIH/NIAID) [E)(b)(6J> ; McGowan, John J. (NIH/NIAID) [E] "':"':"".".'.""."".~======-- =-J. i'1:"1:"(": N'""'..l"''H'.."'/"":.N""'':.I"'A":"."l'~D".:)- :[~E:]- :=: =~~--= (b=H~ >; Gill es, Sharon (NI H/N JAi D) [ E] >;"""-:--:-:--:-:::====:::::::......:..._~Lane, Cliff (NIH/NIAID) [E] (b)(6) ; Johnson, Martin S. (N IH/NIAID) [E] _ __;_ _ __;__,;___..;..:,~'=i-':-:----:-::-:--::-:-:" .(b)( ; Marston, Hilary (NIH/NIAID) [El (b)( ; Bille t,-C-o-ur-tn_e_y'"('.N' IH'"/'.N' IA-ID-:)-'"['.-E'-:l~!,;._--....,;_ _ _(;,b,.):~(6)Cc: Haskins, Melinda (NIH~/ "N."-I'A:.--::1-~D: ):-[:~E:l- :=:===--- ('"b")"''~6=); Selgrade , Sara (NIH/NIAID) [El(b)(6)Subject: Atte ntion: COVID-19 legislative package bill text releasedImportance: HighGood Afternoon,At 4p.m. today (4/21), the U.S. Senate is expected to hold a vote by unanimousconsent on the "Paycheck Protection Program and Health Care Enhancement Act"(bill text attached). In particular please note that the legislat ive package includesthe following supplemental appropriations for diagnostic testing (pages 13-15 ofattached) :• NIH/OD - not less than $1B to develop, validate, improve, and implementtesting and associated technologies; to accelerate research, development,and implementation of point of care and other rapid testing; and forpartnerships with governmental and non-governmental entities toresearch, develop, and implement the activities outlined in this proviso.• funds in the preceding proviso may be transferred to the accounts of theInstitutes and Centers of the National Institutes of Health for thepurposes specified in the preceding proviso• the transfer authority provided in the preceding proviso is in addition toall other transfer authority available to the NIH• NCI - not less than $306M to develop , validate, improve, and implementserological testing and associated technologies for the purposes specifiedunder this paragraph in this Act:• NIBIB - not less than $S00M to accelerate research, development, andimplementation of point of care and other rapid testing related tocoronavirus:• CDC - not less than $1B for surveillance, epidemiology, laboratory capacityexpansion, contact tracing, public health data surveillance and analyticsinfrastructure modernization, disseminating information about testing, andworkforce support necessary to expand and improve COVID-19 testing• BARDA- not less than $1B for necessary expenses of advanced research,development, manufacturing , production , and purchase of diagnostic ,serologic, or other COVID-19 tests or related supplies, and other activitiesrelated to COVID-19 testing at the discretion of the Secretary• FDA-$22M to support activities associated with diagnostic, serological,antigen, and other tests, and related administrative activitiesWe will keep you updated on any developments related to this legislation. Pleaselet us know if you have any questions.Thanks,ChaseFrom:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 21:01:27 +0000Billet, Courtney (NIH/N IAID) [E]RE: Ryan ZimmermanIf cleared, I would love to.Anthony S. Fauci , MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)(6)FAX: (30 496"'4409E-mail Cb()6 )(b)(5)- PCThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Billet, Courtney (NIH/NIAID) [E] (b)(6)Sent: Tuesday, April 21, 2020 4:43 PM ------ == To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)>Cc: Conrad, Patricia (NIH/NIAID) [E] CbH6l>; Routh, Jennifer (NIH/NIAID) [E](b)(6); Stover, Kathy (NIH/NIAID) [E] (b)( ·; Folkers, Greg"('.N -'"-1'-H/-:N--I-A--ID ~)-:[-E::]"=:'====:!.;___...;._ =(b)=(6~)Subject: Ryan ZimmermanWould you be interested in doing something with Ryan Zimmerman? Format TBD. We' ll pursue furtherdiscussion if you give the green light.From: Billet, Courtne y (NIH/NIAID) [E]Sent : Tuesday, April 21, 2020 4:41 PMTo: Judee Ann Wi lliams <judeeann.will iams@caa.com>Cc: Christine Lancman <christine. lancman@caa.com >; Routh, Jennifer (NIH/NIAID) [E)(b)(6)Subject: RE: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundHi - thanks for your message - we will check and someone will get back to you in the next few days. Onecaveat is that as a Federal official , Dr. Fauci cannot be associated with fundrais ing in any way . Pleaseconfirm that is something you would be able to work around?From: Judee Ann Williams <jude eann.will iams@caa.com>Sent: Monday , April 20, 2020 5:21 PM -------~~ To: Routh, Jennifer (NIH/NIAID) [E] (b)(6); Billet, Courtney (NIH/NIAID) [E](b)(6)>Cc: Christine Lancman <christine. lancman@caa .com>Subject: Request for Dr. Fauci+ Ryan Zimmerman Pros For Heroes I COVID-19 Relief FundJennifer & Courtney -Hello ! Our friends from Steph Curry's team passed along you r contact info rmation to us and we work atCAA where we represe nt Wor ld Series Champion, Ryan Zimmerman .Ryan wanted to express his gratitud e first & fo remost to Dr. Fauci, the entire team and all those behindthe scenes working around the clock.Ryan recent ly launched the Pros for Heroes Covid-19 Fund last week, with more than 30 pro fessionalathletes supporting and over $300,000 raised across 1,400 separate donat ions.(www.prosforheroes.org). Since its launch last Tuesday, contributions from the Pros For Heroes Fundhave gone direct ly towards PPE needs throug hout the I nova hospital netwo rk throug hout the midAtlanticand have helped provide meals to those critical care front -line wo rkers - keeping these front -lineheroes covered at wor k and comfo rtab eat home.If Or. Fauci was up to it, Ryan would love to host eit her a short 15 minute Q&A on his Facebook tocontinue raising awareness for how we need to be responding to the ongo ing crisis. Or even simply t hankDr. Fauci for the tir eless work he is doirg and shine a light on how folks can support th ese cr it ical fro ntlineworkers.We are also open to what you think would wo rk best I Would there any openings that would work best?We know Dr. Fauci is big baseball fan, and of course we are all huge fans of his! If we can ever besupport ive or help navigate anyth ing in the world of pop culture, please do not hesitate to ask.Warmes t wishes,Judee AnnJudee Ann Williams I Co-Head, CAA Social ImpactT: 212-277-5294 I M (b)(6) I Washington, DCNEW YORK· LONDON -NASHVILLE· MUNICH - LOS ANGELES -BEIJING· SHANGHAIhttps://www.caa.com/Pros For Heroes"Teamwork is the ability to come together towards a common goal. We are looking forward to attractingas many supporters to help join this cause and give back as much as we can to those who have given usso much," said Washington National All-Star, Ryan Zimmerman, the fund's founder.Social Links:https://www.instagram.com/prosforheroes/https ://twitter. com/prosforheroesToday Show:https://www.today .com/video/ryan-zimmerman-talks -pros-for -heroes-fund -for-feeding -health-careworkers-82202693577Washington Post Launch Article:https ://www. wash i ngton post. com/sports/2020/04/14/nationa ls-rya n-zi mmerma n-sta rts-fund-hea Ithcare-workers-with- lO0k-gift/This e-mail and any files transmitted with it are intended solely for the use of the individua l or entity towhom they are addressed. If the reader of this e-mail is not the intended recipient or the employee oragent responsible for delivering the message to the intended recipient, you are hereby not ified that anyuse dissemination, forwarding, printing or copying of this e-mail is strictly prohibited . CAA is committedto ensuring that clients are free to do their best work without experiencing harassment and want toensure they have the relevant resources they need. Clients can go to https://www.caa.com/legal/sexua lharassment-guidelines-caa -clients to learn more about their rights, and how to report violations .From:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 20:44:40 +0000Conrad, Patricia (NIH/NIAID) [E)Cc:Subject:Billet, Court ney (NIH/NIA ID) [E);clane@niaid .nih .govRE: urgent: CNN requestCliff should do thi s.Anthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)(6)FAX: (3 96':44li9E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devi ces . The National Institute of Alle rgy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Conrad, Patricia (NIH/NIAID) [E) --------- (b) (6):>Se nt: Tuesday, April 21, 2020 4:41 PM -------~= To: Fauci, Anthony (NIH/NIAID) [E]- -------- (b)(6) Subject: Fwd: urgent: CNN requestSent from my iPhoneBegin forwarded message:From: "Conrad, Patricia (NIH/NIAID) [E]" ---------(b) (6)>Date: April 21, 2020 at 4:31 :46 PM EDT ------~~ To: "Billet , Courtney (NIH/NIAID) [E]" -------- (b)(6)> Subje ct: Fwd: urgent: CNN requestSent from my iPhoneBegin forwarded message:From: "Billet, Courtney (NIH/NIAID) [E]"Date: April 21, 2020 at 2:49:39 PM EDT(b)(6)-------~~ To: "Conrad, Patricia (NIH/NIAID) [E]" (b)(6)Cc: "Routh, Jennifer (NIH/NIAID) [E]" ..:======= (~b)::(:6~;,)Subject: FW: urgent: CNN requestPatty - can you please check with Dr. Fauci if he'd like to speak to ElizabethCohen about the treatment guidelines.From: Lane, Cliff (NIH/NIAID) [E] ------- Sent : Tuesday, April 21, 2020 2:48 PM ------~= To: Billet , Courtney (NIH/NIAID) [E] (b)( ; Pau, Alice(NIH/NIAID) [E] (b)(6)>Cc: Doepel, Laurie (NIH/NIAID) [E] (b)(6); Masur, Henry(NIH/ CC/CCMD ) [E]_ .:...__..:....:_.:..== ("b')"::(:6"~')";-M_y_le-s,-R-e-na_te ,(_NI H/0 D) [ E](b) (6)>Subject: Re: urgent: CNN requestI think Dr. Fauci would want the option of first refusal. He has anticipated hewill be asked about these.From: "Bi llet, Courtney (NIH/NIAID) [E]"- --------- (b)(6) Date : Tuesday, Apr il 21, 2020 at 1:35 PMTo: "Pau, Alice (NIH/NIA ID) [E]" -------= Cb =H=6J>Cc: Laur ie Doepe l CbH6)>, "Masur, Henry(NI H/CC/CC MD ) [E'"]:-1:1::-.:::======;;, (b,);(:~:6:), " Lane, Cliff (NIH/NIA ID)[E]" CbH6)", Myles, Renate (NIH/OD) [E]".;....:.--=====~~-- (b )( 6) >Subject: RE: urgent: CNN requestHI Alice - thanks for sending this along. We will confer about how best tohandle media requests about the guidelines - we're calling them NIHguidelines and the press release came from NIH, so I'd like to involve the NIHmedia office in this, hence I've cc'd Renate Myles . I think it's sort of anunsettled question as to who the spokespeople will be. Drs. Lane and Masur- do you have a preference?Also, who is Claire? (The person who forwarded the CNN request to you andDr. Masur. Would be good to have a last name so we can confer with her asneeded going forward.)From: Pau, Alice (NIH/NIAID) [E] ------- (b)(6)>Sent : Tuesday, April 21, 2020 1:24 PMTo: Billet, Courtney (NIH/NIAID) [E] (b)(6) Cc: Doepel, Laurie (N_IH./.:_N..IA_ID..)....[::.E..:]...:.;!=.-::-:=:;=:---=--.="'."="".="9=(_~b)_C~~6 )Masur, Henry(NIH/CC/CCMD) [E] (b)(6)>; Lane, Cliff (NIH/NIAID) [E](b)(6)>Subject: FW: urgent: CNN requestHi Courtney,Please see below the request from CNN. Per Laurie, I will forwardother reques ts to you.Thanks, AliceFrom: COVID19 Treatment Guidelines<C0VID19TreatmentGuidelines@nih.gov >Date: Tuesday, April 21, 2020 at 1:06 PMTo: Henry Masur (b)(6), Alice Pau(b)(6)>Subject: Fw: urgent: CNN requestHi Henry and Alice,I am not sure how we want to handle interview requests like this.Would someone on the Panel want to/be allowed to speak to the pressabout the guidelines?I am happy to politely declin e if we want to handle it that way.It is nice to see that we are being picked up by the press alreadythough. I am glad peop le are already expressing interest.Just let me know!ClaireFrom: Nigam, Minali <Minali.Nigam@turner.com >Sent: Tuesday, April 21, 2020 4:03 PMTo: COVID19 Treatment Guidelines <C0VID19TreatmentGuidelines@nih.gov >Cc: Cohen, Elizabeth <Elizabeth.Cohen@turner.com >; Fine, Amanda (NIH/OD)[E] (b)( >Subjec t: urgent: CNN requestTo the NIH Covid- 19 Treatment Guidel ine Team:My name is Minali Nigam and I work with Elizabeth Cohen at CNNHealth. We wanted to reach out and request to speak with someoneover the phone involved with the NIH treatment guidelines for covid-19. Please let us know as soon as possible for an available time today.We appreciate your help, as we inform our viewers of important healthinformation.Best,MinaliDr. Minali NigamCNN Health(b)(6)(bXS) -PCl1(b)(5) - Pe l
(bX5) -PCI(bX5) -PCI(bX5)-PCI(bX5) -PCI
(bX5) -PCI(bX5) -l'U
From:Sent :To:Subject:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202019 :42:03 +0000Birx, Deborah L. EOP/NSC;Hahn, Stephen;Redfield , Robert R. (CDC/OD)FW: SCMP: Coronavirus's ability to mutate has been vastly underestimated, andmutations aff ect dead liness of strains, Chinese study findsSee belowAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (301) 496-2263FAX: (301) 496-4409E-mail: afauci@niaid.nih.govThe information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Folkers, Greg (NIH/NIAID) (E] (b)(6)Sent : Monday, April 20, 2020 1:53 PMSubject: SCMP: Coronavirus's ability to mutate has been vastly underestimated, and mutations affectdeadl iness of strains, Chinese study findsChina/ ScienceCoronavirus's ability to mutate has been vastlyunderestimated, and mutations affectdeadliness of strains, Chinese study finds• The most aggressive strains of Sars-CoV-2 could generate 270 times as much viral load as theleast potent type• New York may have a deadlier strain imported from Europe, compared to less deadly viruseselsewhere in the United StatesStephen Chen in BeijingPublished: 10:41pm, 20 Apr, 2020Updated: 1:33am, 21 Apr, 2020A team led by Professor Li Lanjuan has studied how the novel coronavirus mutates and possibleimplications for the pandemic. Photo: EPA-EFEA new study by one of China's top scientists has found the ability of the new coronavirus to mutate hasbeen vastly underestimated and different strains may account for different impacts of the disease invarious parts of the world.Professor Li Lanjuan and her colleagues from Zhejiang University found within a small pool of patientsmany mutations not previously reported . These mutations included changes so rare that scientists hadnever considered they might occur.They also confirmed for the first time with laboratory evidence that certain mutations could createstrains deadlier than others."Sars-CoV-2 has acquired mutat ions capable of substantially changing its pathogenicity," Li and hercollaborators wrote in a non-peer reviewed paper released on preprint service medRxiv.org on Sunday.Li's study provided the f irst hard evidence that mutation could affect how severely the virus causeddisease or damage in its host.Li took an unusual approach to investigate the virus mutation . She analysed the viral strains isolatedfrom 11 randomly chosen Covid-19 patients from Hangzhou in the eastern province of Zhejiang, andthen tested how efficiently they could infect and kill cells.The deadliest mutations in the Zhejiang patients had also been found in most patients across Europe,while the milder strains were the predomina nt varieties found in parts of the United States, such asWashington state, according to their paper.A separate study had found that New York strains had been imported from Europe. The death rate inNew York was similar to that in many European countries, if not worse .But the weaker mutation did not mean a lower risk for everybody, according to Li's study . In Zhejiang,two patients in their 30s and 50s who cont racted the weaker strain became severely ill. Although bothsurvived in the end, the elder patient needed treatment in an intensive care unit .This finding could shed light on differences in regional mortality . The pandemic's infection and deathrates vary from one country to another , and many explanations have been proposed .Genetic scientists had noticed that the dominant strains in different geographic regions were inherentlydifferent. Some researchers suspected the varying mortality rates could, in part, be caused by mutationsbut they had no direct proof.The issue was further complicated because survival rates depended on many factors, such as age,underlying health conditions or even blood type .In hospitals, Covid-19 has been treated as one disease and patients have received the same treatmentregardless of the strain they have. Li and her colleagues suggested that defining mutations in a regionmight determine actions to fight the virus."Drug and vaccine development, while urgent, need to take the impact of these accumulating mutations... into account to avoid pote ntial pitfalls," they said.Li was the first scientist to propose the Wuhan lockdown.accord ing to state media reports. Thegovernment followed her advice and in late January, the city of more than 11 million residents was shutdown overnight.The sample size in this most recent study was remarkably small. Other studies tracking the virusmutation usually involved hundreds, or even thousands, of strains.Li's team detected more than 30 mutations. Among them 19 mutations - or about 60 per cent - werenew .They found some of these mutations could lead to functional changes in the virus' spike protein, aunique structure over the viral envelope enabling the coronavir us to bind with human cells. Computersimulation pred icted that these mutations would increase its infectivity .To verify the theory, Li and colleagues infected cells with strains carrying different mutat ions. The mostaggressive strains could generate 270 times as much viral load as the weakest type. These strains alsokilled the cells the fastest.It was an unexpected result from fewer than a dozen patients, "ind icating that the true diversity of theviral strains is still largely underappreciated," Li wrote in the paper.-Professor Li Lanjuan is a leading Chinese epidemiologist. Photo: XinhuaThe mutat ions were genes different from the earliest strain isolated in Wuhan, where the virus was firstdetected in late December last year.The coronavirus changes at an average speed of about one mutation per month. By Monday, more than10,000 strains had been sequenced by scientists around the globe, containing more than 4,300mutations, according to the China National Centre for Bioinformation.Most of these samples, though, were sequenced by a standard approach that could generate a resultquickly. The genes were read just once, for instance, and there was room for mistakes.Li's team used a more sophisticated method known as ultra-deep sequencing. Each building block of thevirus genome was read more than 100 times, allowing the researchers to see changes that could havebeen overlooked by the conventional approach.The researchers also found three consecutive changes - known as tri-nucleotide mutations - in a 60-year-old patient, which was a rare event. Usually the genes mutated at one site at a time. This patientspent more than 50 days in hospital, much longer than other Covid-19 patients, and even his faeceswere infectious with living viral strains."Investigating the functiona l impact of this tri-nucleotide mutation would be highly interesting," Li andcolleagues said in the paper.Professor Zhang Xuegong, head of the bioinformatics division at the National Laboratory for InformationScience and Technology at Tsinghua University, said ultra-deep sequencing could be an effectivestrategy to track the virus' mutation."It can produce some useful info rmation," he said.But this approach could be much more time consuming and costly. It was unlikely to be applied to allsamples."Our understanding of the virus remains quite shallow," Zhang said. Questions such as where the viruscame from, why it could kill some healthy young people while generating no detectab le symptoms inmany others still left scientists scratching their heads."If there is a discovery that overturns the prevailing perception, don't be surprised."Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisionsof U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily representmy views nor those ofNIAID, NIH, HHS, or the U.S. government.From:Sent :To:Subject :Jim:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202018:01:06 +0000Jim Yong KimRE: My art icleVery nice pape r! Thanks for sending it .Best,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)( 6)FAX: (301) 496-4409E-mail Cb()6 )The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Jim Yong Kim <Jim.Yong.Kim@global -infra.com>Sen t: Monday, April 20, 20 20 3:00 PM ------- ~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6):>Subject: My articleTony,Hope you're well and thank you again for all that you are doi ng. I got this out today in the New Yorkerand I'll be ta lking to most of the Democratic caucus today about what we're doing in Mass and thedeveloping worl d.Hang in there and let me know if there is anything more I can do . Mass is tough but we're going to havea 1000 contac t tra cers very soon . Every day we learn so much, wh ich is why it's so im portant foreveryone to get started .JimFrom:Sent:To:Cc:(NIH/N IAID) [ElSubject:Attachment s:Ed:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202017 :43:2 1 +0000EDWARD SCOLNICKMascola , John (NIH/VRC) [El;Cassetti, Cristina (NIH/N IAID) [El;Marston , HilaryRE: for your considerationScient ists_to_Stop _COVID19_2020_04_15_FINAL.pdfThank you for your note and for sending this. The outline that you provide is exactly in sync with what we arealready doing and have definitive plans to do with regard to classic antivirals , monoclonal antibodies, and a varietyof vaccine candid ates. As you know, the candidate developed here at Nll-1 in collaboration with Moderna is wellinco phase I crials and at lease 2 ochers are encer ing into phase 1 trials.Best regard::;,TonyAnthony S. Fauci, MDDirectorNational Tnslitu te of Allergy and Infectious DiseasesBuilding 31, Room 7 A-0331 Center Drive, MSC 2520Nat ional Tnslitutes of HealthBethesda, MD 20892-2520Phone : (b) (6)FAX : (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachmen ts is confidential and may contain sensitive infom1ation . Itshould not be used by anyone who is not the original intended recip ient. If you have received this e-mai l in errorplease infonn the sender and delete it from your mailbox or any other storage devices. The Nat ional Institute ofAllergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's ownand not express ly made on behalf of the NIAID by one of its representatives.-----Original Message-----From: EDWARD SCOLNICK (b)(6)Sent: Sunday, April I 9, 2020 5: 18 PM To: Fauci , Anthony (NIH/NIATD) [El- --T-""-'!-"'~~~-~!"" ' (b_) _C6,.).>_ _______ ~~Cc: David R. Liu (b)(6) ; Schreiber, Stuart (b)(6) ; Michael Rosbash_______ C_b)_(6_),> ; Ramnik Xav ier __________ C_b)_(6)Subject: for your consid erat ionTony . I hope your mail box is not so full that lhere is room for this. A group of concerned scient ists from differentparts of the country was organized to try to encap sulate and focus tbe national effott against Covid. This documenthas been shared with the White House although we are not sure if it has had any effect on their plans. It has alsobeen shared with The Gates Foundation and a few other business and academic leaders. We rhink we have beenfairly comprehens ive in our cons iderations and recommendations . I hope you will find this helpful. We wouldgreatly appreciate a conversation with you after you have had an oppo1tunity to digest the content of the proposal.lfthere is anything else we can do to help you in this National emergency, we stand ready to help. When I was atMerck ,we led the successfuleffort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the dmgs wemade ,and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The CovidPandemic Best wishes Ed scolnickFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [ElTue, 21 Apr 202015 :12:29 +0000Grady, Christine (NIH/CC/BEP) [ElFW: Thank youSee part about you. QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuild ing 31 , Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone : (b)( 6)FAX: (30 96~ 09E-mail: (b)(6)The information m t 1s e-mail and any of its attachments is confidential and may contain sensitiveinformation . It should not be used by anyone who is not the orig inal intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives .From: Conrad, Patric ia (NIH/NIAID) (E]- -------- (b)( > Sent: Tuesday, April 21, 2020 11:07 AM ------~= To: Fauci, Anthony {NIH/NIAID) [E] (b)(6) ______.._...Subject: FW: Thank youThis is a cute note ... you can skip most of it and see highlight - that is the cute partPatricia L. ConradPublic Health Analyst andSpecial Assistant to the DirectorNational Institute of Allergy and Infectious DiseasesThe National Institutes of Health31 Center Drive, MSC 2520 - Room 7A03Bethesda, Maryland 20892(b)(6)301-496-4409 faxDisclaimer:The informat ion in this e-mail and any of its attachments is confidential and maycontain sensitive informat ion. It should not be used by anyone who is not theor iginal intended recipient. If you have received this e-mail in error please informthe sender and delete it from your mailbox or any other storage devices. NationalInstitute of Allergy and Infectious Diseases (NIAID) shall not accept liability forany statement made that are sender's own and not expressly made on behalf ofthe NIAID by one of its representatives .-----Original Message-------------,;- s--=, From: JOAN HUSSEY (bH6lSent: Tuesday, April 21, 2020 9:34 AM ---------=-:- = To: Fauci, Anthony (NIH/NIAID) [E] --------- (bH 6)> Subject: Thank youDear Dr. Fauci,I just wanted to say thank you for everything you are doing to educate us in thiscountry , and keep us safe during this horrendous coronavirus pandemic. I can'teven begin to imagine how difficult it is to maintain your composure andpersevere with your focus, being constant ly in the public eye and also trying toexpert ly guide a president who seems more preoccupied with his own image (andsound of his own voice), and political aspirations than with the actual well beingof his country's citizens.By now, it should be perfectly clear to us that we can't have a healthy economywit hout a healthy population.(b)(6)I (bH ~ We all have beendiligent about staying at home I (b)( ~ordering food and other t hings to be delivered to ourhouse (we all wash our hands 'religiously') . (b)(6) is the only one of uswho occasionally goes to a grocery store or drug sto re if necessary and then, healways wears a mask, gloves, and keeps at least six feet between himself andanyone else, and gets in and out as quickly as possible. In addit ion, (b)( 6)- are so intent on keeping me we ll and alive, we haven't even, any of us,physically visited with each other , in person, inside our house for months .In the past two months, I've been outside only four times - twice on our deck andtwice in my car, dropping off a couple of shopping bags at a friend's house and at-------- CbH6) group home - both times leaving the bags in the dr iveway, and then driving right back home.I'm so t hankful for FaceTime, but we miss hugs and kisses. I know all this mustsound extreme, and it is, but I'm terr ified of becoming a statistic so we're doingwhatever we can to stay healthy for ourselves and one another.------ CHb (i)jM y family is hearing what you're saying and taking your advice. I'm sorry this email is so long but my intention, more than anything, is to thankyou for your wisdom and advice, both grounded in years of experience.(b)( 6)I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. Imet you once, briefly , about 40 years ago(+/ -) in Bldg. 31's fitness room . I hadbeen working in the CC, in the Patient Activities Dep't. (on the POB out - and inpatientunits)at the time. I was incorrectly using a piece of equipment and youwere kind enough to come over and show me the correct way to use it. Irecognized you immediately , and have never forgotten that experience and howgracious you were .I'm well aware from the news that you are up against some very tough peopleand some very tough times but please know you also have an army of gratefulfollowers in this country who are comp letely convinced that what you areadvising is in their very best interest.Thank you again for all you've done for all of us over the years. My family and Iare more grateful than I can e><press .PS I read all about your wife who sounds amazing also. You two make an "AllStar"team .Be well.Gratefully, Joan ("Joanie") HusseySent from my iPhoneFrom:Sent :To:Fauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 202015 :11:29 +0000(b)(6)Subject: FW: Thank youJoanie:Many thanks for your kind note . It is much appreciated . Stay safe !Best,TonyAnthony S . Fauci, MDDirectorNational Institute of Allergy and Infectiou s DiseasesBuild ing 31, Room 7A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda MD 20892-2520Phone : (b)( 6)FAX: (301 496-4409E-mail : (b) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.-----Original Message----- -------~= From: JOAN HUSSEY CbH6lSent: Tuesday, April 21, 2020 9:34 AM To: Fauci, Anthony (NIH/NIAID) [E] --------------~-~- -- CbH6) Subject: Thank youDear Dr. Fauci,I just wanted to say thank you for everything you are doing to educate us in thiscountry , and keep us safe during this horrendous coronavirus pandemic . I can'teven begin to imagine how difficult it is to maintain your composure andpersevere with your focus, being constan t ly in the public eye and also trying toexpertly guide a president who seems more preoccupie d with his own image (andsound of his own voice), and political aspirations than with the actual well beingof his country's citizens.By now, it should be perfectly clear to us that we can't have a healthy economywithout a healthy population.(b)(6)(b)( • We all have beendiligent about staying at home ------------------- (b)(6)1 ordering food and other things to be delivered to ourhouse (we all wash our hands 'religiously'). (b)(6) is the only one of uswho occasionally goes to a grocery store or drug store if necessary and then, healways wears a mask, gloves, and keeps at least six feet between himself andanyone else, and gets in and out as quickly as possible. In addit ion, (b)(6)- are so inten t on keeping me well and alive, we haven1t even, any of us,physically visited with each other, in person, inside our house for months.In the past two months , I've been outside only four times - twice on our deck andtwice in my car1 dropping off a couple of shopping bags at a friend's house and at-------------- (bH6l - both times leaving the bags in the dr iveway,and then driving right back home.I'm so thankful for FaceTime, but we miss hugs and kisses. I know all this mustsound extreme , and it is, but I'm terr ified of becoming a statistic so we're doingwh af_e,ver we._c.a o_to_sia~he.aJtb.._v..fnr nu r.selve_c;_nad on e._a.noib e .__ ____ ~~(b)(6)------- (b)(6) My family is hearing what you're saying and taking your advice.1' m sorry this email is so long but my intention , more than anything, is to thankyou fo r your wisdom and advice, both grounded in years of experience.I worked at NIH for about 25 years - in the CC, in NCI, and in Human Genome. Imet you once, briefly , about 40 years ago(+/-) in Bldg. 31's fitness room . I hadbeen working in the CC, in the Patient Activities Dep't. (on the POB out- and inpatientunits)at the time. I was incorrectly using a piece of equipment and youwere kind enough to come over and show me the correct way to use it. Irecognized you immediately , and have never forgotten that experience and howgracious you were.I'm well aware from the news that you are up against some very tough peopleand some very tough times but please know you also have an army of gratefulfollowers in this country who are completely convinced that what you areadvising is in their very best interest .Thank you again for all you've done for all of us over the years. My family and Iare more grateful than I can express.PS I read all about your wife who sounds amazing also. You two make an "All Star"team.Be well.Gratefully, Joan ("Joanie") HusseySent from my iPhoneFrom :Sent :To :Subject :Att achm ent s:Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/NIAID) [E)Tue, 21 Apr 202014 :52:49 +0000Barasch, Kimberly (NIH/NIAID) [C)FW: White House Coronavirus Task Force PowerPoint - 4.21.20PowerPoint April 21.pptxNational Institute of Allergy and Infectious DiseasesBuild ing 31, Room 7 A-0331 Center Drive , MSC 2520National Institutes of HealthBethesda , MD 20892-2520Phone: (b)( 6)FAX: (3 96':44li9E-mail Cb) (6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the orig inal intended recipient . If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.(bX5)-PCIFrom:Sent:To:Subject :Att achment s:Here it is.Anthony S. Fauci, MDDirectorFauci, Anthony (NIH/N IAID) [E)Tue, 21 Apr 2020 02:52:55 +0000Corey, Larrymanuscr iptCOVID vaccine editoria l_prefinal April20 wfigur e -with Fauci trac ked edit s.docxNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-0331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301) 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices . The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From:Sent :To:(b)(6)Mon, 20 Apr 2020 19:24:58 -0400Mascola, John (NIH/VRC) [E]Subject: Fwd: COVID-19 vaccineLet us discuss. I am not sure how to answer Adrian.Begin forwarded message:From: Adr ian Hill (b)(6)Dat e: April 20, 2020 at 6: 16:30 PM EDT ------~~ To: "Fauci, Anthony (NIH/NIAID) [E]" ------. (b)(6J: Cc: Hildegund Ertl (b)(6) , Sarah Gilbert ----------- (b)( Subject: F,v: COVID-19 vaccineDear Dr Fauci(b) (4)Thank you for your consideration of this at an exceptionally busy time.Yours sincerelyAdrian HillProfessor Adrian V. S. HillDirector, The Jenner InstituteNuffield Department of MedicineUniversity of OxfordOld Road Campus Research BuildingOxford OX3 70QFrom:Sent:To:Subject:Fauci, Anthony (NIH/N IAID) [E)Mon, 20 Apr 2020 20:43:18 +0000Conrad, Patricia (NIH/NIAID) [E)FW: Update: White House Coronavirus Meeting - 4.21.20Yikes .......................... That wou ld make 4 days in a row without a Press Conf erencefor me - Saturd ay, Sunday, Monday and tom orrow Q QAnthony S. Fauci, MDDirectorNational Institute of Allergy and Infectious DiseasesBuilding 31, Room 7A-O331 Center Drive, MSC 2520National Institutes of HealthBethesda, MD 20892-2520Phone: (b)(6)FAX: (301 496-4409E-mail: (b)(6)The information in this e-mail and any of its attachments is confidential and may contain sensitiveinformation. It should not be used by anyone who is not the original intended recipient. If youhave received this e-mail in error please inform the sender and delete it from your mailbox or anyother storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall notaccept liability for any statements made that are the sender's own and not expressly made onbehalf of the NIAID by one of its representatives.From: Hurst, Natalie R. EOP/OVP (b)(6)Sent: Monday , Apri l 20, 2020 4:38 PMSubject : Update: Whit e House Coronavirus Meet ing - 4.21.20Importance: HighAll -There will be no Whit e House Coronavirus Task Force Me eting on Tuesday , April 21st.Enjoy your evening ,Natalie Hur stOperation s Coordin ator , White House Coronaviru s Task Force
Page updated
Report abuse